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Abstract 
Thesis title: Cost-effectiveness modelling for benefit-risk assessment 
Author: Heather Jane Catt 
Introduction and aims 
Benefit-risk assessment is important for summarising the effectiveness and safety profile of an 
intervention.  Current methods for benefit-risk assessment are based upon flawed clinical trial 
data.  For biosimilars, regulatory approval is given on the basis of extrapolated evidence assessed 
in qualitative benefit-risk frameworks, leading to uncertainties. This thesis aimed to investigate 
methods for assessing the benefit-risk balance of therapies, including identifying harms data and 
developing a quantitative framework for assessing whether the cost savings of biosimilars justify 
the increased uncertainties regarding efficacy and safety.  
Methods 
This thesis reports a novel systematic review of the efficacy and harm outcomes reported in 
Crohn’s disease (CD) randomised clinical trials (RCTs) to 2015.  Extracted outcomes and adverse 
events data were categorised and the results benchmarked against a core outcome set (COS) for 
inflammatory bowel disease and the commonly used outcome measurement tools in CD RCTs.  
Summaries of Product Characteristics (SPCs) were investigated as a source of harms data with the 
use of standardised MedDRA (Medical Dictionary for Regulatory Activities) queries (SMQs).  
Finally, this thesis presents a one-year decision analytic model of biosimilar versus originator 
infliximab (IFX) to test the limits of biosimilarity and the value-based price needed to compensate 
for increasing risks. 
Results 
The systematic review yielded 181 studies, 96.1% of which reported primary or secondary 
endpoints (median five per trial).  The reporting of clinical and objective markers of inflammation, 
patient reported outcomes and safety outcomes as primary and secondary endpoints all increased 
over time, but with a lack of standardised definitions.  Within the outcome hierarchy, the efficacy 
outcomes matched to 35 domains, split equally into physical manifestations and the impacts of 
the health condition.  Adverse events matched to a greater number of domains (46), but most 
were physiological manifestations with few reported life impact adverse events.  Key literature for 
IFX identified five uncertain categories of harms, which matched to six SMQs.  Each SMQ included 
adverse events reported in the SPC but not reported in clinical trials, 28 of which allowed an 
estimate of risk.  Immunogenicity is a key concern for the IFX biosimilar, and was an important 
variable in the decision analytic model.  The base-case analysis predicted annual QALYs of 0.803 
for each biologic, and costs of £18,087 and £19,176 for biosimilar and originator, respectively.  The 
incremental net health benefit of 0.04 (95% Central Range 0.00-0.09) favoured the biosimilar.  
Two-way sensitivity analyses suggested that even at high immunogenicity, the value-based price 
would exceed the current market price.   
Conclusions 
The results of the systematic review provide a comprehensive inventory of benefit and harm 
outcomes reported in the literature and could form the basis of a COS development process.  Use 
of additional SPC harms data requires a strong theoretical approach to reduce the “noise” in the 
data.  Categorising outcomes is useful in lieu of the development and widespread use of a COS 
and the results presented here should support the development of much needed new outcome 
measurement tools for Crohn’s disease.  The study presents a novel framework for the 
quantitative benefit-risk assessment of biosimilars, which could be used at the point of health 
technology assessment to trade off the price paid for a biosimilar against the uncertainty in effect 
and risk of the therapy. 
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Chapter 1: Introduction to benefit-risk assessment and cost-
effectiveness modelling 
Any health-related intervention has the potential to cause harm alongside any benefit.  The 
assessment of benefit and harm (more often labelled as “risk”) of a medicine takes place from the 
early development of a drug, to regulatory approval for marketing, and beyond into the post-
marketing period.  Post-marketing assessment of benefit and risk includes health-care payers’ 
decisions on whether to authorise a drug for funding, through to clinical decisions on prescribing 
for individual patients.  Benefit-risk assessment (BRA) should take place at all parts in the life cycle 
of a drug to capture the changes in the benefit-risk balance, which occur over time as new data 
emerges for this and comparator drugs1–4.  BRA is comparative in nature and considers the 
benefits and risks of one intervention against those of a comparator or comparators.  As such, 
changes in the benefit and risk data for a comparator drug will affect the benefit-risk balance of 
the intervention of interest. 
This chapter introduces this thesis beginning with a discussion of BRA, cost-effectiveness 
modelling and outcomes in Section 1.1.  Section 1.2 introduces Crohn’s disease, which is the 
clinical motivation of the thesis. Section 1.3 introduces the case study for this thesis, in the form 
of biosimilars used in Crohn’s disease, which are an area of particular challenge for BRA that has 
required a significant response from all decision makers involved.  Finally, the thesis objective and 
structure are explained in Section 1.4. 
1.1. Introduction to benefit risk assessment and cost-effectiveness modelling 
1.1.1. Benefit-risk assessment 
Essentially BRA has two stages – identify the benefits and risks of the intervention and then 
compare them to decide whether the benefits outweigh the risks at an acceptable level for the 
target population.  The first step is an objective evaluation, whereas the second requires value 
judgements in the form of whether to trade-off some risk against benefits5. The assessment of 
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benefit and risk is not without challenges.  One key challenge is balancing the need to allow 
patients access to medicines in the shortest possible timeframe to extend life or halt the progress 
of a disease, whilst ensuring that they go through an appropriately robust process for assurance 
that they are safe to use or that the harms do not outweigh the benefits.  Failure to ensure an 
adequate benefit-risk balance could result in harm to patients and products being withdrawn after 
authorisation4.   The benefit-risk balance of a pharmaceutical product will vary by indication for 
which it is prescribed and will vary over time, as it will be possible to characterise the benefits and 
the risks more fully once the drug is available to a large population.  Data from multiple sources 
may be used for the assessment of the benefit-risk balance, which increases the complexity of 
analysis and the potential for bias in the results.  Section 1.1.1.1 to Section 1.1.1.4 provides further 
discussion of benefit-risk assessment. 
1.1.1.1. Concepts in benefit-risk assessment 
A number of concepts underpin the process of BRA as described in Mt-Isa et al (2011)1.   Given 
that BRA takes place over the life cycle of a drug, there are numerous decision makers.  First, the 
drug company decides whether to develop a drug, followed by regulators in numerous 
jurisdictions deciding whether to approve the drug for marketing, and the health technology 
assessor (HTA) deciding whether it should be prescribed based on its cost-effectiveness (discussed 
further in section 1.1.2.1).  At a more micro level the healthcare provider decides if they will offer 
it to patients, and the patient decides whether to take (and keep taking) the drug.   
At each point, each decision-maker assesses the benefit-risk balance and each earlier assessment 
affects the ability of later agents to make decisions.  For example, if the HTA decides not to 
approve the drug as cost-effective, then clinicians cannot decide to prescribe it and patients 
cannot technically decide whether to take it.  However, patients can influence further up the 
channel by, for example, requesting earlier access to potentially life extending drugs, or for the 
reinstatement of drugs that have had regulatory approval removed on the basis of their 
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willingness to accept higher than expected risk (discussed further in section 1.1.1.2).  Within the 
UK NHS, the prescriber is usually the agent requesting access to drugs not approved by NICE and 
this is through a system of individual funding requests (IFR). 
Possible actions is a further, simpler, concept: does the patient take the drug or not, does the 
regulator or the HTA approve the drug?  Uncertain consequences are a feature of benefit-risk 
assessment and these differ by decision maker.  For the patient, these will be clinical and personal 
outcomes, for example, whilst for health care providers, the consequences include the health 
outcomes of the population, as well as the budget and the opportunity cost of spending on this 
drug (the lost health gain that could have been achieved by spending the money on alternative 
drugs)1.  The sources of data used by all decision makers are likely to be the same and will primarily 
be evidence from clinical trials.  However, patients may also consider anecdotal or very early phase 
trial data, and will particularly pay regard to their own personal experience.  A patient 
experiencing an event that they perceive as related to the drug may decide to stop taking it. 
Utility assessments are a key concept in some forms of benefit-risk assessment, although other 
methods do not consider utility, as described in section 1.1.1.3.  Essentially utility values are the 
preferences of the decision maker, and these are likely to vary substantially by decision maker 
(discussed further in section 1.1.1.2).    Patients will weigh up the seriousness of potential 
individual consequences to them in terms of harm they could face and the improvement in disease 
that they may experience.  Regulators face the additional consideration of how much certainty in 
the evidence matters in the interest of public health1. 
1.1.1.2. Perceptions of benefits and risks 
The interpretation of the benefit-risk balance depends upon the perspective that is adopted for 
the assessment6.  The perceptions of benefit and risk will vary by context, for example, very 
different levels of risk are likely to be accepted for treatments for serious cancers than for a simple 
headache.  Similarly, there is likely to be a degree of myopia in risk assessment with patients willing 
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to trade an uncertain risk at some point in the future for benefit now.   Further complications arise 
when patients are asked to trade-off risk or harm in the present for the promise of potential 
benefit in the future. This is particularly relevant for public health interventions such as vaccines 
and screening where patients experience harm in order to prevent something that may well not 
have occurred anyway in the absence of the intervention.  A patient and clinician will weigh up 
the likely benefits and risks against clinical history, whilst regulatory agencies evaluate evidence 
from trials on benefits and risks when deciding whether to approve a drug for marketing1.   
The cost of the drug will not be a factor for a regulator, nor is it likely to be of concern for a patient 
in a health care system such as the National Health Service (NHS) in the UK where patients do not 
pay directly for treatment.  However, the cost will be a factor for the health-care payer (including 
patients in health care systems requiring direct payment or co-payment), who will wish to 
maximise the health improvement they can achieve within a fixed healthcare budget and will 
therefore compare the cost of health gained between treatments.  Similarly, an NHS prescriber 
may consider cost if a drug with similar efficacy is available at a cheaper price.  
Therapeutic benefit-risk balances may involve benefits and risks at the margin, which can be 
interpreted differently by the manufacturer, regulator, clinician and patient. Patients, particularly 
those with chronic diseases or late stage diseases, may be more willing to trade the adverse events 
of drugs with the possibility of disease improvement than other decision makers, regulators 
especially, are prepared to do2,5.   Surveys of patients with chronic diseases have found them 
willing to accept a small probability of life-threatening risks in exchange for significant 
improvements in disease-related health outcomes5,7,8.  The drug natalizumab provides a good case 
study of the differences in risk-preference as it was withdrawn from the market by the FDA 
following identification of a risk of fatal degenerative neurological disease PML, but then 
reinstated following pressure from patients who were willing to accept the risks against the 
significant benefits that they perceived9. 
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The evidence supplied for benefits and risks is likely to be limited, especially in the pre-marketing 
stages of BRA. Regulators must decide how much uncertainty in the evidence matters in the 
interest of public health1.  Regulators seek to guarantee adequate processes are in place to ensure 
the efficacy and safety of drugs, but they are often challenged by patients groups demanding early 
access to health care technologies, and they must balance the two arguments4.  Patients should 
be involved in assessments of how much risk a target population will accept as their attitudes to 
risk may differ so much from those of the general public, with greater focus on benefits and less 
on risk-aversion5.  Research is ongoing into patient involvement in benefit-risk assessment with 
the recognition of the need to involve affected patients to supplement data and the development 
of a framework to incorporate patient preferences into benefit-risk processes10–12. The inclusion 
of the patient perspective in benefit-risk assessment is supported by the International Conference 
on Harmonisation (ICH), an international collaboration to improve drug efficacy, safety and quality 
(discussed further in section 1.1.1.3)13. 
1.1.1.3. Benefit-risk assessment in the regulatory framework 
Numerous regulatory bodies operate across the world who receive applications from drug 
manufacturers for approval for new pharmaceuticals.   In Europe, regulation is the remit of the 
European Medicines Agency (EMA), specifically within the Committee for Medicinal Products for 
Human Use (CHMP) who assess the benefits and risks of medicines.  In the United States it falls 
within the remit of the Food and Drug Administration (FDA), who established the Drug Safety and 
Risk Management Advisory Committee to evaluate the safety, efficacy and abuse potential of 
drugs and deal with risk management and risk communication3.   
Other international regulators include Health Canada, the Pharmaceuticals and Medical Devices 
Agency (PMDA) of Japan and the Therapeutics Goods Administration (TGA) in Australia.  The 
International Conference on Harmonisation (ICH) provides guidelines on technical requirements 
for quality, safety and efficacy of drugs14.  The guidelines aim to ensure consistency in the data 
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shared across the jurisdictions for decisions on marketing approval of drugs, thereby streamlining 
the processes internationally. Figure 1 shows the typical regulatory process for a new drug.  It 
starts with drug discovery by researchers who identify active ingredients that offer potential 
benefit.  Preclinical development will include animal studies to determine whether the drug is 
likely to cause harm (toxicity)15,16.  
  Figure 1: Example regulatory process16 
 
Early clinical testing involves pharmacokinetics (PK) and pharmacodynamics (PD) modelling 
studies to establish, amongst other things, how the drug will impact and be dispersed within a 
body and the likely dose-response relationship15,16.  Clinical research then takes place on humans 
in three phases of trials.  Phase one trials take place in a small number of usually healthy 
volunteers and aim to ensure the drug is safe to use in humans and at what dose.  Phase two trials 
involve larger groups of people with the indicated disease and consider whether the drug works 
(efficacy) and whether it has any common dose-related side effects.  Phase three trials involve 
larger groups who receive the drugs over longer periods and are primarily concerned with efficacy, 
but do monitor safety outcomes that occur during the course of the trial (adverse events).    Once 
phase three trials have taken place, the drug should be comprehensively characterised in terms 
of its pharmacology, safety and efficacy and the drug company may submit an application for 
regulatory approval to allow it to market the drug.     
Drug discovery and development
Preclinical development
Clinical development
Phases I, II, III
Regulatory evaluation
Post-marketing safety monitoring
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BRA takes place at each point and is a necessary component of the regulatory evaluation.  It should 
be noted, however, that up to this point the assessments are done on the basis of incomplete data 
on both benefits and risks, which can provide a result at the margin2.  This can result in differences 
in decisions between regulators.  Once a drug receives regulatory approval, monitoring continues 
for any safety (risk) signals.  As more safety data are gathered in the post-marketing period, 
reassessment of the benefit-risk balance may change significantly, especially in the case of a 
marginal result where the real-world benefit (effectiveness) is less than the trial efficacy or the 
risk is greater than expected2.   
A detailed BRA takes place at the point of regulatory evaluation, where the drug company submit 
all their evidence and the regulator determines whether the drug has a positive benefit-risk 
profile.    Historically, this process has been qualitative, with the regulators taking an overall view 
of the data and considering, on balance, whether there is enough evidence to support a positive 
benefit-risk profile.    Where there are uncertainties, the regulator may place conditions on the 
approval.   The EMA require that a summary of product characteristics (SPC) document is 
produced by the manufacturer to obtain marketing approval15.  Additional conditions of 
marketing, for example periodic safety update reports, a risk management plan and any additional 
risk minimisation measures, must be published in the SPC. 
1.1.1.4. Methods and models of benefit-risk assessment 
The methods and models here focus on those used for regulatory decision-making, as this is the 
stage of most formal BRA.  Other methods and models may be more appropriate in different 
contexts of BRA.  Past reviews have found that BRA by regulators tended to be performed in an 
ad-hoc, informal, variable and qualitative way5.  In response, much research has focused on 
improving the quality and consistency of assessments by creating frameworks and tools for 
analysing and presenting complex information5.  Numerous benefit-risk methodologies are 
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available and the factors taken into account in choosing one method over another will vary greatly, 
depending on the perspective of the assessor1.   
A 2014 systematic review identified 47 methodologies for benefit-risk assessment, which were 
classified into four categories (Figure 2, full list in Appendix 1): frameworks, metrics, estimation 
techniques and utility survey techniques17.  The systematic review was conducted as part of the 
Innovative Medicines initiative (IMI) project that aims to “strengthen the monitoring of the 
benefit-risk balance of medicines in Europe” – Pharmacoepidemiological Research on Outcomes 
of Therapeutics by a European Consortium (IMI-PROTECT)6,18.  The vast majority of the 
methodologies are quantitative with only eight qualitative methods included, all within the 
frameworks category. 
Figure 2: Classification of benefit-risk methodologies17 
 
FRAMEWORKS 
BRA frameworks are structured, stepwise methodologies and provide guidance for the whole 
process18.  Descriptive (qualitative) frameworks use structured stepwise questions to identify all 
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elements of the benefit-risk balance, which provides transparency and communicability and allow 
for an overall assessment17.   
Quantitative frameworks are similarly structured but provide explicit methods for measuring 
benefits and risks17.  They break decisions down into elements to be quantified and aggregated to 
provide an overall picture of the benefit-risk balance.  Sensitivity analysis and incorporation of 
value judgements are key aspects of these frameworks18 and are discussed further in Section 
1.1.3.3. 
METRICS 
Metric indices offer numerical representations of benefits and risks18.  Threshold indices provide 
measures of either benefit or risk, but not both, health indices characterise health outcomes and 
implicitly trade off benefits and risks, and trade-off indices explicitly trade off quantified benefits 
and risks into a single metric to indicate whether a treatment option is favourable or 
unfavourable17,18.  Metric indices are primarily what decision-makers will use to judge the right 
decision, but they cannot be used on their own and must be nested within a broader framework18. 
ESTIMATION TECHNIQUES 
Estimation techniques include general statistical techniques that can be useful in synthesising 
benefit-risk evidence from multiple sources and handling statistical uncertainties within a model17.  
As with metric indices, they are best applied within a broader framework, specifically quantitative 
frameworks18. 
UTILITY SURVEY TECHNIQUES 
Utility survey techniques provide the value judgements of stakeholders that are necessary for 
regulatory BRA17,18.  One example is the time-trade off method, where patients are given two 
options: experience a chronic health for a period of time (remaining life expectancy), followed by 
death, or experience a period of perfect health, followed by death19.  The period of time in perfect 
health in the second option is varied (shortened) until the respondent is indifferent between the 
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two options.  At this point, a preference score is calculated based upon a ratio of the healthy life 
expectancy in option 2 and the life expectancy with chronic disease in option 1.   These techniques 
elicit and collect value preferences of various outcomes and help to increase the transparency of 
decisions.   
QUALITATIVE VERSUS QUANTITATIVE BENEFIT-RISK ASSESSMENT 
Most available frameworks and tools for benefit-risk assessment are quantitative5. Despite this, 
research by Phillips et al (2011) found that no regulatory agency employs quantitative modelling 
of the data in applications to obtain a yes or no answer to the assessment of benefit and risk20.  
Regulatory agencies tend to prefer descriptive frameworks: PrOACT-URL is the framework 
adopted by the EMA, but similar ones are used by other regulatory agencies, such as the US FDA 
Benefit-Risk Framework (FDA BRF)6,17,18.  Even where a safety signal is detected in the post-
marketing period, the new data are considered with all previous evidence in a qualitative process 
and the committee takes a decision.  The process does not produce an explicit, transparent 
quantification of risk and lacks clarity on the factors involved3. 
The US FDA see the need for a structured approach to benefit-risk assessment, but argue in favour 
of qualitative approaches.  Uncertainty in available information, especially for risk, creates the 
need for judgement, which can lead to different conclusions.  They argue that qualitative 
approaches lay down these value judgements clearly, making them more transparent.  Conversely, 
the FDA claim that a quantitative approach “requires assigning numerical weights to benefit and 
risk considerations in a process involving numerous judgements that are at best debatable and at 
worst arbitrary”9.    
The EMA argue that structured processes, both qualitative and quantitative, could further 
improve the transparency, communicability, auditability, quality, speed of decision-making, and 
have included quantitative methods in the regulatory agenda3,21.  Mid-way between the EMA and 
the FDA are the ICH, who propose that qualitative approaches are sufficient for regulatory 
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applications.  They suggest that quantitative methods can be presented, but applicants are 
encouraged to think carefully about the “utility, complexity, the extent to which the method is 
established and the ease of interpretation of the results”13. 
Whilst qualitative methods use implicit utilities, formal quantitative processes will make these 
utilities explicit, making the decisions more transparent1.  Quantitative frameworks may be of 
most value when the benefit-risk balance is unclear or contentious, for example by highlighting 
the impact of different factors or disparities in the value judgements of different assessors.  Even 
if quantitative frameworks are not desired in and of themselves, multiple methods of risk-benefit 
assessment can be used to bound the risk-benefit profile3, thereby identifying a likely range of the 
benefit-risk balance, which could be useful in the presence of uncertainty. 
IMI-PROTECT BENEFIT-RISK GROUP  
IMI-PROTECT suggest that no single method will provide a full assessment of benefit and risk and 
as the complexity of the problem increases, so will the need to supplement a  BRA framework with 
other quantitative methods6.  In particular, whilst descriptive frameworks allow for the framing of 
the decision problem, the inclusion of quantitative models allows for the exploration of trade-offs 
between benefits and risks and the consideration of uncertainty6,17.  Quantitative decision models 
aim to both frame the decision problem and incorporate quantitative measures of the benefit risk 
balance. 
IMI-PROTECT recommend thirteen methodologies of benefit-risk assessment for further 
research6,17,18.  Two descriptive frameworks are recommended for further research: 
1. PrOACT-URL framework.  This qualitative framework uses eight steps to assess the 
benefit-risk balance: problems, objectives, alternatives, consequences, trade-offs, 
uncertainty, risk attitudes and linked decisions.  The framework addresses all the 
important elements of decision problems but was criticised for failing to capture the 
importance of identifying appropriate evidence and parties to be involved. 
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2. Benefit Risk Action Team (BRAT) framework.  This framework proposes keeping benefits 
and risks assessment separate to make it accessible and transparent.  However, it is 
criticised for using odds ratios for assessment of the benefit-risk balance as they can be 
misleading and do not approximate the relative risk very well.  
To assess the benefit risk balance and quantify trade-offs, IMI-PROTECT recommend the following 
quantitative frameworks for further research: 
3. Multi-Criteria Decision Analysis (MCDA). This quantitative framework follows the stepwise 
system of PrOACT-URL.  It identifies and values the options, and weights the values of 
separate effects, using the preferences of the decision-makers, to allow benefits and risks 
to be compared on a common scale20,21.  It is able to capture multiple objectives 
simultaneously and integrate them into a common measure which is transparent and 
conceptually simple1.  However, it relies on clinical trials data, which can make it 
problematic in certain situations, especially post-marketing. 
4. Stochastic Multi-Criteria Acceptability Analysis (SMAA).  This is an extension of MCDA, 
which can account for sampling variation due to variability in study designs and missing 
utility values.  It is more complex, however, which may reduce its usefulness. 
Metric indices are useful for summarising evidence numerically and communicate to a general 
audience.  IMI-PROTECT recommend the following threshold indices (5 and 6), health indices (7 
and 8) and trade-off indices (9 and 10) for further research: 
5. Number Needed to Treat (NNT) and Number Needed to Harm (NNH).  These metrics 
estimate the number of patients that need to receive treatment for one to experience the 
benefit (NNT) or the risk (NNH)21.  They are recommended as they are simple to use and 
understand, but with a warning that they should be used to support modelling rather than 
in place of it. 
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6. Impact numbers.  These are an extension of NNT/NNH and indicate the number of people 
affected by the medical condition and treatment18. They are therefore useful in providing 
an indication of the public health burden of disease and the potential impact of treatment.  
They are intuitive and may make the results of a BRA more accessible to a wider audience. 
7. Quality Adjusted Life Years (QALY). This metric provides a measure of the remaining length 
of life adjusted for the quality of that life within each health state across the lifespan.  This 
metric provides a trade-off of time against quality of life and it is a well-established metric 
in chronic disease where time is important in the assessment of benefit and risks. It is 
discussed further in Section 1.1.2.2 and is used in Chapter 5. 
8. Quality Adjusted Time Without Symptoms and Toxicity (Q-Twist).  This metric is an 
extension of the QALY with health states specific to cancer and can aid cancer patients in 
decisions. 
9. Incremental Net Health Benefit (INHB). This metric builds upon the QALY and is 
advantageous as it trades off the extra benefits and extra risks of a treatment over an 
alternative, which is directly applicable to benefit-risk assessment. It is discussed further 
in Section 1.1.2.2 and is used in Chapter 5. 
10. Benefit Risk Ratio (BRR). These metrics are easy to understand as the benefits and risks 
are valued on the same scale and compared.  However, IMI-PROTECT suggest it should 
only be used with careful consideration of weighting to bring them onto the same scale, 
alongside baseline values, and with high quality data and statistical modelling. 
IMI-PROTECT recommend the following estimation techniques may be of use where evidence 
synthesis and complex benefit-risk modelling is needed to address a more complex decision 
problem: 
11. Probabilistic Simulation Method (PSM).  PSM is an estimation technique that uses 
probability distributions to propagate the uncertainty in input variables throughout a 
14 
 
decision model. This method is valued because of the potential to deal with a range of 
uncertainties under different assumptions.  However, it does rely upon good quality data 
to maximise its potential, in line with the adage ‘garbage in, garbage out’.  It is discussed 
further in Section 1.1.2.2 and is used in Chapter 5. 
12. Mixed Treatment Comparison (MTC).  This method is recommended in place of PSM 
where little direct evidence is available.  It is considered the most flexible and is capable 
of dealing with a range of biases and the combining of a mix of evidence. 
To incorporate stakeholder preferences into benefit-risk assessments, IMI-PROTECT recommend 
the following utility survey technique should be researched further: 
13. Discrete Choice Experiments (DCE).  This is considered the most comprehensive and well-
constructed method and therefore should provide the most valid results on stakeholder 
utility.  However, DCE is resource consuming so there is a need for alternatives. 
EMA BENEFIT-RISK METHODOLOGY PROJECT 
The EMA has conducted a benefit-risk methodology project to identify quantitative approaches 
that might be useful to guide the regulatory process.   A necessary first step to measuring benefit 
and risk in a quantitative framework is defining benefit and risk.  A survey of European regulatory 
bodies by Phillips et al (2011) identified consensus in the definitions of benefit (providing a 
clinically meaningful improvement) but large heterogeneity in risk with more than 50 definitions, 
many conflicting20.  This is intuitively possible, since there are a number of potential risks from 
taking a drug – including the risk of worsening of a disease, a risk that the drug does not work and 
risk of side effects from taking that drug.  Phillips et al (2011) applied decision theory, which splits 
consequences and their value from uncertainties about the consequences, and proposed a four-
fold model for defining benefit and risk, which has been adopted by the EMA21.   
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Figure 3: European Medicine Agency's four-fold model of ‘benefits’ and 'risks'21 
 
Favourable effects are defined as “any beneficial effects for the target population (often referred 
to as “benefits” or “clinical benefits”) associated with the product”21.   Unfavourable effects are 
defined as ”any detrimental effects (which may be referred to as risks, harms, hazards both known 
and unknown) that can be attributed to the product or are otherwise of concern for their 
undesirable effect on patients’ health, public health or the environment”.  Uncertainties about 
both types of effects arise from various sources including variation, bias, methodological flaws 
and limitations of the dataset.  These issues are discussed further in Section 1.1.3. 
The EMA identify key features needed for any quantitative method22: 
1. Data for favourable and unfavourable effects 
2. Uncertainties about those effects 
3. Clinical judgements about the desirability, severity and relevance of the effects.   
In practice, this means that the risks and benefits are weighted according to their relative 
importance and the strength of evidence available.  To this end, the EMA suggest that only 
decision theory provides a comprehensive approach as it allows for all effects to be related to 
preference (utility) values and uncertainty of the effects captured from prevalence and incidence 
data. 
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RECOMMENDATIONS OF THE EMA BENEFIT-RISK METHODOLOGY PROJECT 
Many of the conclusions under work package 2 of the benefit-risk methodology project21, which 
assessed the applicability of tools and processes for regulatory benefit-risk assessment, confirmed 
those of the IMI-PROTECT project.  Specifically, they agreed that decision theory is the most 
appropriate basis for a quantitative framework and that MCDA is an appropriate method to 
represent the benefit-risk balance numerically.  A particular role was seen for developing a MCDA 
model, which could be passed onto HTAs who could add costs and QALY data22.  This would help 
to harmonise BRA across regulatory and HTA processes.   
The use of QALYs and conjoint analysis (such as discrete choice experiments) is supported for 
particular cases: modelling multiple health outcomes in the former and examining trade-offs, 
particularly in eliciting patient preferences, in the latter.  Further, they reach the same conclusion 
as IMI-PROTECT, that combinations of approaches will be useful in different situations and that 
BRAs do not make the decision, but are instead aids to decision-making21.   
In addition, the EMA recommend the use of Bayesian statistics and decision analytic models with 
a role for Kaplan Meier estimators and Markov processes as supporting approaches when there is 
uncertainty in the decision. 
Bayesian statistics provide methods for allowing inferences to be made from evidence.  Bayes’ 
theory allows for the updating of “prior” probabilities of events with additional data as they 
becomes available to create “posterior” probabilities. In other words, if we have knowledge of 
conditions that might be related to an event we might be able to obtain the probability of that 
event occurring.  It is the basis of significance tests and methods such as value of information 
analysis, discussed further in Section 1.1.3.3.   
Decision analytic models are a commonly used model in medical literature21,23 and present 
possible outcomes following an intervention as individual pathways.  The model starts with a node 
indicating the decision being taken within the model, as shown in Figure 4.   
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Figure 4: Example decision analytic model24 
 
In the case of an application of regulatory approval of a new drug, this is likely to be whether to 
give a patient the new drug, or an existing treatment.  Chance nodes indicate the potential 
pathways from that decision (which could be benefits or risks) and branch probabilities indicate 
the likelihood of each of those events.   
Moving from left to right, further chance nodes show the likelihood of further uncertain 
(favourable or unfavourable) events.  The combinations of each of the branches provides a 
pathway, each of which is mutually exclusive.  Once patients enter one pathway, they cannot enter 
another.  The probability of a patient following each pathway is a conditional probability, that is, 
it is the result of the multiplication of each probability along the pathway.  All pathways are 
exhaustive and must add to 1 so that the model represents all potential events and pathways.  
Utility values can be elicited and applied to each pathway.  Multiplying the utility values by the 
probability of each pathway results in the overall expected utility from the model. Comparing the 
expected utility between the treatments included in the model forms the basis of an 
understanding of the benefit-risk balance.  Decision models have limitations, including the 
tendency for them to become very large, very quickly, especially for a chronic disease where 
patients may experience multiple health states and adverse events from treatment over time.  
Chance node 
Pathway 
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They also time consuming to programme and analyse23.  However, they are logical and can 
incorporate data from numerous sources21.  A decision-analytic model is developed in Chapter 5. 
Markov processes can be seen as addressing some of the limitations of decision models as they 
capture the dynamic processes of disease progression over time, which makes them useful in 
chronic disease23.  Markov models incorporate disease states that patients can occupy over 
periods of time.  Each disease state is associated with a utility value and therefore an overall 
expected utility can be calculated by measuring the time spent in that state.  Transitions between 
states are governed by a series of transition probabilities, which are taken from the literature.  
They can be seen as an extension of decision trees and should, in fact, arrive at the same 
conclusions as decision trees, but with greater efficiency21.  Limitations of Markov models include 
the lack of memory, meaning that the prior events of patients in a disease state are not considered 
and they are all treated equivalently, which is not clinically realistic23.  For example, patients with 
Crohn’s disease in post-surgical remission following a first resection are likely to experience a 
different future disease course to patients who have had multiple resections.  A Markov will not 
consider this unless it is built into the structure of the model, but this can make a model unwieldy. 
Kaplan Meier estimates enable the display of survival data and can be used to display the results 
of a Markov model21.  At any point, the difference between two curves representing two 
treatments can show the differences in outcomes between the patients.  It is limited to a single 
favourable or unfavourable effect, but has the advantage of showing the effects over time.  The 
Q-TWIST trade off metric (discussed earlier) is an extension of this method. 
Challenges to developing a quantitative methodology for BRA include the heterogeneity and 
multiplicity of benefits and risks, uncertainty in attribution to a particular treatment, temporality 
of exposure and effect and the paucity of drug exposure and outcome data3.  These issues are 
discussed further in section 1.1.3. 
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1.1.2. Cost-effectiveness modelling 
It is not only regulators who seek to understand the benefit-risk balance and involve the views of 
patients.  As the price of modern medicines has increased in excess of the growth of health care 
budgets, the assessment of clinical and cost effectiveness has become more important2.  Scientific 
evaluation of clinical trial data is used to compare a new drug to existing therapies as part of the 
Health Technology Assessment (HTA) process to support decision-making on price and 
remibursement25.  HTA makes judgements about the benefits of a product in the context of its 
safety risks to determine the reimbursement decisions, but also make cost-benefit decisions to 
determine the price of the product5.  As such, HTA deals with benefit and risk but also focuses on 
economic outcomes, which are excluded from traditional benefit-risk approaches due to the 
regulatory perspective17. 
Given the significant overlap in BRA and HTA processes, there is growing international interest in 
optimising the interface between regulatory approval and reimbursement decisions5,25.  Work 
began in the European Union to improve the data contained in the European Public Assessment 
Report (EPAR), which is the regulatory report supporting the licensing of medicines in Europe, so 
that it might contribute to HTA25.  Further areas of collaboration are being explored, including 
information exchange, specifically the timely provision of the outcome of regulatory assessment 
to support joint production of rapid economic assessments (REA)26. 
1.1.2.1. Cost-effectiveness modelling in health technology assessment 
Given the focus on cost-effectiveness, drugs that have proven clinical effectiveness may be 
rejected for use because the additional health gain is simply too costly.  The opportunity cost of 
such drugs is too high as the same money could be spent elsewhere to obtain greater health gain.  
The role of assessing whether a drug is cost effective and should be available for reimbursement, 
and at what price, is determined by HTA agencies at national level25.   
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In the UK, the National Institute for Health and Clinical Excellence (NICE) is one such agency that 
performs HTA.  The purpose of a NICE technology appraisal is “to appraise the health benefits and 
the costs of those technologies…and to make recommendations to the NHS in England and 
Wales”27.  NICE considers evidence on the clinical effectiveness of the intervention being assessed 
and economic effectiveness in terms of whether it represents value for money for the NHS28.  Both 
types of evidence will come from the drug manufacturer and the economic appraisal is likely to 
be in the form of an economic model.  Prior to the start of the HTA, NICE will meet with the drug 
company to discuss the scope of the decision problem and how the problem is to be modelled, 
including the types of evidence to be used and how the model will deal with uncertainty28.  
In addition to forming the basis of a decision as to whether a drug is cost-effective or not and 
should be reimbursed, HTA can support pricing decisions25.  This may be directly, or it may be in 
the form of risk sharing arrangements between the drug manufacturer and the health care payer.  
Risk-sharing helps to reduce the financial risk of a drug by linking pricing and reimbursement 
decisions to real world effectiveness or utilisation29.  These agreements may take many forms and 
help to overcome uncertainty in outcomes and therefore improve the cost-effectiveness of a drug.  
Cost-effectiveness modelling can help support discussions about risk sharing through pricing. 
1.1.2.2. Methods of economic evaluation 
A number of economic methods are available for use in HTA, with the choice informed by the 
decision to be made.  All involve the comparison of the costs and consequences of an intervention 
against those of the next best treatment or intervention.  In BRA for HTA purposes, the comparison 
is of the costs of the interventions against the benefits and risks of the interventions included in 
the analysis.  Four types of economic evaluation are described below: cost-benefit, cost-
effectiveness, cost-utility and cost-minimisation.   
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COST-BENEFIT ANALYSIS 
In simple terms, cost-benefit analysis (CBA) involves comparing the costs of interventions against 
the benefits, which have been valued monetarily.  An intervention is considered worthwhile if 
there is a social benefit, that is, if the monetary benefits exceed the monetary costs.  More 
precisely, CBA involves comparing the discounted future incremental benefits against incremental 
costs, with the difference between the two representing the net benefit to society30.   
One major benefit of CBA is the ability to compare interventions across different sectors because 
all consequences are converted into money.  This helps with decision making in the broadest 
sense, in terms of allocating budgets across all possible programmes and allows for the net benefit 
to society to be maximised by investing in the most worthwhile programmes.  The achievement 
of “allocative efficiency” is possible through CBA, but not other forms of economic evaluation23.  
Historically, the act of valuing health states has been considered controversial, but methods 
described earlier in section 1.1.1.3 have become more popular in health care for this purpose, 
specifically conjoint analysis and discrete choice experiments30. 
COST-EFFECTIVENESS ANALYSIS 
Cost effectiveness analysis (CEA) is another method of comparing the costs and consequences of 
treatments. However, only one effectiveness measure is used and it is a measurement in natural 
units, for example, heart attacks prevented, reduction in tumour growth or years of life gained.  
Typically this approach is used when a decision maker is interested in maximising the 
measurement of interest within a fixed budget31,32.  An advantage of CEA is its simplicity, but this 
is also its downfall as it is not possible to consider a range of outcomes that are likely to define a 
health condition or disease.  Further, as this method tends to be about maximising health gain 
within a budget it does not consider wider societal impacts and whether programmes are 
worthwhile, based upon the preferences of society. That is, it addresses technical efficiency but 
not allocative efficiency.  Further weaknesses are that it is not possible to compare treatments 
22 
 
with different objectives and that it might not be clear how the chosen outcome measure relates 
to health, particularly when using a biological marker such as tumour response31,32.   
COST-MINIMISATION ANALYSIS 
Cost-minimisation analysis (CMA) is a form of CEA that can be applied where two treatments are 
equivalent in terms of efficacy and safety, and therefore the one with lower cost is chosen.  Critics 
argue that it is not a useful type of economic evaluation as it is very unlikely that effectiveness 
would be equivalent31,32.  However, the growth of new drugs called biosimilars has seen a return 
in the implicit use of CMA by NICE and the NHS33,34.  CMA is discussed further in Section 1.3.3.1. 
COST-UTILITY ANALYSIS 
Cost-utility analysis (CUA) overcomes some of the limitations of CEA by utilising a standard 
measure of health outcome, the quality-adjusted life-year (QALY).  The QALY allows for the 
capture of information on both length of life gained and the quality of that life.  The QALY is a 
measure of utility or patient preferences and is accepted as the standard unit of measurement for 
economic evaluation by NICE27,32.  Societal preferences are elicited for particular health states and 
these data are combined with survival data to generate a QALY.  The value of a QALY typically 
ranges from one, which is equivalent to a year in perfect health, to zero, which is death.  Negative 
QALYs are possible in the case of health states that are considered worse than death.  Also of note 
is that one QALY gained in one patient is considered equivalent to 0.01 QALYs gained in 100 
patients, and that a QALY gained in one population is equal in value to a QALY gained in another 
patient population. 
Using CUA allows for the comparison of a range of different health care interventions due to the 
consequences taking a common value.  It overcomes the limitation of CEA that stems from the 
inability to consider whether a programme or intervention is worthwhile rather than simply 
maximising health gain, and therefore helps decisions concerning allocative efficiency.  It is very 
useful in the comparison of treatments for chronic conditions because it considers the wider 
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quality of life.  However, it is limited to the comparison of health care interventions unlike CBA.  
CUA is a special case of CEA due to the use of QALYs, but is frequently referred to as CEA32,35. 
INCREMENTAL COST-EFFECTIVENESS RATIOS 
Like CEA, CUA compares the incremental costs and consequences of treatments.  With QALYs, the 
result is an incremental cost effectiveness ratio (ICER).  The ICER is the ratio of the incremental 
costs between a new treatment in comparison with the next best alternative, divided by the 
incremental effectiveness (QALYs).  The ICER can indicate whether a treatment is cost-effective 
and is calculated as shown in Equation 1.   
Equation 1: Incremental cost-effectiveness ratio formula 
𝐼𝐶𝐸𝑅 =
𝐶1 − 𝐶0
𝐸1 − 𝐸0 
=
∆𝐶
∆𝐸
 
Where C1 and E1 are the costs and effectiveness of the intervention of interest and C0  and E0 are 
the costs and effectiveness of the comparator intervention.  The costs include the total 
management of the intervention, which may include drug costs, resource use for delivering the 
intervention and the costs of consequences from the intervention, which may include harms. 
The incremental costs and incremental benefits versus a comparator treatment can be plotted on 
a cost-effectiveness plane as shown in Figure 5. An intervention in the North West quadrant has 
higher costs and lower QALYs and is dominated by the comparator, which is the more cost-
effective option.  An intervention with coordinates in the South East quadrant has lower costs and 
higher QALYs and is the cost-effective option as it dominates the comparator treatment.  Points 
in the North West and South East quadrants will both be negative ICERs. Results in the North East 
quadrant, with higher costs and QALYs, and the South West quadrant, with lower costs and QALYs, 
both result in positive ICERs but their interpretation is less clear.   
Where there is a positive ICER there are trade-offs between cost and effectiveness to consider32.  
In these cases, reference is made to a cost-effectiveness threshold, often denoted as lambda (λ).  
This is the opportunity cost of investing in this option, as it represents the value that could be 
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gained from other options.  If the new option is in the North East quadrant, with higher costs and 
higher QALYs, the decision rule is that if ICER < λ, the activity is cost-effective, and vice versa.  For 
options in the South West quadrant, the decision rule is reversed so that if ICER > λ than the 
activity is cost-effective. 
Figure 5: Example cost-effectiveness plane 
 
NICE traditionally operates with an acceptable cost-effectiveness threshold (λ) of £20,000 to 
£30,000 per QALY27, as indicated by the green line in Figure 5.  Treatments that cost more per 
QALY are not deemed cost-effective and are unlikely to be approved for use on the NHS.  However, 
this is no longer a strict threshold.  A number of schemes have been created by NICE which allow 
for varying thresholds, such as £50,000 per QALY for end of life treatments and £100,000 to 
£300,000 for ‘very rare diseases’36.  In addition, processes have been created for certain drug 
categories, including a cancer drug fund allowing earlier access to experimental treatments, and 
an expedited review for drugs costing less than £10,000 per QALY.  Whilst NICE operates with 
transparency in these approaches, it has been argued that these changes are implicitly inequitable 
as different values are being placed on different conditions36. 
  
λ = £30,000 per QALY 
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INCREMENTAL NET BENEFIT APPROACHES 
The QALY is, in effect, a measure of the net benefit of a treatment, weighted by societal 
preferences for benefits and harms.  Whilst the ICER has benefits in being relatively intuitive and 
allowing direct comparison of interventions, it can be difficult to use as it has no meaningful 
interpretation without the context of the cost-effectiveness plane quadrant and the cost-
effectiveness threshold (λ)37.  Net benefit approaches offer an alternative as they result in a 
meaningful statistic that can be directly interpreted as the additional benefit from a treatment.  It 
is possible to consider either net health benefit (NHB) or net monetary benefit (NMB) as shown in 
Equation 2 and Equation 3:  
Equation 2: Net health benefit 
𝑁𝐻𝐵 = 𝐸𝑖 −
𝐶𝑖
λ⁄  
Equation 3: Net monetary benefit 
𝑁𝑀𝐵 = 𝐸𝑖𝜆 − 𝐶𝑖 
Where Ei is the effectiveness of intervention i, Ci is the cost of intervention i and λ is the cost-
effectiveness threshold, as previously defined37.  NMB converts the effectiveness into a monetary 
unit and defines the results in terms of currency, whilst NHB converts the costs into health units32.  
Either approach can be used to compare a new treatment against a comparator, resulting in 
incremental net health benefit (INHB) and incremental net monetary benefit (INMB).  If the 
resulting INHB or INMB is positive, the new treatment delivers a net benefit and is the cost-
effective option.  INHB is discussed further and applied in the model in Chapter 5. 
1.1.2.3. Cost-effectiveness modelling 
Whichever methods of economic evaluation and modelling are selected, there are a number of 
good practice principles that should be followed, from design to reporting38–42.  These include that 
the model should be structured to answer the decision problem being addressed and should be 
transparent, internally consistent and reproducible.   The model should be consistent with 
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available knowledge of the health condition and evidence regarding causal linkages in variables, 
as well as exploring all forms of uncertainty38,39.   
Models should incorporate important factors and health states should not be excluded because 
of a lack of evidence, for example adverse events not observed in clinical trials.  Instead, health 
states can be included where they are coherent with the theory of the condition39.  At the same 
time, however, models should not be unnecessarily complex and should only include variables 
that are important to the decision problem38.  Typically, models in the literature focus more on 
benefits of therapies and fail to capture the adverse events.  A systematic review of model-based 
economic evaluations of anti-TNF therapies in rheumatoid arthritis found that models have not 
routinely considered the direct costs or consequences of adverse events, which can bias the 
estimates of relative cost-effectiveness and affect the validity of associated recommendations.43  
There are numerous reasons behind this, which are discussed in section 1.1.3.2. 
1.1.3. Outcomes 
When considering the benefit-risk balance of an intervention, it is necessary to be able to draw 
from the evidence base on outcomes.  All forms of evaluation and modelling require good quality 
data on health outcomes.  Health outcomes are defined by the International Committee of 
Medical Journal Editors (ICMJE) as any biomedical or health-related measures, including 
pharmacokinetic measures (such as how long the drug takes to be absorbed or how it is 
distributed) and adverse events44. 
The RCT is the gold standard for determining efficacy and safety, but they have some well-known 
flaws including cost and time requirements, and the assessment of efficacy under perfect 
conditions meaning the results do not necessarily translate in clinical practice4.  Uncertainty in 
BRA stems from the uncertainty in the component benefits and risks.  Uncertainty about efficacy 
can result from bias and errors, whilst uncertainty about safety outcomes is likely to be greater 
due to the fact that studies are powered for efficacy4.  Uncertainty in the benefits and risks of a 
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product may be highest at the point of marketing authorisation, once it begins to be marketed to 
a wider population who are using the treatment in a less-controlled manner than in clinical trials5.  
Post-marketing research is useful to detect safety signals, but can also provide evidence on the 
effectiveness of a drug, which also informs the benefit-risk balance4. 
Benefits and risks may be considered as absolute values, such as the percentage of patients who 
experience an improvement in disease or who avoid an adverse event from taking a drug.  They 
may also be considered as relative benefits and risks, where they are compared to the outcomes 
of other therapies.  Relative risks may be used to assess the improvement in condition or reduction 
in the occurrence of an adverse event, for example, patients taking the intervention of interest 
experienced a relative risk reduction of 10% compared to patients on the alternative therapy.  
Economic evaluation methods consider comparative risks and benefits, but it is important to also 
monitor the absolute values of risks and benefits.  As way of example, a treatment may lead to a 
50% increase in the risk of an adverse event, which appears large and concerning.  However, if the 
absolute increase is from 0.4% to 0.6%, the actual risk remains very low and the increase may not 
be considered clinically significant, especially if accompanied by an improvement in disease 
activity.  Conversely, a treatment may result in a 10% improvement in the number of patients 
achieving a benefit, which may seem relatively small, but may mean that 88% of patients achieve 
an outcome, instead of 80% and could result in considerable improvement in population health.  
If this is balanced against no increased risks, or small increased risks, it is an even more positive 
result. 
1.1.3.1. Benefits 
Assessment of benefit is important for all BRAs and the considerations are likely to be similar for 
all decision makers – essentially, will this treatment make the patient’s condition improve?  This 
type of information will come from clinical trials, usually RCTs.  RCTs are considered the gold 
standard method for assessing benefit of a therapy because of the randomisation of patients 
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between treatment arms, which should ensure that any additional benefit is the result of the 
treatment and no other differences.  Generally, the benefit, or efficacy, of an intervention is tested 
in the primary and secondary endpoints of a trial.  These endpoints are pre-specified in the trial 
protocol as an aide to ensure transparency in trial reporting to support the collection and 
publication of best evidence and prevent outcome reporting bias.  The International Committee 
of Medical Journal Editors (ICMJE): 
“requires, and recommends that all medical journal editors require, registration of clinical trials 
in a public trials registry at or before the time of first patient enrolment as a condition of 
consideration for publication”44. 
Clinical trial endpoints incorporate the outcome to be measured, the outcome measurement and 
the outcome measurement tool.  For example, 2006 EMA guidelines recommended the 
measurement of the proportion of patients achieving remission (CDAI<150) within four to six 
weeks to demonstrate short-term efficacy.  In this endpoint, the outcome is remission, the 
measurement is CDAI <150 and the outcome measurement tool is the CDAI. 
The International Conference on Harmonisation (ICH) guidelines on clinical trial data suggest how 
key benefits should be identified for inclusion in a BRA13.  Key benefits are defined as favourable 
effects that are assessed by primary and other clinically important endpoints.  The clinical 
importance of the benefit is a stressed requirement, which should include consideration of the 
magnitude of the difference in effect between treatment populations.  Further, the guidelines 
highlight that other findings might be used in the BRA beyond primary endpoints, including 
secondary and exploratory endpoints. 
However, RCTs are very expensive to run and tend to take place over the short term, which can 
reduce their ability to assess efficacy over the longer term.  This is problematic for chronic 
conditions, where therapy may be received for years or decades to keep a disease under control. 
Further, clinical trials monitor efficacy of a drug, which can be summarised as what a drug could 
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do in a patient population.  However, there is often a gap between this and what a drug actually 
does do in the patient population, which is known as effectiveness4. 
Intention-to-treat can help to identify the effectiveness of a treatment, rather than the efficacy.  
Intention-to-treat (ITT) is the method of analysing patients in their original randomised group, 
which aims to maintain the original sample size and the split of prognostic factors between the 
groups, irrespective of study withdrawals, missing data and non-adherence to therapy45,46.  If ITT 
analysis is used in the reporting of studies, patients who have withdrawn due to adverse events 
should be followed up and are still included in the analysis.  This might not be the case in per-
protocol analysis, where patients are analysed in terms of the treatment they receive.  Where per-
protocol analysis is used, it can bias the results, creating a more optimistic view of the benefits of 
a drug than can be achieved in reality45,46.  ITT analysis was previously required by the CONSORT 
statement and the 2010 version offers clarity for trialists that analysis should be done by the 
original groups with complete follow up of patients to preserve randomisation47. 
CORE OUTCOME SETS 
The multitude of outcomes that can be measured for a condition make it difficult to synthesise 
data and establish more precise estimates of benefits and risks from treatment.  Core outcome 
sets (COS) are one method for resolving this issue.  A COS is a standardised set of outcome 
measures that should be reported in research48,49.  It is not an exhaustive list, and researchers may 
measure additional outcomes of their choosing.  The intention is that all trials should measure and 
report the core set as a minimum requirement so that it is possible to produce precise outcomes 
that allow for the comparison of benefit and risk within and across treatments.  Ideally, the COS 
should also be used in clinical practice to further add to the evidence base of effectiveness and 
longer-term outcomes49.   
The Core Outcomes Measurement in Effectiveness Trials (COMET) initiative50 is a leading 
contributor to the research field of COS, but COS groups also operate for individual conditions.  A 
30 
 
key example is the Outcomes Measurement in Rheumatology (OMERACT)51 initiative which 
advocates the use of COS in rheumatology trials.   Key to the development of COS is the use of 
consensus methods, which means that the final outcomes selected for inclusion are agreed by all 
stakeholders, including patients49.   Core outcome sets are discussed further in Chapter 2 and 
Chapter 3. 
1.1.3.2. Risks 
Regulatory agencies use a number of methods to identify risks: RCTs, observational studies, 
automated databases linking drugs and disease, spontaneous reporting systems and patient 
registries3.  The system as a whole is called pharmacovigilance and is designed to ensure that drugs 
are safe, and the benefits outweigh the risks, at all points in the life cycle.   
Understanding the risks of treatments tends to be more complicated than benefits because trials 
are powered for efficacy rather than safety endpoints, but also because the assignment of 
causation is more complicated.  Clinical Good Practice (CGP) requires that all adverse events 
occurring during clinical trials should be recorded13.  Adverse events are then assessed as being 
serious or not, and treatment-related or not. The ICH recommends that this information should 
be presented in the application for regulatory approval, but also suggest that the analysis of 
common adverse events should be on the total number, regardless of causation, because 
“evaluations of causality are inherently subjective and may exclude unexpected adverse events 
that are in fact treatment related”13.  This subjective nature of causality assessment is problematic 
in various ways, and is discussed in Chapter 4 on the consideration of methods for capturing long-
term harms from drugs. 
Further, whilst harms would ideally be identified in the controlled environment of clinical trials, 
the cost and time requirements, and safety database required to detect small safety signals of 
rare harms, and small increases in common events, makes this unfeasible4,9. As such, the true 
safety profile of a drug is unavailable at the time of approval and post-marketing monitoring is a 
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necessary component of the regulatory process.  To this end, the EMA requires that sponsors must 
submit detailed risk-management plans with an application for market authorisation, which 
contains: 
 “the identification or characterisation of the safety profile of the medicinal product, with 
emphasis on important identified and important potential risks and missing information, 
and also on which safety concerns need to be managed proactively of further studies 
(‘safety specification’); 
 The planning of pharmacovigilance activities to characterise and quantify clinically 
relevant risks, and to identify new adverse reactions (the ‘pharmacovigilance plan’); 
 The planning and implementation of risk minimisation measures, including the evaluation 
of the effectiveness of these activities (the ‘risk minimisation plan’)”52 
The pharmacovigilance plan contains information on the collection of additional data on harms 
from the drug to inform the benefit-risk balance.  It contains sections for routine 
pharmacovigilance activities and for additional pharmacovigilance activities that are not 
considered routine52.  Long term follow up studies of clinical trial patients or cohort studies of 
patients receiving the drug over a long period, are examples of potential additional activities.   
Traditional forms of pharmacovigilance rely upon the spontaneous reporting of adverse reactions.  
Whilst the lack of denominator and controls makes it difficult to distinguish signals from 
background noise, important drug safety issues can, and are, identified through such systems4 
(see further discussion in Chapter 4).  Rarely, drugs may be withdrawn because serious safety 
signals are identified in the post-marketing phases and this should be viewed as a success of the 
pharmacovigilance mandated by regulatory processes4. 
DEFINITIONS 
Many terms are used to describe risks of drugs and this section provides a summary of some of 
the main classification systems. 
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INTERNATIONAL CONFERENCE ON HARMONISATION (ICH) 
ICH guidance on clinical safety data management53 define adverse events (AEs) as:  
“any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and which does not necessarily have to have a causal relationship with 
this treatment”53.   
Adverse drug reactions (ADRs) are defined according to whether they occur in a pre-approval or 
post-approval setting.  In a pre-approval setting, they are defined as:  
“all noxious and unintended responses to a medicinal product related to any dose should be 
considered adverse reactions”.   
In a post-approval setting, they are described as:  
“a response to a drug which is noxious and unintended and which occurs at doses normally used 
in man…”53.   
Unexpected adverse drug reactions are described as:  
“an adverse reaction, the nature or severity of which is not consistent with the applicable product 
information”53.  
Further defined are serious adverse events or reactions:  
“a serious adverse event or reaction is any untoward medical occurrence that at any dose: results 
in death; is life-threatening; requires inpatient hospitalisation or prolongation of existing 
hospitalisation; results in persistent of significant disability /incapacity, or is a congenital 
anomaly / birth defect”53. 
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) 
The MHRA is the UK regulatory agency for medicines and medical devices.  The MHRA operate the 
UK’s spontaneous reporting scheme for adverse events, the Yellow Card scheme54. Suspected 
adverse reactions are reported to the MHRA and statistical methods are used to identify potential 
signals of harm.  The processes and methods are discussed in more detail in Chapter 4.  Once 
causality is established, and events are determined to be adverse drug reactions, the MHRA 
classifies them into different types55.   
Type A and type B reactions are the most common.  Type A reactions are related to the mechanism 
of action of the drug, and are usually (though not exclusively) an exaggeration of the normal 
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pharmacological response.  Type B reactions are unexpected reactions that could not be predicted 
from what is known about the drug. Whilst Type A reactions are likely to be identified in clinical 
trials, type B may only be discovered once the drug has been marketed55.  Three other reaction 
types are identified.  Type C reactions are related to continued use of a drug over time, for 
example, osteoporosis with extended steroid use.  Type D reactions are delayed reactions where 
the harm occurs sometime after the exposure, even if the medicine has been discontinued since.  
For example, the thalidomide effects on unborn foetuses.  Type E reactions are related to 
withdrawal of a medicine, for example withdrawal syndrome with antidepressants.  A further type 
of reaction, type F, reported by Aronson (2002) in Aronson and Ferner (2003)56 is failure of 
therapy.   
DOSE, TIME AND SUSCEPTIBILITY CLASSIFICATION SYSTEM 
The system outlined by MHRA to classifying adverse drug reactions is based upon dose response, 
and this has been criticised as simplistic and inadequate56.  Aronson and Ferner (2003)56 propose 
a three-dimensional system that also incorporates the time course and patient susceptibility, 
knows as DoTS, which stands for dose, time and susceptibility.  The dose-relatedness component 
can be classified as ‘toxic’ effects, where the reaction occurred with excessive dose, ‘collateral’ 
with standard doses, and ‘hyper-susceptibility’ with sub-therapeutic doses.  Time relatedness is 
classified as time-independent or time-dependent.  Time-dependant effects are ‘rapid reactions’ 
when the drug is delivered too rapidly, ‘early reactions’, which occur early in treatment but the 
patient develops tolerance over time, ‘intermediate reactions’, which occur after some delay, ‘late 
reactions’, which occur with increasing risk with continued treatment, and ‘delayed reactions’, 
which appear after a delay even if the treatment has already been stopped.  Sources of 
susceptibility to adverse drug reactions are classified as genetic, age, sex, physiology altered (such 
as pregnancy), exogenous factors (including drug interactions) and disease. 
The range of definitions and classifications highlights some of the difficulties in identifying harm 
outcomes for all areas of BRA.  These issues are discussed further in Chapter 4. 
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1.1.3.3. Dealing with uncertainty 
Uncertainty in the benefit and risks inputs to any model are unavoidable, particularly when 
decisions are made early in the life cycle of a drug.  As highlighted by the earlier discussion in 
section 1.1.2.3, uncertainty about input data is not an adequate reason to omit important 
variables from the model38,39.  Particularly when modelling complex decisions, speculation in input 
parameters may be necessary and this should be explicit 57.  As such, any quantitative benefit-risk 
model needs to be able to explore the uncertainties and the impact on the benefit-risk balance22.  
Many sources of uncertainty exist in modelling but the most important ones for this thesis are 
those related to input data and model structure. 
Probabilistic sensitivity methods (PSM) allow for the exploration of uncertainty around input data 
as described in section 1.1.1.4.  By sampling values for input parameters from a distribution, it is 
possible to produce estimates of the benefits and risks, with precision estimates in the form of 
confidence intervals.  An additional value of PSM is the ability to use the results to conduct a value 
of information analysis (VOI), which supports decision makers in their understanding of the value 
of delaying a decision to gather further information58.   
VOI methods expose the costs of uncertainty by quantifying the probability that the decision is 
wrong and the (cost) consequences if it is wrong57.  The expected costs that result from this 
process are known as the expected value of perfect information (EVPI) which highlights the value 
of additional information.  If the cost of conducting further research is below the EVPI, than it is 
potentially cost-effective to conduct the research to reduce the decision uncertainty57.  Further, it 
is possible to calculate the expected value of perfect parameter information (EVPPI), which can 
help to inform decisions on which parameters to research and potentially which endpoints would 
be suitable57.  The VOI method has the potential to establish how much evidence is enough for a 
regulatory or HTA decision and to inform the requirements for post-marketing research58. 
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Scenario analysis is used to address structural uncertainty in the model and future uncertainty22.  
This is especially useful for the crucial element of quantitative modelling – explicit statements of 
value judgements.  Scenario analysis allows for underlying assumptions in the model to be altered 
and the impact explored and is considered a necessary part of quality models38–40,42. 
All these methods of dealing with uncertainty are applied in the quantitative model developed in 
Chapter 5. 
1.2. Crohn’s disease 
Crohn’s disease and ulcerative colitis are the two main types of Inflammatory Bowel Disease (IBD).  
Crohn’s disease is a relapsing and remitting disease, which can cause inflammation and ulceration 
anywhere along the gastrointestinal tract and can impair the body’s ability to digest food, absorb 
nutrients and eliminate waste.  The presenting symptoms vary but tend to include diarrhoea (with 
or without blood and mucus), abdominal pain and weight loss, and potentially malaise (general 
feeling of being unwell), anorexia or fever59.   Crohn’s disease is characterised by periods of active 
disease followed by time spent in remission.  There is no known cure and the causes of the disease 
are unclear but are believed to be the result of an interplay between genetic susceptibility and 
environmental factors, and potentially linked to triggering events, such as gastroenteritis 
infections59–61.  An overactive immune response is believed to be at least partially responsible for 
the inflammation in the intestinal mucosa and is the basis of many new biological therapies (see 
section 1.3.3). 
Crohn’s disease is estimated to affect at least 115,000 people in the UK and can affect patients of 
any age62.  Crohn’s disease has a significant impact on patients’ lives, affecting their education, 
work, family and social lives due to repeat hospitalisation, repeated operations and poor 
nutrition61.  It is difficult to diagnose, associated with a range of complications and comorbidities 
and the treatments available are variable in their effectiveness and linked to risks of very serious 
adverse events. The disease is associated with high healthcare costs. Diagnostic techniques, new 
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biological treatments, hospitalisations and surgeries are all very costly, and the annual average 
cost of care per Crohn’s disease patient in the UK has been estimated as £83863.  
1.2.1. Disease course 
1.2.1.1. Disease classification 
Crohn’s disease is classified using the Montreal phenotype classification, which is advocated by 
the European Crohn’s and Colitis Organisation (ECCO) in their evidence based consensus paper59.  
The classification identifies the location and phenotype of Crohn’s disease.  A survey of adults with 
Crohn’s disease by Thia et al (2010), reported in Baumgart and Sandborn (2012)60, found Crohn’s 
disease was located in the terminal ileum in 45%, colon in 32%, ileocolon in 19% and upper GI 
tract in 4%.  The phenotype was inflammatory in 81%, structuring in 5% and penetrating 
(fistulising) in 14%.  However, whilst location tends to remain the same, severity tends to progress 
over time and 51% of patients in the survey by Thia et al (2010) had moved to a more serious 
phenotype within 20 years of diagnosis59,60. 
1.2.1.2. Disease severity 
Crohn’s disease is commonly categorised based upon clinical symptoms and response to 
treatment.  Disease activity indices such as the Crohn’s Disease Activity Index (CDAI)64, the Harvey-
Bradshaw Index (HBI)65 and the Perianal Disease Activity Index (PDAI)66 are used extensively to 
define the severity of Crohn’s disease and are discussed in detail in Chapter 2.  All three indices 
record the severity of disease at a point in time, which is considered a flawed approach by some 
given the progressive nature of the disease67. 
ECCO consensus is that there are no precise definitions for mild, moderate and severe disease, 
but clinical trials tend to define active disease as CDAI>22059.  NICE defines severe disease as very 
poor health, with one of more symptoms of weight loss, fever, severe abdominal pain and 
frequent diarrhoea, corresponding to a CDAI score above 300 or a HBI score above 862. 
37 
 
Remission is commonly measured by a CDAI score below 150, although as discussed in Chapter 2, 
there is an increasing movement towards objective measures of inflammation and patient-
reported outcomes (PROMs)59,68.  Response is defined as a change in CDAI of at least 100 points, 
although an alternative endpoint of a 70-point change is also used.  Relapse is defined as a CDAI 
score above 150 with an increase of more than 70 points59.    Relapse in clinical terms is a flare in 
symptoms following a period of remission, and ECCO recommend it should be confirmed by 
objective measures such as those discussed in section 1.2.3.1.  Recurrence is a flare of disease 
following surgical remission and is defined in both clinical terms and objectively by the recurrence 
of ulcers. 
Patients are defined as having steroid-refractory disease if they have active disease despite 4 
weeks of steroid treatment.  Steroid-dependent disease is defined where patients are unable to 
reduce steroids without recurrent active disease or who relapse within 3 months of stopping 
steroids59. 
Peyrin-Biroulet et al (2016)67 have argued that none of the available systems for characterising the 
disease course are flexible enough in terms of measuring the disease course over time, and fail to 
account for the underlying inflammatory processes and wide impact of disease on patient’s lives.  
The lack of availability of validated instruments for accurately measuring disease activity is 
discussed in the work in Chapter 2 and Chapter 3. 
1.2.2. Complications and comorbidities of Crohn’s disease 
The irreversible damage caused by inflammation within the intestine can lead to a number of 
complications of Crohn’s disease. Fistulas occur when inflammation leads to the development of 
connections between different parts of the intestine, from the intestine to other organs (for 
example, recto-vaginal) or from the intestine to outside the body (for example, to the stomach or 
the perianal area).  The fistula tracts allow faecal matter to pass through, and can have significant 
negative impact on a patient’s quality of life69.   
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Strictures are a narrowing of the intestine and result from the build-up of scar tissue due to 
repeated inflammation.  They can lead to abdominal obstruction in the intestine and carry a risk 
of perforation where severe, which can be life threatening.  Intra-abdominal abscesses may also 
occur with Crohn’s disease where the bowel is compromised and bacteria can enter.  Control of 
these complications may necessitate surgery where they don’t response to medical therapy60,61.  
As many as 80% of patients with Crohn’s disease are expected to require a surgery at some point 
in their life for strictures, fistula, perforation or failure of medical therapy62. 
Crohn’s disease may be accompanied by extra-intestinal manifestations, such as mouth ulcers 
(aphthous mouth ulcers) or skin conditions that cause painful ulcers (pyoderma gangrenosum) or 
painful lumps followed by bruising (erythema nodosum).  Joints can be affected by arthralgia and 
frank arthritis.  Complications can also affect the eyes, with inflammation resulting in episcleritis, 
scleritis and uveitis. These extra intestinal manifestations were deemed important by physicians 
and researchers in the 1970s and were therefore included in the CDAI when it was designed64.  It 
is unclear whether these complications are important to patients and clinicians today, and this is 
discussed further in Chapter 3. 
A number of other conditions are linked to Crohn’s disease including osteoporosis, which can 
result from steroid use and reduced ability to absorb minerals, and iron deficiency anaemia, which 
can result from blood loss in the digestive tract and from poor absorption of iron60–62.  Crohn’s 
disease patients face a higher risk of some cancers, which are related both to the condition and 
to the treatments, and fertility can be reduced, which is understood to be voluntary and due to 
mistaken beliefs about pregnancy outcomes61. 
1.2.3. Diagnosis and treatments for Crohn’s disease 
Diagnosis is complex because of the variability of the disease, the difficulty of distinguishing it 
from other conditions like irritable bowel syndrome (IBS) and the lack of a gold standard method.  
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Instead, diagnosis is via a combination of clinical evaluation, endoscopic, histological, radiological 
and biochemical investigations59,61. 
1.2.3.1. Diagnosis 
CLINICAL EVALUATION 
Initial diagnosis by a clinician is based upon the presentation of symptoms related to Crohn’s, 
which may be initially in the form of extra-intestinal manifestations.   
LABORATORY INVESTIGATIONS 
Laboratory tests can include C-reactive protein, erythrocyte sedimentation rate and full blood 
count, which are markers of inflammation59–61,70.  Faecal calprotectin correlates well with 
inflammation and is a useful measure, recommended by NICE, to differentiate IBD from irritable 
bowel syndrome without the need for invasive endoscopy59–61,70.  Genetic studies have been 
successful in identifying a number of loci that infer susceptibility to Crohn’s disease, however, 
none has enough sensitivity or specificity to help in diagnosis and no genetic tests are currently 
recommended59,71. 
ENDOSCOPIC AND HISTOLOGICAL INVESTIGATIONS 
Where Crohn’s disease is suspected, endoscopy with biopsies is considered the first line method 
for diagnosis in secondary care59,70.  A colonoscopy can examine the entire colon, but is considered 
a risk for bowel perforation when a patient has severe disease.  In this case it is recommended to 
use flexible sigmoidoscopy and return to colonoscopy when the clinical condition has improved59.  
Where there are no signs indicative of Crohn’s disease from colonoscopy (and radiological 
investigations) or if there is concern about the small bowel, camera endoscopy can be used59,70.  
Endoscopies are also used for monitoring purposes due to the higher risk of colorectal cancers in 
patients with Crohn’s. 
Endoscopic investigations look for particular features to identify Crohn’s including patchy 
distribution of inflammation, cobblestone appearance and rectal sparing.  However, a number of 
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characteristic features of Crohn’s disease cannot be identified with endoscopy and microscopic 
examination is required of histological samples.  A reliable diagnosis requires multiple biopsies 
throughout the colon and the identification of multiple microscopic features of Crohn’s disease59.  
Whilst mucosal biopsies can identify mucosal inflammation, they are criticised for being unable to 
represent the bowel-thickness inflammation (transmural) characteristic of Crohn’s disease72.   
A number of endoscopic and histologic scoring systems are used to help diagnose Crohn’s disease 
and assess the impact of treatment, which are discussed in Chapter 2. 
RADIOLOGICAL INVESTIGATIONS 
Radiological investigations are recommended as complementary tools to endoscopy as they can 
be used when disease is suspected to be out of reach of an endoscope, and can help to assess the 
stage and extent of disease, including complications like fistula and abscesses59. Magnetic 
resonance imaging (MRI) and computed tomography enterography (CT) are used for imaging.  CT 
is more widely available and less time-consuming, but involves exposure to radiation, which may 
be repeated many times over the lifetime of a Crohn’s disease patient; consequently, MRI is 
preferred59. Trans-abdominal ultrasonography (US) also allows for the assessment of the extent 
of the disease by assessing the increased bowel wall thickness and has the benefit of being non-
invasive, not involving radiation and being well tolerated by patients59.  Endoscopic anorectal 
ultrasound (EUS) is also recommended for diagnosis of perianal disease and is necessary to 
support surgical drainage of complicated fistula73. Barium X-rays can be used for imaging where a 
barium solution is swallowed to line the gut and give a clearer view.  However, barium X-rays 
expose patients to radiation and have low sensitivity in identifying Crohn’s disease so MRI, CT and 
US are preferred, all of which have high sensitivity and specificity59. 
1.2.3.2. Treatment 
Crohn’s disease treatment focuses on inducing and maintaining remission.  Treatment aims are to 
reduce symptoms and improve quality of life whilst minimising toxicity over the short and long 
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term.  Further, treatments aim to halt the progression of disease and minimise the damage that 
leads to intestinal failure and complications such as fistula, strictures and abscesses60.  
Patient perceptions of benefit and risk are an important point in the treatment process.  NICE 
promotes patient-centred care, where patients should be supplied with appropriate evidence-
based information so that they can make informed decisions62.  Research shows that Crohn’s 
disease patients are willing to trade-off risk against therapeutic effects, but that risk tolerance is 
not homogenous across the population7. This must be factored into decisions about treatment, 
especially the pursuit of top-down approaches using more aggressive therapies earlier, or the use 
of less established therapies.  The lack of adequate tools for measuring the course and severity of 
disease has implications for patients who may benefit from more intensive treatment but may not 
be identified as having severe disease using currently classification systems74. 
Treatments for Crohn’s disease include glucocorticosteroids, 5-aminosalicylates, antibiotics, 
immunosuppressives, biologics, nutritional therapy and surgery.  The appropriate treatment will 
be dependent upon the type of Crohn’s disease, the extent of the disease, the presence of 
complications, and the patient’s preferences for risk.  Individual therapies carry some serious risks 
such as the risk of infections in immunosuppressive therapy, including anti-TNF agents, increased 
risks of malignancy with combination immunosuppressive therapy (steroids, thiopurines and anti-
TNF agents) and infusion and anaphylactic reactions with anti-TNF agents59.  Such risks must be 
balanced against the benefits, and with consideration to the views of the patient and their clinical 
profile. 
The following sections on induction and maintenance therapy present the recommendations of 
the ECCO consensus statements for diagnosis and medical management59 and surgical 
management73 and the NICE clinical guideline for managing Crohn’s disease62.  
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INDUCTION 
Glucocorticosteroids are recommended by NICE to induce remission with those first presenting 
with Crohn’s disease, with budesonide offered as an option for those who cannot tolerate 
conventional glucocorticosteroids62.  5-aminosalicylates can be used for patients who cannot 
tolerate glucocorticosteroids treatment.  If systems persist, azathioprine or mercaptopurine 
immunomodulators can be added as second-line treatments.  Methotrexate can be used if 
azathioprine or mercaptopurine are not tolerated. 
For patients who present with severe disease (defined in section 1.2.1.2) and who have failed or 
are intolerant to the described conventional treatment, anti-TNFα agents can be prescribed.  
Adalimumab and infliximab are the options and patients start on the cheapest drug.   The ECCO 
consensus is that patients with clinical features suggesting a poor prognosis and high disease 
activity should be considered for early introduction of anti-TNF in a ‘top-down’ approach, rather 
than the standard ‘step up’, although the potential for toxicity from treatments must be 
considered59.  Two new biological therapies, vedolizumab and ustekinumab, have also been 
approved by NICE for use by patients with severe disease that has not responded to anti-TNF 
therapy75,76. 
Patients with fistulising disease may require a different treatment package which starts with 
antibiotics to treat infection, drainage (through the placement of setons, which are threads passed 
through the fistula that allow it to heal), and immunosuppressive treatments73,77.    Infliximab or 
adalimumab may be prescribed to patients with active fistulising disease if they do not respond 
to conventional treatment.  Where these treatments fail, surgical options are available dependant 
on the location and extent of the fistula.  A fistulotomy is used for an anal fistula and involves 
cutting the fistula to lay it flat and allow it to heal and is a recommended option from simple anal 
fistula73.  Surgical treatments for perianal fistula carry a risk of leaving a patient incontinent.   
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Surgical treatments in inflammatory Crohn’s disease are intended to be curative by removing the 
section of intestine that is affected.  Surgery might be considered as an alternative to medical 
treatment in early disease course for patients with disease limited to the distal ileum62,73.  Surgery 
is generally an option when patients fail all medical treatment, but carries a risk of short bowel 
syndrome where a lot of bowel is removed as absorption of nutrients and medications is 
compromised.  Surgery may involve a resection resulting in an anastomosis, where sections are 
reconnected.  Surgery may also result in a colectomy or partial colectomy, where the healthy 
remainder of the intestine is brought out as a stoma and a bag is fit.  This can be a permanent 
stoma or a temporary one to allow a section of bowel to heal. 
Simple strictures should be managed by balloon dilation, where a balloon is used to widen and 
reshape the section of intestine, guided by colonscopy62.  Surgical back up should be available 
should there be complications or the dilation fails73.  Strictureplasty is the surgical procedure that 
involves opening up, reshaping and sewing together a narrowed section. 
MAINTENANCE 
Choice of maintenance therapy depends upon the treatment that induced remission and on the 
preferences of the patient.  Where remission was achieved with glucocorticosteroids, azathioprine 
or mercaptopurine should be offered to maintain remission, with methotrexate available for those 
who are intolerant or needed methotrexate to achieve remission62. 
Infliximab or adalimumab may continue to be used to maintain remission until failure of the 
medication and the need for surgery, or until the treatment is received for one year, when it 
should be reviewed62.  The same procedures apply to maintenance therapy with ustekinumab or 
vedolizumab75,78 and they are believed to have a lower adverse event profile than anti-TNF 
agents59.  Patients with fistulising disease who achieved remission medically may maintain 
remission with a combination of thiopurines, anti-TNFs and seton drainage73. 
44 
 
For patients who achieved remission through surgery, 5-ASA treatment is recommended, with 
azathioprine or mercaptopurine recommended with patients who have had more than one 
resection or previously had complicated disease62.  ECCO also recommends anti-TNF therapy in 
patients with risk factors for recurrence73.   
Where relapses occur, patients can “step up” therapy.  Confirmed loss of response to anti-TNF 
agents should initially be managed by dose optimisation, which involves either shortening the 
interval between doses or increasing the dose.  The measurement of levels of the drug and anti-
drug antibodies in the blood are recommended to guide clinical decision making59.  Medical failure 
in patients with perianal fistulising disease may require an ostomy73. 
OTHER TREATMENTS 
Nutritional therapy involves the use of enteral food, which allows the bowel to rest.  It may be 
used following surgery to allow bowel rest, but is not recommended to maintain remission 
following surgery and is otherwise not recommended by NICE for treatment in adults62.  However, 
ECCO see a role for nutritional therapy in support of conventional therapy, and for patients who 
decline conventional therapy for induction of remission.  Further, parenteral nutrition, where 
nutrition is supplied intravenously and bypassing the gastrointestinal system entirely, is 
recommended in the case of complex fistulising disease59. 
The use of complementary and alternative methods is not considered part of conventional 
therapy. 
1.3. Benefit-risk challenges of biosimilars 
1.3.1. Biosimilars 
As patents for biological therapies expire, biosimilars, which are near identical to the originator 
products, are changing the therapeutic landscape.79  Biosimilars is the term given by the EMA to a 
biological drug that contains a version of the active substance of an authorised biological medical 
reference product (RMP).  The EMA is the leading regulator in the field and consequently many 
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regulators have adopted the term.  Both the Australian TGA80 and the US FDA81 use the term 
biosimilar.  Health Canada refers to such products as Subsequent Entry Biosimilars (SEBs) but 
acknowledges the equivalence of this term with biosimilar82.  The Japanese PMDA uses both 
biosimilar and follow-on biologics for such drugs83. 
Biosimilars are generally less expensive, or prompt a reduction in the price of the RMP while 
achieving comparable health outcomes.  Biosimilars offer the opportunity for less expensive 
treatment of chronic conditions, which allows for reduced expenditure on the therapies or the 
extension of treatment to allow more patients to benefit within the same budget.  Regulators seek 
reassurance that they will offer efficacy and safety that is not different, in terms of clinical 
significance, to the RMP79–83. 
1.3.2. Regulatory processes for biosimilars 
The EMA has been the leading regulator in the biosimilars approval process and have adopted a 
“totality of evidence” approach84 to assessing the benefit-risk balance of a biosimilar, which has 
been adopted by regulators across the world80–83.  The EMA requires that product sponsors 
conduct a comprehensive comparability exercise to demonstrate similarity in terms of quality 
characteristics, biological activity, safety and efficacy.  In practice, this requires a stepwise 
approach to conducting non-clinical and clinical studies.  Key elements of the requirements 
include: 
 The non-clinical studies should begin with physicochemical and biological characterisation 
studies before determining whether in vivo work in animal studies is required.   
 The clinical studies should begin with PK and PD studies, followed by clinical trials to 
establish safety and efficacy.   
 The clinical study population should be representative of the approved therapeutic 
indication and should be sensitive for detecting potential differences between the 
biosimilar and the reference products.  
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 The EMA allows for extrapolation to other indications as long as adequate scientific 
justification is provided, again based upon the totality of data.   
Figure 6 shows how this approach differs from the typical approach for the development of a new 
drug85.  Drug development begins with some physicochemical and biological characterisation but 
the emphasis is placed upon clinical trials, especially to establish efficacy and safety.  The emphasis 
in biosimilar development is to reverse engineer a product and then demonstrate similarity to the 
RMP85.  Regulatory agencies regard biosimilars as sufficiently similar to the originator that they 
can follow a shortened approval process33.  
Figure 6: Illustration of the differences in process development between biosimilar (B) and reference 
medical product (A)85 
 
1.3.3. Regulatory approval of infliximab biosimilars 
The first Crohn’s disease biological treatment patent to expire was for Remicade (Merck Sharp & 
Dohme Limited, Hertfordshire, UK), which is the brand name for the anti-TNF agent infliximab.  
The biosimilar developer selected rheumatoid arthritis (RA) and ankylosing spondylitis (AS) as 
sensitive populations for the clinical studies, which were used to demonstrate biosimilarity and 
justify extrapolation to Crohn’s disease.  The timeline of regulatory approvals for infliximab 
biosimilars (Inflectra, Pfizer Europe, Belgium, and Remsima, Biogen Idec Ltd, Maidenhead, UK), 
shown in Table 1, highlights the difficulties arising from the subjective nature of qualitative BRA, 
and extrapolation from evidence in other indications. 
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Table 1: Timeline of regulatory decisions for infliximab biosimilars 
Date Detail 
June 2013 CHMP gave approval for Inflectra as a biosimilar for infliximab in all indications.  
Small differences in quality data, related to antibody-dependent cellular 
cytotoxicity (ADCC) were not determined to be clinically meaningful86. 
January 2014 Health Canada approves Inflectra as a biosimilar for limited indications.  
Extrapolation to Crohn’s disease and ulcerative colitis is not recommended due 
to differences that could potentially impact on clinical safety and efficacy in 
these indications87. 
July 2014 PMDA (Japan) approval given for Inflectra to be considered an infliximab 
biosimilar for all indications88. 
May 2015 FDA refuse approval of Inflectra as an infliximab biosimilar because of 
uncertainty in the observed differences in ADCC and what clinical impact it may 
have.  This is especially important to IBD due to the potential mechanism of 
action of ADCC in IBD89.  
July 2015 TGA (Australia) approves the listing of Inflectra as a biosimilar infliximab for all 
indications90. 
August 2015 Health Canada determine a favourable benefit risk assessment for Inflectra in 
Crohn’s disease and ulcerative colitis based upon newly submitted 
physiochemical and biological data and observational clinical safety data for IBD 
patients.  The issues related to ADCC are mitigated by sponsor provided 
rationales addressing the potential mechanisms of action and their relationships 
to clinical outcomes91. 
April 2016 CHMP approve Flixabi as a biosimilar for infliximab for all indications. Small 
differences are detected in quality attributes that are determined not to 
translate to clinical meaningful differences.  A divergent position statement is 
provided due to concerns over safety and efficacy differences92. 
May 2016 The FDA approve Inflectra for all indications following submission of sponsor 
data from ongoing open-label marketing studies and registries and interim 
immunogenicity data from an ongoing, randomised controlled study in patients 
with Crohn’s disease93.  
 
STRAIGHTFORWARD APPROVALS 
Some regulators have offered complete approval with extrapolation to all indications without any 
concerns, despite noting differences between the biosimilar and reference product in terms of 
quality data.  The first such approval for an infliximab biosimilar was granted in the European 
Union in June 2013 when the CHMP approved Inflectra for all indications.  Some differences were 
noted in the data provided, especially with regard to antibody-dependent cellular cytotoxicity 
(ADCC) and the number of adverse events reported, but the CHMP decided that the differences 
were not clinically meaningful.  On balance, they determined that the benefit risk balance, based 
on qualitative assessment, was positive for all indications but would monitor long-term efficacy 
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and safety data from post-authorisation studies and registries, including IBD86.  Japan’s PMDA 
followed with full approval in all indications in July 201488 and the Australian TGA in July 201590.  
COMPLICATED REGULATORY DECISIONS 
Other regulatory decisions have not been so straightforward.  Health Canada approved Inflectra 
as a biosimilar in January 2014 but refused indication extrapolation to IBD as they felt the 
differences in the data could have an impact on safety and efficacy in these indications87.  A more 
favourable decision was given in July 2015 after consideration of new evidence supplied by the 
sponsor91. This new evidence included additional physicochemical and biological data and 
rationales addressing the various potential mechanisms of action and their relationship to IBD.  
On this basis, Health Canada approved the extrapolation of indications to IBD. 
The US FDA refused the application for Inflectra to be an infliximab biosimilar on the basis of 
differences in ADCC in May 201589.  The clinical reviewer interpreted that the differences not only 
meant that it would not be possible to extrapolate due to the potential role of ADCC as a 
mechanism of action in Crohn’s disease, but that they also meant that the drug could not be 
considered biosimilar.  The sponsor submitted additional data from ongoing post-marketing 
studies and registries and interim safety data from a trial in patients with Crohn’s disease and full 
approval with extrapolation was given in May 201693. 
The CHMP approved Flixabi  as a biosimilar for infliximab in April 201692.  However, not all 
members of the committee agreed with the majority decision and a divergent position statement 
was issued.  Some members felt that approval should not be given for the following reasons: 
- A higher number of adverse events reported for the biosimilar than the reference; 
- Lower efficacy in the RA trial for the biosimilar than the reference (although within the 
pre-specified equivalency margins). 
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- The use of immunosuppressives in the RA trial could have reduced the level of 
immunogenicity in these patients.  The consequence on adverse events and efficacy in 
other indications is not understood. 
1.3.3.1. Uncertainties 
The approach of all the regulators has been one based on the “totality of evidence” to determine 
the benefit-risk balance.  This is a subjective process and there remain numerous uncertainties.  
Many regulators identified differences in quality data related to ADCC but the interpretation has 
differed with some suggesting it could not be ruled out as a plausible mechanism of action in 
Crohn’s disease and therefore indication extrapolation could not be approved.  Many of these 
decisions were later reversed but there remains uncertainty, as highlighted by the divergent 
position statement offered by the CHMP for Flixabi.   
The main concern with biosimilars is the potential for developing anti-drug antibodies, something 
that the trials in RA are not able to rule out for Crohn’s disease due to the dampening effect of the 
concomitant use of methotrexate and AS trials cannot rule out as patients with the condition 
historically have lower risk of anti-drug antibodies than CD patients94.  The consequences of 
developing anti-drug antibodies are: 
- Alterations in the drug pharmacokinetics and bioavailability; 
- Reductions in drug efficacy; 
- Cross reaction with endogenous proteins and inhibition of the latter’s physiological 
behaviour; 
- Allergic drug reactions, such as infusion reactions. 
Further uncertainty arises as immunogenicity results depend upon many factors including the 
time point of sampling, the technical protocols adhered to in taking and storing the samples, the 
treatment dosing and schedule and the different assays used95. 
50 
 
Uncertainty can also be introduced with regards to the use of non-inferiority trials and the choice 
of non-inferiority margin, which is pre-specified in comparative trials for biosimilars96,97.  
Traditional RCTs compare a new treatment against an existing one and aim to demonstrate 
superiority of the treatment, which is achieved with a point estimate for the difference in efficacy, 
supported by a 95% confidence interval to demonstrate statistical significance.  A non-inferiority 
trial, however, is hoping to demonstrate that the new product is not worse than the existing 
product, with differences in efficacy allowed within a pre-specified margin, subject to an 
assessment of statistical significance through a 95% confidence interval97.  Non-inferiority trials 
are used for biosimilars because the interventions are assumed equally efficacious.  In the RA trial 
used to demonstrate non-inferiority for Inflectra, the non-inferiority margin is set to ±15%.  
Consequently, Inflectra can be deemed non-inferior with marginally lower efficacy evidenced in 
RA.  In the context of BRA, where the focus is on incremental benefits and risks, a marginal 
difference may be significant.  However, such uncertainties appear to be accepted in exchange for 
the cost-saving opportunities. 
1.3.3.2. Uncertainties in decision modelling 
The goal in decision modelling is to extend statistical analysis to include the effects of uncertainty 
and value judgements on the overall BRA of drugs22.  Usually, decision modelling input uncertainty 
is primarily on harms.  Efficacy of a treatment is reasonably certain where clinical trials are 
conducted as studies are powered to detect this with accuracy.  However, in biosimilars, even the 
efficacy is uncertain, greatly adding to overall uncertainty in benefit-risk.  The assumption of 
equivalent efficacy leads to the approval of biosimilars by the UK NHS on the basis of cost-
minimisation34.  However, certainty of equivalent efficacy requires head to head trials, which are 
rarely available for biosimilars33.  It is therefore unclear whether cost-minimisation analysis is 
appropriate and whether the price reduction compensates enough for the increased uncertainty 
faced by the HTA agency.  Due to the level of uncertainty, a modelling method is required with 
sensitivity analyses and scenario analyses to test the impact of the uncertainties on the decision 
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of the HTA.  Indeed, this approach has been previously suggested by Stewart et al (2010)33 who 
propose that HTA should use a model of cost-utility analysis, which makes use of efficacy, utility 
and cost data based on the originator drug and use threshold analysis of treatment efficacy to 
determine the point at which the willingness to pay threshold is exceeded. 
1.4. Thesis objective and structure 
BRA is a necessary process for summarising the effectiveness and safety profile of an intervention, 
to provide evidence that can be used by decision makers in a range of settings.  Understanding 
and quantifying the harms from treatments is especially problematic, particularly those related to 
long-term treatment.  As an example, in the field of Crohn’s disease research, the motivating 
example of this thesis, outcome measurement tools have been developed over the years but are 
no longer considered valid, and there is a current shift away from clinical-composite outcome 
measures towards objective measures of inflammation alongside patient reported outcome 
measures.  There is a need to understand what is being measured, what should be measured (and 
how) and how else we can capture the scale of benefits and harms to provide evidence to facilitate 
decision-making.  Further uncertainty is present in decision-making related to biosimilars, 
stemming from the use of extrapolated evidence assessed in qualitative benefit-risk frameworks.  
This thesis aims to investigate methods for assessing the benefit-risk balance of therapies, 
including identifying sources of harms data and developing a quantitative framework for assessing 
whether the cost savings of biosimilars justify the increased uncertainties regarding efficacy and 
safety.  
Chapter 2 reports the pattern of endpoints and adverse events measured in randomised 
controlled trials (RCTs) of treatments to induce or maintain remission in adults with Crohn’s 
disease.  The results highlight the reliance upon outcome measurement tools that are now 
considered invalid for measuring disease status.  There is a need for a core outcome set for Crohn’s 
disease to standardise outcomes measurement, including harms, and reporting to ensure that 
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good quality data are available on benefits and risks of treatments.  The trial endpoints were 
disaggregated into individual signs, symptoms and events and categorised into a framework in 
Chapter 3.  In the absence of a core outcome set for Crohn’s disease, the results were compared 
against a core set for IBD and the dominant outcome measurement tools used in Crohn’s disease 
trials to highlight the gaps in measurement and provide a starting point for the development of a 
new outcome measurement tool. 
Chapter 4 proposes a method to identify and quantify harms to attempt to fully characterise the 
safety profile of drugs, making use of the SPC documents that result from the regulatory process.  
Chapter 5 uses some of the methods discussed here to develop a decision-analytic model to help 
regulators involved in HTA to quantify what price reduction is necessary to trade off for the 
increased uncertainty involved in biosimilar infliximab. 
The final chapter, Chapter 6, summarises the findings of the previous chapters, reflects upon the 
implications for both clinical practice and research, and suggests areas for future research. 
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Chapter 2: A systematic review of outcomes and adverse events in 
randomised controlled trials in Crohn’s disease 
2.1. Introduction 
Defining the key outcomes of therapeutic interventions and the best way to measure those 
outcomes is essential for clinical and regulatory decision-making.  Due to the complexity of 
Crohn’s disease and the multitude of treatment choices, many different measurements of 
outcomes have historically been reported in clinical trials, for example response (outcome), might 
be measured with the Crohn’s Disease Activity Index (outcome measurement tool) as a 70 point 
score reduction (outcome measurement).  The Crohn’s literature is characterised by an array of 
instruments such as disease activity indices and quality of life questionnaires used by researchers 
to measure the variety of different outcomes98,99. Clinical and regulatory decision making also 
relies on the availability of good information on the unintended effects, or harms, from 
treatments, which are reported as adverse events and study withdrawals in clinical trials.  
Accurate reporting of the outcomes from treatment enables the synthesis of data to establish 
more certain estimates of the effect of treatment and identify potential harms.  This supports the 
assessment of the benefit-risk balance at the clinical level as well as at the regulator level and for 
the NHS. 
Diversity in reported outcomes and measurement instruments may hinder the comparison of 
results within systematic reviews, due to heterogeneity in outcome measurement, but may also 
inhibit the meaningful interpretation of individual studies48.   One way to mitigate the problems is 
the introduction of an agreed minimum set of standardised outcomes, to be measured and 
reported in all trials for a particular disease or condition, referred to as a core outcome set 
(COS)48,49.  There is no COS for Crohn’s disease, although a model has been proposed for classifying 
outcomes for inflammatory bowel disease (IBD) using the World Health Organisation (WHO) 
International Classification of Functioning, Disability and Health (ICF).  The result is the ICF 
comprehensive core set for IBD and a brief core set for IBD, the latter known as the IBD disability 
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index.100 In 2017, the International Consortium for Health Outcomes Measurement (ICHOM) 
developed a ‘Standard Set’ for IBD with recommendations for measuring outcomes in routine care 
to support benchmarking101. Also recently published are a study protocol for the development of 
a COS for IBD102 and a COS for fistulising Crohn’s disease103, indicating the importance of this 
research area.  Future trial design and COS development for Crohn’s disease would benefit from 
a systematic synthesis of outcome reporting across published clinical trials.  
In this chapter, the literature was systematically reviewed to extract data on the outcomes and 
measurement instruments used (trial endpoints), and the adverse events and study withdrawals 
reported, in randomised clinical trials (RCTs) of treatments for Crohn’s disease (CD).  The aims 
were to explore the extent of heterogeneity among existing trials, to examine time trends in 
reporting and to generate insights to support future trial design and COS development.  The 
results are supported by recently published literature in this research area103,104. 
2.2. Methods 
2.2.1. Protocol and registration 
A protocol with defined aims, objectives and methods was developed for the review.  The 
systematic review was registered with the International Prospective Register of Systematic 
Reviews (PROSPERO) database (CRD42016027656 http://www.crd.york.ac.uk/PROSPERO) and 
with the Core Outcome Measures in Effectiveness Trials (COMET) database (http://www.comet-
initiative.org/studies/details/867).  The protocol for the systematic review is in Appendix 2. 
2.2.2. Information sources 
A systematic electronic search was used to retrieve all RCTs conducted in an adult population 
using any treatments for Crohn’s disease to 3rd November 2015. No date limits were placed on the 
searches.  The following electronic databases were searched: Cochrane Register of Controlled 
Trials (CENTRAL), EMBASE, MEDLINE, and the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL).  It was possible to restrict the searches to adult only studies in all databases 
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except CENTRAL. The disease term ’Crohn’s disease’ and the key word ‘outcome’ was used.  The 
detailed search strategies used for all databases are provided in Appendix 3. 
2.2.3. Inclusion and exclusion criteria 
The eligibility criteria were designed to maximise the data captured by the review.  As discussed 
in Section 1.2.3.2, treatment options for patients with Crohn’s are varied and patients tend to 
move through numerous treatment types during the course of their disease, often receiving a 
combination of treatments at any period in time.  Ultimately, all interventions that aim to achieve 
remission, maintain remission or treat complications were included.   
2.2.3.1. Inclusion criteria 
 Adults (aged 18 years and over).  
 Due to the overlap in outcomes with other inflammatory bowel diseases (IBD), the scope 
of the review included IBD, as long as outcomes were specified for Crohn’s.   
 Interventions including drug therapies (corticosteroids, 5-ASAs, immunosuppressants, 
biologics and antibiotics), surgery and non-drug therapies (enteral nutrition, 
complementary and alternative medicine (CAM), probiotics and prebiotics) and 
treatments for complications of Crohn’s disease (strictures, fissures, abscesses and 
perforations). Innovative interventions such as granulocyte or monocyte apheresis were 
also included. 
 All comparator interventions, such as placebo, alternative dose or standard treatment.   
 All years of publication.   
 Randomised controlled trials. 
 English language. 
 Full text available. 
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2.2.3.2. Exclusion criteria 
 Patients aged less than 18 years.  Children with Crohn’s disease face a range of 
outcomes that are not relevant to adults (related to growth, for example), which leads to 
differences between the two groups in the outcomes that are considered 
important105,106. 
 Other specific forms of IBD, including ulcerative colitis, other forms of colitis such as 
microscopic, ischaemic, collagenous and lymphocytic, and other forms of bowel disease, 
such as diverticulitis, irritable bowel syndrome, colon cancer and intestinal. 
 Treatments for common sequelae and comorbidities (commonly iron-deficiency 
anaemia, osteoporosis, vitamin B12 or folate deficiency anaemia, erythema nodosum, 
pyoderma gangrenosum, inflammation of the eyes, blood clots, primary sclerosing 
cholangitis and ankylosing spondylitis). Some methods used for therapy, such as 
endoscopy, when used only for diagnosis.  Pre-surgery interventions, such as bowel 
preparation.   
 Foreign language studies. 
 Abstract only studies.   
 Systematic reviews, non-randomised controlled trials, case series and case studies, 
letters, editorials, commentaries. 
2.2.4. Study selection 
The records retrieved from the search were exported to Microsoft Excel and combined.  Duplicates 
were removed after a complete list of studies was identified from the searches.  Two reviewers 
(HC and JJK) independently assessed a random sample of 100 studies resulting from the search 
against the screening criteria in the title screening and abstract screening stages.  Discrepancies 
were resolved by discussion.  Following good inter-rater reliability, HC screened the remaining 
papers independently with reference to JJK when uncertain of eligibility.  Full copies were 
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obtained of all potentially eligible studies and reassessed independently by the primary 
researcher. Reference was made to JJK where needed. 
A critique of the methodological quality of the studies was unnecessary, as this project did not 
involve synthesis of outcome data. 
2.2.5. Data Collection process 
A pilot data extraction template was developed and tested.  JJK reviewed the template and offered 
feedback, which led to modifications such as the inclusion of the country of the study (or the lead 
author when the study was multi-centred).  Data were extracted from the eligible studies with an 
initial sample of ten checked by JJK.  Regular reporting to the PhD supervision team provided a 
check that all outcomes had been identified. 
2.2.6. Demographic data items 
The following demographic information was collected from each study: 
1. Author(s). 
2. Year and journal of publication. 
3. Country of study / lead author. 
4. Sample size. 
5. Disease behaviour in study population. 
6. Duration of follow up. 
7. Intervention(s) under investigation. 
8. Comparator intervention(s). 
Trials were categorised as induction (of remission) where participants had active disease or 
maintenance (of remission) where patients were in remission.  Some studies had patients with 
active disease entering but the study aimed to achieve remission and then maintain it, so followed 
up only those patients who achieved remission. Trials were sub-categorised as ‘medical induction’ 
when patients received medical therapies and had active disease; ‘surgical induction’ when 
58 
 
patients had active disease and received surgical therapy; ‘maintenance of medically-induced 
remission’ where patients received interventions to maintain remission achieved through medical 
interventions; and ‘maintenance of surgically-induced remission’ where patients received 
interventions to maintain remission achieved through surgery.  Studies were flagged if they were 
of interventions to treat solely patients with fistulising disease to identify any differences in 
outcomes reporting. 
The drug name and dosage instructions of the intervention under investigation was recorded and 
the interventions grouped into the main intervention types for Crohn’s disease: 
 5-ASAs or aminosalicylates to treat inflammation such as mesalazine and sulphasalazine. 
 Antibiotics to treat infections such as metronidazole, ciprofloxacin and clarithromycin. 
 Biologics to treat inflammation such as infliximab, adalimumab, certolizumab pegol and 
natalizumab. 
 Corticosteroids to treat inflammation such as prednisolone, hydrocortisone and 
budesonide. 
 Dietary treatments provide all required nutrition whilst allowing the bowel to rest.  They 
are either liquid foods such as polymeric and elemental diets or parenteral diets, which 
are delivered intravenously.  Interventions of this type can also be diets to reduce 
symptoms such as low micro particle diets, whole-wheat diets or low residue diets.  
Finally, they may also be interventions that involve dietary supplements such as omega 3 
fish oils, oral glutamine and lactulose syrup. 
 Immunosuppressives to treat inflammation such as azathioprine, mercaptopurine, 
methotrexate and cyclosporine. 
 Surgery to remove severely inflamed sections of bowel or repair strictures or fistula. 
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 Complementary and alternative medicines (CAM) such as prebiotics and probiotics, 
acupuncture, cannabis, exercise, relaxation therapy, osteopathy, trichuris suis ova and 
plant extracts. 
Other interventions were used which are not part of the standard therapies for Crohn’s disease.  
Examples include novel treatments in the earliest stages of research, such as blood apheresis to 
remove cells involved in inflammation and spherical carbon adsorbent, which absorbs toxins that 
may be involved in inflammation so that they can be excreted through faeces.  These were 
grouped together as ‘other interventions’.  Where trials examined combination therapies, they 
were classified as ‘combination interventions’. 
2.2.7. Outcomes data items 
The following data on trial endpoints was extracted from each trial report: 
1. The designation of the endpoint as primary, secondary or not specified. 
2. The outcome. 
3. The outcome measurement tool. 
4. The outcome measurement. 
The  outcomes were categorised as follows106–108: 
 Biomarker and serologic outcomes, which are measurable characteristics indicating 
disease process. For Crohn’s disease, this could include a blood test or faecal sample 
such as C-reactive protein or faecal calprotectin, which are indicators of intestinal 
inflammation. 
 Clinical or composite-clinical outcomes, such as clinician assessment of symptoms or 
weight measurement or disease activity indices. 
 Economic outcomes, including the cost of interventions and associated utility values. 
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 Endoscopic outcomes, which were measurements resulting from endoscopies and 
included scores and the presence or absence of ulcers in the intestine. 
 Histologic outcomes, which were measurements based upon tissue samples taken from 
the intestine, frequently reported as scores. 
 Patient reported outcomes (PROs), such as daily diary reporting of symptoms such as 
diarrhoea, blood in the stool or abdominal pain and quality of life questionnaires.  
 Safety-related outcomes, which were pre-specified as trial endpoints in the methods 
sections of the paper. 
2.2.8. Adverse event data items 
Data were taken from tables reporting adverse events and the descriptive text, where present in 
the reports.  Some papers reported the occurrence, or not, of pre-specified serious adverse events 
such as deaths.  These were recorded as an adverse event report event if no events were observed 
in the study. 
Adverse event reporting was recorded in specific categories: adverse events (AEs), serious AEs, 
treatment-related AEs, treatment-related serious AEs, study withdrawal, abnormal laboratory 
results and AEs by preferred term according to the Medical Dictionary for Regulatory Activities 
(MedDRA)109. 
The adverse events were recorded verbatim and standardised using the Medical Dictionary for 
Regulatory Activities (MedDRA) terminology web-based browser.110 MedDRA is an international 
medical terminology developed for biopharmaceutical regulatory purposes.  It is structured in a 
hierarchy with five levels: 
1. Lowest level terms (LLTs) are the lowest level and allow for the capture of different 
terms for the same medical concept, including abbreviations, different word order 
and slight variants. 
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2. Preferred terms (PTs) are a single medical concept for a symptom, sign, disease, 
diagnosis, therapeutic indication, investigation or medical or surgical procedure.  
Many LLTs can link to a PT. 
3. High-level terms (HLTs) are a grouping level for PTs.  They link together PTs that are 
related by anatomy, pathology, physiology, aetiology or function, 
4. High-level group terms (HLGTs) group together HLTs that are related by anatomy, 
pathology, physiology, aetiology or function. 
5. System organ class (SOC) is the highest level and gives the broadest concept.  SOCs 
may be based upon aetiology (e.g. infections and infestations), manifestation site 
(e.g. gastrointestinal disorders) or purpose (e.g. surgical and medical procedures).  
PTs can be linked to more than one SOC but will only have one primary SOC. 
Each level of the MedDRA hierarchy was recorded for every adverse event.  Where a difference 
was noted between the SOC reported in the paper and that recorded as the primary SOC in 
MedDRA, the primary SOC was recorded. 
2.2.9. Study withdrawals 
Data were extracted on reports of participants who discontinued treatment.  Study withdrawals 
were categorized as due to AEs, serious AEs, treatment-related AEs, treatment-related serious 
AEs, treatment failure (insufficient therapeutic effect, exacerbation of CD, development of 
complications or need for additional therapy, surgery or hospitalisation) or other reasons 
(protocol non-compliance, lost to follow-up, prohibited medicine use or withdrawal of consent). 
2.2.10. Data presentation 
A comprehensive record of efficacy and safety-related outcomes was generated and organised by 
outcome category as described in section 2.2.7.  The main analysis of the efficacy outcomes 
focused on those designated as primary and secondary end-points in the papers.  A similar 
approach was adopted for safety-related outcomes, which were specified as primary and 
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secondary endpoints.  All reported data for AEs and study withdrawals were analysed.  AE 
reporting was considered at two levels of the MedDRA hierarchy: SOC and HLGT, the latter of 
which is considered a clinically relevant grouping of MedDRA preferred terms109. 
A secondary analysis considered the reporting of outcomes that were not specified as primary or 
secondary end-points.  To mirror the increased focus on the importance of objective measures of 
inflammation and mucosal healing111, the numbers of studies reporting any additional endoscopic 
or histologic outcomes or the faecal calprotectin biomarker was assessed. 
The proportion of studies reporting each category of outcome (section 2.2.7) was calculated, by 
trial category as described in section 2.2.6.  The results were stratified a priori into pre-2009 and 
2009 onwards, to capture differences in the most recent trials.  The changes over time in reporting 
was summarised in matrix form with outcome categories listed in rows and frequency of outcome 
reporting plotted in greyscale on a time axis108.   
The review was reported in line with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement and harms checklist112,113. 
2.3. Results 
2.3.1. Study selection 
The database searches yielded 9,561 records after duplicates were removed.  Title screening 
excluded 4,585 records and abstract screening excluded a further 4,755.  The results of the initial 
double screening were comparable, which allowed for the rest of the sample to be screened 
independently.  The large number of exclusions is indicative of the broad nature of the search, 
which identified numerous records related to Crohn’s disease and outcomes, but not to 
treatments for Crohn’s disease.  The full text reports were obtained for 211 records.  Thirty of 
these were excluded upon full review due to the reasons indicated in Figure 7.  The review 
considered the 181 records that met the criteria for inclusion. 
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Figure 7: PRISMA flow diagram 
 
2.3.2. Study demographics 
The review included 181 studies and a summary of their characteristics is shown in Table 2 (full 
list in Appendix table 6).  Induction of remission was the focus of 110 studies: 104 (94.5%) through 
medical approaches114,115,124,214–217,125–133,116,134–143,117,144–153,118,154–163,119,164–173,120,174–183,121,184–
193,122,194–203,123,204–213 and 6 (5.5%) through surgical approaches218–223.  Nine (of 110, 8.2%) induction 
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studies solely treated patients with fistula with medical 135,163,178,185,190,209,212 or surgical 218,219 
therapies.   
Maintenance of remission was the focus of 71 studies: 52 (73.2%) sought to maintain remission 
achieved through medical therapies224,225,234–243,226,244–253,227,254–263,228,264–273,229,274,275,230–233 and 19 
(26.8%) aimed to maintain surgically-induced remission 276,277,286–294,278–285.  One study aimed to 
maintain medically induced remission in patients with fistulising disease245. 
Table 2: Characteristics of Randomised-Controlled Trials in Crohn's Disease 
 
Induction 
(n=110) 
Maintenance 
(n=71) 
Total 
(n=181) 
Trial participants 13,153  10,697  23,850 
Trial participants (median (IQR) 77 (36-169) 89 (56-167) 83 (40-168) 
Trial year publication 
  
 
1979-2008 78 (70.1%) 47 (66.2%) 125 (69.1%) 
2009-2015 32 (29.1%) 24 (33.8%) 56 (30.9%) 
Country of lead author    
UK and Europe 61 (55.5%) 40 (56.3%) 101 (55.8%) 
USA and Canada 39 (35.5%) 24 (33.8%) 63 (34.8%) 
Rest of world 10 (9.1%) 7 (9.9%) 17 (9.4%) 
Subgroup 
  
 
Medically induced 104 (94.5%) 52 (73.2%) 156 (86.2%) 
Fistula 7 (6.4%) 1 (1.4%)  
Surgically induced 6 (5.5%) 19 (26.8%) 25 (13.8%) 
Fistula 2 (1.8%) 0  
Intervention of interest    
5-ASAs 3 (2.7%) 8 (11.3%) 11 (6.1%) 
Antibiotics 8 (7.3%) 3 (4.2%) 11 (6.1%) 
Biologics 40 (36.4%) 15 (21.1%) 55 (30.4%) 
Corticosteroids 9 (8.2%) 9 (12.7%) 18 (9.9%) 
Immunosuppressants 7 (6.4%) 7 (9.9%) 14 (7.7%) 
Surgery 6 (5.5%) 0 6 (3.3%) 
Dietary 16 (14.5%) 5 (7.0%) 21 (11.6%) 
CAM, prebiotics/probiotics 8 (7.3%) 15 (21.1%) 23 (12.7%) 
Combination interventions 6 (5.5%) 8 (11.3%) 14 (7.7%) 
Other 7 (6.4%) 1 (1.4%) 8 (4.4%) 
Comparator intervention    
Placebo 66 (60.0%) 45 (63.4%) 111 (61.3%) 
Active 44 (40.0%) 26 (36.6%) 70 (38.7%) 
Follow up weeks (median (IQR)) 16 (8.0-25.1) 52.0 (48.0-60.0) 25.1 (12.0-52.0) 
Note: 5-ASAs – aminosalicylates; CAM – complementary and alternative medicine; IQR – interquartile 
range 
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2.3.2.1. Year of publication 
The earliest study included in the review was from 1979.  Over 30% of studies were published 
after 2009 (56 of 181, 30.9%). 
2.3.2.2. Country of research and journal of publication 
Examination of the studies by the country of the research (or lead author in multi-centre studies), 
highlights a geographical concentration.  90.6% (164 of 181) of all studies either took place or had 
a lead author residing in Europe or North America.  The vast majority, 74.6% (135/181), of the 
studies were either conducted in, or led from, one of six countries: the USA (45/181, 24.9%), 
Germany (24/182, 13.2%), the UK (22/181, 12.2%), Canada (18/181, 9.9%), Italy (15/181, 8.3%) 
and France (11/181, 6.1%).    
Similarly, there is a concentration by journal of publication as 47.0% (85/181) of the included 
studies are published in one of three journals: Gastroenterology, Gut and Alimentary 
Pharmacology & Therapeutics.  The remaining 53% of articles (96/181) are published in 36 
journals. 
2.3.2.3. Sample size and trial length 
In total, 23,850 patients were involved in the studies, with median sample size of 77 (IQR: 36-169) 
in induction studies and 89 (IQR: 40-168) in maintenance studies.  Follow up was a median 16 
weeks (IQR: 8.0 - 25.1) in induction studies and 52 weeks (IQR: 48.0-60.0) in maintenance studies. 
2.3.2.4. Intervention of interest and comparator 
Over 90% of the studies considered a single therapy (167/181, 92.3%).  Biologics were the 
intervention of interest in 33.7% studies (61 of 181), either as monotherapy or part of a 
combination therapy, demonstrating the level of research interest in this particular treatment.  
Induction trials were also common for dietary interventions (16/110, 14.5%) and corticosteroids 
(9/110, 8.2%).  Maintenance trials were common for CAM therapies including prebiotics and 
probiotics (15/71, 21.1%) and corticosteroids 9/71 (12.7%). 
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Placebo treatments were the comparator in the majority of trials (111/181, 61.3%).  Just over a 
third of studies (70/181, 38.7%) used an active comparator treatment.  Active treatments include 
the use of standard medication, alternative therapies, alternative doses of the treatment of 
interest or tapering or withdrawal of a particular treatment.  EMA guidance for Crohn’s disease 
recommends that active treatments should be used for trials supporting a first line indication and 
placebo should be used as an add-on comparator for add-on treatments68.  This indicates that the 
majority of trials identified are for add-on treatments rather than first line. 
2.3.3. Outcomes 
Outcomes data were extracted from the 181 included studies.  A median of nine outcomes were 
reported per paper (IQR: 6-11).  Almost all the studies (174/181, 96.1%) reported primary or 
secondary outcomes, only seven studies (3.9%) did not specify either primary or secondary 
outcomes.  95.6% (173/181) of studies reported primary outcomes, with a median of one primary 
outcome per paper (IQR: 1-2).   Three quarters (136/181, 75.1%) of studies reported secondary 
outcomes with a median of three outcomes reported per paper (IQR: 1-5). The reporting of 
outcomes not specified as primary or secondary endpoints was common (158/181, 87.3%) and 
was consistent across the time periods.  A median of three outcomes per paper were reported 
that were not specified as primary or secondary endpoints (IQR: 2-6).   
Table 3 shows a summary of the primary and secondary outcomes reported in CD RCTs by category 
and highlights the wide range of outcomes and outcome measures.  The full detail of reported 
primary and secondary outcomes by outcome categories type are provided in Appendix table 7 to 
Appendix table 12.  
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Table 3: Primary and Secondary Efficacy Outcomes and Measurement Tools in Crohn's Disease 
Randomised Controlled Trials 
Outcome 
category 
Primary or Secondary 
Outcomes 
Other 
Outcomes 
Measurement Tools 
Clinical or 
composite-
clinical 
outcomes 
Clinical response 
Clinical remission 
Disease relapse or worsening 
Fistula remission / response 
Corticosteroid-free remission / 
response 
Recurrence 
Corticosteroid-sparing 
Sustained remission / response 
Change in individual sub score 
components 
Combined clinical and 
endoscopic remission / 
recurrence 
Post-operative recovery 
Sustained corticosteroid-free 
remission 
Sustained fistula remission 
Complete response 
Treatment compliance 
Treatment 
acceptability 
Crohn’s Disease Activity Index 
Harvey Bradshaw Index 
Perianal Disease Activity Index 
Physician Global Assessment 
Van Hees Activity Index 
European Co-operative Crohn’s 
Disease Study based ranking system 
Severity and Activity Index 
Clinical recurrence grading scale 
Dutch Index 
International Organisation of 
Inflammatory Bowel Disease (IOIBD) 
score 
Partial Harvey Bradshaw Index 
Present Score 
 
Endoscopic 
outcomes 
Endoscopic recurrence 
Endoscopic response 
Endoscopic mucosal healing 
Endoscopic remission 
 Rutgeerts endoscopic score 
Crohn’s Disease Endoscopic Index of 
Severity 
Simple Endoscopic Score for Severity 
D’Haen’s endoscopic categories 
Marteau endoscopic score 
Radiological grading scale 
Histologic 
outcomes 
Histologic recurrence 
Tissue cytokine, leukocyte, 
receptor or gene expression 
Histologic response 
Histologic remission 
Tissue bacteria 
concentrations 
Average Histology Score 
D’Haens-Geboes score 
Dieleman histological score 
Histological Activity Score 
Regueiro histology score 
Biomarker 
and 
serologic 
outcomes 
Serum C-reactive protein 
Serum erythrocyte 
sedimentation rate 
Serum full blood count and 
subsets 
Antidrug antibodies 
Drug concentration and 
pharmacokinetics 
Serum cortisol level 
Serum protein concentrations 
Intestinal permeability 
Serum albumin 
Autoantibodies 
Faecal calprotectin 
Serum lymphocyte count and 
subset expression 
Serum cytokine or 
immunoglobulin levels 
Body mass 
Faecal bacteria 
concentrations 
Serum fatty 
acids 
Treatment 
compliance 
 
Economic 
outcomes 
Cost of treatment 
Utility 
 Quality-Adjusted Life Years 
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Outcome 
category 
Primary or Secondary 
Outcomes 
Other 
Outcomes 
Measurement Tools 
Patient-
reported 
outcomes 
Quality of life 
Pain 
Defecation functions 
Bowel symptoms 
Treatment compliance 
Treatment acceptability 
 
 
 IBDQ 
SF-36 (and component sub scores) 
Patient Global Assessment 
Visual analogue scale 
Gastrointestinal Quality of Life Index 
Hamilton Depression Scale 
Short IBDQ 
Adapted Vaizey Faecal Incontinence 
Score 
Assessment of Quality of Life 
Questionnaire 
Beck’s Depression Inventory 
Fatigue Impact Scale 
Hospital Anxiety and Depression 
Scale 
IBD Quality of Life Scale 
IBS Severity Scoring System 
IBD Self-Efficacy Scale 
IBD Stress Index 
Medical Adherence Scale 
Perceived Stress Questionnaire – 
Recent 
Psychiatric and Socio-communicative 
finding standardised clinical 
interview 
Quality of Life instrument 
SF-12 
Short Health Scale 
State Trait Anxiety Inventory 
instrument 
 
Safety-
related 
outcomes 
Adverse events 
Abnormal laboratory or ECG 
parameters 
Complications of surgery 
Death 
Adverse events 
Treatment 
related 
adverse events 
Serious 
adverse events 
Treatment 
related serious 
adverse events 
Study 
withdrawal 
due to AEs, 
treatment 
failure and 
other reasons. 
Medical Dictionary for Regulatory 
Activities 
Coding Symbols for a Thesaurus of 
Adverse Reactions Terms 
WHO Toxicity Grading Criteria 
Note: AEs, adverse events; IBDQ, inflammatory bowel disease questionnaire; SF-36, Short-Form 36; 
IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; SF-12, Short-Form 12; ECG, 
electrocardiogram; WHO, World Health Organisation. 
 
Figure 8 shows the evolution of primary and secondary outcomes reporting over the decades of 
Crohn’s disease RCTs. In general, the reporting of all outcome categories has increased over 
time. 
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Figure 8: Proportion of Crohn's Disease RCTs reporting key primary and secondary outcome categories, stratified by decade of publication 
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2.3.4. Clinical or composite-clinical efficacy outcomes and definitions 
As shown in Figure 8, clinical or composite-clinical efficacy outcomes were reported as primary or 
secondary endpoints in 92.3% of trials, which was consistent across the two time-periods. Table 4 
shows the top nine reported clinical or composite-clinical efficacy outcomes.  The full detail of the 
primary and secondary clinical or composite-clinical outcomes is shown in Appendix table 7.   
Table 4: Clinical and composite-clinical primary and secondary outcomes reported and number of studies 
reporting, by trial category and sub-category 
 
Induction of remission Maintenance of remission 
 
Total Medical Surgical Fistula Total Medic-
ally 
induced 
Surgic-
ally 
induced 
Fistula 
Outcome 110  
n(%) 
104  
n(%) 
6  
n(%) 
9  
n(%) 
71  
n(%) 
52  
n(%) 
19  
n(%) 
1  
n(%) 
Clinical 
response 
77 (70.0) 75 (72.1) 2 (33.3) 7 (77.8) 31 (43.7) 26 (50.0) 5 (26.3) 1 (100) 
Clinical 
remission 
72 (65.5) 72 (69.2) 0 0 14 (19.7) 14 (26.9) 0 0 
Disease 
relapse or 
worsening 
14 (12.7) 13 (12.5) 1 (16.7) 0 38 (53.5) 38 (73.1) 0 1 (100) 
Recurrence 
 
1 (0.9) 0 1 (16.7) 0 14 (19.7) 0 14 (73.7) 0 
Fistula 
response 
14 (12.7) 12 (10.5) 2 (33.3) 9 (100) 1 (1.4) 1 (1.9) 0 0 
Fistula 
remission 
10 (9.1) 9 (7.9) 1 (16.7) 6 (66.7) 2 (3.8) 2 (2.8) 0 0 
Cortico-
steroid 
sparing 
11 (10.0) 11 (10.6) 0 0 3 (4.2) 3 (5.8) 0 0 
Cortico-
steroid-free 
remission 
8 (7.3) 8 (7.7) 0 0 4 (5.6) 4 (7.7) 0 0 
Sustained 
remission 
4 (3.6) 4 (3.8) 0 0 7 (9.9) 7 (13.5) 1 (5.3) 0 
NB: percentages are calculated from the number of studies in the top line of each column. 
 
Clinical response was reported by 70.0% (77 of 110) induction studies; 75 (of 104, 72.1%) 
medical117,118,140–149,120,150–152,155,157–162,121,163–167,169–173,128,176–180,182–184,186,187,129,188–195,197,198,131,199–
206,208,210,135,211–216,136,139 and two (of six, 33.3%) surgical218,219 interventions.  Clinical response was 
reported less frequently in maintenance trials (31 of 71, 43.7%) and was more commonly reported 
in studies of maintenance of remission from medical interventions (26, 50%)224,227,253–256,259–
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262,264,266,230,267,268,270–272,275,234,239,241,245,248–250 than from surgical interventions (5, 
26.3%)278,279,288,291,293.  Clinical response was an outcome in 80% of studies that included only 
patients with fistulae (seven of nine induction and one maintenance)135,163,178,190,212,218,219,245. 
Clinical remission was reported in 65.5% of induction studies (72 of 
110)115,117,132,136,137,139,140,142,143,146,147,149,118,150–154,157–161,119,162,164–172,120,173,174,176,177,179,182–
184,186,188,121,189,191,192,195–200,202,123,203–206,210,211,213–216,124,217,125,127 and 19.7% of maintenance studies (14 
of 71)224,230,260,264,268,270,240,242,246,252–255,257, all of which examined medical therapies (69.2% of 
medical induction and 26.9% of maintenance of medically induced remission studies).  Clinical 
remission was not reported as a primary of secondary outcome in any surgical studies nor those 
focused on patients with fistulae.  
Disease relapse or worsening was a primary or secondary outcome in 12.7% of induction studies 
(13 medical114,121,202,211,217,124,141,148,151,170,177,187,188 and one surgical223) and 38 (53.5%) studies of 
maintenance of medically induced remission224,225,235–244,227,245,247–252,257,259,260,228,261,262,265–
267,271,272,275,229–234. Recurrence was an outcome reported in 73.7% of maintenance studies of 
surgery-induced remission (14 of 19)278,280,289,290,292,294,281–288 and one surgical induction study222. 
Fistula response and remission were commonly reported in medical induction studies for patients 
with fistulae (nine of nine135,163,178,185,190,209,212,218,219 and six of nine135,185,190,209,212,218, respectively).  
Overall, 14 induction studies135,143,209,212,218,219,146,162,163,172,178,182,185,190 and one maintenance study250 
reported fistula response and 10 induction135,146,155,162,182,185,190,209,212,218 and two maintenance 
studies250,253 reported fistula remission. 
Corticosteroid sparing and corticosteroid-free remission were reported in 
11117,128,187,136,142,144,151,155,174,175,180 and eight128,136,142,151,155,175,181,187 medical induction studies and 
three227,248,250 and four253,255,260,272 maintenance of medically induced remission studies, 
respectively.  All studies, with one exception, were published prior to 2009.  Sustained remission 
was recorded in four medical induction184,202,216,217 and seven maintenance studies of medically 
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induced remission224,229,243,246,267,270,273.  Corticosteroid sparing, corticosteroid-free remission or 
sustained remission were not reported as outcomes in any surgical induction study or 
maintenance study of surgically induced remission. 
2.3.4.1. Outcome definitions 
The Crohn’s Disease Activity Index (CDAI) dominated as the primary measurement tool for clinical 
and clinical-composite primary and secondary outcomes (Table 3) with 77.9% (141 of 181) of 
studies reporting its use, which was common across both induction (86 of 110)114,115,131,132,135–
142,117,143–147,149–153,118,154,155,157–162,164,165,120,166–175,121,176,177,179–184,186,187,123,188–192,194–198,125,199–
206,210,211,128,212–216,219,129 and maintenance (55 of 71)224,225,236,238–241,243–247,227,248–255,257,259,228,260–262,264–
268,270,271,229,272,273,275,278–280,282,283,285,286,230,287–289,291,293,231–234 studies.  A large number of outcomes 
were measured with CDAI in the studies including response or remission (in 113 studies), disease 
relapse or worsening (38 studies), corticosteroid -sparing or -free response or remission (14 
studies), sustained remission and response (12 studies) and recurrence (nine studies). 
Outcome definitions using the CDAI were heterogeneous with 35 different definitions of response 
or remission reported in the studies (Appendix table 7).  CDAI 100 was the reported response 
measurement in 38 studies120,139,167,169,171,173,176,182,183,188,189,192,142,195,197–199,202–205,213,214,143,215,216,253–
255,260,264,268,270,146,149,161,162,164,166, only one before 2000.  CDAI 70 as a primary or secondary response 
measurement was also reported in 38 studies121,129,158,162,164,167,170–
172,179,180,182,136,184,188,189,191,194,198,200,201,211,213,140,215,216,245,253,255,264,268,270,142,143,146,151,152,157, all but three 
after 2001.  Response measures involving changes in the CDAI score mean or median, or mean or 
median changes in the CDAI score were commonplace across the time-period of the studies.  The 
most common measure involving CDAI was the remission benchmark CDAI <150, which was 
reported in 81 studies115,117,137,139–143,146,147,149,150,118,151–153,157–162,164,120,165–174,121,176,177,179,182–
184,186,188,189,191,123,192,195–200,202–204,125,205,206,210,211,213–216,224,230,131,240,246,252–255,257,260,264,268,132,270,136 either 
as a solo or combination primary or secondary endpoint.  However, reporting of CDAI <150 
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reduced between the two time-periods from 46.4% to 41.4% of studies.    Conversely, the 
reporting of CDAI 70 and CDAI 100 increased between the periods (20.8% to 21.4% and 16.8% to 
30.4%, respectively). Fistula studies most commonly reported the change in CDAI score (5, 50%). 
Other tools used less frequently to measure clinical response or remission include the Harvey 
Bradshaw Index (HBI)118,127,147,148,186,199,217,230,256,295, Physician Global 
Assessments118,119,124,147,198,210,279 and the Van Hees Activity Index(VHAI)118,140,165,186,230 (Table 3).  
The Perianal disease Activity Index (PDAI) was used in four (40%) studies of fistula patients and in 
one non-fistula study135,163,190,193,219. 
There were more than 30 definitions of disease worsening or relapse, the majority of which 
required the CDAI to exceed a benchmark level such as 150, 200 or 250 with, or without an 
increase from baseline score (Appendix table 7).  The need for additional therapy and/or surgery 
were also commonly used definitions.  In maintenance studies, disease recurrence or relapse were 
frequently defined by benchmark levels of CDAI and the need for additional therapies or surgery.  
Studies of penetrating disease most commonly used physician assessments of draining fistulas 
(50% (9, 90.0%) or 100% (6, 60%) reduction from baseline) as trial endpoints.  Two (20.0%) studies 
of fistula patients used imaging techniques, MRI and diagnostic ultrasound, to assess response, 
one in each time-period163,219. 
2.3.5. Endoscopic efficacy outcomes and definitions 
The reporting of endoscopic outcomes doubled between the two time-periods, from 14.4% to 
30.4% of studies (Figure 8).  A summary of outcomes is listed in Table 5  and a full list in Appendix 
table 8. The reporting of endoscopic outcomes occurred in 31% (22 of 71) of maintenance trials, 
with reporting more likely in studies of surgically (19 of 19)276,277,286–294,278–285 than medically (three 
of 52)225,252,261 induced remission.  Endoscopic outcomes were infrequently reported in induction 
trials (11.8%), with reporting more likely in surgical (three of six)219,221,222 than medical (10 of 
104)139,168,172,175,187,192,201,204,210,211 interventions, and in trials in penetrating disease (1, 10.0%)219.  
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Reporting of endoscopic outcomes is a more recent phenomenon in induction trials, with their 
first use in a study reported in 2000, as compared with 1984 in maintenance trials. 
Table 5: Endoscopic primary and secondary outcomes reported and number of studies reporting, by trial 
category and sub-category 
 
Induction of remission Maintenance of remission  
Total Medical Surgical Fistula Total Medically 
induced 
Surgically 
induced 
Fistula 
Number of 
studies 
110 104 6 9 71 52 19 1 
Any 
endoscopic 
outcome 
13 (11.8) 10 (9.6) 3 (50.0) 1 (11.1) 22 (31.0) 3 (5.8) 19 (100) 0 
Endoscopic 
recurrence 
2 (1.8) 0 2 (33.3) 0 19 (26.8) 1 (1.9) 18 (94.7) 0 
Endoscopic 
response 
10 (9.1) 9 (8.7) 1 (16.7) 1 (11.1) 6 (8.5) 1 (1.9) 4 (21.1) 0 
Mucosal 
healing 
2 (1.8) 2 (1.9) 0 0 2 (2.8) 1 (1.9) 1 (5.3) 0 
Endoscopic 
remission 
1 (0.9) 1 (1.0) 0 0 0 0 0 0 
Note: number of studies (percentage) 
 
Endoscopic recurrence was the most frequently reported endpoint, especially in maintenance 
trials (19 of 71, 26.8%).  Eighteen maintenance studies of surgically achieved 
remission276,277,286,287,289–294,278–285 reported endoscopic recurrence (94.7%) and one of medically 
achieved remission225.  Only two induction studies221,222 reported endoscopic recurrence, both of 
which were of surgical interventions.  Endoscopic response was more commonly reported in 
induction trials (10 of 110, 9.1%)139,168,172,175,187,192,197,201,211,219 than in maintenance trials (6 of 71, 
8.5%)252,261,276,285,288,291.  Endoscopic mucosal healing was reported in two (of 110, 1.8%) 
induction187,210 and two (of 71, 2.8%) maintenance261,288 studies and endoscopic remission in one 
induction study201.  
2.3.5.1. Outcome definitions 
Endoscopic recurrence was commonly defined with the Rutgeerts endoscopic score, 
predominantly >=2278,279,292,294,280,282,284,286,287,289–291, although a number of benchmarks were used 
(Appendix table 8).    Endoscopic outcomes in induction trials report changes in the Crohn’s 
Disease Endoscopic Index of Severity (CDEIS) score139,168,172,175,192,197,201,211,219 or changes in the 
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Simple Endoscopic Score for Crohn’s Disease (SES-CD) score187,197,210,219 in place of the Rutgeerts 
score.  The D’Haens261 and Marteau290 endoscopic scores were each reported in one trial. 
2.3.6. Histologic efficacy outcomes and definitions 
Histologic outcomes have been reported with greater frequency since 2009 (Figure 8), but remain 
uncommonly used (11 of 181, 6.1%) and are unused in studies of fistula patients. Three (of 110, 
1.7%) induction studies161,201,211 (all medical) reported histologic response, one (of 77, 1.9%) 
maintenance study of medically induced remission261 reported histologic remission and four (of 
77, 5.2%) maintenance studies of surgically induced remission278,281,287,292 reported histologic 
recurrence.  Three (of 110, 1.7%) induction studies139,161,196 and one (of 77, 1.4%) maintenance 
study293 reported outcomes related to cytokine expression in mucosal tissues.  A number of 
histology scores are used in the small number of outcomes including D’Haens161,211,281,287, 
Dieleman201 and Reguiero292 (Appendix table 9).  The reporting of histologic outcomes as 
additional outcomes increased between the time-periods from 3.2% of studies to 7.1%. 
2.3.7. Biomarker outcomes and definitions 
Biomarker outcomes were reported in 39 (of 110, 35.5%) induction studies, 38 (of 104, 36.5%) 
medical interventions117,123,148,149,151,155,157,158,162,164,165,168,128,172,176,177,182,186–
188,191,192,195,133,199,200,203,205,206,208,211,216,217,136,137,143,145–147 and one (of 6, 16.7%) surgical219.  
Biomarkers were reported in 21 (of 77, 29.6%) maintenance trials, 16 (of 52, 30.8%) of which were 
maintaining medically induced remission228,230,252,258,262,271,272,275,232,234,239,243,244,248–250 and five (of 19, 
26.3%) surgically induced279,281,287,288,291.  Reporting has increased over time and 35.7% of trials 
since 2009 have reported a primary or secondary biomarker outcome (Figure 8).  Only one (10.0%) 
study of penetrating disease reported a biomarker outcome219.   
Serum C-reactive protein measurements117,123,177,182,186–
188,191,195,199,200,205,145,208,211,216,219,248,250,262,271,272,277,147,279,287,288,291,155,157,162,165,168,176 were the most 
frequently reported biomarkers (34/181, 18.8%), followed by serum erythrocyte sedimentation 
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measurements (16 of 181, 8.8%) 117,145,252,262,271,279,287,291,147,155,158,165,208,211,230,248 (Appendix table 10).  
Faecal calprotectin was reported as an outcome in only two studies (1.1%)165,200, one in each time-
period. The biomarker was an additional outcome in three (1.7%) further trials213–215, all reported 
in 2014 and 2015. 
2.3.8. PROs and definitions 
PROs were reported in 47 (of 110, 42.7%) of induction studies, 45 (of 104, 43.3%) medical 
induction studies118,123,145–147,149,150,157–159,162,165,128,167–172,180–182,185,136,187,188,190,191,193–
195,197,199,200,137,205,208,210,211,138–140,142,143 and two (of six, 33.3%) surgical induction studies219,220.  In 
maintenance studies, 28 (of 77, 36.4%) primary or secondary PROs were reported, 24 (of 52, 
46.2%) in studies of maintenance of medically-induced remission227,232,253,255,256,259–
263,267,268,233,269,272,274,275,239,241,242,245,248,250,252, and four (of 19, 21.1%) in maintenance of surgically-
induced remission278,288,289,293.  The use of PROs has increased over time, with almost half of RCTs 
reporting a primary or secondary PRO since 2009 (Figure 8).   
Quality of life was the most common outcome, reported in 40.3% (73 of 181) of studies (Appendix 
table 11).  The Inflammatory Bowel Disease Questionnaire (IBDQ) was frequently used to record 
quality of life, and typically endpoints were specified as the final score or changes in the score 
(from baseline, mean or median)123,128,150,157–159,162,165,167–
170,136,171,172,181,182,187,188,190,191,197,199,138,200,208,211,227,232,233,239,241,245,248,139,250,252,253,255,256,260–
263,267,140,268,269,274,275,288,289,293,142,143,146,149.  The use of IBDQ to measure PROs increased from 30.4% 
to 37.5% between 1979-2008 and 2009-2015.  The growth in use was in maintenance studies 
(25.5% to 50.0%), whilst its use in induction studies reduced (33.3% to 28.1%).  Reporting of IBDQ 
in studies of fistula patients was in line with the overall average (three of 10, 30.0%). 
Other tools for measuring quality of life included the Short-Form 36139,149,205,219,220,252,259,260,268,272 
and its components149,220,268, Patient Global Assessments147,190,278, the Gastrointestinal Quality of 
Life Index210,220, the Hamilton Depression Scale180,194 and the Short IBDQ145,219.  Patient diaries were 
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used to measure outcomes related to bowel symptoms137, defecation functions118,145,185,195 and 
pain118,145,185, with reports comparatively high (2,20%) in fistula patient studies185,219. 
2.3.9. Economic outcomes and definitions 
Economic outcomes were reported in three studies217,220,263; two induction and one maintenance 
study.  All three studies reported a measure of the cost of the intervention and one reported the 
quality adjusted life-years as a measure of utility217. 
2.3.10. Safety-related outcomes and definitions 
Safety-related outcomes were specified as primary or secondary endpoints in 42 (of 110, 38.2%) 
of induction studies, 38 (of 104, 36.5%) medical induction119,120,150–152,155,160–162,164,168,170,123,174–
176,181,188,192,195,198,202,204,124,206,207,210–212,215,216,125,131,136,138,139,146 and four (of 6, 66.7%) surgical 
induction218–221 (Appendix table 12).  Twenty-two maintenance studies (of 77, 31.0%) also 
reported primary or secondary safety endpoints; 17 (of were studies of maintenance of medically-
induced remission225,232,259–262,266,270,272,234,235,239–241,243,252,257 and five were studies of maintenance 
of surgically-induced remission279,281,286,288,290.  Safety outcome reporting has increased steadily 
over the timeframe with 25% of studies reporting them in the period from 1979 to 1988, rising to 
46% between 2009 and 2015 (Figure 8).  The most common safety-related were adverse events, 
which were reported as primary or secondary outcomes in 39 (35.5%) induction 
studies119,120,146,150–152,155,160–162,164,168,123,174–176,181,188,192,195,198,202,204,124,207,210,212,215,216,218–
221,125,131,136,138,139,142 and 22 (31%) maintenance studies225,232,259–262,266,270,272,279,281,286,234,288,290,235,239–
241,243,252,257.  The reporting of adverse events as primary or secondary trial endpoints was most 
frequently the totality of adverse events but some studies looked for specific treatment related 
adverse events or reported the stopping of treatment due to adverse events (Appendix table 13). 
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2.3.10.1. Adverse events 
Reporting of any adverse events occurred in 88 (of 110, 80%) induction studies114,117,132,134–
136,138,139,141–144,118,146–153,155,156,119,157–159,161–164,166–168,121,170–179,123,181,183–191,124,192,193,195–202,125,203–207,209–
213,128,214–220,253,129 and 61 (of 77, 85.9%) maintenance studies224,225,234,235,237–241,243,245,247,226,248,250–
255,257–259,227,260–262,264–268,270,271,228,272,274–276,279–284,229,285–294,230,296,231–233 (Appendix table 13).  
Reporting of AEs increased slightly between the two periods from 80.0% to 87.5% (Figure 9). 
Serious adverse events were reported in 60 (of 110, 54.5%) induction120,124,146,147,149–151,157–
161,129,162,164,166–168,170–174,131,175,176,179,182,184,185,187–189,202,135,203,204,206,207,209–214,136,215–218,138,139,142,143 and 
31 (of 77, 43.7%) maintenance studies225,230,255,257,260,262,264,267,268,270–272,237,278–
281,284,288,290,291,293,239,240,245,248,252–254, and was higher in fistula patient trials (6, 
60.0%)135,185,209,212,218,245.  The reporting of serious AEs increased from 46.4% of studies before 2009 
to 58.9% from 2009 to 2015. 
Treatment related adverse events, including those reported as serious, were reported in 69 (of 
110, 62.7%) induction114,118,136,138,139,142,143,145,146,149–151,119,152,155,157,158,160–164,166,120,167–
175,177,123,178,179,182–184,187–191,124,192,195,197–199,201–204,206,128,207,210,211,213,214,217,219,220,222,129,131,135 and 44 (of 
77, 62%) maintenance studies224,225,243,245,248,253,257,264,266–268,271,232,272,274,275,277–
280,282,285,287,233,288,290,292–294,234,237–241.  Six (60.0%) fistula studies reported treatment-related AEs. The 
reporting of treatment-related adverse events (including serious) grew from 56.8% to 66.1% of 
trials between the time-periods, respectively.   
Gastrointestinal adverse events, including the exacerbation of CD and gastrointestinal signs and 
symptoms, were the most commonly reported AEs by system organ classification (SOC), reported 
in 85 (of 110, 77.3%) induction trials and 57 (of 77, 80.3%) maintenance studies ( 
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Appendix table 14).   
The ten most commonly reported AEs by higher-level group term (HLGT) are shown in Table 6.  
Gastrointestinal signs and symptoms, including nausea, vomiting and pain, were reported as AEs 
in 65.2% (of 181, 118) of studies.  Two other HLGTs within the gastrointestinal conditions were in 
the ten most reported:  gastrointestinal inflammatory conditions (71/181, 39.2%), which includes 
CD as an AE, and gastrointestinal motility and defecation conditions (63/181, 34.8%).    Joint 
disorders, another HLGT, possibly related to CD and the failure of treatment, were reported in 
32.6% (59/181) studies.   
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Figure 9: Proportion of Crohn's Disease RCTs reporting key adverse event and study withdrawal categories, stratified by decade of publication 
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  Table 6: Most Commonly Reported Adverse Events by MedDRA Higher Level Group Terms (HLGT) in Randomised Controlled Trials in Crohn’s disease 
System Organ Classification Higher Level Group Term Studies 
reporting  
n (%) 
Example preferred terms 
Gastrointestinal disorders Gastrointestinal signs and symptoms 118 65.2% Nausea, vomiting, abdominal pain, 
flatulence, abdominal distention 
Infections and infestations Infections - pathogen unspecified 95 52.5% Abscess, infection, opportunistic 
infection, respiratory tract infection, 
nasopharyngitis 
Nervous system disorders Headaches 91 50.3% Headache, migraine 
General disorders and administration conditions General system disorders NEC 73 40.3% Chest pain, fatigue, oedema 
Gastrointestinal disorders Gastrointestinal inflammatory conditions 71 39.2% CD, enteritis, colitis 
Gastrointestinal disorders Gastrointestinal motility and defaecation conditions 63 34.8% Diarrhoea, constipation, GORD 
Musculoskeletal and connective tissue disorders Joint disorders 59 32.6% Arthralgia, arthritis, joint swelling, joint 
stiffness 
General disorders and administration conditions Fatal outcomes 48 26.5% Death, sudden cardiac death 
Nervous system disorders Neurological disorders NEC 46 25.4% Dizziness, paraesthesia 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions 46 25.4% Rash, pruritus, dermatitis 
Note: NEC  not elsewhere classified; GORD – gastro-oesophageal reflux disease 
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2.3.10.2. Study withdrawals 
Withdrawals were most frequently reported due to AEs (102/181, 56.4%) and least frequently for 
serious AEs (7/181, 3.9%) (Appendix table 13).  Withdrawals due to treatment failure were 
reported in 41.4% (75/181) of studies, and in 45.9% (83/181) of studies for reasons related to non-
compliance and loss to follow-up.   Withdrawals due to treatment-related AEs (including serious) 
were reported by 13.8% (25/181) studies, but the proportion fell from 15.2% to 10.7% between 
the two time-periods (Figure 9).  The reduction in the reporting of study withdrawals was common 
across all categories except serious AEs, which rose slightly from 3.2% to 5.4% of studies.   
Study withdrawals were more frequently reported due to adverse events reported in maintenance 
studies (51/77, 71.8%) than induction studies (68/110, 61.8%). Withdrawals due to treatment 
failure were more commonly reported in induction trials (50/110, 45.5%) than maintenance trials 
(25/71, 35.2%).  Withdrawals for other reasons (such as protocol non-compliance or loss to follow 
up) were reported in similar proportions across induction studies (50/110, 45.5%) and 
maintenance studies (33/71, 46.5%). 
2.4. Discussion 
2.4.1. Summary of evidence 
A comprehensive systematic review of the outcomes and outcome measures reported in RCTs of 
interventions for Crohn’s disease was conducted, summarising data from 181 RCTs.   The results 
demonstrate that trialists have adopted a wide and variable approach to outcomes measurement 
in the past.  Over the decades of clinical trials, more measurement tools have become available 
and trialists have perhaps opted to measure more outcomes rather than decide which are most 
important.  The results in this chapter provide insights to guide future trial design and support 
COS development for Crohn’s disease by providing a preliminary list of outcomes.    Further, the 
consideration of the measurement instruments used could assist the follow on phase to a COS; 
deciding how to measure the core outcomes. 
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The results confirm the predominance of clinical or composite-clinical primary and secondary trial 
endpoints.  Over the history of RCTs for Crohn’s disease, the reporting of all types of outcomes 
has increased with almost half of all studies between 2009 and 2015 now reporting PROs.  
Biomarkers, endoscopic and histologic outcomes have also increased in reporting, presumably as 
researchers seek more objective measures of disease activity.  Economic outcomes remain rarely 
reported.  Safety-related primary and secondary trial endpoint reporting increased from 25% of 
studies in the decade from 1979 to 1988 to 41% between 2009 and 2015.   
Reporting of adverse events has increased over the same period, whilst the reporting of study 
withdrawals has generally reduced.  It is unclear from the results why the reporting of study 
withdrawals has reduced.  There are likely to be a number of factors and the fact that study 
withdrawals categories are themselves composite adds complexity.  For example, withdrawals 
from treatment due to adverse events may include a range of different harms that have occurred 
with the broad category seeking to give an overview of the tolerability of treatment.  The 
reduction in withdrawals may reflect the improvements in follow up that stem from the updated 
CONSORT statement47.  In order to ensure the correct approach to ITT analysis, the guidelines now 
stress that all patients should be followed up.  Therefore, patients who withdraw from treatment 
may not by withdrawn from the study because they continue to be followed up and this could be 
a factor in the results.    
Clinical response was the most commonly reported outcome across all studies.  Clinical remission 
was most commonly reported in studies of induction of remission, and disease relapse or 
worsening was the most commonly reported outcome in studies of maintenance of remission.   
Endoscopic endpoints were more commonly reported in maintenance studies, but their use in 
induction studies is increasing. PROs, biomarkers and safety-related outcomes were all reported 
in more than a third of studies.  
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Key disease activity indices and quality of life questionnaires dominate the listings of outcomes. 
The Crohn’s Disease Activity Index (CDAI) was developed over forty years ago as a composite 
measure incorporating symptoms, signs and simple laboratory parameters297. It was the dominant 
measurement instrument used in the published trials (primary or secondary endpoint in 77.9%), 
but with substantial variation including thirty-five definitions of response or remission. Whilst this 
observation highlights a need for greater standardisation of end-points, the CDAI per se is 
increasingly regarded as sub-optimal as an endpoint for comparative effectiveness research and 
regulatory approval.  The index does not correlate closely with objective signs of inflammation or 
with mucosal healing at endoscopy298,299. EMA guidance published in 2016 discourages the use of 
the CDAI as a trial endpoint, and recommends that signs and symptoms of disease activity and 
inflammation should be measured separately instead of within a combined index68.  Specifically 
the primary outcome should be a combination of PROs for signs and symptoms and endoscopy 
finding of mucosal healing for inflammation. The time trends observed in clinical trials endpoints 
reporting illustrate how the emphasis is shifting towards inclusion of discrete, objective measures 
of the inflammatory process (biomarkers, endoscopy and histology).  The EMA guidance itself did 
not affect the studies included in the review as they were all published before the date of the 
guidance, suggesting that the regulatory decision has been driven to an extent by a research 
agenda.  Given the length of time from trial registration to publication, it is likely to be some time 
before the impact of the guidance is seen in newer endpoints in trials published in the literature. 
C-reactive protein (CRP) is a routinely employed biomarker in clinical practice and was frequently 
reported among clinical trial outcomes, albeit rarely as a primary endpoint (5 studies). However, 
CRP lacks sensitivity for active intestinal inflammation in Crohn’s disease300, and this limits its value 
as a primary end-point. There remains active exploration of alternative serum markers of disease 
activity301 but this review suggests no strong candidate has emerged. 
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Stool biomarkers offer potential to reliably measure gut-related inflammation and in recent years 
faecal calprotectin (FCP) has become available in routine IBD practice302.  Uncertainty remains as 
to its performance properties particularly for measuring the varied forms of Crohn’s disease 
activity303 and research continues to explore other stool assays to measure the inflammatory 
process304.  FCP was reported as an endpoint in only two trials included in this review165,200. 
An increase in the report of endoscopy and histology-based outcome measures over time was 
found, albeit they remained at a low level and without emergence of a standardised approach. 
This heterogeneity likely reflects the current sub-optimal psychometric properties of individual 
measurement tools, the cost and invasiveness of endoscopy and the inability to quantify the 
overall extent of intestinal inflammation in Crohn’s disease305,306.  There is a growing body of 
research on the potential use of quantitative imaging such as CT and MRI307, but only one trial 
included in this review included radiological outcomes219.  
PROs were reported as end-points in almost half of studies since 2009, although commonly as a 
secondary outcome (60, 33.1%) rather than a primary outcome (10, 5.5%).  Questionnaires 
administered in clinical trials ranged from ‘generic’ (e.g. EQ-5D) and ‘disease specific’ (e.g. IBD-Q) 
health-related QoL instruments to tools focusing on individual domains (e.g. Fatigue Impact 
Score).  Although the IBDQ was the most frequently reported PROM in the trials (85% of studies 
reporting PROMs), it is currently not deemed valid as it was not developed according to the latest 
FDA recommendations for product labelling claims308. New disease-specific PROMs tools are 
under development to meet the stringent guidelines and enable PROMs to support future 
regulatory approvals of licencing for Crohn’s disease. 
The review covered data for safety outcomes in clinical trials and found substantial heterogeneity 
in reporting, which highlights the challenges in categorizing adverse events for a complex, chronic 
condition with a variable disease course and multisystem manifestations. Lack of treatment 
efficacy in Crohn’s disease may manifest with a diversity of symptoms, which are difficult to 
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distinguish from genuine treatment side effects.  Nevertheless, these data should support 
renewed attempts to define disease- and intervention-specific adverse events and to standardise 
safety outcomes as discrete end-points.  This is an important consideration for future COS 
developers. 
The results highlight how the reporting of outcomes in trials in fistula patients align with overall 
reporting. The use of PROS and safety-related endpoints is common across all trials, regardless of 
disease type.  Clinical response was less commonly measured by CDAI, and more frequently 
measured by fistula closure and the PDAI. These three outcome measures were the most 
commonly used in fistula trials identified by this review, which supports the findings of a recently 
developed COS for fistulising disease103.  Biomarker, histology and endoscopy outcomes were 
rarely used in fistula trials and are not included in the COS either, contrary to the general shift in 
outcomes reporting in Crohn’s disease trials.  However, patient reports (e.g. incontinence and 
drainage) were more common endpoints in trials of fistula patients than in non-fistula trials, and 
their importance is borne out in the COS for fistulising disease, which lists several PROMs to be 
reported in future trials.   
The results of this review are independently supported by the key findings of a 2018-published 
systematic review of outcomes in Crohn’s disease104.  It confirms heterogeneity in definitions of 
response and remission and the need for a core outcome set to standardise endpoint definitions.  
Both studies unsurprisingly identified the use of CDAI as the most popular outcome measurement 
tool overall and of IBDQ as the most commonly used PROM.  Similarly, CDEIS and SES-CD are 
highlighted as endoscopic tools most used in induction trials and Rutgeerts in post-surgical trials.  
Both reviews confirmed the common use of C-reactive protein and increasing use of biomarkers.   
However, this review had less restrictive inclusion criteria, leading to inclusion of a larger number 
of RCTs (181 versus 116). This resulted in extra heterogeneity in findings, which are arguably more 
extensive, particularly in the reporting of safety-related outcomes.  Furthermore, whereas this 
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review focused on primary and secondary endpoints (with supplementary analysis of other 
outcomes), Ma et al considered all outcomes in a singular analysis. This results in differences in 
the breadth and depth of scope of the reviews and some nuances in key findings between the two 
reviews. For example, Ma et al found that a higher proportion of studies used CDAI, which likely 
reflects the requirement that trials must have used CDAI (or HBI) at enrolment to be included. 
Their tighter restrictions on therapies included may also explain the higher proportion reporting 
adverse events, as the search criteria in this chapter included trials of less traditional therapies.  
Ma et al also found that CDAI 100 was more prevalent as a measure of response than in this 
chapter’s results (although there was an increased use over time), and reported an increased use 
of faecal calprotectin.  These results may reflect some more recent trials included in their review. 
2.4.2. Strengths and limitations 
One strength of this review was the focus on synthesising data on safety outcomes.  The results 
confirm the variability that exists in reporting of outcomes in published clinical trials of 
interventions for Crohn’s disease. These data provide a comprehensive resource to support 
current and future efforts102 to redefine optimal outcomes and measurement tools to be included 
in future studies of comparative effectiveness.  The search strategies employed for this review 
were broad, ensuring that the systematic review was comprehensive in identifying both the 
potential range of treatments for Crohn’s disease and the outcomes from those treatments.  
Focusing on RCTs ensures the capture of the best evidence possible.   
However, alternative methods are needed to identify the longer terms outcomes and this is one 
limitation of this work.  The systematic review would have been strengthened by the inclusion of 
systematic reviews, prospective cohorts and retrospective cohorts alongside RCTs and other 
clinical trials. In particular, this would help to characterise important longer-term harms and may 
be a useful future piece of research. The limitation of time prevented their inclusion in this review. 
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This chapter has further limitations.  Whilst it includes a comprehensive listing of outcomes from 
available Crohn’s disease trials, it cannot account for publication bias.  Further, the validity or 
reliability of the outcome measures identified in the review were not assessed, although this 
would form a part of any COS development process and the consideration of outcome measures 
provides a jump start to the second stage of a COS where developers decide how to measure the 
chosen outcomes.  The screening process would have benefited from an additional reviewer for 
increased validity.  Due to the scale of the project with 9,561 records to be screened, it was not 
possible to secure the involvement of a second reviewer to the extent that might be involved in a 
non-PhD piece of research.  A more narrowly focused search would have resulted in fewer records 
to be screened, which might have made it possible to involve a second reviewer, but this could 
have compromised the strength of the extensiveness of the review. 
2.4.3. Conclusions 
Our study confirms the variability that exists in reporting of outcomes in published clinical trials 
of interventions for Crohn’s disease. The systematic review of treatments of Crohn’s disease in 
adults identified 181 relevant studies, identifying the key primary and secondary endpoints 
measured.  A median of one primary endpoint and three secondary endpoints are reported per 
paper in the literature and clinical and composite-clinical outcomes are the most common type of 
trial endpoints. The reporting of all outcome types has increased over time, with the exception of 
the reporting of study withdrawals, which has reduced.   
The data provide a comprehensive resource to guide the development of new trial endpoints for 
Crohn’s disease and could provide the starting point for a core outcome sets (COS), which would 
standardise outcomes measured within clinical trials by specifying a minimum set of outcomes 
that should be measured and reported in trials of a particular condition49. COS are usually 
developed using consensus methods involving patients, health professionals and other 
stakeholders to decide the most important outcomes for a condition and the first step of that 
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process is to identify the outcomes currently being measured and reported, which is covered by 
the work in this chapter. 
The results have shown that, over time, there has been the beginning of a shift towards the use 
of patient reported outcome measures (PROMs) and objective measures of inflammation, rather 
than the use of composite-clinical measurement tools such as the Crohn’s Disease Activity Index 
(CDAI).  This shift, which is supported by regulatory guidance on trial design, requires new 
outcome measurement tools be developed, which must be transparent and validated.  To support 
this process, there is a need to understand what is being measured within the current composite 
measurement tools, that is, what individual facets of Crohn’s disease are being measured and then 
aggregated within tools to produce a summary measure of disease status, such as remission or 
response.  The work reported in Chapter 3, tackles this question by disaggregating the endpoints 
reported in trials to their constituent parts and taking an overview of the lowest level of signs, 
symptoms and events that are measured in trials. 
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Chapter 3: Categorisation of outcomes and adverse events in 
Crohn’s disease 
3.1. Introduction 
A systematic review of the outcomes reported in randomised controlled trials (RCTs) of Crohn’s 
disease in Chapter 2 highlights the measurement of many different types of outcomes as primary 
and secondary endpoints, and the changing patterns of outcomes measured over time.  In 
particular, the reporting of all types of efficacy and safety outcomes has increased over time, with 
the exception of study withdrawals reporting, which has reduced.  Within efficacy outcomes, there 
is a reliance on the flawed Crohn’s Disease Activity Index (CDAI) (as discussed in Chapter 2) to 
measure primary and secondary endpoints in trials.  The use of such composite measures appears 
to make the measurement of outcomes across RCTs in Crohn’s disease seem homogenous.  
Guidance from the European Medicines Agency (EMA)68 highlights the need for new endpoints in 
clinical trials that separate out the signs and symptoms of Crohn’s disease, measured by patient 
reported outcomes (PROs), and inflammation, measured by imaging techniques such as 
endoscopy.  The reporting of PROs is in itself complicated and lacks transparency.  As an example, 
a study of PROs reported in cancer trials found that PRO scales with identical names contained 
different components, which made it difficult to synthesise results309. 
Understanding the breakdown of the endpoints measured in RCTs to the level of individual signs, 
symptoms and events will provide greater transparency on what is measured in the literature.  In 
this chapter such signs, symptoms and events are referred to as “outcomes” where reported in 
the context of trial endpoints, and “adverse events” where reported in the context of safety 
sections of trials.  Developing such a comprehensive recording of outcomes and adverse events 
(AEs) may help guide the development of new trial endpoints for Crohn’s disease.  It could provide 
the starting point for a core outcome set (COS), which would standardise outcomes measured by 
specifying a minimum set of outcomes that should be measured and reported in trials of a 
particular condition49.  
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The complexity of Crohn’s disease and the broad scope of treatment suggests there are likely to 
be numerous and various definitions of outcome measures and a wide reporting of adverse events 
and this was confirmed in the systematic review in Chapter 2.  As such, it is useful to be able to 
categorise outcomes and AEs and the OMERACT Filter 2.0310 provides a conceptual framework to 
aid such an exercise.  OMERACT are a well-stablished international collaboration aimed at 
improving outcome measurement in rheumatoid arthritis (RA)51.  Filter 2.0 was developed by the 
group to assist in COS development and provides a framework within which outcomes can be 
categorised.   
Filter 2.0 was selected as a framework for categorising outcomes and AEs in this chapter for 
several reasons; firstly, both Crohn’s disease and RA are chronic inflammatory diseases with 
overlapping treatments and sequelae and as such, there is likely to be an overlap in the outcomes 
and AE categories.  A well-established tool with pre-defined categories is useful to assist non-
clinical outcomes researchers and methodologists (lacking detailed medical knowledge), providing 
a useful start to categorisation.  Secondly, Filter 2.0 includes AEs alongside efficacy outcomes, 
categorising them using the same domains, rather than putting them into a single category 
“adverse events” or “safety-related events”.  This was important to this research with its focus on 
identifying the often-overlooked harms of treatment.  Thirdly, Filter 2.0 makes use of a range of 
existing and validated taxonomies and dictionaries to populate its categories, which means it is a 
robust categorisation framework. 
Whilst there is no established COS for Crohn’s disease, a disability index for inflammatory bowel 
disease (IBD) has been proposed using the World Health Organisation’s international Classification 
of Functioning, Disability and Health (ICF)100.  Peyrin-Biroulet et al present two IBD ICF core sets, a 
comprehensive and a brief core set.  The comprehensive set aims to fully characterise what it 
means to live life with IBD.  The authors argue that the brief set captures the essence of the 
disability faced by patients with IBD and provides a disability index that can be used in both clinical 
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practice and as a clinical trial endpoint.  Within this chapter, the core sets serve as a useful tool to 
benchmark against the results of the classification.  Further, by breaking down the key 
measurement tools into their composite outcomes, it is possible to check how well they address 
the proposed core sets. 
3.1.1. Aims and objectives 
The aim of this chapter is to identify a comprehensive categorisation of outcomes and AEs 
recorded in RCTs to induce or maintain remission of Crohn’s disease at the level of individual 
symptoms, signs and events, the results of which could support the development of new trial 
endpoints in RCTs or inform the development of a COS for Crohn’s disease. The key objectives are: 
- To identify the signs, symptoms and events (outcomes and adverse events) measured in 
trials of Crohn’s disease from the data extracted from a systematic review of outcomes 
in Chapter 2. 
- To categorise the identified outcomes and adverse events into an existing theoretical 
framework (Filter 2.0) to provide a comprehensive inventory.  
- To map the ICF IBD core outcomes onto the theoretical framework to establish how well 
it reflects the literature. 
- To map the most commonly used composite measurement tools onto the theoretical 
framework to establish how well they reflect the ICF IBD core outcomes and the 
outcomes reported in the literature. 
3.2. Methods 
3.2.1. Systematic review 
The methods of the systematic review are recorded in Chapter 2. 
3.2.2. Outcomes data 
To capture the broadest range of outcomes measured, and in contrast to the methods in Chapter 
2, all endpoints reported in the trials were disaggregated to their component outcomes and 
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categorised.  These endpoints included those specified as primary and secondary, and those 
additional endpoints reported in the trials but not pre-specified as primary or secondary 
endpoints.  The point here is to count what is being measured, not how it is being measured.  In 
order words, this was a move away from counting composite-clinical outcome measures and 
patient reported outcome measures (PROMs), and instead aimed to define the discrete, individual 
outcomes that they are seeking to measure. 
Data on trial endpoints, the measurement tools and definitions used were extracted from the 
papers as discussed in Chapter 2.  Combined endpoints were disaggregated into individual 
outcome measures, which could then be disaggregated further into a larger number of discrete 
outcomes. 
3.2.2.1. Identifying component outcomes from outcome measurement tools 
Disease activity indices (DAIs) and patient reported outcome measures (PROMs) are used to 
measure disease states that are not directly observable.  The decision to categorise all endpoints, 
rather than just primary and secondary endpoints, in the 181 studies identified in the systematic 
review in Chapter 2 led to the inclusion of a range of exploratory endpoints.  To avoid 
consideration of tools used on an ad-hoc basis and to focus on those used more reliably in the 
literature, the decision was taken to break down into components those tools reported three or 
more times in the trials identified by the systematic review.  Those used less frequently were 
classed as measuring an outcome in their summary form, for example as measuring general 
quality of life. 
If an outcome measure was used for measuring multiple outcomes, e.g., albumin levels were 
reported as both a measure of nutritional status and inflammation, it was aligned with the most 
common use to ensure each outcome measure was recorded uniquely within the framework.   
The component outcomes within each outcome measurement tool were recorded only once per 
paper, even if the tool was used for several endpoints.  For example, the CDAI might be used to 
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report remission, response and recurrence endpoints in a study, but the component outcomes at 
the level of symptoms, signs and events such as the presence of fistula, or diarrhoea, were 
measured once using that measurement tool. 
3.2.3. Adverse events data 
AE data were extracted from the papers in the systematic review and standardised using the 
Medical Dictionary for Regulatory Activities (MedDRA) terminology311 as described in Chapter 2.  
The three levels considered most clinically relevant in the MedDRA hierarchy were used for the 
categorisation process: 
1. Preferred terms (PTs): single medical concept for a symptom, sign, disease, diagnosis, 
therapeutic indication, investigation or medical or surgical procedure. 
2. High-level group terms (HLGTs): groups of PTs related by anatomy, pathology, 
physiology, aetiology or function.   
3. System organ class (SOC): the broadest concept, based upon aetiology (e.g. infections 
and infestations), manifestation site (e.g. gastrointestinal disorders) or purpose (e.g. 
surgical and medical procedures). 
PTs can be linked to more than one SOC but the primary SOC suggested in the MedDRA hierarchy 
was recorded in the data, even where this disagreed with the SOC reported in the study.  This 
ensured that each AE appeared uniquely in the hierarchy. 
The numbers of trials reporting the following categories of AEs was also recorded: 
- Adverse events 
- Serious adverse events 
- Treatment-related adverse events 
- Treatment-related serious adverse events 
- Treatment withdrawal due to adverse events 
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- Treatment withdrawal due to serious adverse events 
- Treatment withdrawal due to treatment-related adverse events 
- Treatment withdrawal due to treatment-related serious adverse events 
- Treatment withdrawal due to treatment failure defined as insufficient therapeutic 
effect, exacerbation of Crohn’s, development of complications or Crohn’s or need for 
additional therapy or surgery.   
- Treatment withdrawal due to various reasons including protocol non-compliance, lost to 
follow up, use of prohibited medication and withdrawal of consent. 
3.2.4. Data presentation 
A frequency count and percentages of studies reporting each outcome and AE was presented.  A 
frequency count and percentages of studies reporting key DAIs and PROMs was presented, with 
a breakdown of the constituent outcomes measured. 
3.2.5. Outcome categorisation 
Once a comprehensive list of outcomes and AE was generated, they were categorised into 
domains within the OMERACT Filter 2.0310 framework. 
3.2.5.1. OMERACT Filter 2.0 
The OMERACT Filter 2.0 framework, shown in Figure 10 below, is designed to support the 
development of a COS and ensure that it provides a true picture of a disease by covering both the 
impact of the health condition and its pathophysiological manifestations.  Both outcomes and AEs 
can be situated in the framework.   
The framework includes three core areas that cover the impact of the condition (death, life impact 
and economic impact) and one core area that covers the pathophysiological manifestations of the 
disease.   Below the core areas, the intention is that COS developers should select domains of 
importance to the condition, ideally at least one within each core area, to form the “core domain 
set”.  Within each domain, at least one outcome measure should be selected to form the “core 
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outcome measurement set”. In this chapter, Filter 2.0 was applied in a different way as outcomes 
measures were extracted from the systematic review, listed as a series of outcomes and then 
categorised into domains within the framework.  AEs were similarly extracted, standardised and 
categorised within the framework.   
Figure 10: OMERACT Filter 2.0 framework for developing Core Outcome Sets (COS)310 
 
 
OMERACT provide guidance on sources of domains: the WHO International Classification of 
Functioning, Disability and Health (ICF)312; a model of health-related quality of life by Wilson and 
Cleary (1995)313; and additional domains suggested by OMERACT to ensure a comprehensive 
representation of the condition. 
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3.2.5.2. International Classification of Functioning, Disability and Health (ICF) 
The ICF is the World Health Organisation (WHO) framework for describing health and health-
related states312.  It was used as the primary source for categorising the outcomes and adverse 
events into domains due to its hierarchical classification system and the potential for ease of 
alignment of the resultant framework with the ICF core sets for IBD. The ICF covers four domains: 
 b – Body Functions, which focuses on impairments in body function, such as mental 
function or sensory functions, for example. 
 s – Body Structures, which focuses on impairment in body structure, such as the nervous 
system or respiratory systems, for example. 
 d – Activities and Participation, which focuses on performance problems or capacity 
limitations across the full range of life areas, such as basic learning or composite areas 
such as social tasks. 
 e – Environmental factors, which are contextual factors that might be a facilitator or 
barrier on the lives of people with health conditions, such as the built environment or 
the availability of services.  This domain was not considered relevant to outcomes and 
AE reporting. 
The online browser314 was searched for each verbatim outcome and AE identified through the 
systematic review.  Each outcome and AE was coded to the lowest possible level of the ICF and 
aggregated to clinically appropriate Filter 2.0 domains with clinical support (KB).  An example is 
shown in Table 7 below of how similar outcomes were grouped into one outcome domain.  Five 
outcomes are coded at ICF level 4 but all related to defecation so are grouped into an outcome 
domain at an ICF level 3 code of “defecation functions”.  For completeness, the ICF level 2 and 
level 1 codes are shown.   
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Table 7: Example of coding outcomes into domains using the ICF 
Chapter heading 
(level 1) 
Chapter sub-
heading (Level 2) 
Domain (level 3) Outcome (level 4) 
Code Name Code Name Name Name Code Name 
b Body 
functions 
b5 Functions 
of the 
digestive, 
metabolic 
and 
endocrine 
systems 
b525 
 
Defecation 
functions 
b5250 Elimination 
of faeces 
b5251 Faecal 
consistency 
b5252 Frequency 
of 
defecation 
b5253 Faecal 
continence 
b5254 Flatulence 
 
3.2.5.3. Wilson and Cleary health-related quality of life 
Where it was not possible to align outcomes and adverse events with the ICF, the Wilson and 
Cleary model of health-related quality of life313 was used as second choice.  The model includes 
the following domains: 
1. Biological and physical variables, which focus on the functions of components of the 
body; 
2. Symptom status, which focus on the functions of the body as a whole; 
3. Functional status, which assess the ability of an individual to perform tasks;  
4. General health perceptions, which are a subjective rating of personal health; and  
5. Overall quality of life. 
Domains one to three align with domains in ICF so these domains were not used.  The domains of 
general health perceptions and overall quality of life are not covered well by the ICF so these 
domains were considered appropriate for use in categorising outcomes and AEs. 
3.2.5.4. Other domains 
Finally, Filter 2.0 allows for specification of other domains, dependent upon the specific context 
in which the core set is being applied, in this case, for treatment of adults with Crohn’s disease.  
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Where it was not possible to align outcomes and AEs to either the ICF or the health-related quality 
of life model313,315, other domains suggested by OMERACT100 were used as appropriate.  This was 
a process undertaken with the support of KB to ensure that the domains were of clinical relevance.  
The domains resulting from this process were: 
- Death due to Crohn’s disease; 
- Utility of treatment; 
- Individual resource use; 
- Health care cost;  
- Infections;  
- Cancers (where not listed by location); 
- General system conditions; and 
- Biomarkers. 
3.2.6. Outcome hierarchy, key indices and questionnaires and the ICF core sets 
Filter 2.0 populated with Crohn’s disease outcomes was presented in table format with the core 
areas, domains, outcomes and outcome measures listed.  AEs were presented in a separate table 
with the preferred terms (PTs) and higher-level group terms (HLGTs).  
The top level of the resulting Filter 2.0 for Crohn’s disease outcomes and AEs in adults, which 
highlights the outcome domains, was presented in table format and the ICF core set for IBD 
overlaid to compare the two.   
Given the importance of some key disease activity indices and PROMs in Crohn’s trials, additional 
analysis focused on how their composite outcomes map against the populated Filter 2.0 
framework. 
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3.3. Results 
Trial endpoint data was extracted from 181 studies identified by the systematic review in Chapter 
2. 
3.3.1. Outcomes measured by key measurement tools used in Crohn’s disease trials 
Disease activity indices and patient reported outcome measures were used extensively in Crohn’s 
disease trials and have a significant impact on the frequency reporting of outcomes, and 
consequently the categorisation process. Table 8 shows the disease activity indices and PROMs 
identified by the search, the number of studies in which they are used and the number of 
outcomes they measure.  A discussion of how the outcome measurement tools reduce to the 
outcomes follows and discussion of their impact upon the Filter framework mapping of outcomes 
is in Section 3.3.5.2.  The detail of the items measured in each outcome measure and how they 
mapped against the Filter 2.0 domains is shown in Appendix table 17 to Appendix table 22. 
Table 8: Commonly used indices of disease activity and patient reported outcome measures, the number 
of outcomes in each and their use in 181 Crohn’s disease trials in adults 
Measure name Measure type Number of 
outcomes 
measured 
Trials in which it is 
used (n=181) 
No. % 
CDAI Composite-clinical 15 156 86.2 
IBDQ PROM 32 77 42.5 
SF-36 PROM 33 15 8.3 
HBI Composite-clinical 12 14 7.7 
PDAI Composite-clinical 5 10 5.5 
VHAI Composite-clinical 8 7 3.9 
Important disease activity indices in the articles found by the systematic review were 
the Crohn’s Disease Activity Index (CDAI), the Harvey Bradshaw Index (HBI), the 
Perianal Disease Activity Index (PDAI) and the Van-Hees Activity Index (VHAI).  
 Important quality of life questionnaires were the Inflammatory Bowel Disease 
Questionnaire (IBDQ) and the Short-Form 36 questionnaire (SF-36).   
 
3.3.1.1. Crohn’s Disease Activity Index (CDAI) 
The CDAI is the most commonly used index in the studies in our review, reported by 156/181 
studies (86.2%).  It is a composite-clinical outcome measure and has seven questions: four on 
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symptoms and captured by patient diary, two on complications that are assessed by a clinician, 
one measure of body weight and, finally, a blood test biomarker64.  The index disaggregates into 
15 separate outcomes and is mapped to 15 domains. (Appendix table 17). 
3.3.1.2. Inflammatory Bowel Disease Questionnaire (IBDQ) 
The IBDQ is the second most commonly used outcome measurement tool in the included studies 
(77/181, 42.5%).  It is a validated PROM of health-related quality of life316 that is noted in current 
EMA guidance as a potential secondary endpoint68. There are 32 questions in the questionnaire, 
related to four sub-scales: bowel, emotional, social and systemic.  Each sub-scale aims to capture 
an element of quality of life that is affected in people with IBD.  Within the framework, the IBDQ 
is coded as 32 outcomes, split over 12 domains (Appendix table 18).  As with the CDAI, it is possible 
to report an overall score and this can be measured against cut off values to indicate disease 
states.  It is most commonly used as an average score, but studies also report the separate sub-
scales, usually in addition to the overall score. Further detail on its use as a primary or secondary 
endpoint was discussed in Chapter 2. 
3.3.1.3. Short-Form 36 (SF-36) 
The SF-36 is also a commonly used health-related quality of life questionnaire, which measures 
functioning and wellbeing in terms of physical, mental and social dimensions317,318.  It lists 36 
questions, which group into concepts and provide scores for physical functioning; role limitations 
due to physical problems; social functioning; bodily pain; general mental health; role limitations 
due to emotional problems; vitality; and general health perceptions.  The scores are also further 
grouped to provide summary scores: the mental component score and the physical component 
score.  Many studies reported these summary scores along with the overall score.  The SF-36 
measures 33 outcomes across 10 domains and its use was reported in 15/181 (8.3%) of the 
included studies (Appendix table 19). 
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3.3.1.4. Harvey-Bradshaw Index (HBI) 
The HBI is a simplified version of the CDAI, designed to make it easier to collect and calculate65.  
Body weight, blood test and the use of anti-diarrhoeal medication are removed to simplify the 
index.  The HBI maps to 11 outcomes and 10 domains in the Filter 2.0 framework (Appendix table 
20).  It is reported by 14/181 (7.7%) of the included studies. 
3.3.1.5. Perianal Disease Activity Index (PDAI) 
The PDAI combines scores on the severity of symptoms on five scales: discharge; pain/restriction 
of activities; restriction of sexual activity; type of perianal disease; and degree of induration66.  The 
PDAI maps to five outcomes and five domains in the Filter 2.0 framework and is reported in 10/181 
(5.5%) of the included studies (Appendix table 21). 
3.3.1.6. Van-Hees Activity Index (VHAI) 
The VHAI was designed to overcome some of the perceived disadvantages of the CDAI, mostly the 
predominance of subjective variables319.   As such, the VHAI uses a combination of nine measures, 
proposed as objective measures, to produce an index score.  The index maps to eight outcomes 
and eight domains in Filter 2.0 (sex is not included as an outcome) and is reported by 7/181 (3.9%) 
of the included papers (Appendix table 22). 
3.3.2. Outcomes measured in Crohn’s disease trials 
Breaking down all endpoint data into individual components results in the identification of 93 
outcomes to be categorised into the Filter 2.0 framework.  Table 9 lists the outcomes measured 
in more than 90% of trials in decreasing order of frequency of reporting.  The most commonly 
reported outcomes were abdominal pain, faecal consistency, fistula / fissure / abscess, frequency 
of defecation, abdominal mass, wellbeing, arthralgia, extra-intestinal lesions and fever.  Given that 
the CDAI is reported in almost 90% of trials, the table is essentially a list of the discrete 
components of the CDAI.  The list of all 93 outcomes in decreasing order of reporting is in Appendix 
table 15.  Thirteen of the 93 outcomes (14.0%) were measured in only one trial. 
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Table 9: The most common outcomes measured in 90% of Crohn’s disease trials in adults, listed by 
frequency of reporting 
Outcome Trials measuring 
outcome 
No. % (of 181) 
Abdominal pain 169 93.4% 
Faecal consistency 169 93.4% 
Fistula / fissure / abscess 168 92.8% 
Frequency of defecation 168 92.8% 
Abdominal mass 164 90.6% 
Wellbeing 164 90.6% 
Arthralgia 163 90.1% 
Extra-intestinal lesions 163 90.1% 
Fever 163 90.1% 
 
3.3.3. Adverse events recorded in Crohn’s disease trials 
577 AEs were identified in the trials from the systematic review, plus the 10 pre-specified AE 
categories outlined in the methods chapter, Section 3.2.3.    More than half of the AEs (301/577, 
52.2%) were reported only once.  The most commonly reported AEs, reported in more than 40% 
of studies were abdominal pain, headache, crohn’s disease (aggravated) and nausea.  A number 
of the pre-specified categories were also reported in more than 40% of studies: total adverse 
events, discontinuation of treatment due to various reasons, total serious adverse events and 
discontinuation of treatment due to treatment failure (Table 10).  The full list of reported adverse 
events is shown in Appendix table 16. 
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Table 10: The most common adverse events reported in Crohn’s disease trials in adults identified by 
systematic review, listed by frequency of reporting 
Outcome Trials measuring 
outcome 
No. % (of 
181) 
Discrete adverse events 
Abdominal pain 102 56.4% 
Headache 96 53.0% 
Crohn's disease (aggravated) 89 49.2% 
Nausea 88 48.6% 
Pre-specified adverse event categories 
Discontinuation of treatment due to adverse events 102 56.4% 
Total adverse events 93 51.4% 
Discontinuation of treatment due to various reasons (Protocol non-
compliance, lost to follow up, prohibited medication use, withdrawal of 
consent) 
83 45.9% 
Total serious adverse events 76 42.0% 
Discontinuation of treatment due to treatment failure (insufficient 
therapeutic effect, exacerbation of Crohn's, development of complications 
of Crohn's, need for additional therapy or surgery) 
75 41.4% 
 
3.3.4. Categorisation into Filter 2.0 
The 93 outcomes identified in the systematic review were mapped to 35 outcome domains in the 
Filter 2.0 framework.  The framework is shown in Figure 11 below, showing the outcome domains 
listed in order of the number of trials measuring the outcomes within their trial endpoints.  The 
domains in bold are those which match, identically or closely, the core outcomes from the brief 
and comprehensive ICF core sets for IBD100. A discussion of the alignment between the mapped 
outcomes in Filter 2.0 and the ICF core sets is presented in a later section (3.3.5). The Filter 2.0 
framework with the comprehensive list of domains, outcomes, and outcome measures is shown 
in Appendix table 23. 
The 577 adverse events and 10 pre-specified AE categories have been categorised into the 
framework across 46 domains, as shown in Figure 12.  Again, the domains in bold are those that 
match the core outcomes from the ICF core sets for IBD and a discussion of fit takes place in a 
later section (3.3.5).  The Filter 2.0 framework of adverse events with the comprehensive list of 
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domains, the MedDRA preferred terms and the corresponding higher-level group terms (HLGT) is 
in Appendix table 16. 
3.3.4.1. Impact of health conditions concept 
A key difference between the outcomes and AEs versions of Filter 2.0 is the split of domains.  For 
outcomes, 15 domains are within the impact of health conditions concept, whilst the same 
category includes only four domains for the AEs framework (Figure 11, Figure 12). 
DEATH CORE AREA 
Outcomes in the core area of death were rarely recorded as endpoints in trials (2/181, 1.1%) but 
were reported in AE sections much more commonly (49/181, 27.1%). 
ECONOMIC IMPACT CORE AREA 
Two domains were identified for outcomes under the economic impact core area.  Outcomes 
related to individual resource use were reported in 163/181 (90.1%) studies, measured as part of 
indices in 156/181 (86.1%) and as additional single measures in 83/181 (45.9%) reports. The 
outcomes included in this domain are the need for additional steroids, therapy or surgery; the 
need for hospitalisation; steroid dose; withdrawal or tapered steroids; and resection surgery.  A 
number of measures are used for this including indices (CDAI and HBI) but commonly clinician 
reported outcomes and PROMs (Appendix table 23). A second outcome domain is health care 
costs, which were measured by three trials (1.7%).  Outcomes included costs of interventions, 
costs per QALYs gained and incremental cost effectiveness ratios, which are the comparison of 
the differences in costs and QALYs between two treatments. 
Only one domain was identified for AEs in the economic impact core areas.  Individual resource 
adverse events were reported in 38/181 (21.0%) trials.  These AEs included the need for 
hospitalisation, surgery and antibiotic therapy (Appendix table 24). 
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Figure 11: Filter 2.0 showing domains of outcomes measured in endpoints in Crohn's Disease trials (frequency & percentage of studies reporting outcomes in this domain) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact Economic impact Pathophysiological manifestations 
Domains Death 
due to 
Crohn’s 
(2/181, 
1.1%) 
Quality of life (167/181, 92.3%) 3,4 
ICF d810-d839: Education (82/181, 
45.3%) 1, 2 
ICF d840-d859: Work and 
employment (82/181, 45.3%) 1, 2 
ICF d9: Community, social and civic 
life (82/181, 45.3%) 3 
Patient perception of health (82/181, 
45.3%) 
ICF d5301: Regulating defecation 
(77/181, 42.5%) 1, 2 
Utility of treatment (71/181, 39.2%) 
ICF d4: Mobility (14/181, 7.7%) 
ICF d5: Self-care (14/181, 7.7%) 3,4 
ICF d640: Doing housework (14/181, 
7.7%) 
ICF d240: Handling stress and other 
psychological demands (3/181, 1.7%) 
ICF d7: Interpersonal interactions 
(1/181, 0.6%) 1, 2 
Individual 
resource use 
(163/181, 90.1%) 
Health care cost 
(3/181, 1.7%) 
ICF s540: Structure of intestine (174/181, 96.1%) 1, 2 
ICF b525: Defecation functions (172/181, 95.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (169/181, 93.4%) 1, 2 
ICF s810: Structures of areas of skin (166/182, 91.7%) 3 
ICF b28016: Pain in joints (163/181, 90.1%) 1 
ICF b5500: Body temperature (163/181, 90.1%) 
ICF s220: Structure of eyeball (162/181, 89.5%) 
ICF s770: Additional musculoskeletal structures related to 
movement (162/181, 89.5%) 1, 2 
ICF b530: Weight maintenance functions (157/181, 86.7%) 1 
ICF b430: Haematological system functions (156/181, 86.2%) 1 
Biomarkers (102/181, 56.4%) 
ICF b152: Emotional functions (83/181, 45.9%) 1, 2 
ICF b640: Sexual functions (83/181, 45.9%) 1 
ICF b130: Energy and drive functions (82/181, 45.3%) 1, 2 
ICF b535: Sensations associated with the digestive system 
(77/181, 42.5%) 1 
ICF b134: Sleep functions (77/181, 42.5%) 1, 2 
ICF b280: Sensation of pain (25/181, 13.8%) 3 
ICF b515: Digestive functions (14/181, 7.7%) 1, 2 
ICF b510: Ingestion functions (6/181, 3.3%)  
ICF b540: General metabolic function (2/181, 1.1%) 
 
1 In IBD ICF comprehensive set 
2 In ICF brief set 
3 Similar item in ICF comprehensive set 
4 Similar item in ICF brief set 
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Figure 12: Filter 2.0 showing domains of adverse events reported in Crohn's Disease trials (frequency and percentage of studies reporting outcomes in this domain) 
Top level Crohn’s Filter framework of adverse events reported in Crohn's Disease trials (number of studies reporting outcomes in this domain) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
Domains Death 
(49/181, 
27.1%) 
Utility of 
treatment 
(53/181, 29.3%)* 
Patient 
perception of 
health (5/181, 
2.8%) 
Individual 
resource 
use 
(38/181, 
21.0%) 
Infections (106/181, 58.6%) 
ICF b280: Sensation of pain (105/181, 58.0%) 3 
ICF s540: Structure of intestine (96/181, 53.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (90/181, 49.7%) 1, 2 
ICF b535: Sensations associated with the digestive system (90/181, 49.7%) 1 
ICF b8: Functions of the skin and related structures (76/181, 42.0%) 3 
ICF b435: Immunological system functions (65/181, 35.9%) 1 
ICF b525: Defecation functions (65/181, 35.9%) 1, 2 
ICF b510: Ingestion functions (59/181, 32.6%)  
ICF b28016: Pain in joints (58/181, 32.0%) 1 
ICF b540: General metabolic function (50/181, 27.6%) 
ICF b130: Energy and drive functions (47/181, 26.0%) 1, 2 
ICF b5500: Body temperature (47/181, 26.0%) 
ICF b430: Haematological system functions (39/181, 21.5%) 1 
ICF b515: Digestive functions (35/181, 19.3%) 1, 2 
ICF b7: Neuromusculoskeletal and movement-related functions (33/181, 18.2%) 
ICF b240: Sensations associated with hearing and vestibular function (31/181, 17.1%) 
ICF b555: Endocrine gland functions (25/181, 13.8%) 
ICF b415: Blood vessel functions (24/181, 13.3%) 
ICF b152: Emotional functions (22/181, 12.2%) 1, 2 
ICF b6: Genitourinary and reproductive functions (22/181, 12.2%) 3 
Unspecified: cancer (20/181, 11.0%) 
ICF b440-b460: Respiratory functions (20/181, 11.0%) 
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Top level Crohn’s Filter framework of adverse events reported in Crohn's Disease trials (number of studies reporting outcomes in this domain) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
ICF s6: Structures related to the genitourinary and reproductive systems (20/181, 11.0%) 
ICF b134: Sleep functions (19/181, 10.5%) 1, 2 
ICF b410: Heart functions (18/181, 9.9%) 
ICF b545: Water, mineral and electrolyte balance functions (18/181, 9.9%) 1 
Unspecified: general system conditions (18/181, 9.9%) 
ICF b420: Blood pressure functions (16/181, 8.8%) 
ICF s550-s580: Structures related to the metabolic and endocrine systems (16/181, 8.8%) 
ICF b530: Weight maintenance functions (13/181, 7.2%) 1 
ICF s3: Structures involved in voice and speech (12/181, 6.6%) 
ICF b210-b220: Seeing functions and sensations associated with the eye (11/181, 6.1%) 
ICF b110-b147: Other mental functions (10/181, 5.5%) 
ICF s8: Skin and related structures (10/181, 5.5%) 
Biomarkers (9/181, 5.0%) 
ICF b250: Taste function (8/181, 4.4%) 
ICF s4: Structures of the cardiovascular, immunological and respiratory systems (8/181, 4.4%) 
ICF s530: Structure of stomach (5/181, 2.8%) 
ICF s1: Structures of the nervous system (4/181, 2.2%) 
ICF s7: Structures related to movement (2/181, 1.1%) 3,4 
ICF s2: The eye, ear and related structures (1/181, 0.5%) 
1 In IBD ICF comprehensive set 2 In IBD ICF brief set 3 Similar item in IBD ICF comprehensive set 4 Similar item in IBD ICF brief set  
* includes reports of 10 pre-specified events: Adverse events, Serious adverse events, Treatment-related adverse events, Treatment-related serious adverse events, Treatment withdrawal 
due to adverse events, Treatment withdrawal due to serious adverse events, Treatment withdrawal due to treatment-related adverse events, Treatment withdrawal due to treatment-
related serious adverse events, Treatment withdrawal due to treatment failure (defined as insufficient therapeutic effect, exacerbation of Crohn’s, development of complications or Crohn’s 
or need for additional therapy or surgery), and treatment withdrawal due to various reasons (including protocol non-compliance, lost to follow up, use of prohibited medication and 
withdrawal of consent). 
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LIFE IMPACT CORE AREA 
OUTCOMES 
Outcomes were categorised into 12 domains in the core area of life impact. Most trials measured 
outcomes within the quality of life domain (167/181, 92.3% with 163/181, 90.1% as part of a 
composite index and 16/181, 8.8% reporting single outcome measures).  The outcomes in this 
domain were wellbeing and general quality of life.  Measurement of quality of life was through 
both disease-specific PROMs such as the Gastrointestinal Quality of Life Index320 and generic 
quality of life questionnaires, such as the Short-Form 12 health survey321.  Wellbeing measures 
were predominantly PROMs, and included diary card assessments and global assessments of 
wellbeing (Appendix table 23). 
Between 77/181 and 82/181 (42.5% and 45.3%) studies measured outcomes in the following 
domains: education; work and employment; community, social and civic life; patient perception 
of health; carrying out daily routine; and regulating defecation.  These numbers were primarily 
accounted for by the use of the IBDQ, which included outcomes such as condition interferes with 
social life, unable to attend school or work, and needing to rush to the toilet. 
39.2% (71/181) of trials measured outcomes within the domain of utility of treatment.  This 
domain includes outcomes related to the efficacy, acceptability and tolerability of treatment.  All 
71 trials used individual measures to record them such as pill counts, PROMs and clinician 
reported outcomes.   
A minority of studies (14/181, 7.7%) measured outcomes in the domains mobility, self-care, and 
doing housework.  The use of the SF-36 as an outcome measurement tool accounts for these 
outcomes, which include bending, kneeling or stooping; bathing or dressing; and moderate 
activities. 
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The final life impact outcome domains, which were only reported in two or fewer papers, were 
handling stress or other psychological demands (2/181, 1.1%) and interpersonal interactions and 
relationships (1/181, 0.6%).  The outcomes were measured by questionnaires. 
ADVERSE EVENTS 
Only two domains in the core area of life impact were relevant for AEs.  Utility of treatment was 
the largest domain with 88.4% of trials reporting AEs within this category.  MedDRA preferred 
terms within this domain included all types of injection or infusion site reactions, post procedural 
complications, drug intolerance and overdoses (Appendix table 24).  In addition, the pre-specified 
categories of AEs in the methods section 3.2.3 (including all reasons for withdrawal) were counted 
within this domain.  Five trials reported AEs within the patient perspective of health domain and 
two adverse events were reported: malaise and feeling abnormal. 
3.3.4.2. Pathophysiological manifestations concept 
Adverse event domains were much more common within the concept of pathophysiological 
manifestations.  Whilst 20 domains were matched to the outcomes measured by Crohn’s disease 
trials, the AEs reported in the same trials matched to 42 domains (Figure 11, Figure 12). 
PATHOPHYSIOLOGICAL MANIFESTATIONS CORE AREA 
OUTCOMES 
The vast majority of trials (174/181, 96.1%) measured outcomes related to the structure of the 
intestine, including the presence of fistula, abscesses, ulcers or perianal disease.  In 85/181 
(47.0%) of these studies the presence of changes in the structure of the intestine were not 
measured as part of a disease activity index (such as the CDAI).  Outcome measures included a 
number of endoscopic scores, such as the Crohn’s Disease Endoscopic Index of Severity (CDEIS)322, 
the Simple Endoscopic Score for Crohn’s Disease (SES-CD)322, D’Haens endoscopic score323, and 
Rutgeert’s score324, as well as histological scores and other measures such as ultrasound scans and 
physician assessment (Appendix table 23). Discussion of the endoscopic measures used as primary 
and secondary endpoints was presented in Chapter 2.  
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Most trials, 172/181 (95.0%), measured outcomes in the defecation functions domain; 170/181 
(93.9%) included endpoints that measured these outcomes as part of an index and 19/181 (10.5%) 
included endpoints that measured these outcomes as individual measurements.  Outcomes within 
this domain are faecal output, faecal consistency, frequency of defecation, faecal continence, 
flatulence, diarrhoea, blood with stool and fistula discharge. Measurement of these outcomes was 
with the CDAI, HBI, VHAI, IBDQ, PDAI, adapted-Vaizey faecal incontinence score, IBS severity 
scoring system and diary card assessments. 
Outcomes in some domains were generally only measured as part of key disease activity indices 
such as CDAI and HBI and therefore were reported in similar numbers of trials (162/181 - 166/181, 
89.5% - 91.7%).  These pathophysiological manifestation outcome domains, with examples of 
outcomes in brackets, were pain in abdomen or stomach; changes in structures of areas of skin 
(extra intestinal lesions and perianal duration); pain in joints (arthralgia), changes in body 
temperature (fever or prolonged fever), changes in the structure of the eyeball (uveitis); additional 
musculoskeletal structures related to movement (arthritis).  Similar numbers of trials measured 
outcomes in two other domains: weight maintenance functions (body mass) was measured by key 
indices (CDAI, VHAI, 156/181, 86.2%) but also by individual measures (15/181, 8.3%) including BMI 
and mid-arm muscle circumference.  Similarly, haematological system functions (blood 
abnormalities) were measured through the same key indices (156/181, 86.2%) but also by blood 
counts and various tests such as haematocrit (23/181, 12.8%). 
Outcomes in a second tier of domains were reported by between 77/181 and 83/181 (42.5% and 
45.9%) trials, which largely reflects the use of the IBDQ to measure endpoints.  These domains 
were emotional functions, sexual functions, energy and drive functions (including appetite), 
sensations associated with the digestive system (including nausea and bloating) and sleep 
functions. There were some individual outcome measures used for each domain too, including 
outcome specific questionnaires and patient diaries (PROMs). 
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Biomarkers are reported in 102/181 (56.4%) studies with 102 individual outcome measures, 
indicating a large amount of variability in measurement, due to exploratory endpoints.  The 
outcomes reported are inflammation and intestinal permeability and a range of measures are 
used including erythrocyte sedimentation rate, the presence of cytokines and bacteria in mucosal 
tissues and plasma, and intestinal permeability tests.  
Between 2/181 and 25/181 (1.1% and 13.8%) papers measured outcomes in four other domains: 
sensation of pain (bodily pain and perianal pain), digestive functions (absorption of nutrients), 
ingestion functions (vomiting, calorie intake, maintenance of full diet, return to full diet and return 
to liquid diet) and general metabolic functions (liver or kidney function).  These outcomes were 
measured using a range of measurement tools from blood tests through to PROMs. 
ADVERSE EVENTS 
Out of 42 domains, approximately half of the trials reported AEs in five domains (Figure 12).  AEs 
in the domain of infections were reported in 106 trials (of 181, 58.6%).  Infections is not a domain 
for outcomes.    Sensation of pain was reported in 105 trials (of 181, 58.0%) and the most common 
AEs reported in that domain were headache, back pain, myalgia, pain and proctalgia (adverse 
events detail is in Appendix table 16).    AEs in the structure of the intestine domain were reported 
in 53.0% (96/181) of trials and the most common AEs were Crohn’s disease (aggravated or 
exacerbated), fistula, rectal haemorrhage and anal fissure.  Sensations associated with the 
digestive system were reported by 49.7% of trials (90/181) and the most common AEs were 
nausea, dyspepsia and abdominal distention.  AEs in the pain in the abdomen domain were 
reported in 90/181, 49.7% of trials. 
Between 58 and 76 (/181, 32.0%-35.9%) of trials report AEs in five domains.  AEs in the domain of 
functions of the skin and related structures were reported in 76/181 trials (42%) with rash, acne, 
pruritus and alopecia the most common events.  Immunological system function domain (65/181, 
35.9%) includes the presence of drug-specific antibodies, leukopenia and hypersensitivity as the 
most common events.  Within the defecation function domain (65/181, 35.9%), diarrhoea, 
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flatulence and constipation are the most common AEs.  The domain of Ingestion functions 
(59/181, 32.6%) is made up of vomiting, dry mouth and retching AEs.  The pain in joints domain 
(58/181, 32.0%) includes arthralgia as its only AE. 
A further nine AE domains match those identified in the Filter 2.0 outcomes domains (example 
outcomes in parentheses): body temperature (pyrexia) (47/181, 26.0%), weight maintenance 
functions (weight loss) (13/181, 7.2%), haematological system functions (blood abnormalities) 
(39/181, 21.5%), biomarkers (C-reactive protein) (9/181, 5.0%), emotional functions (e.g. 
depression) (22/181, 12.2%), energy and drive functions (fatigue, appetite) (47/181, 26%), sleep 
functions (19/181, 10.5%), digestive functions (intestinal obstructions) (35/181, 19.3%) and 
general metabolic functions (e.g. laboratory parameters) (50/181, 27.6%). 
AEs were reported in a further 23 domains as shown in Figure 12 and Appendix table 16, including 
cancer (20/181, 11.0%) and general system conditions (swelling, oedema) (18/181, 9.9%) which 
were not coded from the ICF. 
3.3.5. Mapping the ICF core sets for IBD against Filter 2.0 
Table 11 shows the Filter 2.0 domains and the key indices and questionnaires mapped against the 
brief ICF core set for IBD.  The brief set, known as the disability index for IBD100 is the main 
comparison as this set is designed to be reported in clinical trials.  Appendix table 25 shows the 
same information but mapped against the comprehensive core set for IBD.  The outcomes from 
the environment chapter of the ICF have been omitted as they are contextual and environmental 
and are not relevant to outcomes and AEs reporting. 
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Table 11: Filter 2.0 domains and key outcome measurement tools mapped against the ICF brief core set for IBD (disability index for IBD) 
Brief set Filter 2.0? CDAI? IBDQ? SF-36? HBI? PDAI? VHAI? Adverse 
events? ICF code ICF name 
b130 Energy and drive functions yes     yes yes       yes 
b134 Sleep functions yes     yes         yes 
b152 Emotional functions yes     yes yes       yes 
b1801 Body image                  
b28012 Pain in stomach or abdomen yes   yes yes b280 - 
sensation 
of pain 
yes b280 - 
sensation 
of pain 
  yes 
b515 Digestive functions yes               Yes 
b525 Defecation functions yes   yes yes   yes yes yes Yes 
s540 Structure of intestine yes   yes     yes yes yes Yes 
s770 Additional musculoskeletal 
structures related to 
movement 
yes   yes     yes      
d5301 Regulating defecation yes     yes          
d570 Looking after one's health d5 Quality of 
life 
Self-care 
yes - 
quality 
of life 
  yes - self 
care 
yes - 
quality 
of life 
     
d7 Interpersonal interactions and 
relationships 
yes     yes          
d810-
d839 
Education yes      yes yes        
d840-
d859 
Work and employment yes      yes yes        
Note: CDAI – Crohn’s Disease Activity Index; IBDQ – Inflammatory Bowel Disease Questionnaire; SF-36 – Short Form 36; HBI – Harvey 
Bradshaw Index; PDAI – Perianal Disease Activity Index; VHAI – Van Hees Activity Index 
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3.3.5.1. Filter 2.0 results and the ICF core sets for IBD 
There is a good degree of fit between the outcomes measured in Crohn’s disease trials and the 
core sets as shown in Table 11 and Appendix table 25, but there are differences to note.   The 
domains under core areas of death and economic impact / resource use within the impact of 
health conditions concept, are not covered by the ICF core sets.   
The life impact section of Filter 2.0 for Crohn’s disease outcomes includes domains for patient 
perception of health, mobility, doing housework, handling stress and other psychological 
demands and utility of treatment, none of which is captured by the ICF core sets.  
On the pathophysiological manifestations side of the hierarchy, Crohn’s disease outcomes are 
reported in the domains of body temperature, changes in the structure of the eyeball, biomarkers, 
ingestion functions and general metabolic function, which are not covered the ICF core sets. 
There are four outcomes reported in the ICF comprehensive core set for IBD that are not reported 
in the literature and are not measured by any of the key measures for disease activity and quality 
of life: body image; immunological system functions; water, mineral and electrolyte balance 
functions; and procreation functions.  Body image is also reported as part of the brief core set, 
indicating its importance for patients with IBD, according to the consensus process undertaken in 
developing the IBD ICF core sets.   This is the only outcome from the brief core set not captured 
by the domains in Filter 2.0. Additionally, digestive functions, which involves the breakdown of 
food and absorption of nutrients, is captured as an AE domain, but not as an outcome domain. 
A comparison of the core sets against the AE domains highlights a good level of fit with the body 
structures and body functions domains of the ICF.  Within the brief core set, the only domain not 
captured is body image.  Within the comprehensive set additional missing AE domains are sexual 
functions and procreation functions.  As might be expected, none of the domains related to 
activities and participation are included as AE domains. 
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3.3.5.2. Filter 2.0 results, the ICF core sets for IBD and the key measurement tools used in Crohn’s 
disease 
CROHN’S DISEASE ACTIVITY INDEX (CDAI) 
The CDAI measures mainly outcomes of pathophysiological nature and only one outcome in a 
domain of the life impact side of the framework (Figure 13): general wellbeing, which sits in the 
quality of life domain.  A number of the comprehensive ICF core outcomes are not represented by 
the CDAI.  More importantly, given its intended use as a clinical trial outcome measure, a number 
of the brief core set outcomes are not part of the CDAI.  The CDAI measures outcomes related to 
five out of 14 of the brief core set but it does not measure outcomes related to energy and drive, 
sleep, emotions, body image, digestive functions, regulating defecation and interpersonal 
interactions and relationships. 
INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) 
The IBDQ covers a broad number of the outcomes of the ICF core sets, which are split reasonably 
equally across the two Filter 2.0 core areas of life impact and pathophysiological manifestations 
(Figure 14).  Out of the mapped outcome measures, it has the best coverage of the brief core set, 
as it includes nine of the 14 outcomes.  The IBDQ does not include any measure of body image, 
digestive functions, structure of the intestine, additional musculoskeletal structures related to 
movement, and looking after one’s health.  It is interesting to note that if the IBDQ is used in 
combination with the CDAI, as it frequently is in the literature (71/181, 39.2% of trials) 12 of the 
brief set outcomes would be measured, leaving only two outcomes unmeasured; body image and 
digestive functions. 
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Figure 13: Crohn’s Disease Activity Index (CDAI) mapped against Filter 2.0 outcomes in Crohn’s trials and the ICF core sets for IBD (measured in 156 studies) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
Domains Death 
due to 
Crohn’s 
(2/182, 
1.1%) 
Quality of life (167/181, 92.3%) 3,4 
ICF d810-d839: Education (82/181, 
45.3%) 1, 2 
ICF d840-d859: Work and employment 
(82/181, 45.3%) 1, 2 
ICF d9: Community, social and civic life 
(82/181, 45.3%) 3 
Patient perception of health (82/181, 
45.3%) 
ICF d5301: Regulating defecation 
(77/181, 42.5%) 1, 2 
Utility of treatment (71/181, 39.2%) 
ICF d4: Mobility (14/181, 7.7%) 
ICF d5: Self-care (14/181, 7.7%) 3,4 
ICF d640: Doing housework (14/181, 
7.7%) 
ICF d240: Handling stress and other 
psychological demands (3/181, 1.7%) 
ICF d7: Interpersonal interactions 
(1/181, 0.5%) 1, 2 
Individual 
resource use 
(163/181, 
90.1%) 
Health care 
cost (3/182, 
1.6%) 
ICF s540: Structure of intestine (174/181, 96.1%) 1, 2 
ICF b525: Defecation functions (172/181, 95.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (169/181, 93.4%) 1, 2 
ICF s810: Structures of areas of skin (166/181, 91.7%) 3 
ICF b28016: Pain in joints (163/181, 90.1%) 1 
ICF b5500: Body temperature (163/181, 90.1%) 
ICF s220: Structure of eyeball (162/181, 89.5%) 
ICF s770: Additional musculoskeletal structures related to 
movement (162/181, 89.5%) 1, 2 
ICF b530: Weight maintenance functions (157/181, 86.7%) 1 
ICF b430: Haematological system functions (156/181, 86.2%) 1 
Biomarkers (102/181, 56.4%) 
ICF b152: Emotional functions (83/181, 45.9%) 1, 2 
ICF b640: Sexual functions (83/181, 45.9%) 1 
ICF b130: Energy and drive functions (82/181, 45.3%) 1, 2 
ICF b535: Sensations associated with the digestive system (77/181, 
42.5%) 1 
ICF b134: Sleep functions (77/181, 42.5%) 1, 2 
ICF b280: Sensation of pain (25/181, 13.8%) 3 
ICF b515: Digestive functions (14/181, 7.7%) 1, 2 
ICF b510: Ingestion functions (6/181, 3.3%)  
ICF b540: General metabolic function (2/181, 1.1%) 
 
1 In IBD ICF comprehensive set 
2 In IBD ICF brief set 
3 Similar item in IBD ICF comprehensive set 
4 Similar item in IBD ICF brief set 
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Figure 14: Inflammatory Bowel Disease Questionnaire (IBDQ) mapped against Filter 2.0 outcomes in Crohn’s trials and the ICF cores sets for IBD (measured in 77 studies) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
Domains Death 
due to 
Crohn’s 
(2/182, 
1.1%) 
Quality of life (167/181, 92.3%) 3,4 
ICF d810-d839: Education (82/181, 45.3%) 
1, 2 
ICF d840-d859: Work and employment 
(82/181, 45.3%) 1, 2 
ICF d9: Community, social and civic life 
(82/181, 45.3%) 3 
Patient perception of health (82/181, 
45.3%) 
ICF d5301: Regulating defecation (77/181, 
42.5%) 1, 2 
Utility of treatment (71/181, 39.2%) 
ICF d4: Mobility (14/181, 7.7%) 
ICF d5: Self-care (14/181, 7.7%) 3,4 
ICF d640: Doing housework (14/181, 7.7%) 
ICF d240: Handling stress and other 
psychological demands (3/181, 1.7%) 
ICF d7: Interpersonal interactions (1/181, 
0.5%) 1, 2 
Individual 
resource 
use 
(163/181, 
90.1%) 
Health 
care cost 
(3/182, 
1.6%) 
ICF s540: Structure of intestine (174/181, 96.1%) 1, 2 
ICF b525: Defecation functions (172/181, 95.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (169/181, 93.4%) 1, 2 
ICF s810: Structures of areas of skin (166/181, 91.7%) 3 
ICF b28016: Pain in joints (163/181, 90.1%) 1 
ICF b5500: Body temperature (163/181, 90.1%) 
ICF s220: Structure of eyeball (162/181, 89.5%) 
ICF s770: Additional musculoskeletal structures related to 
movement (162/181, 89.5%) 1, 2 
ICF b530: Weight maintenance functions (157/181, 86.7%) 1 
ICF b430: Haematological system functions (156/181, 86.2%) 1 
Biomarkers (102/181, 56.4%) 
ICF b152: Emotional functions (83/181, 45.9%) 1, 2 
ICF b640: Sexual functions (83/181, 45.9%) 1 
ICF b130: Energy and drive functions (82/181, 45.3%) 1, 2 
ICF b535: Sensations associated with the digestive system 
(77/181, 42.5%) 1 
ICF b134: Sleep functions (77/181, 42.5%) 1, 2 
ICF b280: Sensation of pain (25/181, 13.8%) 3 
ICF b515: Digestive functions (14/181, 7.7%) 1, 2 
ICF b510: Ingestion functions (6/181, 3.3%)  
ICF b540: General metabolic function (2/181, 1.1%) 
 
1 In IBD ICF comprehensive set 
2 In IBD ICF brief set 
3 Similar item in IBD ICF comprehensive set 
4 Similar item in IBD ICF brief set 
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SHORT-FORM 36 HEALTH SURVEY (SF-36) 
The SF-36 survey populates more domains on the life impact side of the Filter 2.0 framework 
(Figure 15), which is to be expected, as it is a health-related quality of life measure.  It also captures 
emotional and energy and drive functions, as well as a broad definition of bodily pain, all domains 
of pathophysiological manifestations.  It includes several domains not considered in the ICF core 
sets: patient perception of health, mobility and doing housework.  However, it reports only six of 
the brief set outcomes.  If the SF-36 were used in place of the IBDQ alongside the CDAI it provides 
a much worse fit of the brief set, measuring just nine of the outcomes with the loss of sleep 
functions, defecation functions,  regulating defecation and interpersonal interactions and 
relationships. 
HARVEY-BRADSHAW INDEX (HBI) 
The HBI is slightly narrower in scope than the CDAI with the removal of three items (Figure 16).  
However, in terms of the match with the brief core set, the switch between the CDAI and the HBI 
would have no impact as they cover (and miss) the same core outcomes.  As such, the use of HBI 
with either the IBDQ or the SF-36 would have the same results as those described above. 
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Figure 15: Short-Form 36 (SF-36) mapped against Filter 2.0 outcomes in Crohn’s trials and the ICF cores sets for IBD (measured in 14 studies) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
Domains Death 
due to 
Crohn’s 
(2/182, 
1.1%) 
Quality of life (167/181, 92.3%) 3,4 
ICF d810-d839: Education (82/181, 45.3%) 
1, 2 
ICF d840-d859: Work and employment 
(82/181, 45.3%) 1, 2 
ICF d9: Community, social and civic life 
(82/181, 45.3%) 3 
Patient perception of health (82/181, 
45.3%) 
ICF d5301: Regulating defecation (77/181, 
42.5%) 1, 2 
Utility of treatment (71/181, 39.2%) 
ICF d4: Mobility (14/181, 7.7%) 
ICF d5: Self-care (14/181, 7.7%) 3,4 
ICF d640: Doing housework (14/181, 7.7%) 
ICF d240: Handling stress and other 
psychological demands (3/181, 1.7%) 
ICF d7: Interpersonal interactions (1/181, 
0.5%) 1, 2 
Individual 
resource 
use 
(163/181, 
90.1%) 
Health 
care cost 
(3/182, 
1.6%) 
ICF s540: Structure of intestine (174/181, 96.1%) 1, 2 
ICF b525: Defecation functions (172/181, 95.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (169/181, 93.3%) 1, 2 
ICF s810: Structures of areas of skin (166/181, 91.7%) 3 
ICF b28016: Pain in joints (163/181, 90.1%) 1 
ICF b5500: Body temperature (163/181, 90.1%) 
ICF s220: Structure of eyeball (162/181, 89.5%) 
ICF s770: Additional musculoskeletal structures related to 
movement (162/181, 89.5%) 1, 2 
ICF b530: Weight maintenance functions (157/181, 86.7%) 1 
ICF b430: Haematological system functions (156/181, 86.2%) 1 
Biomarkers (102/181, 56.4%) 
ICF b152: Emotional functions (83/181, 45.9%) 1, 2 
ICF b640: Sexual functions (83/181, 45.9%) 1 
ICF b130: Energy and drive functions (82/181, 45.9%) 1, 2 
ICF b535: Sensations associated with the digestive system 
(77/181, 42.5%) 1 
ICF b134: Sleep functions (77/181, 42.5%) 1, 2 
ICF b280: Sensation of pain (25/181, 13.8%) 3 
ICF b515: Digestive functions (14/181, 7.7%) 1, 2 
ICF b510: Ingestion functions (6/181, 3.3%)  
ICF b540: General metabolic function (2/181, 1.1%) 
 
1 In IBD ICF comprehensive set 
2 In IBD ICF brief set 
3 Similar item in IBD ICF comprehensive set 
4 Similar item in IBD ICF brief set 
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Figure 16: Harvey-Bradshaw Index (HBI) mapped against Filter 2.0 outcomes in Crohn’s trials and the ICF cores sets for IBD (measured in 14 studies)  
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
Domains Death 
due to 
Crohn’s 
(2/181, 
1.1%) 
Quality of life (167/181, 92.3%) 3,4 
ICF d810-d839: Education (82/181, 45.3%) 1, 
2 
ICF d840-d859: Work and employment 
(82/181, 45.3%) 1, 2 
ICF d9: Community, social and civic life 
(82/181, 45.3%) 3 
Patient perception of health (82/181, 
45.3%) 
ICF d5301: Regulating defecation (77/181, 
42.5%) 1, 2 
Utility of treatment (71/181, 39.2%) 
ICF d4: Mobility (14/181, 7.7%) 
ICF d5: Self-care (14/181, 7.7%) 3,4 
ICF d640: Doing housework (14/181, 7.7%) 
ICF d240: Handling stress and other 
psychological demands (3/181, 1.7%) 
ICF d7: Interpersonal interactions (1/181, 
0.5%) 1, 2 
Individual 
resource 
use 
(163/181, 
90.1%) 
Health 
care cost 
(3/181, 
1.7%) 
ICF s540: Structure of intestine (174/181, 96.1%) 1, 2 
ICF b525: Defecation functions (172/181, 95.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (169/181, 93.4%) 1, 2 
ICF s810: Structure of areas of skin (166/181, 91.7%) 3 
ICF b28016: Pain in joints (163/181, 90.1%) 1 
ICF b5500: Body temperature (163/181, 90.1%) 
ICF s220: Structure of eyeball (162/181, 89.5%) 
ICF s770: Additional musculoskeletal structures related to 
movement (162/181, 89.5%) 1, 2 
ICF b530: Weight maintenance functions (157/181, 86.7%) 1 
ICF b430: Haematological system functions (156/181, 86.2%) 1 
Biomarkers (102/181, 56.4%) 
ICF b152: Emotional functions (83/181, 45.9%) 1, 2 
ICF b640: Sexual functions (83/181, 45.9%) 1 
ICF b130: Energy and drive functions (82/181, 45.3%) 1, 2 
ICF b535: Sensations associated with the digestive system 
(77/181, 42.5%) 1 
ICF b134: Sleep functions (77/181, 42.5%) 1, 2 
ICF b280: Sensation of pain (25/181, 13.8%) 3 
ICF b515: Digestive functions (14/181, 7.7%) 1, 2 
ICF b510: Ingestion functions (6/181, 3.3%)  
ICF b540: General metabolic function (2/181, 1.1%) 
 
1 In IBD ICF comprehensive set 
2 In IBD ICF brief set 
3 Similar item in IBD ICF comprehensive set 
4 Similar item in IBD ICF brief set 
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PERIANAL DISEASE ACTIVITY INDEX (PDAI) 
The PDAI is by its nature much more narrow in scope than either the CDAI or the HBI, which is 
reflected in its mapping to the domains of the Filter 2.0 framework (Figure 17).  All of the outcomes 
from the PDAI map to the pathophysiological manifestations domains.  Only three of the 
outcomes are included in the brief core set.  However, it is the only key index or questionnaire 
from the literature that is entirely contained in the comprehensive set: all five outcomes measured 
in the PDAI are part of the comprehensive set.  If used alongside the SF-36 it would cover eight of 
the brief set core outcomes, which is only one less than the combination of the CDAI and the SF-
36.  The difference is the loss of the outcome measuring additional musculoskeletal structures 
related to movement (arthralgia).  There would also be a switch from the specific reporting of pain 
in the abdomen or stomach to a broader category of bodily pain. 
VAN HEES ACTIVITY INDEX (VHAI) 
The VHAI is by nature designed to be complete with objective outcome measures and, as such, it 
falls entirely within domains of the pathophysiological manifestations core area (Figure 18).  It 
performs weakly against the ICF core sets, with five items within the comprehensive set and only 
two within the brief set; the latter matched domains are defecation functions and structure of 
intestine. 
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Figure 17: Perianal Disease Activity Index mapped against Filter 2.0 outcomes in Crohn’s trials and the ICF cores sets for IBD (measured in 10 studies) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
Domains Death 
due to 
Crohn’s 
(2/181, 
1.1%) 
Quality of life (167/181, 92.3%) 3,4 
ICF d810-d839: Education (82/181, 45.3%) 1, 
2 
ICF d840-d859: Work and employment 
(82/181, 45.3%) 1, 2 
ICF d9: Community, social and civic life 
(82/181, 45.3%) 3 
Patient perception of health (82/181, 
45.3%) 
ICF d5301: Regulating defecation (77/181, 
42.5%) 1, 2 
Utility of treatment (71/181, 32.6%) 
ICF d4: Mobility (14/181, 7.7%) 
ICF d5: Self-care (14/181, 7.7%) 3,4 
ICF d640: Doing housework (14/181, 7.7%) 
ICF d240: Handling stress and other 
psychological demands (3/181, 1.7%) 
ICF d7: Interpersonal interactions (1/181, 
0.5%) 1, 2 
Individual 
resource 
use 
(163/181, 
90.1%) 
Health 
care cost 
(3/181, 
1.7%) 
ICF s540: Structure of intestine (174/181, 96.1%) 1, 2 
ICF b525: Defecation functions (172/181, 95.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (169/181, 93.4%) 1, 2 
ICF s810: Structures of areas of skin (166/181, 91.7%) 3 
ICF b28016: Pain in joints (163/181, 90.1%) 1 
ICF b5500: Body temperature (163/181, 90.1%) 
ICF s220: Structure of eyeball (162/181, 89.5%) 
ICF s770: Additional musculoskeletal structures related to 
movement (162/181, 89.5%) 1, 2 
ICF b530: Weight maintenance functions (157/181, 86.7%) 1 
ICF b430: Haematological system functions (156/181, 86.2%) 1 
Biomarkers (102/181, 56.4%) 
ICF b152: Emotional functions (83/181, 45.9%) 1, 2 
ICF b640: Sexual functions (83/181, 45.9%) 1 
ICF b130: Energy and drive functions (82/181, 45.3%) 1, 2 
ICF b535: Sensations associated with the digestive system 
(77/181, 42.5%) 1 
ICF b134: Sleep functions (77/181, 42.5%) 1, 2 
ICF b280: Sensation of pain (25/181, 13.8%) 3 
ICF b515: Digestive functions (14/181, 7.7%) 1, 2 
ICF b510: Ingestion functions (6/181, 3.3%)  
ICF b540: General metabolic function (2/181, 1.1%) 
 
1 In IBD ICF comprehensive set 
2 In IBD ICF brief set 
3 Similar item in IBD ICF comprehensive set 
4 Similar item in IBD ICF brief set 
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Figure 18: Van-Hees Activity Index (VHAI) mapped against Filter 2.0 outcomes in Crohn’s trials and the ICF cores sets for IBD (measured in 7 studies) 
Concepts Impact of health conditions Pathophysiological manifestations 
Core areas Death Life impact 
Economic 
impact Pathophysiological manifestations 
Domains Death 
due to 
Crohn’s 
(2/181, 
1.1%) 
Quality of life (167/181, 92.3%) 3,4 
ICF d810-d839: Education (82/181, 45.3%) 1, 
2 
ICF d840-d859: Work and employment 
(82/181, 45.3%) 1, 2 
ICF d9: Community, social and civic life 
(82/181, 45.3%) 3 
Patient perception of health (82/181, 
45.3%) 
ICF d5301: Regulating defecation (77/181, 
42.5%) 1, 2 
Utility of treatment (71/181, 39.2%) 
ICF d4: Mobility (14/181, 7.7%) 
ICF d5: Self-care (14/181, 7.7%) 3,4 
ICF d640: Doing housework (14/181, 7.7%) 
ICF d240: Handling stress and other 
psychological demands (3/181, 1.7%) 
ICF d7: Interpersonal interactions (1/181, 
0.5%) 1, 2 
Individual 
resource 
use 
(163/181, 
90.1%) 
Health 
care cost 
(3/181, 
1.7%) 
ICF s540: Structure of intestine (174/181, 96.1%) 1, 2 
ICF b525: Defecation functions (172/181, 95.0%) 1, 2 
ICF b28012: Pain in stomach or abdomen (169/181, 93.4%) 1, 2 
ICF s810: Structures of areas of skin (166/181, 91.7%) 3 
ICF b28016: Pain in joints (163/181, 90.1%) 1 
ICF b5500: Body temperature (163/181, 90.1%) 
ICF s220: Structure of eyeball (162/181, 89.5%) 
ICF s770: Additional musculoskeletal structures related to 
movement (162/181, 89.5%) 1, 2 
ICF b530: Weight maintenance functions (157/181, 86.7%) 1 
ICF b430: Haematological system functions (156/181, 86.2%) 1 
Biomarkers (102/181, 56.4%) 
ICF b152: Emotional functions (83/181, 45.9%) 1, 2 
ICF b640: Sexual functions (83/181, 45.9%) 1 
ICF b130: Energy and drive functions (82/181, 45.3%) 1, 2 
ICF b535: Sensations associated with the digestive system 
(77/181, 42.5%) 1 
ICF b134: Sleep functions (77/181, 42.5%) 1, 2 
ICF b280: Sensation of pain (25/181, 13.8%) 3 
ICF b515: Digestive functions (14/181, 7.7%) 1, 2 
ICF b510: Ingestion functions (6/181, 3.3%)  
ICF b540: General metabolic function (2/181, 1.1%) 
 
1 In IBD ICF comprehensive set 
2 In IBD ICF brief set 
3 Similar item in IBD ICF comprehensive set 
4 Similar item in IBD ICF brief set 
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3.4. Discussion 
3.4.1. Summary of evidence 
A systematic review of the literature on treatments for adults with Crohn’s disease identified 181 
studies.  Trial endpoints and AE data was extracted from the included studies, which resulted in 
the identification of 93 unique outcomes and 577 AEs at the level of individual signs, symptoms 
and events.   Key outcome measurement tools (disease activity indices and PROMs) dominate the 
listings of outcomes, which is not surprising given their prominence in EMA guidance for Crohn’s 
disease.68,325 The CDAI is used in 156/181 (86.2%) studies and contributes 15 outcomes to the 
Crohn’s Filter 2.0 framework.  IBDQ is used in 77/181 (42.5%) studies and contributes 32 outcomes 
to the framework.    All of the most commonly reported outcome domains are those that include 
outcomes measured by the CDAI, which is an outdated measurement tool and no longer 
recommended for use as a trial endpoint, as discussed in Chapter 2. 
A large number of discrete AEs are reported (577) but half of these are reported only once across 
all 181 trials.  The most common AEs are abdominal pain, headache, Crohn’s disease (aggravated) 
and nausea.  Some of the pre-specified AE categories are also commonly reported: discontinuation 
due to adverse events; total adverse events; study withdrawal due to various reasons (including 
loss to follow up and non-compliance); total serious adverse events; and withdrawal due to 
treatment failure.  Treatment-related adverse events were reported in fewer than half of the trials 
(36.5%, 66/181), highlighting the difficulty in accessing good data on harms caused by the 
therapies in clinical trials.  It is difficult to distinguish whether an adverse event reported without 
attribution of causality is related to the drug, the underlying disease process, or a drug-disease 
interaction. 
Individual resource use was a well reported domain for outcomes, which certainly reflects the use 
of CDAI and its question on anti-diarrhoeal medications, but may also reflect the recommendation 
in EMA guidance that steroid sparing and a reduction in surgical procedures make suitable 
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secondary endpoints68.  Individual resource use outcomes were also reported in more than a fifth 
of studies as AEs, specifically as the need for hospitalisation or surgery. Other economic outcomes 
were less well measured. 
96.1% of trials measured outcomes related to the structure of the intestine, which is the influence 
of CDAI, but in half of the trials the presence of changes was measured in other ways, often 
endoscopic and histological scores.  Objective assessments of mucosal healing are recommended 
as co-primary endpoints (with PROMs) of symptomatic remission in the EMA guidance for Crohn’s 
disease68.  As discussed in Chapter 2 the reporting of such primary and secondary endpoints has 
increased over the years. 
AE domains were predominantly in the pathophysiological core area and infections, pain, the 
structure of the intestine, sensations associated with the digestive system and pain in the 
abdomen were all reported in almost half of the trials.  All but infections were also outcome 
domains.  Whilst infections are not reported as specific trial endpoints, they are important for 
many treatments, especially immunosuppressives and biological therapies and often form 
monitoring requirements in clinical trials and in clinical use68,326. 
Biomarkers were measured as outcomes in 102/181(56.4%) of trials.  The importance of this 
domain may be reflective of the inclusion of laboratory measures of inflammation as a potential 
secondary trial endpoint in EMA guidance68.  It may also be reflective of the monitoring capabilities 
and new technologies available to the people running trials.  Whilst only 9/181 (5.0%) of trials 
reported AEs that were classified as biomarkers, many other reported AEs could have been 
classified in a biomarkers category had it not been possible to categorise them more specifically 
using the ICF.  For example, immunological system functions, haematological system functions 
and general metabolic functions are all types of biomarkers and AEs in these domains were 
reported in 35.9%, 21.5% and 27.6% of trials, respectively.  
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The overlaying of the ICF core sets to the Filter 2.0 domains for outcomes and AEs in Crohn’s 
disease trials, highlighted a good deal of fit, although there are differences.  The ICF core sets have 
been through a rigorous process involving both professionals and patients to identify what is most 
important for IBD100 so it might be expected that there should be complete fit.  However, it may 
be too early to expect the core sets to have filtered through to clinical trials in the time from 
publication (2012) to the dates covered by the systematic review (up to 2015).  It is also possible 
that the important outcomes for Crohn’s disease could be different to those that are important 
for all inflammatory bowel diseases. 
The ICF brief core set for IBD, identified as a disability index for IBD by its authors100, has been 
designed for reporting in trials and is reasonably well covered; 13 out of 14 outcomes in the brief 
set are also found in the literature and included in Filter 2.0 domains for Crohn’s disease trials.  
Body image was included as an outcome in both the comprehensive and brief ICF core sets, which 
indicates a high level of importance was placed in it during the robust development process.  
However, this domain did not feature in the trial outcomes or AEs.  In the IBD ICF comprehensive 
set, three other domains were included as important – carrying out daily routine, sexual function 
and procreation function and none of these are reported in the outcomes and AEs (with the 
exception of sexual function being measured within the PDAI in five trials).  This may reflect an 
unwillingness by patients to report such AEs and a focus by trialists on more focused efficacy 
outcomes rather than the wider life impacts. 
Some domains within Filter 2.0 are excluded from the ICF core sets, as they are not covered within 
the scope of the ICF, such as death and economic impact domains.  Further, on the life impact side 
of Filter 2.0, the trials measured outcomes in the domains of patient perception of health, 
mobility, doing housework, handling stress and utility of treatment.  Two important domains, 
reflected in both outcomes and AEs, which are not covered by the IBD ICF sets are patient 
perception of health and the utility of treatment.  This may reflect the fact that these domains are 
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less about measurable characteristics of function and structure of particular organ systems and 
more about the perceptions of patients and physicians on the disease course and treatment and 
therefore again not captured by the design of the ICF.  
Some frequently reported pathophysiological outcome domains are not included in the core sets 
but are within the most reported outcome measurement tool, the CDAI: body temperature and 
changes in the structure of the eyeball (uveitis).  Body temperature was also a well-reported 
adverse event domain. 
None of the outcome measurement tools fit exactly with the ICF core set and only one, the PDAI, 
was contained entirely within it.  This tool is only used in five studies and is used in trials with 
patients with fistulising disease.   The disability index (ICF brief set) has 14 items and the CDAI, 
HBI, PDAI and VHAI cover only five of the core set items whilst the IBDQ and SF-36 cover nine and 
six, respectively. No combination of the measurement tools covers the IBD disability index.  
Interestingly, the use of the CDAI and IBDQ together, which occurs in 40% of the trials, covers only 
12 of the 14 outcomes in the brief core set, and the use of a simpler disability index such as the 
HBI has no impact on the coverage. 
3.4.2. Strengths and limitations 
One of the key difficulties in capturing the impact of a treatment is understanding the impact on 
health states that are not directly measurable.  Outcome measurement tools are designed to help 
overcome this problem but it is often not clear exactly what is being measured.  Measurement 
tools can be used for long periods without being updated, as has been the case for the CDAI.  A 
key strength of this research has been to introduce transparency into the outcome measurements 
by breaking them down into the component signs, symptoms and events that are being measured.  
Matching the findings of the Filter 2.0 categorisation against the ICF core sets for IBD has provided 
an external benchmark to a set of outcomes that have been identified through a rigorous and 
robust process involving reviews, expert surveys, cross-sectional study and a Delphi process.  The 
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method provides a framework for assessing which measurement tools used in the literature 
address current core outcome sets.  Whether the IBD disability index, in the form of the ICF brief 
core set, is to become an important secondary endpoint as argued for by the authors remains to 
be seen and there is some doubt as to its relevance327,328.  However, it currently stands as the only 
form of COS that could be applied to Crohn’s disease and as such is an appropriate comparison.   
The approach taken in this chapter has indirectly developed a method that could be used to assess 
the uptake of core outcome sets, which also includes the measurement instruments.  This is a 
unique element to the research.  The ICF core sets were published in 2012 and the systematic 
review only included trials published up to 2015, which means that the method applied in this 
context is unlikely to reflect the uptake of the core sets due to the time it takes for RCTs to be 
planned, conducted and reported.  However, there is the potential for this method to be applied 
in other contexts where core outcome sets have been recommended and clinical–composite 
measurement tools and PROMs are frequently used. 
The use of existing models for outcome classification in the Filter 2.0310, the ICF312 and the Wilson 
and Cleary model of quality of life313 provide a sound basis for the synthesis of the outcomes into 
a single model.  In particular, the ability to categorise both outcomes and AEs within the same 
domains, rather than by including an “adverse events” domain to catch all is a strength and helps 
to highlight the need for greater consideration of harms of therapy alongside benefits.  The 
method of sorting the outcomes and AEs into domains and reporting how many trials report those 
domains gave an understanding of the facets of life being measured in patients with Crohn’s 
disease and was a pragmatic approach to assessing the important events in lieu of other consensus 
methods.   
However, one key weakness of the use of Filter 2.0 stems from the categorisation in domains.  The 
flexibility of the model is also its downfall as it would be possible for another researcher to 
categorise the outcomes and AEs differently.  Decisions were taken on the grouping of ICF coded 
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outcomes and AEs, with the clinical expertise of KB, but another researcher may have grouped 
codes to different levels, with a resultant impact on the number of outcomes and AEs captured in 
that domain and therefore the number of trials reporting those domains.  The ICF provides an 
objective measure of disability to capture a broader range of the impact of a medical condition, 
but it does not capture how an individual feels about the disability experienced329.  It will therefore 
always be necessary to include domains from other models, such as quality of life models, to 
capture how an individual feels about the disabling nature of their condition and their response 
to it.  Within this classification process, it was also necessary to add additional domains and once 
again, the flexibility in those choices may mean that another researcher would choose differently.   
A recently published taxonomy, which suggests a 38 category scale for outcomes classification 
covering pathophysiological, functioning and resource use elements, identified through a 
systematic review of outcome classification methodologies, may have resolved this issue, 
however, by providing a fully specified alternative to Filter 2.0330.  This new taxonomy is more 
granular than the OMERACT framework and allows for specification on two levels, firstly by 
classifying into a relevant domain and secondly by identifying entries as adverse events of 
outcomes. One significant advantage of this taxonomy is the ease of use as it provides a single and 
comprehensive taxonomy, which avoids the need to compile domains from several different 
models. 
Matching the outcomes from the ICF core sets for IBD against the Crohn’s Filter has highlighted 
what current research might be failing to capture.  Perhaps more important has been the 
approach of mapping the most commonly used disease activity indices and PROMs against both 
the Filter 2.0 framework for Crohn’s disease outcomes and AEs and the ICF core sets for IBD which 
has highlighted many points.  Firstly, it has shown some of the gaps in the measures in terms of 
the important outcomes that are not included and therefore additional outcomes that researchers 
may want to measure or additions that should be considered when developing new outcome 
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measurement tools. Body image is a case in point as it has been ranked as important enough to 
be included as one of only 14 outcomes in the disability index for IBD, but is not measured at all 
in the Crohn’s trials, and digestive functions is only included as an AE.  Secondly, the approach has 
made clear the choices that researchers currently face when combining disease activity indices 
and quality of life questionnaires and provides a method for checking how well those tools cover 
existing core outcome sets.  This should support research to develop additional measurement 
tools to meet existing core outcome sets.  It may also help trialists in deciding which measurement 
tools to use based on their views on the most important aspects of quality of life and on pragmatic 
decisions of the now explicit trade-off between the ease of measurement of the outcome 
measurement tools versus the outcomes captured.   
The usefulness of frequency reporting of the outcomes within domains was undermined as the 
disease activity indices and PROMs featured so heavily, i.e. any outcome measured by the CDAI 
would automatically be at the top of the list due to the reporting of the CDAI in 156/181 (86.2%) 
papers.  This is clearly not necessarily appropriate given that outcomes such as uveitis then appear 
to be some of the most important but are not in the either of the ICF core sets.  Perhaps this is 
reflective of the fact that the ICF sets are for IBD as a whole and uveitis is important only for 
Crohn’s and would therefore be in a core set for Crohn’s, but it is impossible to know without 
some sort of consensus process. 
The usefulness of frequency reporting of adverse event categories such as discontinuation due to 
adverse events; total adverse events; study withdrawal due to various reasons (including loss to 
follow up and non-compliance); total serious adverse events; and withdrawal due to treatment 
failure may also be questioned.  These outcomes are composites as they are made up of individual 
adverse event reports, rather than an aggregation of the same events.  As such, it can be difficult 
to understand what to infer from them.  A shared criticism with benefit composite measures is 
that they are not transparent in what they capture.  Whilst they can provide a general measure of 
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how tolerable the treatment is, they are likely to be subject to variation in reporting processes 
that would make comparisons between trials and drugs difficult.  The standardisation of 
composite outcome measurement tools means that this is not a difficulty for benefit outcomes. 
There is a general dilemma in categorisation of adverse events that reflects the challenge of 
distinguishing between: a. side effects of the drug treatment that are independent of the disease 
process and could happen to any patient; b. adverse events that are a manifestation of the 
underlying disease process, reflecting worsening or complications of the disease; and c. adverse 
events that only happen in people in a particular indication (Crohn’s disease in this case) but are 
specifically caused by the drug.  These issues were introduced in Section 1.1.3 and are discussed 
in detail in Chapter 4. 
3.4.3. Conclusions 
The systematic review for treatments of Crohn’s disease in adults identified 181 relevant studies, 
yielding 93 outcomes and 577 adverse events.  The outcomes and adverse events have been 
categorised across 35 outcome domains and 46 adverse event domains in the OMERACT Filter 2.0 
framework, many of which overlap.  The capturing of both outcomes and adverse events within a 
single model has provided a useful overall assessment, which may support the development of 
new outcome measurement tools, and a core outcome set.     
The comparison with a robustly developed, if somewhat restrictive, core set for IBD and the 
common disease activity indices and PROMs provides a useful view of the state of outcomes 
measured in the literature and has highlighted that the currently used measurement tools do not 
cover all of the outcomes in the IBD disability index.   Further research is needed into the gaps, 
specifically; the omission of body image and digestive functions from trial endpoints and the 
inclusion of uveitis in the most commonly used disease activity index should be understood.   
The results of this chapter and the systematic review of endpoints in Chapter 2 have provided a 
clear overview of the outcomes and harms recorded in trials of treatments for Crohn’s disease 
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over relatively short periods.  However, trial reporting of adverse events is known to be flawed 
and Crohn’s disease is a chronic disease and patients receive therapy over the long term so there 
is a need to characterise the harms beyond relatively short-term trial periods. Chapter 4 looks at 
a potential source of additional harms in the summary of product characteristics documents 
produced for each drug as a condition of regulatory approval. 
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Chapter 4: Summary of product characteristics as an additional 
source of adverse events in Crohn’s disease 
4.1. Introduction 
4.1.1. Adverse events monitoring 
Randomised controlled trials (RCTs) are the gold standard for monitoring the efficacy of 
interventions and can identify immediate and common adverse events associated with treatment. 
Adverse events (AEs) were defined in Chapter 1 as “any untoward medical occurrence in a patient 
or clinical investigation subject administered a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this treatment”53.   As discussed in Chapter 1, 
capturing all AEs in RCTs is good practice both to protect individuals taking part in studies and to 
characterise the toxicity profile.   
When an AE occurs, the principal investigator assesses whether it is related to the trial 
intervention and its seriousness53.  The outcome of their assessments dictates the speed of 
reporting and to whom the events are reported, as outlined in the study protocol.  For example, 
international standards require that all serious adverse events (SAEs) that are not previously 
known to be related to the study drug and documented in the study protocol, must be reported 
immediately to the sponsor331.  Within a UK trial, if the sponsors determine that an SAE is related 
to the study drug, and is therefore a suspected unexpected serious adverse drug reaction, it will 
be notified to the Medicines and Healthcare products Regulatory Agency (MHRA) and the trial 
ethics committee332.  At the end of a trial, all AE data is provided to the sponsor and should be 
published alongside efficacy results by the trialists in line with the extension of the CONSORT 
(Consolidated Standards of Reporting Trials) statement333.   
In comparison to clinical use over time, RCTs test drugs on a small number of carefully selected 
patients over relatively short periods, which may affect the generalisability of the results334.  As 
such they are less useful for reporting AEs that are unexpected, rare, associated with long-term 
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use, have a long latency, or are related to drug-drug interactions, drug-disease interactions, co-
morbidities or other susceptibility factors that have not been identified in clinical trials335,336.  
Difficulties in planning safety analyses in trials include the difficulty in determining which of the 
event attributes (e.g. dose, duration, severity) should be considered the primary analysis and the 
inability to pre-specify some events334.   
Further, there is evidence that harms in trials are poorly, and selectively, reported.  The omission 
of adverse events prevents a full assessment of benefit and risk of an intervention, and further 
compromises the ability to synthesise data in systematic reviews and meta-analyses.  Missing 
safety data may occur simply because adverse events take place in between study visits334, but 
more serious forms are also highlighted in the literature. “Distorted reporting” of AEs has been 
evidenced: 86% of trials included in a sample of Cochrane reviews, and 46% of trials included in 
systematic reviews synthesising harm outcomes were found to have inadequately reported the 
primary harm outcome and to have withheld, or downplayed, statistically significant increases in 
harm337,338.  A systematic review by Golder et al (2016) comparing published and unpublished trials 
found that omitted harms data has an impact on the number of AEs, types of AEs and risk ratios 
of AEs reported339.  Surveys of trialists find that outcome reporting bias, where pre-specified 
outcomes are omitted from final publications, occur because of journal space restriction and 
because of a perceived lack of clinical importance or lack of statistical significance in the 
outcomes338.  
The CONSORT statement extension should support better reporting of harms.   An additional ten 
items have been added, which include requirements to provide denominators for harms analyses 
and to “present the absolute risk per arm and per adverse event type, grade and seriousness, and 
present appropriate metrics for recurrent events, continuous variables, and scale variables, 
wherever pertinent”333. However, a systematic review of the reporting of harms according to the 
CONSORT statement demonstrated that adherence to the extended reporting requirements is 
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inadequate and variable in RCTs340.  A study of trials published in high impact journals in 2009 
demonstrated that only one in ten (10.8%) trials met all the requirements of the CONSORT 
statement341.  It is unclear whether this is due to a lack of knowledge of the statement on the part 
of trialists or journals. 
Compounding these issues of selective reporting is the failure to publish results of trials at all.  As 
many as half of medical and health-related studies are not published, which is primarily because 
of non-submission due to lack of time or low priority and fear of the research being rejected by 
journals342.  The failure to publish research leads to selective reporting, which may mean that trials 
with “negative” results are missing from the literature.  This may have the greatest impact on rarer 
and more serious harms, which require systematic review to detect, but which incomplete 
reporting of RCTs can hamper343.  A systematic review comparing published and unpublished data 
confirmed that a greater number and a wider range of adverse events were contained in 
unpublished research343. 
Given these limitations of trial AE reporting in RCTs, other methods of harms reporting are 
necessary to fully characterise the risk of an intervention.  Pharmacovigilance is the practice of 
monitoring, detecting, understanding and preventing AEs as introduced in Chapter 1.  Safety 
reporting in RCTs is one element of pharmacovigilance, but it continues over the lifecycle of a 
product, including at marketing authorisation stage and beyond into the post-marketing phase. 
4.1.2. Adverse reactions monitoring 
Adverse reactions, also known as adverse drug reactions (ADRs) differ from AEs as they are “any 
untoward and unintended response in a subject to an investigational medicinal product which is 
related to any dose administered to that subject”344. 
Pharmacovigilance captures additional information beyond the point of marketing to monitor 
potential AEs and identify where there are associations between a drug and an AE345. One 
important element is the summary of product characteristics (SPC), which is the key document 
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required as part of the regulatory process and provides information to communicate risk, and to 
advise on the safe and effective use of the drug.  Within Europe, the drug manufacturer produces 
the SPC, which the European Medicines Agency (EMA) approves.  It is a living document, initially 
created mainly from trial data, but regularly updated as more data becomes available in the post-
marketing phase.   
Spontaneous reports of AEs that occur during the course of treatment are the primary source of 
update data.  Spontaneous reporting systems are an important way to track adverse drug 
reactions that are rare and drug manufacturers are required to report serious reactions so they 
should provide comprehensive data346.  In the UK, health professionals and members of the public 
can voluntarily make reports to the Yellow Card scheme when adverse events occur during clinical 
use of a drug54.  Disproportionality analysis methods are used to automatically generate signals 
from pharmacovigilance databases, which identify whether more events occur than would be 
expected given the background rate of those events347.  Signals are investigated to determine if 
they are causally related to the drug; that is, whether they are adverse reactions or adverse drug 
reactions (ADRs), rather than adverse events (AEs).   
Section 4.8 of the SPC details the undesirable effects, which is a summary of “all adverse reactions 
from clinical trials, post-authorisation safety studies and spontaneous reporting for which, after 
thorough assessment, a causal relationship between the medicinal product and the adverse event 
is at least a reasonable possibility”15.  Unlike in trials, AEs without any suspected causal 
relationship should not be included.  Section 4.4 of the SPC details special warnings and 
precautions for use, which are messages to healthcare professionals.  Messages include, but are 
not limited to, information on risk management plans, population groups who face greater risk of 
harm, serious adverse reactions that may occur and the conditions in which they could occur, 
adverse reactions associated with starting or stopping therapy and any monitoring 
requirements15. 
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4.1.3. Measuring frequency of adverse reactions 
Estimating frequency of adverse reactions aides risk assessment, which supports clinical decision-
making and health technology assessment.  The frequency of adverse reactions is calculated from 
trials and post-marketing data and is included in section 4.8 of the SPC.   The frequency of adverse 
reactions is currently reported in six categories from very common (affecting more than or equal 
to one in ten patients exposed to the drug) to very rare (affecting fewer than one in 10,000), as 
shown in Table 12.   
Table 12: Frequency categories for adverse reactions reported in Summary of Product Characteristics 
(SPCs) 
Frequency of adverse event Numbers affected in frequency category 
Very common ≥ 1/10  
Common ≥ 1/100 to < 1/10 
Uncommon ≥ 1/1,000 to < 1/100 
Rare  1/10,000 to < 1/1,000 
Very rare < 1/10,000 
Frequency not known cannot be estimated from the available data 
 
A number of methods are used to estimate the frequency of adverse reactions to be reported in 
SPCs.  If the different sources of adverse reactions data indicate different frequencies, the highest 
one is included in the SPC15.   
Optimally, data on AEs is pooled across (ideally placebo controlled) trials, where possible without 
introducing bias, to estimate frequency.  Point estimates of the crude incidence rate of an adverse 
reaction can also be obtained from safety studies designed to detect specific AEs over a defined 
time-period that can be reasonably attributed to the product.  Where adverse reactions are 
indicated from spontaneous reporting systems, such as the MHRA yellow card scheme54, well 
designed trials can be investigated to choose a frequency category.   
In cases where ADRs are suspected, but no AEs have been reported in trials, statistical methods 
can be used to estimate frequency.  The “rule of three” allows the upper limit of a 95% confidence 
interval to be estimated when an observed event rate is zero.  The rule of three states that if a 
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drug has been tested on patients and none have experienced an event, a reasonable estimate is 
that the probability of that event occurring is less than 3/n, where n is the total sample size of 
patients receiving the drug across all relevant trials and studies15.  Statistically, the rule of three is 
derived as follows in Equation 4 to Equation 6348.  A single event (X) has not been observed in n 
Bernoulli trials (individual trials asking a yes or no question) and the aim is to identify the 
probability p for that event.  Assuming a binomial distribution with parameters n and p, then: 
Equation 4: Probability of event in binomial distribution 
𝑃(𝑋 = 0|𝑛, 𝑝) = (1 − 𝑝)𝑛 
Solving for the upper confidence limit (1- p ≥ α) the equation becomes: 
Equation 5: Upper limit of probability of event in binomial distribution 
𝑝𝑢 = 1 − 𝛼
1
𝑛⁄  
This approximates to: 
Equation 6: Natural logarithm of upper limit of probability of event in binomial distribution 
1 − 𝛼
1
𝑛⁄ ≅ −𝑙𝑛(𝛼)/𝑛 
The solution of –ln (α) = 2.996 and therefore the upper confidence limit of a zero-observed event 
approximates to 3/n.  This can be similarly solved using a Poisson distribution. 
4.1.4. Aims and objectives 
The aim of this chapter is to investigate potential methods to make use of the SPCs to identify and 
quantify harms that may be incompletely reported in the literature or those that are less well 
characterised by trials, such as longer term and rarer harms or those that may be underreported.  
The objectives are to: 
 Match the trials identified in the systematic review in Chapter 2 to their summary of 
product characteristics. 
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 Extract data on adverse reactions from the SPCs, standardise using the Medical 
Dictionary for Regulatory Activities (MedDRA) and match against the adverse events 
data extracted from the RCTs in Crohn’s disease. 
 Examine differences between the datasets of SPC adverse reactions and RCT adverse 
events to gain an understanding of the best methods to gather data and the usefulness 
of the data obtained. 
4.2. Methods 1 
A systematic review of clinical trials was conducted which identified 181 eligible studies from 
which efficacy outcomes and adverse events data was extracted.  The methods used in the 
systematic review, including how the extracted data were standardised using the Medical 
Dictionary for Regulatory Activities (MedDRA) terminology, are outlined in Chapter 2. 
4.2.1. Inclusion criteria for therapies 
SPCs are only available for drugs once they become licensed medicines and therefore all non-drug 
therapies and experimental and unlicensed drug therapies were excluded from this chapter.  
Further, given the aim of fully characterising the harms from Crohn’s disease treatment, other 
therapies that would not be considered “standard” treatment were excluded.  Conventional 
therapies were identified from UK clinical guidelines for the treatment of Crohn’s disease62. 
AEs in trials and adverse reactions in the SPCs were compared by therapeutic class rather than at 
the level of individual drugs.  This maximises the availability of adverse event and reactions data 
and allows for a more detailed view of the harms associated with drugs.  The BNF drug 
classification was used to group therapies. 
4.2.2. Selection of summary of product characteristics (SPCs) 
SPCs were identified for the maximum possible number of therapies listed in the trials identified 
through the systematic review in Chapter 2.  The electronic Medicines Compendium (eMC)349 was 
searched for each formulation used in the trials.  Where an exact match was found, the SPC was 
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copied to a word document.  Where an exact match was unavailable, the closest match was found.  
Due to the period of the systematic review results, other pharmaceutical companies now produce 
generic forms of some drugs in the exact same formulation as the trial.  These SPCs were copied 
to the word document.   
Where a SPC was unavailable for an identical formulation, the closest matching SPC was identified. 
To be considered a close match, the drug must be administered in the same formulation and route 
of administration as the original paper, although doses could differ as patients could take more 
than one tablet, for example.  As an example, one trial tested Asacol 800mg modified-release 
tablets.  Asacol is one brand of mesalazine and is available in gastro-resistant tablets of 250mg to 
800mg, but it is also available as modified-release tablets, modified-release granules, foam, 
enema and suppositories.  In this case, the SPC for gastro-resistant tables of 800mg was used as 
an exact match. 
4.2.3. Data extraction 
Data was extracted data from section 4.8 of the SPCs, Undesirable effects and recorded in a 
Microsoft Excel spreadsheet.  The descriptions of selected adverse reactions were read to identify 
any additional data.   
Specific data items were: 
 The adverse reaction. 
 The MedDRA system organ class (SOC), where reported. 
 The frequency of the adverse reaction. 
The data was standardised using the same methods as reported in Section 2.2.8 of Chapter 2.  In 
brief, the adverse reactions were mapped against preferred terms (PTs) in the MedDRA hierarchy.  
The primary system organ classification (SOC) for each preferred term was used, even where it 
contradicted the SOC reported in the SPC, so that it would be possible to align the extracted data 
with the RCT data.   
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The sample sizes for each matched trial were obtained from the results in Chapter 2.  The number 
of patients randomised to the treatment of interest was extracted.  The rule of three was used to 
calculate the upper 95% confidence interval value for the frequency of adverse event that would 
be expected to be detected in each trial and group of trials using Equation 7. 
Equation 7: Rule of three 
𝑈𝑝𝑝𝑒𝑟 𝑙𝑖𝑚𝑖𝑡 𝑜𝑓 95% 𝐶𝐼 = 3/𝑛 
Where n is the trial sample size or aggregated sample size.  From this value, it was possible to 
identify the upper value of adverse reaction risk if a group of trials did not detect an adverse event, 
which could be matched to a frequency category.  In addition, it is possible to draw inference 
about the frequency category of adverse event that the individual trials will be expected to detect 
given their size.  
4.2.4. Combining data from SPCs within drug classes 
Presenting data at the level of drug class required the pooling of data extracted from a number of 
SPCs.  For some therapies in the same drug class, the adverse reaction profile was similar which 
resulted in the inclusion of multiple entries of the same preferred terms.  Each preferred term was 
included in each frequency category in which it was reported in the SPCs.  For example, headache 
was reported to occur both uncommonly and rarely in one drug class, but this approach was taken 
to preserve the detail in the data. 
4.2.5. Data presentation 
Summary tables were produced of preferred terms (PTs) by intervention type that were: 
 Recorded as common or very common in the SPCs. 
 Recorded as rare or very rare in the SPCs. 
 Recorded in SPCs at any frequency, but not in trials. 
 Recorded in trials, but not in SPCs. 
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4.3. Results 1 
14 therapies were included in the analysis, which grouped into five therapeutic classes (Table 13): 
aminosalicylates (5-ASAs), antibiotics, anti-TNFs, corticosteroids and immunosuppressives. 
Antibiotics were split into sub-classes of macrolides, natroimidazole derivatives and quinolones.  
Immunosuppressives were split into two sub-classes of antimetabolites and methotrexate. 
The SPCs were found for all medicines recommended for use in NICE guidance (69 of 181 (38.1%) 
trials identified in Chapter 2).  57 (of 181, 31.5%) trials were excluded as they were not drug 
therapies. The remaining 55 (of 181, 30.4%) studies were excluded as they involved drugs that are 
not standard therapy for Crohn’s disease.  The drug class with most trials for which an SPC could 
be identified was corticosteroids (19 trials), followed by TNFα inhibitors (17 trials).  Budesonide 
was the active ingredient for most trials for which an SPC could be matched (17), followed by 
mesalamine (12), azathioprine (11) and infliximab (10). 
Three active ingredients were included in the drug class 5-ASAs: mesalamine, which was the focus 
of 12 trials with three formulations (and therefore three SPCs); Olsalazine, which was the focus of 
one trial with one formulation and a single SPC; and sulfasalazine, which was the focus of two 
trials with a single formulation, and therefore one SPC.   
Three active ingredients were included in the antibiotics drug class, one in each sub-class, each 
with a single formulation and therefore a single SPC.  Clarithromycin was the macrolides antibiotic 
and was the active ingredient in three trials.  Metronidazole was the nitroimidazole derivative 
antibiotic and was the active ingredient in three trials.  Ciprofloxacin is a quinolone antibiotic and 
was the active ingredient in seven trials. 
Two active ingredients, matching to two formulations and two SPCs, were identified as anti-TNFα 
biologics.  Infliximab was the most common, with ten trials, followed by adalimumab with seven. 
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Corticosteroids included three different active ingredients.  Beclomethasone dipropionate and 
methylprednisolone were tested in single trials, with one formulation and one SPC in the analysis.  
There were 14 budesonide trials with three different formulations and therefore three SPCs 
included. 
Three active ingredients were included in the immunosuppressives drug class.  Methotrexate was 
tested in two trials and mercaptopurine (an antimetabolite) had a single trial, and each involved 
one formulation and one SPC each.  There were 11 trials for azathioprine, with two different 
formulations matched to two SPCs. 
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Table 13: Table of therapies included in analysis, by drug class, active ingredient, brand name and formulation 
Therapeutic Class 
(n= number of trials) 
Active ingredient 
(n= number of trials) 
Brand name, strength and formulation Trial 
sample 
size 
range 
 
Frequency value (category) 
determined by rule of 3 upper 95% 
CI for identifiable AEs 
5-ASAs (n=15) Mesalamine (n=12) Salofalk 500mg125,198,241,277 15-153 2 in 100 (common) to 2 in 10 ( very 
common) 
Pentasa slow release 500mg118,233,276,280,284 44-230 1.3 in 100 (common) to 6.8 in 100 
(common) 
Asacol 800mg MR tablets121,228,283 20-206 1.5 in 100 (common) to 1.5 in 10 
(very common) 
Olsalazine (n=1) Olsalazine Sodium / Dipentium 250mg238 167 1.8 in 100 (common) 
Sulfasalazine (n=2) Salazopyrin tablets224,225 43-229 1.3 in 100 (common) to 7 in 100 
(common) 
Antibiotics, Macrolides (n=3) Clarithromycin (n=3) Klaricid XL 500mg tablets148,186,252 19-102 2.9 in 100 (common) to 2 in 10 (very 
common) 
Antibiotics, Nitroimidazole 
derivatives (n=3) 
Metronidazole (n=3) Metronidazole tablets 500mg150,190,286 7-81 3.7 in 100 (common) to 4.3 in 10 
(very common) 
Antibiotics, Quinolones (n=7) Ciprofloxacin (n=7) Ciproxin tablets 500mg132,150,153,163,190,209,290 10-66 4.5 in 100 (common) to 3 in 10 (very 
common) 
Biologics, TNFα inhibitors 
(n=17) 
Adalimumab (n=7) Humira 40mg/0.8ml pre-filled pen / 
syringe171,182,209,253,255,268,289 
16-517 6 in 1000 (uncommon) to 1.9 in 10 
(very common) 
Infliximab (n=10) Remicade 100mg powder for concentrate 
for solution for 
infusion129,134,135,174,175,187,217,240,245,287 
11-251 1.2 in 100 (common) to 2.7 in 10 
(very common) 
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Therapeutic Class 
(n= number of trials) 
Active ingredient 
(n= number of trials) 
Brand name, strength and formulation Trial 
sample 
size 
range 
 
Frequency value (category) 
determined by rule of 3 upper 95% 
CI for identifiable AEs 
Corticosteroids (n=19) Beclomethasone 
dipropionate (n=1) 
Clipper 5mg sustained release tablets266 37 8.1 in 100 (very common) 
Budesonide (n=17) Budenofalk 3mg gastro-resistant 
capsules131,160,257,278 
43-157 1.9 in 100 (common) to 7 in 100 
(common) 
Budenofalk 9mg gastro-resistant 
granules210 
471 6 in 1000 (uncommon) 
Entocort CR 3mg 
capsules120,123,249,279,149,198,206,232,234,237,239,241 
29-192 1.6 in 100 (common) to 1 in 10 (very 
common) 
Methylprednisolone 
(n=1) 
Medrone tablets 100mg225 225 1.3 in 100 (common) 
Immunosuppressive, 
antimetabolites (n=12) 
Azathioprine (n=11) Azathioprine 50mg 
tablets117,181,244,247,261,275,286,288,292 
11-58 5.2 in 100 (common) to 2.7 in 10 
(very common) 
Imuran injection136,187 51-67 4.5 in 100 (common) to 5.9 in 100 
(common) 
Mercaptopurine 
(n=1) 
Mercaptopurine 50mg284 47 6.4 per 100 (common) 
Immunosuppressive, 
methotrexate (n=2) 
Methotrexate (n=2) Methotrexate 10mg tablets235,272 15-63 4.8 per 100 (common) 
to 2 per 10 (very 
common) 
Note: Numbers in brackets indicate count of trials in drug class and active ingredient.  Sum to greater than 69 as some trials test multiple drugs. 
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4.3.1. Common or very common adverse events recorded in SPCs 
Common or very common adverse events are those that occur in more than one in 100 patients, 
as defined in Table 12.  Given the sample sizes of the included trials and based on the rule of three 
calculations (Table 13), it might be expected that most trials would have the power to detect very 
common adverse reactions (occurring in one in ten), if not common adverse reactions.  Table 14 
demonstrates that the trials capture 50% or more of the common or very common adverse 
reactions identified in the SPCs by drug class.  The only exception is anti-TNFα agents, where 75% 
of the very common or common adverse reactions are not captured in the Crohn’s disease trials. 
Table 14: Very common and common adverse reactions reported in the Summary of Product 
Characteristics (SPC) for Crohn's disease treatments, compared with those reported as adverse events in 
trials, by drug class 
Drug class Very common Common Very common and 
common 
SPC In trials SPC In trials SPC In trials 
No. % No. % No. % 
5-ASAs 3 2 66.7% 26 15 57.7% 29 17 58.6% 
Antibiotics, Macrolides 0 0 -- 11 6 54.5% 11 6 54.5% 
Antibiotics, Nitroimidazole 
derivatives 
0 0 -- 0 0 -- 0 0 -- 
Antibiotics, Quinolones 0 0 -- 2 2 100.0% 2 2 100.0% 
Biologics, TNFα inhibitors 16 11 68.8% 94 27 28.7% 110 38 34.5% 
Corticosteroids 0 0 -- 38 19 50.0% 38 19 50.0% 
Immunosuppressive, 
antimetabolites 
5 4 80.0% 14 7 50.0% 19 11 57.9% 
Immunosuppressive, 
methotrexate 
7 5 71.4% 13 5 38.5% 20 10 50.0% 
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10;  
4.3.1.1. 5-ASAs 
29 adverse reactions were reported as common or very common for 5ASAs in the SPCs identified 
from the results of the systematic review, as shown in Table 14.  Of these 29 adverse reactions, 
only seven were reported in the 14 relevant trials. One very common adverse drug reaction that 
is not reported in Crohn’s disease trials is interstitial lung disease, which is a progressive and 
incurable disease causing scarring of the lungs.  The full detail of the common and very common 
adverse drug reactions recorded in SPCs is shown in Table 15.   
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Table 15: Very common and common adverse reactions recorded in summary of product characteristics (SPCs) - 5-ASAs 
SOC HLGT PT Frequency Not 
reported 
in trials 
Blood and lymphatic system 
disorders 
White blood cell disorders Leukopenia Common X 
Ear and labyrinth disorders Inner ear and VIIIth cranial nerve disorders Tinnitus Common  
Eye disorders Ocular infections, irritations and inflammations Scleritis Common X 
Gastrointestinal disorders Anal and rectal conditions NEC Anorectal disorder Common X 
Gastrointestinal motility and defaecation 
conditions 
Diarrhoea Common  
Gastrointestinal signs and symptoms Abdominal pain Common  
Dyspepsia Common  
Dyspepsia Very common  
Flatulence Common X 
Nausea Common  
Nausea Very common  
Vomiting Common  
Oral soft tissue conditions Stomatitis Common X 
General disorders and administration 
site conditions  
Body temperature conditions Pyrexia Common  
Infections and infestations Infections - pathogen unspecified Respiratory tract infection Common X 
Rhinitis Common X 
Sinusitis Common X 
Viral infectious disorders Influenza Common  
Musculoskeletal and connective 
tissue disorders 
Joint disorders Arthralgia Common  
Muscle disorders Myalgia Common  
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SOC HLGT PT Frequency Not 
reported 
in trials 
Nervous system disorders Headaches Headache Common  
Neurological disorders NEC Dizziness Common  
Dysgeusia Common X 
Sleep disturbances (incl subtypes) Insomnia Common  
Renal and urinary disorders Urinary tract signs and symptoms Proteinuria Common X 
Respiratory, thoracic and mediastinal 
disorders 
Lower respiratory tract disorders (excl 
obstruction and infection) 
Interstitial lung disease Very common X 
Respiratory disorders NEC Cough Common X 
Skin and subcutaneous tissue 
disorders 
Epidermal and dermal conditions Pruritus Common  
Rash Common  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: VERY COMMON, affecting more than or equal to one in ten patients exposed to the drug; COMMON, affecting more than or equal to one 
in 100, but fewer than one in ten patients. 
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4.3.1.2. Antibiotics 
11 adverse reactions were reported as common in the SPCs for macrolide antibiotics (Table 14), 
six of which were reported in the three trials identified through the systematic review (Appendix 
table 26).  The adverse reactions not reported in Crohn’s disease trials were minor; dyspepsia, 
headache, insomnia, rash and hyperhidrosis (excess sweating). 
No common or very common adverse reactions were identified in the SPCs for nitroimidazole 
derivatives.  
Only two common adverse reactions were reported in the SPC for quinolone antibiotics, both of 
which related to gastrointestinal disorders and both of which were reported in trials (Appendix 
table 27). 
4.3.1.3. Anti-TNFα 
110 adverse reactions were reported as occurring commonly or very commonly in the anti-TNFα 
therapies infliximab and adalimumab (Table 14).  Five very common adverse reactions, reported 
to occur in at least one in ten patients, were not recorded in Crohn’s disease trials; leukopenia, 
infusion related reaction, viral infection, lipids increased and musculoskeletal pain. Only one of 
the very common and seven of the common adverse reactions were reported in the 17 trials for 
these therapies.  Two potentially serious adverse events were not identified in Crohn’s disease 
trials: gastrointestinal haemorrhage and skin cancer (Table 16).
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Table 16: Very common and common adverse reactions recorded in summary of product characteristics (SPCs) - anti-TNFα 
SOC HLGT PT Frequency Not 
reported 
in trials 
Blood and lymphatic system 
disorders 
Anaemias nonhaemolytic and marrow depression Anaemia Common x 
Platelet disorders Thrombocytopenia Common x 
Spleen, lymphatic and reticuloendothelial system 
disorders 
Lymphadenopathy Common x 
White blood cell disorders Leukocytosis Common x 
Leukopenia Very common x 
Leukopenia Common x 
Neutropenia Common x 
Cardiac disorders Cardiac arrhythmias Tachycardia Common x 
Cardiac disorders signs and symptoms Palpitations Common x 
Ear and labyrinth disorders Inner ear and VIIIth cranial nerve disorders Vertigo Common x 
Eye disorders Eye disorders NEC Eye swelling Common x 
Ocular infections, irritations and inflammations Blepharitis Common x 
Conjunctivitis Common x 
Vision disorders Visual impairment Common x 
Gastrointestinal disorders Gastrointestinal haemorrhages NEC Gastrointestinal haemorrhage Common x 
Gastrointestinal motility and defaecation 
conditions 
Constipation Common   
Diarrhoea Common   
Gastrooesophageal reflux 
disease 
Common x 
Gastrointestinal signs and symptoms Abdominal pain Very common   
Dyspepsia Common   
Nausea Very common   
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SOC HLGT PT Frequency Not 
reported 
in trials 
Vomiting Very common   
Salivary gland conditions Sjogren's syndrome Common x 
General disorders and 
administration site conditions  
Administration site reactions Injection site reaction Very common   
Injection site reaction Common   
Body temperature conditions Pyrexia Common   
General system disorders NEC Chest pain Common x 
Chills Common x 
Fatigue Common   
Infusion related reaction Very common x 
Oedema Common x 
Pain Very common   
Tissue disorders NEC Impaired healing Common x 
Hepatobiliary disorders Hepatic and hepatobiliary disorders Hepatic function abnormal Common x 
Immune system disorders Allergic conditions Allergic respiratory system Common x 
Hypersensitivity Common   
Infections and infestations Bacterial infectious disorders Bacterial infection Common x 
Cellulitis Common x 
Fungal infectious disorders Candida infection Common x 
Fungal infection Common x 
Infections - pathogen unspecified Arthritis infective Common x 
Ear infection Common   
Impetigo Common x 
Lower respiratory tract infection Common x 
Necrotising fasciitis Common x 
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SOC HLGT PT Frequency Not 
reported 
in trials 
Oral infection Common x 
Paronychia Common x 
Respiratory tract infection Very common   
Sepsis Common   
Sinusitis Very common   
Upper respiratory tract 
infection 
Very common   
Urinary tract infection Common   
Viral infectious disorders Herpes zoster Common x 
Influenza Common   
Viral infection Very common x 
Investigations Enzyme investigations NEC Blood lactate dehydrogenase 
increased 
Common x 
Haematology investigations (incl blood groups) Activated partial 
thromboplastin time prolonged 
Common x 
Hepatobiliary investigations Hepatic enzyme increased Very common   
Transaminases increased Common   
Immunology and allergy investigations Autoantibody positive Common x 
Lipid analyses Lipids increased Very common x 
Metabolic, nutritional and blood gas 
investigations 
Blood uric acid increased Common x 
Water, electrolyte and mineral investigations Blood sodium abnormal Common x 
Metabolism and nutrition 
disorders 
Bone, calcium, magnesium and phosphorus 
metabolism disorders 
Hypocalcaemia Common x 
Hypophosphataemia Common x 
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SOC HLGT PT Frequency Not 
reported 
in trials 
Electrolyte and fluid balance conditions Dehydration Common   
Hypokalaemia Common x 
Glucose metabolism disorders (incl diabetes 
mellitus) 
Hyperglycaemia Common x 
Musculoskeletal and connective 
tissue disorders 
Joint disorders Arthralgia Common   
Muscle disorders Muscle spasms Common   
Myalgia Common   
Musculoskeletal and connective tissue disorders 
NEC 
Back pain Common   
Musculoskeletal pain Very common x 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Miscellaneous and site unspecified neoplasms 
benign 
Benign neoplasm Common x 
Skin neoplasms malignant and unspecified Skin cancer Common x 
Nervous system disorders Headaches Headache Very common   
Migraine Common x 
Neurological disorders NEC Dizziness Common   
Hypoaesthesia Common x 
Paraesthesia Common x 
Sleep disturbances (incl subtypes) Insomnia Common   
Spinal cord and nerve root disorders Nerve root compression Common x 
Psychiatric disorders Anxiety disorders and symptoms Anxiety Common x 
Depressed mood disorders and disturbances Depression Common   
Mood disorders and disturbances NEC Mood altered Common x 
Renal and urinary disorders Renal disorders (excl nephropathies) Renal impairment Common x 
Urinary tract signs and symptoms Haematuria Common x 
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SOC HLGT PT Frequency Not 
reported 
in trials 
Respiratory, thoracic and 
mediastinal disorders 
Bronchial disorders (excl neoplasms) Asthma Common x 
Respiratory disorders NEC Cough Common   
Dyspnoea Common   
Upper respiratory tract disorders (excl infections) Epistaxis Common x 
Skin and subcutaneous tissue 
disorders 
Angioedema and urticaria Urticaria Common   
Epidermal and dermal conditions Dermatitis Common x 
Dry skin Common x 
Eczema Common   
Pruritus Common   
Psoriasis Common x 
Rash Very common   
Rash Common   
Skin and subcutaneous tissue infections and 
infestations 
Fungal skin infection Common x 
Skin appendage conditions Alopecia Common   
Hyperhidrosis Common x 
Onychoclasis Common x 
Skin vascular abnormalities Ecchymosis Common x 
Epidermal and dermal conditions Contusion Common x 
Skin vascular abnormalities Flushing Common x 
Vascular disorders Decreased and nonspecific blood pressure 
disorders and shock 
Hypotension Common x 
Vascular disorders NEC Hot flush Common x 
Vascular haemorrhagic disorders Haematoma Common x 
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SOC HLGT PT Frequency Not 
reported 
in trials 
Vascular hypertensive disorders Hypertension Common X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: VERY COMMON, affecting more than or equal to one in ten patients exposed to the drug; COMMON, affecting more than or equal to one 
in 100, but fewer than one in ten patients. 
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4.3.1.4. Corticosteroids 
There were 39 adverse reactions reported as occurring commonly in the SPCs for corticosteroids 
(Table 14).  Only nine of these were also identified in the trials of corticosteroid use in Crohn’s 
disease patients, with notable exceptions including osteoporosis, cataracts and arthralgia 
(Appendix table 28). 
4.3.1.5. Immunosuppressives 
There were 19 adverse reactions reported as occurring commonly or very commonly in patients 
taking antimetabolites in the SPCs (Table 14).  All but one adverse reaction reported to occur in as 
many as one in ten patients were reported in the trials in Crohn’s disease; decreased appetite.  
Half of the common adverse reactions were not reported as adverse events in Crohn’s disease 
trials, including several malignancies (Table 17). 
20 adverse reactions were listed in the SPC as occurring commonly or very commonly in patients 
taking methotrexate (Table 14).  Stomatitis and decreased appetite are identified as occurring very 
commonly in the SPCs (at least one in ten patients) but were not reported in trials for Crohn’s 
disease (Appendix table 29).  A further eight common adverse reactions were not identified in 
trials, including skin disorders (e.g. rash) and respiratory disorders (e.g. interstitial lung disease). 
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Table 17: Very common and common adverse reactions recorded in summary of product characteristics (SPCs) - immunosuppressives - antimetabolites 
SOC HLGT PT Frequency Not in 
trials 
Blood and lymphatic system 
disorders 
Anaemias nonhaemolytic and marrow 
depression 
Anaemia Common   
Platelet disorders Thrombocytopenia Very common   
Thrombocytopenia Common   
White blood cell disorders Leukopenia Very common   
Gastrointestinal disorders Exocrine pancreas conditions Pancreatitis Common   
Gastrointestinal signs and symptoms Nausea Very common   
Nausea Common   
Vomiting Very common   
Vomiting Common   
Hepatobiliary disorders Hepatic and hepatobiliary disorders Cholestasis Common x 
Hepatotoxicity Common   
Liver disorder Common x 
Infections and infestations Infections - pathogen unspecified Infection susceptibility increased Common   
Metabolism and nutrition disorders Appetite and general nutrition disorders Decreased appetite Very common x 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Lymphomas non-Hodgkin's unspecified 
histology 
Non-Hodgkin's lymphoma Common x 
Miscellaneous and site unspecified neoplasms 
malignant and unspecified 
Squamous cell carcinoma Common x 
Reproductive neoplasms female malignant 
and unspecified 
Cervix carcinoma Common x 
Vulval cancer Common x 
Soft tissue neoplasms malignant and 
unspecified 
Kaposi's sarcoma Common X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified    Frequency: VERY COMMON, affecting more than or equal to one in ten patients exposed to the drug; COMMON, affecting 
more than or equal to one in 100, but fewer than one in ten patients. 
159 
4.3.2. Rare or very rare adverse events recorded in SPCs 
Rare or very rare adverse events occur in fewer than one in 1,000 patients, as defined in Table 12.  
Given the size of trials and power of three calculations, which place their power to detect adverse 
reaction at the level of, at most, uncommonly occurring events (Table 13), trials are not powered 
to identify rare and very rare events.  Indeed, this is the purpose of pharmacovigilance, as 
discussed in Chapter 1 and the introduction to this chapter.  A summary of the identified rare and 
very rare adverse reactions is shown in Table 18 and confirms that a minority of rare and very rare 
adverse reactions, between 8.5% and 27.6%, were reported as adverse events in drug trials in 
Crohn’s disease. 
Table 18: Rare and very rare adverse reactions reported in the Summary of Product Characteristics (SPC) 
for Crohn's disease treatments, compared with those reported as adverse events in trials, by drug class 
Drug class Rare Very rare Rare and very rare 
SPC In trials SPC In trials SPC In trials 
 
No. % 
 
No. % 
 
No. % 
5-ASAs 41 12 29.3% 35 9 25.7% 76 21 27.6% 
Antibiotics, Macrolides 0 0 -- 0 0 -- 0 0 -- 
Antibiotics, Nitroimidazole 
derivatives 
1 0 0.0% 24 6 25.0% 25 6 24.0% 
Antibiotics, Quinolones 45 5 11.1% 26 1 3.8% 71 6 8.5% 
Biologics, TNFα inhibitors 50 5 10.0% 2 0 0.0% 52 5 9.6% 
Corticosteroids 13 4 30.8% 17 4 23.5% 30 8 26.7% 
Immunosuppressive, 
antimetabolites 
24 5 20.8% 11 3 27.3% 35 8 22.9% 
Immunosuppressive, 
methotrexate 
33 3 9.1% 52 6 11.5% 85 9 10.6% 
Frequency: RARE, 1/10,000 to < 1/1,000; VERY RARE, < 1/10,000 
 
4.3.2.1. 5-ASAs 
The SPCs for 5-ASAs identify 76 adverse reactions that rarely or very rarely occur.  55 of these 
were not reported in Crohn’s disease trials (Table 18).  Nine very rare adverse reactions identified 
in the SPC (occurring in fewer than one in 10,000 patients) were also reported in the trials: 
anaemia, pancytopenia, pyrexia, death, transaminases increased, arthralgia, myalgia, Stevens-
Johnson syndrome and alopecia (Appendix table 30).  A number of rare and very rare adverse 
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events that were not captured in trials were serious disorders of the blood and lymphatic (e.g. 
aplastic anaemia), respiratory, thoracic and mediastinal (e.g. lung infiltration), hepatobiliary (e.g. 
hepatotoxicity) and renal and urinary systems (e.g. renal failure). 
4.3.2.2. Antibiotics 
No rare or very rare adverse reactions were reported in the SPCs for macrolide antibiotics (Table 
18).   
One rare and 24 very rare adverse reaction entries were present in the SPCs for nitroimidazole 
derivative antibiotics. Six of the very rare adverse reactions were also reported in trials in Crohn’s 
disease: pancreatitis, arthralgia, myalgia, headache, dizziness and rash (Appendix table 31).   Rare 
and very rare adverse reactions not captured by trials were commonly disorders of the blood and 
lymphatic and nervous systems (e.g. white blood cell disorders and seizures). 
45 rare and 26 very rare adverse reactions were recorded in the SPCs for quinolone antibiotics.  
Five of the rare were also reported in the trials for Crohn’s disease: anaemia, oedema, clostridium 
difficile colitis, myalgia and photosensitivity reaction (Appendix table 32).  One very rare reaction, 
pancreatitis, was also recorded in the Crohn’s disease trials.  Rare and very rare adverse reactions 
not reported by trials were commonly of the blood and lymphatic (e.g. bone marrow failure) and 
nervous systems (e.g. seizure and migraine), although other serious adverse reactions were 
reported in other system classes including necrosis (skin) and anaphylactic reactions (immunity). 
4.3.2.3. Anti-TNFα 
50 rare and two very rare adverse reactions were reported in the SPCs for anti-TNFα therapies 
(Table 18).  Whilst none of the very rare reactions were also reported in the Crohn’s disease trials, 
five rare reactions were (opportunistic infections, lupus-like syndrome, lymphoma, demyelination 
and multiple sclerosis), leaving 45 rare adverse reactions not detected through Crohn’s disease 
trials.  Common categories of disorders were blood and lymphatic (e.g. aplastic anaemia) and 
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respiratory systems (e.g. interstitial lung disease), disorders of the skin (e.g. Stevens-Johnson 
syndrome) and neoplasms, including malignancies (Table 19).  
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Table 19: Rare and very rare adverse reactions recorded in summary of product characteristics (SPCs) - biologics: anti-TNFα 
SOC HLGT PT Not 
reported 
in trials 
Frequency 
Blood and lymphatic system disorders Anaemias nonhaemolytic and marrow depression Pancytopenia x Rare 
Haemolyses and related conditions Haemolytic anaemia x Rare 
Platelet disorders Immune 
thrombocytopenic 
purpura 
x Rare 
Thrombotic 
thrombocytopenic 
purpura 
x Rare 
White blood cell disorders agranulocytosis x Rare 
Leukopenia x Rare 
Cardiac disorders Cardiac arrhythmias Cardiac arrest x Rare 
Cardiac disorders signs and symptoms Cyanosis x Rare 
Pericardial disorders Pericardial effusion x Rare 
Eye disorders Ocular infections, irritations and inflammations Endophthalmitis x Rare 
Gastrointestinal disorders Gastrointestinal ulceration and perforation Intestinal perforation x Rare 
General disorders and administration site 
conditions  
General system disorders NEC Granuloma x Rare 
Hepatobiliary disorders Hepatic and hepatobiliary disorders Autoimmune hepatitis x Rare 
Hepatitis x Rare 
Hepatitis B x Rare 
Jaundice x Rare 
Immune system disorders Allergic conditions Anaphylactic reaction x Rare 
Anaphylactic shock x Rare 
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SOC HLGT PT Not 
reported 
in trials 
Frequency 
Immune disorders NEC Sarcoidosis x Rare 
Infections and infestations Bacterial infectious disorders Furuncle x Rare 
Infections - pathogen unspecified Infection parasitic x Rare 
Meningitis x Rare 
Opportunistic infection  
 
Rare 
Viral infectious disorders Hepatitis B x Rare 
Investigations Immunology and allergy investigations Complement factor 
abnormal 
x Rare 
Musculoskeletal and connective tissue 
disorders 
Connective tissue disorders (excl congenital) Lupus-like syndrome 
 
Rare 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Leukaemias Leukaemia x Rare 
Lymphomas Hodgkin's disease Hodgkin's disease x Rare 
Lymphomas NEC Lymphoma 
 
Rare 
Lymphomas non-Hodgkin's unspecified histology Non-Hodgkin's 
lymphoma 
x Rare 
Reproductive neoplasms female malignant and 
unspecified 
Cervix carcinoma x Rare 
Skin neoplasms malignant and unspecified Malignant melanoma x Rare 
Nervous system disorders Central nervous system infections and 
inflammations 
Myelitis transverse x Rare 
Demyelinating disorders Demyelination 
 
Rare 
Multiple sclerosis 
 
Rare 
Psychiatric disorders Mood disorders and disturbances NEC Apathy x Rare 
Bronchial disorders (excl neoplasms) Bronchospasm x Rare 
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SOC HLGT PT Not 
reported 
in trials 
Frequency 
Respiratory, thoracic and mediastinal 
disorders 
Lower respiratory tract disorders (excl obstruction 
and infection) 
Interstitial lung disease x Very rare 
Pulmonary fibrosis x Rare 
Pulmonary oedema x Rare 
Pleural disorders Pleural effusion x Rare 
Pleural disorders Pleurisy x Rare 
Skin and subcutaneous tissue disorders Angioedema and urticaria Angioedema x Rare 
Epidermal and dermal conditions Dermatomyositis x Very rare 
Stevens-Johnson 
syndrome 
x Rare 
Toxic epidermal 
necrolysis 
x Rare 
Skin vascular abnormalities Petechiae x Rare 
Epidermal and dermal conditions Erythema multiforme x Rare 
Skin vascular abnormalities Cutaneous vasculitis x Rare 
Vascular disorders Arteriosclerosis, stenosis, vascular insufficiency and 
necrosis 
Vasospasm x Rare 
Decreased and nonspecific blood pressure 
disorders and shock 
Circulatory collapse x Rare 
Vascular inflammations Vasculitis x Rare 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; 
NEC – not elsewhere classified     
Frequency: RARE, affecting more than or equal to one in 10,000 patients, but fewer than one in 1,000; VERY RARE, affecting less than one in 
10,000. 
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4.3.2.4. Corticosteroids 
There are 13 rare and 17 very rare adverse reactions reported in the SPCs for corticosteroids (Table 
18). Of these, four rare reactions were also reported in the Crohn’s disease trials: adrenal 
suppression, Cushingoid, obesity and rosacea (Appendix table 33). Four of the very rare reactions 
were also reported in trials in Crohn’s disease: Cushing’s syndrome, pancreatitis, constipation and 
dyspepsia.  Rare and very rare adverse reactions not reported in Crohn’s disease trials included 
blood and lymphatic system disorders (white blood cell disorders), eye disorders (e.g. cataract), 
general disorders (e.g. fatigue and malaise) and disorders of the musculoskeletal and connective 
tissues (e.g. osteoporosis and myalgia) 
4.3.2.5. Immunosuppressives 
24 rare and 11 very rare adverse reactions are recorded in the SPC for antimetabolites (Table 18).  
Five of the rare reactions were also reported in the Crohn’s disease trials: diarrhoea, death, 
hypersensitivity, myelodysplastic syndrome and alopecia (Table 20).  Three of the adverse 
reactions were also reported as very rare in the SPCs: death, hypersensitivity and myelodysplastic 
syndrome.  Adverse reactions that were not reported in trials included serious blood and 
lymphatic system disorders (such as bone marrow failure), malignant neoplasms (including 
lymphomas and leukaemias) and skin conditions (such as toxic epidermal necrosis).  
There were 33 rare and 52 very rare adverse reactions recorded in the SPC for methotrexate and 
the vast majority were not recorded in trials (76 of 85, 89.4%) (Table 18).  Three of the rare 
reactions were also recorded in the trials for Crohn’s disease: vision blurred, hepatitis acute and 
acne (Appendix table 34).  Six very rare adverse reactions recorded in the SPC were also reported 
in the Crohn’s disease trials of methotrexate: neutropenia, pyrexia, pain, pneumonia, 
cytomegalovirus infection and insomnia. 
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Table 20: Rare and very rare adverse reactions recorded in summary of product characteristics (SPCs) - immunosuppressives: antimetabolites 
SOC HLGT PT frequency Not 
reported 
in trials 
Blood and lymphatic system disorders Anaemias nonhaemolytic and marrow 
depression 
Anaemia megaloblastic Rare x 
Aplastic anaemia Rare x 
Bone marrow failure Rare x 
Pancytopenia Rare x 
White blood cell disorders agranulocytosis Rare x 
Granulocytopenia Rare x 
Gastrointestinal disorders Gastrointestinal motility and defaecation 
conditions 
Diarrhoea Rare   
Gastrointestinal ulceration and perforation Gastrointestinal ulcer Very rare x 
Oral soft tissue conditions Mouth ulceration Rare x 
General disorders and administration site 
conditions  
Fatal outcomes Death Rare   
Death Very rare   
Hepatobiliary disorders Hepatic and hepatobiliary disorders Hepatic necrosis Rare x 
Liver injury Rare x 
Venoocclusive liver disease Rare x 
Immune system disorders Allergic conditions Hypersensitivity Rare   
Hypersensitivity Very rare   
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Leukaemias Acute myeloid leukaemia Rare x 
Acute myeloid leukaemia Very rare x 
Myelodysplastic syndrome Rare   
Myelodysplastic syndrome Very rare   
Lymphomas non-Hodgkin's T-cell Hepatosplenic T-cell lymphoma Very rare x 
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SOC HLGT PT frequency Not 
reported 
in trials 
Lymphomas non-Hodgkin's unspecified 
histology 
Non-Hodgkin's lymphoma Rare x 
Metastases Metastasis Very rare x 
Reproductive neoplasms female malignant 
and unspecified 
Cervix carcinoma Rare x 
Skin neoplasms malignant and unspecified Skin cancer Rare x 
Soft tissue neoplasms malignant and 
unspecified 
Sarcoma Rare x 
Reproductive system and breast disorders Sexual function and fertility disorders Oligospermia Very rare x 
Respiratory, thoracic and mediastinal 
disorders 
Lower respiratory tract disorders (excl 
obstruction and infection) 
Interstitial lung disease Rare x 
Pneumonitis Very rare x 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Photosensitivity reaction Rare x 
Stevens-Johnson syndrome Rare x 
Stevens-Johnson syndrome Very rare x 
Toxic epidermal necrolysis Rare x 
Toxic epidermal necrolysis Very rare x 
Skin appendage conditions Alopecia Rare   
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – not 
elsewhere classified     
Frequency: RARE, affecting more than or equal to one in 10,000 patients, but fewer than one in 1,000; VERY RARE, affecting less than one in 10,000. 
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4.3.3. Adverse reactions reported in SPCs and not in trials 
Overall, a large number of adverse reactions recorded in SPCs, and that would be expected to be 
in clinical trials, were not reported (Table 21).  The lowest proportion of these reactions not 
captured in trials were in the very common and common frequency categories.  Given that adverse 
reactions in these categories occur in more than one in 100 patients, trials would be expected to 
capture these. Generally, as adverse reactions become rarer, the number of adverse reactions 
reported in the SPCs, but not in trials increases.  Significant proportions of adverse reactions 
reported in the SPCs are deemed to be related to the drug, but there is not enough information 
to estimate how many people might be affected with the particular reaction.  These are captured 
in the “frequency not known” category, and account for 40% and more of adverse reactions 
reported in SPCs, but not in trials, in some drug classes. 
4.3.3.1. 5-ASAs 
128 adverse reaction entries were recorded in the 5-ASAs SPCs that were not reported in the 
Crohn’s disease clinical trials (Table 21 and full list in Appendix table 35).  The vast majority of the 
adverse reactions for 5-ASAs were in the rare, very rare or frequency unknown categories (85.2%).   
The trial sample sizes and rule of three calculations in Table 13 suggest that the upper limit of 
adverse event detection would be common events. 
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Table 21: Adverse reactions reported in the Summary of Product Characteristics (SPCs), but not in the clinical trials, of therapies for the treatment of Crohn's disease in 
adults, numbers and proportions 
Drug class Very 
common 
Common Uncommon Rare Very rare Frequency 
not known 
Total 
No. % of  
total 
No. % of  
total 
No. % of 
 total 
No. % of  
total 
No. % of  
total 
No. % of  
total 
 
5-ASAs 1 0.8% 11 8.6% 7 5.5% 29 22.7% 26 20.3% 54 42.2% 128 
Antibiotics, macrolides 0 0.0% 5 6.1% 42 51.2% 0 0.0% 0 0.0% 35 42.7% 82 
Antibiotics, nitroimidazole derivatives 0 0.0% 0 0.0% 0 0.0% 1 2.9% 18 52.9% 15 44.1% 34 
Antibiotics, quinolones 0 0.0% 0 0.0% 18 20.5% 40 45.4% 25 28.4% 5 5.7% 88 
Biologics, Anti-TNFα 5 2.6% 67 35.1% 65 34.0% 45 23.6% 2 1.0% 7 3.7% 191 
Corticosteroids 0 0.0% 19 10.3% 2 44.8% 9 4.4% 13 6.4% 69 34.0% 112 
Immunosuppressives, antimetabolites 1 2.4% 7 17.1% 5 12.2% 19 46.3% 8 19.5% 1 2.4% 41 
Immunosuppressives, methotrexate 2 1.5% 8 6.0% 35 26.3% 30 22.6% 46 34.6% 12 9.0% 133 
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY 
RARE, < 1/10,000; and frequency not known, cannot be estimated from the available data. 
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4.3.3.2. Antibiotics 
There were 82 adverse reactions recorded in the SPCs for macrolide antibiotics that are not 
recorded in Crohn’s disease trials (Table 21 and full list in Appendix table 36).  More than half of 
these (51.2%) are recorded as uncommon, meaning that they occur in between one in 100 and 
one in 1,000 patients).  The rule of three calculations suggested that the trials should have been 
able to detect common events at the upper limit, given the trial sample sizes (Table 13). The 
remaining bulk are of unknown frequency, which is where the frequency cannot be estimated 
from the available data. 
The SPCs for nitroimidazole derivatives recorded 34 adverse reactions that are not reported in 
trials, which are listed in Appendix table 37.   The majority of these were very rare (52.9%); 
occurring in less than one in 10,000 patients (Table 21), which it is unlikely could be detected in 
the drug trials given the sample sizes (Table 13).  The frequency of occurrence could not be 
estimated for 44.1% of the adverse reactions. 
There were 88 adverse reactions recorded in the quinolone SPCs, but not in the corresponding 
trials for Crohn’s disease patients (Appendix table 38). The majority of these (94.0%) were 
reported to occur uncommonly, rarely or very rarely, which would be beyond the power of the 
trials to detect based on their sample sizes (Table 13).  Only 5.7% could not be assessed for 
frequency of occurrence. 
4.3.3.3. Anti-TNFα 
A large number of adverse reactions (191) were recorded in the anti-TNFα SPCs above those 
recorded in the clinical trials for Crohn’s disease (Table 21).  The full list is in Appendix table 39.  
More than two thirds of these adverse events (69.1%) were of common or uncommon occurrence.  
This pattern is in contrast to the other drug classes where more rarer and unknown harms 
recorded and is different in terms of the rule of three calculations (Table 13). 
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4.3.3.4. Corticosteroids 
The SPCs for corticosteroids identify 112 adverse reactions that are not reported in the 
corresponding clinical trials in Crohn’s disease (Table 21 and full list in Appendix table 40).  44.8% 
of these adverse events were reported to occur uncommonly (between one in 100 and one in 
1,000 patients), which is more common than the level indicated the trial sample sizes (Table 13).  
The frequency could not be estimated for a further third of the adverse events (34.0%) (Table 4). 
4.3.3.5. Immunosuppressives 
41 adverse reactions were reported in the SPCs for antimetabolites, but not in the corresponding 
clinical trials in Crohn’s disease (Table 21 and full list in Appendix table 41).  Almost two thirds of 
these (65.9%) were rarely or very rarely occurring and are unlikely to be identified in trials of those 
identified for Crohn’s disease (Table 13). 
For methotrexate, the SPC recorded 133 adverse reactions that were not reported in Crohn’s 
disease trials (Appendix table 42).  83.5% of these were reported to occur uncommonly, rarely or 
very rarely, above the predicted upper limit for detection, according to the rule of three 
calculations in (Table 13). 
4.3.4. Adverse events reported in trials but not in SPCs 
Large numbers of adverse events were recorded in the 69 trials, which were not reported as 
adverse reactions in the SPCs (Table 22 and detail in Appendix table 43 to Appendix table 50).    
Overall, three in ten trials did not assess whether the adverse events recorded were possibly 
related to the study drug.  Additionally, whilst some trials indicated the overall numbers of 
possible treatment-related adverse events, some did not list the adverse events that were 
possible adverse drug reactions.  41 of 69 (59.4%) trials named adverse events as treatment 
related, although this varied by drug class from 0% of macrolides trials to 89.5% of corticosteroid 
trials.  88 of the 488 (18.0%) adverse events that were reported in trials, but not included in the 
SPCs, were identified as potentially related to treatment in the trials. 
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Table 22: Adverse events reported in trials but not in the Summary of Product Characteristics (SPCs) of 
therapies for the treatment of Crohn's disease in adults, numbers and proportions 
Drug class Trials Trial AEs 
not 
reported 
in SPCs 
Trials 
assessing 
causation 
Trials 
reporting 
treatment 
related AEs 
AEs 
identified as 
potential 
ADRs 
No. No. No. % No. % No. % 
5-ASAs 15 44 9 60.0% 8 53.3%  11 25.0% 
Antibiotics, 
Macrolides 
3 6 0 0.0% 0 0.0%       -    0.0% 
Antibiotics, 
Nitroimidazole 
derivatives 
3 39 2 66.7% 1 33.3%       5  12.8% 
Antibiotics, 
Quinolones 
7 39 4 57.1% 2 28.6%       5  12.8% 
Biologics, TNFα 
inhibitors 
17 120 13 76.5% 12 70.6%     18  15.0% 
Corticosteroids 19 76 19 100.0% 17 89.5%     35  46.1% 
Immunosuppressive, 
antimetabolites 
12 121 6 50.0% 5 41.7%     13  10.7% 
Immunosuppressive, 
methotrexate 
2 43 1 50.0% 1 50.0%       1  2.3% 
All trials matched to 
SPCs 
69 488 48 69.6% 41 59.4%     88  18.0% 
Note: AE – adverse event; ADR – adverse drug reaction; SPC – summary of product 
characteristics 
 
4.3.4.1. 5-ASAs 
There were 44 adverse events reported in the trials of 5-ASAs in Crohn’s disease patients that are 
not reported as adverse reactions in the relevant SPCs (Table 22).  The adverse events were in 16 
SOCs, with the most reported under the gastrointestinal disorders (12) and general disorders and 
administration conditions (9) SOCs (Appendix table 43).  11 (25.0%) of these were believed to be 
possible adverse drug reactions in the trials in the seven trials that reported treatment-related 
adverse events (Table 23).  
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Table 23: Possible treatment related events in Crohn’s disease trials, not reported in summary of product characteristics (SPCs) – 5-ASAs 
SOC HLGT PT 
Blood and lymphatic system disorders Platelet disorders Thrombocytosis 
Gastrointestinal disorders Gastrointestinal motility and defaecation conditions Diarrhoea haemorrhagic 
Gastrointestinal signs and symptoms Abnormal faeces 
General disorders and administration conditions General system disorders NEC Asthenia 
Oedema 
Therapeutic and nontherapeutic effects (excl toxicity) Drug intolerance 
Infections and infestations Infections - pathogen unspecified Pyuria 
Investigations Physical examination and organ system status topics Weight decreased 
Protein and chemistry analyses NEC C-reactive protein increased 
Metabolism and nutrition disorders Lipid metabolism disorders Hyperlipidaemia 
Musculoskeletal and connective tissue disorders Musculoskeletal and connective tissue disorders NEC Back pain 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; 
ADR – adverse drug reaction; NEC – not elsewhere classified 
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4.3.4.2. Antibiotics 
There were six adverse events reported in the Crohn’s disease trials of macrolide antibiotics that 
did not also appear in the SPCs (Table 22).  None of the included trials assessed causation of the 
adverse events.  Five of the adverse events appear to be features of the disease: Crohn’s disease 
(aggravated), anal abscess, arthralgia, hospitalisation and surgery (Appendix table 44).  The final 
adverse event is vulvovaginal candidiasis.   
39 adverse events were reported in trials of nitroimidazole derivatives in patients with Crohn’s 
disease, but not in the drug SPCs.  The adverse events were across 13 SOCs, with most under the 
infection and infestations (9) and gastrointestinal disorders (7) headings (Appendix table 45).  Only 
one trial reported possible adverse drug reactions and identified five that were not included in the 
SPCs: cushingoid, oedema, insomnia, acne and purpura. 
In trials of quinolones in Crohn’s disease patients, 37 adverse events were reported that did not 
feature in the SPCs (Appendix table 46).  The adverse events were reported across 10 SOC 
headings, with the most common reports under infections and infestations (15 adverse events) 
and gastrointestinal disorders (4) headings.  Two trials assessed causation and reported five 
treatment-related adverse events: cushingoid, infusion related reaction, insomnia, acne and 
purpura. 
4.3.4.3. Anti-TNFα 
120 adverse events were reported in the Crohn’s disease clinical trials for anti-TNFα therapies that 
did not feature in the corresponding SPCs (Table 22).  Most adverse events were reported under 
the SOC headings of infections and infestations (44) and gastrointestinal disorders (16).  Overall, 
the excess trial adverse events were reported across 21 SOC headings (Appendix table 47).  18 of 
the 120 adverse events were assessed as being potential ADRs: cushingoid, six injection site 
reactions, chest discomfort, chest pain, flushing, type IV hypersensitivity reaction, pharyngitis, 
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pneumonia, serum sickness, liver function test abnormal, hyperphagia, neoplasm malignant and 
mood swings (Table 24). 
4.3.4.4. Corticosteroids 
In trials of corticosteroids, 76 adverse events were reported above those reported in the relevant 
SPCs (Table 22).  Overall, adverse events were reported under 18 SOC headings, with the highest 
numbers under gastrointestinal disorders (14) and investigations (12) (Appendix table 48).  Almost 
half of these were assessed as being related to the study drug in the 17 (of 19, 89.5%) trials 
reporting treatment-related adverse events (Table 25).
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Table 24: Possible treatment related events in Crohn’s disease trials, not reported in summary of product characteristics (SPCs) – biologics: anti-TNFα 
SOC HLGT PT 
Endocrine disorders Adrenal gland disorders Cushingoid 
General disorders and administration 
conditions 
Administration site reactions Injection site bruising 
Injection site erythema 
Injection site haemorrhage 
Injection site irritation 
Injection site pain 
Injection site pruritus 
General system disorders NEC Chest discomfort 
Chest pain 
Flushing 
Immune system disorders Allergic conditions Type IV hypersensitivity reaction   
Pharyngitis 
Pneumonia 
Liver function test abnormal 
Metabolism and nutrition disorders Appetite and general nutritional disorders Hyperphagia 
Neoplasm malignant 
Psychiatric disorders Mood disorders and disturbances NEC Mood swings   
Surgery 
Vascular disorders Embolism and thrombosis Venous thrombosis 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; ADR 
– adverse drug reaction; NEC – not elsewhere classified 
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Table 25: Possible treatment related events in Crohn’s disease trials, not reported in summary of product characteristics (SPCs) – corticosteroids 
SOC HLGT PT 
Blood and lymphatic system 
disorders 
Anaemias nonhaemolytic and marrow depression Anaemia 
Coagulopathies and bleeding diatheses (excl thrombocytopenic) Increased tendency to bruise 
Gastrointestinal disorders Gastrointestinal haemorrhages NEC Melaena 
Gastrointestinal signs and symptoms Vomiting 
Salivary gland conditions Dry mouth 
General disorders and 
administration site conditions 
General system disorders NEC Flushing 
Oedema 
Oedema peripheral 
Infections and infestations Fungal infectious disorders Vulvovaginal candidiasis 
Infections - pathogen unspecified Anal abscess 
Conjunctivitis 
Injury, poisoning and procedural 
complications 
Bone and joint injuries Hand fracture 
Investigations Endocrine investigations (incl sex hormones) Blood cortisol decreased 
Haematology investigations (incl blood groups) White blood cell count increased 
Hepatobiliary investigations Alanine aminotransferase increased 
Aspartate aminotransferase increased 
Protein and chemistry analyses NEC Blood albumin decreased  
Protein total decreased 
Renal and urinary tract investigations and urinalyses Blood creatinine increased 
Water, electrolyte and mineral investigations Blood calcium decreased 
Metabolism and nutrition disorders Appetite and general nutritional disorders Decreased appetite 
Bone, calcium, magnesium and phosphorus metabolism disorders Hypocalcaemia 
Lipid metabolism disorders Lipohypertrophy 
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SOC HLGT PT 
Musculoskeletal and connective 
tissue disorders 
Joint disorders Joint swelling 
Musculoskeletal and connective tissue disorders NEC Back pain 
Psychiatric disorders Mood disorders and disturbances NEC Affect lability 
Mood altered 
Respiratory, thoracic and 
mediastinal disorders 
Upper respiratory tract disorders (excl infections) Nasal mucosal ulcer 
Skin and subcutaneous tissue 
disorders 
Epidermal and dermal conditions Eczema 
Skin appendage conditions Alopecia 
Hair growth abnormal 
Hypertrichosis 
Hot flush 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; 
NEC – not elsewhere classified 
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4.3.4.5. Immunosuppressives 
121 excess adverse events were reported in Crohn’s disease trials for antimetabolites above those 
reported in the relevant SPCs (Table 22).  The highest numbers of adverse events were reported 
under the SOC headings infections and infestations (22) and investigations (16), with reports 
under 24 headings overall (Appendix table 49).  Only five of 12 trials (41.7%) reported possible 
treatment-related adverse events and 35 (28.9% of 121) of these were not included in the SPCs 
(Table 26). 
Adverse events that were reported in Crohn’s disease trials of methotrexate, but not the SPC, 
were across 13 SOC headings, and numbered 43 in total (Table 22). Trial excess adverse events 
were most commonly reported under the investigations (9), infections and infestations (5) and 
gastrointestinal disorders (5) headings (Appendix table 50).  Only one trial assessed causation of 
adverse events and identified one potential treatment-related adverse event; infusion related 
reaction. 
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Table 26: Possible treatment related events in Crohn’s disease trials, not reported in summary of product characteristics (SPCs) – immunosuppressives: antimetabolites 
SOC HLGT PT 
Endocrine disorders Adrenal gland disorders Cushingoid 
Eye disorders Anterior eye structural change, deposit and degeneration Cataract 
General disorders and administration 
conditions 
Administration site reactions Injection site reaction 
 Injury, poisoning and procedural 
complications 
Procedural related injuries and complications NEC Post procedural complication 
Investigations Haematology investigations (incl blood groups) White blood cell count decreased 
Hepatobiliary investigations Transaminases increased 
Musculoskeletal and soft tissue investigations (excl enzyme tests) Bone density decreased 
Metabolism and nutrition disorders Appetite and general nutritional disorders Hyperphagia 
Nervous system disorders Neurological disorders NEC Paraesthesia 
Psychiatric disorders Mood disorders and disturbances NEC Mood swings 
Skin and subcutaneous tissue disorders Skin appendage conditions Acne 
Surgical and medical procedures Therapeutic procedures and supportive care NEC Surgery 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC 
– not elsewhere classified 
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4.4 Discussion 1 
Identifying common, very common, rare and very rare adverse reactions that are identified in the 
SPCs but not in the trials was a potentially sound way to identify additional harms from Crohn’s 
disease treatments that are not captured in RCTs.   We might expect a trial testing an active 
substance in 100 patients to identify very common and common adverse reactions provided the 
risk of those events was distributed equally across all patient factors, such as age, sex, disease 
severity, co-morbidities, additional therapies, etc.  23 of the 69 (33.3%) trials included in the work 
in this chapter had a sample size of at least 100 patients, with the majority (46 of 69, 66.7%) 
therefore having a lower power to detect adverse events.   
Even for the larger trials, it is unlikely that adverse reactions are distributed evenly across a 
population, and it is well understood that certain adverse reactions may occur commonly but only 
after a lengthy exposure, which would be beyond the follow up period of trials.  The classic 
example of this phenomenon is osteoporosis with long-term corticosteroid use350, and this 
adverse reaction is picked up in the results of common and very common adverse reactions that 
are not reported in trials, but are captured in the SPC.  However, it is one of 39 common or very 
common adverse reactions, 30 of which were not identified in trials, and osteoporosis and its 
frequency in corticosteroid use is identified as important because of the prior knowledge of the 
causal relationship.  It is difficult to pick out which are the important ones without in depth 
knowledge of the condition and the therapy. 
Looking at the rare and very rare adverse reactions confirmed that the majority are not reported 
in trials, as expected, given that they occur in fewer than 1 in 1,000 patients.  However, this then 
leads to questions about the ones that are identified in trials.  They cover a broad range; for 
example, in 5 ASAs, the rare and very rare adverse reactions reported in both SPCs and trials 
ranged from alopecia and pyrexia to Steven-Johnsons syndrome (a rare and serious disorder that 
affects the skin, mucous membrane, genitals and eyes, causing skin erosion, blindness and 
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death)351.  In addition, some of the rare and very rare adverse reactions are classic signs of CD, 
such as arthralgia, fistula, constipation and dyspepsia, which are reported in the SPCs and trials 
for macrolide antibiotics and corticosteroids.  It could be argued these adverse events represent 
the obvious things that cannot be missed and may suggest selective reporting. There is also a risk 
that the SPCs are identifying false positives, if the exploratory methods used to generate signals 
fail to account for the increased risk of falsely identifying a signal when conducting multiple 
statistical tests, a phenomenon known as ‘multiplicity’352. 
Examination of the adverse reactions captured in SPCs but not recorded in trials leads to some 
queries, particularly in the case where rule of three calculations suggest they should have been 
identified in trials.  Anti-TNFα agents have a different pattern to the other drug classes, with many 
more common and very common adverse reactions that are not identified in trials.  This may 
reflect the fact that these drugs are newer to market and are being monitored more actively and 
therefore more adverse reactions are being detected. New biologics are marketed under the black 
triangle scheme, which alerts prescribers to the need for intensive monitoring and reporting of all 
adverse reactions.  This requirement would not have been in place for older treatment like 
azathioprine and 5-ASAs and represents a source of bias in what is reported to the regulators.    It 
could also reflect the greater disease severity in the population receiving this drug class, who may 
have a higher tolerance for drugs with more side effects, as discussed in Chapter 1.   
The additional adverse reactions in the SPCs may also reflect the fact that in a trial setting, a 
patient might stop their treatment upon experiencing an ADR, and so would not have the 
opportunity to experience other ADRs. In other words, there are competing risks that remove 
patients from the pool and mean that trials cannot fully characterise the safety profile. The 
potential for this to impact upon the adverse events identified in trials may be compounded if the 
events are not independent.  Multiplicity remains a concern for signal generating statistical 
methods352. 
183 
Making sense of the adverse events reported in trials, but not in SPCs, is also complex.  Within our 
results for 5-ASAs, gastrointestinal disorders such as Crohn’s disease, enteritis, intestinal 
obstruction were reported in the trials, but not in the SPCs for the drugs.  Such adverse events are 
features of Crohn’s disease and may indicate failure of therapy rather than an adverse reaction.  
An adverse event of surgery reported in the trials but not in the corresponding SPC may be a 
surgery related to Crohn’s disease or something unrelated.  There are clearly irrelevant adverse 
events reported in the trials, such as arthropod sting, fracture and pregnancy, which is a result of 
good practice procedures of reporting everything to allow for complete capture and signal 
detection methods.   Further, 18 adverse events were assessed as potential adverse drug reactions 
in the trials, but were not included in the SPCs.  This may be because the initial assessment was 
deemed incorrect or that post-marketing surveillance determined that the link was not causal 
after all once data was aggregated for all  
An issue that is common to all the strands of analysis in the preceding sections is related to the 
coding of adverse events.  As an example, lower respiratory tract infection is reported as an 
adverse reaction in the SPCs for anti-TNFα therapies but not in the trials.  However, upper 
respiratory tract infection and respiratory tract infection are reported in the trials and the SPCs.  
In any system where data is coded, there will be inter-observer variability due to the potential to 
code one data item in different ways.  For example, the MedDRA hierarchy places hepatic function 
abnormal is in the hepatobiliary disorders SOC, whilst liver function test abnormal belongs under 
the investigations SOC.  These are potentially the same event.  MedDRA is constantly updated and 
specific training is needed to be able to code adverse events: a systematic review found that this 
leads to variability in coding and even inaccurate coding353.  Additional coding might lead to 
greater accuracy and specificity, but it may also dilute signals. 
Complicating the issue is that the SPC includes data for all patient populations.  Therefore, the 
data may relate to a number of different disease groups, all of which might have distinct co-
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morbidities or co-therapies.  Some therapies for Crohn’s disease are also prescribed for 
rheumatoid arthritis (RA), potentially in different doses and with dissimilar drug combinations.  As 
the RA population is almost quadruple the size of the CD population, adverse reactions signals 
may be lost in a broad review if they differ, a phenomenon known as “masking” or “cloaking”354. 
Differences in the safety profiles of different drug classes may also reflect the age of the drugs.  
SPCs developed over different time-periods may have reported the occurrence of adverse 
reactions differently, specifically with the use of fewer frequency groups.  As such, SPCs for older 
groups may not report any adverse events as occurring in some groups, as was seen in the results 
section.   
The multitude of difficulties in the results suggest the need for an alternative method, which 
provides a greater focus and helps to reduce the uncertainty. Whilst combining different therapies 
into drug classes offered a way to maximise data use, it may be further complicating the approach. 
It was decided to simplify the analysis by focusing on one drug as a case study.   An alternative 
method to investigating long term and rare harms was developed which identified key harms from 
the literature and the use of data tools, which allow for the grouping of different terms used to 
describe the same harm.  This new method is discussed in the next section, 4.5. 
4.5. Methods 2 
Infliximab was selected as a single drug case study. The adverse events for the infliximab trials 
were used from the work reported in the previous section alongside the SPC for Remicade (Merck, 
Sharp & Dohme Limited, Hertfordshire, UK)355.  This drug was chosen due to its prominence in the 
literature at the time of the research, the need to balance risks against the benefits for patients, 
the occurrence of both common and rare adverse reactions, the comprehensive monitoring of 
adverse reactions through the black triangle scheme, and because of the authorisation of 
biosimilars (see Chapter 5).  In an attempt to counter the issues related to the broad range of 
preferred terms captured in the preceding results, the focus was reduced to those harms that 
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were known to occur and be causally related, or were theoretically possible based upon factors 
such as the mechanism of action.  Further, the decision was taken to focus on serious harms, as 
those would be the ones of most concern to those interested in assessing risk. 
4.5.1 Identifying and categorising key serious harms 
The primary sources for harms are the list of conditions identified in the SPC section 4.4 Special 
warnings and precaution for use355, the British National Formulary monitoring requirements326 
and the EMA guideline on the development of new medicines for Crohn’s disease68.  Additionally, 
a drug class review on targeted immune mediators was consulted which located evidence on 
adverse events356.  A single list of adverse events and reactions was created from the sources, 
which were grouped into harm categories. 
4.5.3. Standardised MedDRA queries (SMQs) 
Where possible, the harm categories were matched to standardised MedDRA queries (SMQs).  
This matching was done using the definition and inclusion criteria of the SMQs from MedDRA357.  
SMQs were developed by MedDRA in response to the recognition of the need for tools to support 
the identification and retrieval of safety data, which may be complicated due to the potential for 
multiple ways of coding the same event357.  They aim to group all preferred terms that are relevant 
to a defined condition and may include signs, symptoms, diagnoses, and physical and laboratory 
findings.   SMQs are designed to support the identification of individual safety case reports, but 
are being used in this chapter to investigate whether additional safety data can be identified from 
the SPCs to support the characterisation of harms beyond the trials. The use of SMQs offers the 
potential to group initial symptoms of adverse events that might be detected in trials with longer-
term adverse reactions that are identified in the post-marketing period.   
A working group determines the list of conditions for which a SMQ will be defined; at March 2018 
there were 103 SMQs available for use and a further seven in development or testing358. All SMQs 
offer a “narrow” scope and a “broad” scope.  The “narrow” scope is the grouping of preferred 
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terms that are highly likely to represent the condition, designed to maximise the specificity of the 
search.  The “broad” scope maximises sensitivity by including preferred terms that might relate to 
the condition of interest, but need further investigation of the case to be certain.  Additionally, 
some SMQs use an algorithmic approach to identify likely cases, such that a combination of 
preferred terms in a single patient might indicate the particular condition.  An example might be 
the identification of acute hepatitis for an individual case, which might be through the recording 
of the preferred term for acute hepatitis, or instead via a combination of preferred terms involving 
a laboratory result alongside signs and symptoms.  The multiple adverse events recorded for that 
individual case would then highlight acute hepatitis.  As the analysis in this chapter does not 
incorporate case data, both the broad scope terms and the algorithmic approach are irrelevant. 
4.5.3. Data presentation and analysis 
Once each harm category was matched against an SMQ (or SMQs), the preferred terms were listed 
in tables per SMQ.  Included in the tables is the following data: 
 either the system organ classification (SOC) or higher-level group term (HLGT);  
 the preferred term (PT);  
 a marker of whether they were reported in infliximab trials;  
 a marker of whether they were reported in the SPC; and 
  the frequency of reporting in the SPC.   
Only those preferred terms in the SMQ and reported in either the trials or the SPC were included 
in the analysis, but a summary of the total number of preferred terms in each SMQ is reported. 
4.6 Results 2 
The focus on infliximab resulted in the inclusion of adverse events from ten trials (referenced in 
Table 13).  The median sample size of these trials was 112 participants (IQR: 42-222). 
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4.6.1. Identifying harm categories 
The SPC for Remicade highlights potential serious adverse reaction relating to infusion reactions 
and hypersensitivity, hepatobiliary events, neurological events, heart failure and haematologic 
reactions355.  
The BNF requires that patients receiving infliximab be monitored for delayed hypersensitivity, 
hypersensitivity reactions, infection and non-melanoma skin cancer326. 
In addition, the EMA suggests that for drugs acting as immunomodulators (such as biologics), 
particular attention should be paid to serious infections, autoimmune diseases and tumours and 
that the long term nature of treatment of biologicals requires that attention be paid to the 
development of antibodies68. 
A drug class review on targeted immune mediators located evidence on serious infection, 
malignancy, autoimmunity, demyelination, serious hepatic incidents, cardiovascular harms and 
specific events such as injection site reactions356. 
As a result, eight adverse reaction categories were identified, as shown in Table 27: autoimmunity; 
blood disorders; cardiac events; hepatic events; hypersensitivity; immunogenicity; infection; 
malignancies; and neurological events. 
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Table 27: Harm categories identified through review of key literature, and matched standardised MedDRA queries (SMQs) 
Harm category Matched SMQ Adverse event / reaction Source Listed in source as 
Autoimmunity No relevant SMQ. 
Autoimmune diseases / 
immune mediated conditions 
SMQ in development. 
Autoimmune diseases CHMP68 Special attention 
Autoimmunity Thaler et al356 Groups of interest 
Autoimmune processes SPC355 Special warnings / precautions for use 
Antibodies CHMP68 Must investigate 
Blood disorders No relevant SMQ.  Haematologic reactions SPC355 Special warnings / precautions for use 
Cardiac events Cardiac failure. Cardiovascular events & congestive heart failure Thaler et al356 Groups of interest 
Heart failure SPC355 Special warnings / precautions for use 
Hepatic events Drug-related hepatic 
disorders. 
Hepatic events Thaler et al356 Groups of interest 
Hepatobiliary events SPC355 Special warnings / precautions for use 
Hypersensitivity Hypersensitivity. 
Infusion-related reaction SMQ 
in development. 
Delayed hypersensitivity BNF326 Monitoring requirement 
Hypersensitivity reaction BNF326 Monitoring requirement 
Injection site or infusion reactions Thaler et al356 Groups of interest 
Infusion reactions and hypersensitivity SPC355 Special warnings / precautions for use 
Infection No relevant SMQ.  
Opportunistic infection SMQ 
in development. 
 
Infection BNF326 Monitoring requirement 
Serious infections CHMP68 Special attention 
Serious infections Thaler et al356 Groups of interest 
Infections SPC355 Special warnings / precautions for use 
Hepatitis B reactivation SPC355 Special warnings / precautions for use 
Malignancies Malignancies Non-melanoma skin cancer BNF326 Monitoring requirement 
Tumours CHMP68 Special attention 
Lymphoma and other malignancies Thaler et al356 Groups of interest 
Malignancies and lymphoproliferative disorders SPC355 Special warnings / precautions for use 
Neurological 
events 
Demyelination 
Peripheral neuropathy 
Demyelination Thaler et al356 Groups of interest 
Neurological events  SPC355 Special warnings / precautions for use 
Note: CHMP – Committee for Medicinal Products for Human Use; SPC – summary of product characteristics; SOC – system organ classification; SMQ – 
standardised MedDRA query 
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4.6.2. Matched SMQs and AE and ADR results by harm category 
4.6.2.1. Autoimmunity 
Autoimmunity, autoimmune diseases or autoimmune processes are listed as adverse reactions of 
concern in three of the sources consulted (Table 27).  There is no SMQ for autoimmunity, although 
a SMQ for autoimmune diseases / immune mediated conditions is under development by the 
MedDRA working group358.  As such, this category was excluded. 
4.6.2.2. Blood disorders 
The SPC for infliximab highlights that haematologic reactions have been reported with the use of 
anti-TNFα agents and that these should be monitored for355.    Whilst there are plenty of SMQs 
related to specific haematological disorders, there was no SMQ closely matching the description 
in the SPC and therefore this category was excluded from the analysis (Table 27). 
4.6.2.3. Cardiac events 
Heart failure is listed as a special warning and precaution for use in the SPC for infliximab355 (Table 
27).  Cardiovascular events and congestive heart failure are listed as adverse events of interest for 
anti-TNFα therapy patients in Thaler et al356.  The cardiac failure SMQ is defined as “a condition in 
which the heart is unable to pump an adequate amount of blood to meet metabolic and 
physiological needs of body”357.   The narrow scope query includes terms that describe existing 
cardiac failure as well as a small number of terms for signs, symptoms, investigation findings and 
procedures that indicates or specify cardiac failure.  30 preferred terms are included in the narrow 
scope.  Two of these terms were also reported in the SPC, but none was reported in the trials 
(Table 28).  Cardiac failure and pulmonary oedema were reported as uncommon in the SPC.  The 
preferred terms are linked to Cardiac disorders SOC and respiratory, thoracic and mediastinal 
disorders SOC, respectively.  Uncommon events are unlikely to occur in trials with median 112 
participants. 
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4.6.2.4. Hepatic events 
Hepatic events and hepatobiliary events are identified as adverse events of interest and special 
warnings and precautions for use (Table 27)355,356.  Jaundice, non-infectious hepatitis and liver 
failure are reported to have occurred with use of Remicade in the SPC.  The drug-related hepatic 
disorders SMQ was the closest match, which is a sub-SMQ of the much broader hepatic disorders 
SMQ.  It includes terms for potentially drug-related liver disorders and there are 233 preferred 
terms in the narrow definition.  Seven of these terms are recorded in the SPCs, three are reported 
in the trials and one is reported in both SPC and trials ( 
Table 29).  
Hepatic function abnormal is under the SOC of hepatobiliary events and is reported to occur 
commonly in the SPC (between one in 100 and one in 10 patients).  It is not reported in trials 
though.  However, three related preferred terms that fall under the investigations SOC are 
reported: alanine aminotransferase abnormal, hepatic enzyme increased and transaminase 
increased.  The latter was reported as a possible treatment-related adverse event in trials and is 
reported in the SPC as commonly occurring.   
Hepatitis and hepatocellular injury are reported to occur uncommonly (between one in 1,000 and 
one in 100), autoimmune hepatitis and jaundice are reported to occur rarely (between one in 
10,000 and one in 1,000) and hepatic failure is reported to occur but with unknown frequency in 
the SPC.  Hepatocellular injury and hepatic failure are also included in the SMQ of drug related 
hepatitis – severe events only, which includes 79 preferred terms. 
.
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Table 28: Cardiac events standardised MedDRA query (SMQ) matched against the summary of product characteristics (SPC) and trial adverse events data 
    Frequency of reporting in SPC 
SOC PT Reported 
in trials 
Reported 
in SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Cardiac disorders Cardiac failure   x     x       
Respiratory, thoracic and mediastinal 
disorders 
Pulmonary oedema   x      x 
 
    
Note: SOC – System Organ Classification; PT – preferred term.   Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 
1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 1/10,000; and frequency not known, cannot be estimated from the available data. 
 
Table 29: Drug related hepatic disorders standardised MedDRA query (SMQ) matched against the summary of product characteristics (SPC) and trial adverse events data 
SOC PT Reported 
in trials 
Reported 
in SPC 
Frequency of reporting in SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Hepatobiliary disorders 
 
Autoimmune hepatitis   x       x     
Hepatic failure   x           x 
Hepatic function abnormal   x   x         
Hepatitis   x     x       
Hepatocellular injury   x     x       
Jaundice   x       x     
Investigations 
 
 
Alanine aminotransferase abnormal x               
Hepatic enzyme increased x               
Transaminases increased X TRAE x   x         
Note: SOC – System Organ Classification; PT – preferred term.  Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 
1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 1/10,000; and frequency not known, cannot be estimated from the available data. 
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4.6.2.5. Hypersensitivity 
As shown in Table 27, the SPC for Remicade identifies infusion reactions and hypersensitivity, 
including anaphylactic shock and delayed hypersensitivity, as special warnings and precautions for 
use355.  The BNF lists delayed hypersensitivity and hypersensitivity reactions as monitoring 
requirements326. Injection site or infusion reactions were adverse events of interest in a drug class 
review of anti-TNF agents356.   
There is a SMQ for hypersensitivity and a further SMQ is in development for infusion-related 
reactions358.  The hypersensitivity SMQ is designed to identify “all cases possibly related to 
hypersensitivity / allergic reactions”357. The narrow definition, with greatest specificity, includes 
270 preferred terms for which allergy is one of the main (and most likely) causes.  This is 
distinguished from the broad definition, where hypersensitivity is only one of many possible 
causes of the included events.  
18 preferred terms from the hypersensitivity SMQ are also featured in the SPC and trials for 
Remicade (Table 30).  One preferred term is recorded in the SPC, but not the trials, in each of the 
following system organ classification (SOC) headings: blood and lymphatic system disorders; eye 
disorders; respiratory, thoracic and mediastinal disorders; and vascular disorders. Each of these 
adverse reactions are recorded to occur uncommonly or rare and therefore might not be expected 
to be found in the trials.   
Six preferred terms under the immune system disorders SOC heading are recorded in either SPC 
or trials.  One preferred term, serum sickness, is reported in both trials and the SPC, where it is 
reported to occur uncommonly.  Two events are reported solely in trials and both are reported as 
potentially treatment related: hypersensitivity and type IV hypersensitivity reaction (delayed 
hypersensitivity).  Three preferred terms were recorded solely in the SPCs: anaphylactic shock as 
a rare reaction; anaphylactic reaction as an uncommon event; and allergic respiratory symptom 
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as a common reaction.  A commonly occurring reaction would be expected to occur in trials, but 
this may reflect the variable coding. 
Eight preferred terms under the skin and subcutaneous skin disorders SOC were recorded in either 
SPC or trials.  Three preferred terms were reported in both trials and the SPC, all as common 
adverse reactions in the SPC.  Two of these terms were reported as potentially treatment related 
in the trials: rash and urticarial.  One other event, hypersensitivity vasculitis, appeared solely in 
trials.  A further four terms appeared solely in the SPCs, all either as uncommon or rare reactions.  
Two of these, Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare and very serious 
reactions.
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Table 30: Hypersensitivity standardised MedDRA query (SMQ) matched against the summary of product characteristics (SPC) and trial adverse events data 
SOC PT Reported 
in trials 
Reported 
in SPC 
Frequency of reporting 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Blood and lymphatic 
system disorders 
Immune thrombocytopenic 
purpura 
  x       x     
Eye disorders Periorbital oedema   x     x       
Immune system disorders Allergic respiratory symptom   x   x         
Anaphylactic reaction   x     x       
Anaphylactic shock   x       x     
Hypersensitivity X TRAE               
Serum sickness x x     x       
Type IV hypersensitivity 
reaction 
X TRAE               
Respiratory, thoracic and 
mediastinal disorders 
Bronchospasm   x       x     
Skin and subcutaneous 
tissue disorders 
Dermatitis bullous   x     x       
Eczema x x   x         
Erythema multiforme   x       x     
Hypersensitivity vasculitis x               
Rash X TRAE x   x         
Stevens-Johnson syndrome   x       x     
Toxic epidermal necrolysis   x       x     
Urticaria X TRAE x   x         
Vascular disorders Circulatory collapse   x       x     
Note: SOC – System Organ Classification; PT – preferred term.   
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, 
< 1/10,000; and frequency not known, cannot be estimated from the available data. 
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4.6.2.6. Malignancies 
A number of malignancy terms, including tumours, malignancies, non-melanoma skin cancer, 
lymphoma, and lymphoproliferative disorders, were identified as important adverse reactions for 
infliximab in the literature (Table 27)68,326,355,356. The SMQ for malignancies was identified, which 
is a combination of four sub-SMQs for malignancy-related tumours, malignancy related 
therapeutic and diagnostic procedures, malignant or unspecified tumours and tumour markers.  
The SMQ includes 2,205 unique preferred terms in the narrow definition.   
19 of these terms were recorded in either the SPC or trials, none was reported in both (Table 31).  
All but one, intestinal resection (reported in trials), are under the SOC heading neoplasms, benign, 
malignant and unspecified.  Ten further preferred terms appeared only in trials: basal cell 
carcinoma, bladder cancer, breast cancer, carcinoma in situ, natural killer-cell lymphoblastic 
lymphoma, neoplasm malignant (as a potentially treatment related event), neoplasm skin, rectal 
adenocarcinoma, rectal cancer and renal cell carcinoma.  Eight preferred terms are recorded in 
the SPC, 6 as rare reactions (cervix carcinoma, Hodgkin’s disease, leukaemia, lymphoma, 
malignant melanoma and non-Hodgkin’s lymphoma) and 2 with unknown frequency 
(hepatosplenic T-cell lymphoma and neuroendocrine carcinoma of the skin).
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Table 31: Malignancies standardised MedDRA query (SMQ) matched against the summary of product characteristics (SPC) and trial adverse events data 
SOC PT Reported 
in trials 
Reported 
in SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Neoplasms benign, 
malignant and 
unspecified (incl cysts 
and polyps) 
Basal cell carcinoma x               
Bladder cancer x               
Breast cancer x               
Carcinoma in situ x               
Cervix carcinoma   x       x     
Hepatosplenic T-cell 
lymphoma 
  x           x 
Hodgkin's disease   x       x     
Leukaemia   x       x     
Lymphoma   x       x     
Malignant melanoma   x       x     
Natural killer-cell 
lymphoblastic lymphoma 
x               
Neoplasm malignant X TRAE               
Neoplasm skin x               
Neuroendocrine carcinoma 
of the skin 
  x           x 
Non-Hodgkin's lymphoma   x       x     
Rectal adenocarcinoma x               
Rectal cancer x               
Renal cell carcinoma x               
Surgical and medical 
procedures 
Intestinal resection x               
Note: SOC – System Organ Classification; PT – preferred term.  Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; 
UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 1/10,000; and frequency not known, cannot be estimated 
from the available data. 
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4.6.2.7. Neurological events 
Neurological events, namely demyelinating disorders and peripheral neuropathy, were identified 
as important adverse events associated with the use of Remicade (Table 27)355,356.  There is no 
SMQ available for neurological events, but there are SMQs for both demyelination and peripheral 
neuropathy. An SMQ is also available for Guillain-Barre syndrome, and the SMQ introductory 
document recommends all three are included in any case search to identify all demyelination 
disorders.  However, none of the narrow search terms in the Guillain-Barre syndrome SMQ 
matched any preferred terms in the trials or SPC, so it is not reported. 
Demyelination is defined in the SMQ as the “loss of myelin with preservation of the axons or fibre 
tracts”, and identifies central demyelination as occurring within the central nervous system and 
peripheral as affecting the peripheral nervous system.357  Included in the SMQ are terms for 
central and peripheral demyelination, but also terms containing the root “demyel” and other 
terms for conditions specifically related to demyelination.  40 preferred terms are included in the 
narrow definition SMQ and three matched terms in trials and the SPC (Table 32).  Demyelination 
was listed in both trials and the SPC.  Multiple sclerosis was listed in the trials and myelitis 
transverse, which is often any early symptom of MS, was listed as a rarely occurring adverse 
reaction in the SPC for Remicade. 
Within the SMQ for peripheral neuropathy, the condition is defined as  an “impairment of the 
peripheral motor, sensory and autonomic nervous system”357.  It includes all terms for peripheral 
neuropathy and related concepts, as well as signs, symptoms and laboratory findings.  There are 
36 preferred terms in the narrow definition SMQ, two of which are reported in either trials or SPC 
(Table 33).  Neuropathy peripheral was identified as an uncommon reaction in the SPC for 
Remicade and sensory loss, which can be an early symptom of peripheral neuropathy, was 
identified as an adverse event in the trials.
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Table 32: Demyelination standardised MedDRA query (SMQ) matched against the summary of product characteristics (SPC) and trial adverse events data 
SOC PT Reported 
in trials 
Reported 
in SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Nervous system disorders 
 
 
Demyelination x x       x     
Multiple sclerosis x               
Myelitis transverse   x       x     
Note: SOC – System Organ Classification; PT – preferred term.   
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY 
RARE, < 1/10,000; and frequency not known, cannot be estimated from the available data. 
 
Table 33: Peripheral neuropathy standardised MedDRA query (SMQ) matched against the summary of product characteristics (SPC) and trial adverse events data 
SOC PT Reported 
in trials 
Reported 
in SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Nervous system disorders 
 
Neuropathy peripheral   x     x       
Sensory loss x               
Note: SOC – System Organ Classification; PT – preferred term.   
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY 
RARE, < 1/10,000; and frequency not known, cannot be estimated from the available data. 
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4.6.2.8. Infection 
Infections and serious infections were listed in all four sources of literature on important harms 
for Remicade (Table 27)68,326,355,356. An SMQ for infection is unavailable, although one for 
opportunistic infections is under development358.  The SOC heading of infections and infestations 
offers an opportunity to consider the differences and similarities in reporting between trials and 
the SPC for Remicade.  27 preferred terms for infections and infestations were reported in the 
trials, three of which were reported as potentially treatment related – infection, pharyngitis and 
pneumonia (Table 34).    Only one preferred term, tuberculosis, was also reported in the SPC and 
was listed as occurring uncommonly.    However, the SPC lists a number of types of infections and 
gives examples, and some of the examples do match the adverse events reported in trials.  For 
example, the SPC lists bacterial infections as occurring commonly and specifies abscess as one 
type.  Five preferred terms for abscess were reported as in the trials adverse events: abdominal 
abscess, abdominal wall abscess, abscess, anal abscess and pelvic abscess.   Sepsis was also an 
example and is reported in the trials.  
Viral infections are reported to occur very commonly and two of the examples given in the SPC, 
herpes virus infection and influenza, were reported in the trials.  The SPC reports that 
opportunistic infections occur rarely and a number of examples are given with one clearly 
corresponding to a preferred term reported in trials: cytomegalovirus infection.  Five further 
preferred terms are listed in the SPC but not the trials: fungal infection reported to occur 
uncommonly: infection parasitic, meningitis and hepatitis B reactivation reported to occur rarely; 
and vaccine breakthrough infection reported with unknown frequency.
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Table 34: Infections under the SOC Infections and infestations matched against summary of product characteristics (SPCs) and Crohn’s disease trials adverse events data 
HLGT PT In trials In 
SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Comment 
Bacterial 
infectious 
disorders 
Bacterial infection   x   x         SPC: (e.g. sepsis, 
cellulitis, abscess) 
Legionella infection x                 
Nocardiosis x                 
Fungal 
infectious 
disorders 
Fungal infection   x     x       SPC: (e.g. 
candidiasis) 
Infections - 
pathogen 
unspecified 
Abdominal abscess x                 
Abdominal wall abscess x                 
Abscess x               SPC: listed as 
example of 
bacterial infection 
Anal abscess x                 
Appendicitis x                 
Bronchitis x               Listed as an 
example of LRTI in 
SPC 
Ear infection x                 
Eye infection x                 
Gastroenteritis x                 
Gastrointestinal infection x                 
Infection X TRAE                 
Infection parasitic   x       x       
Infectious colitis X                 
Meningitis   x       x       
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HLGT PT In trials In 
SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Comment 
Nasopharyngitis x                 
Opportunistic infection    x       x     SPC: (such as 
invasive fungal 
infections 
[pneumocystosis, 
histoplasmosis, 
aspergillosis, 
coccidiodomycosis, 
cryptococcosis, 
blastomycosis], 
bacterial infections 
[atypical 
mycobacterial, 
listeriosis, 
salmonellosis], and 
viral infections 
[cytomegalovirus]) 
Pelvic abscess x                 
Pharyngitis X TRAE                 
Pneumonia X TRAE               Listed as example 
of LRTI in SPC 
Respiratory tract infection X                 
Rhinitis X                 
Sepsis x               SPC: listed as 
example of 
bacterial infection 
Skin infection x                 
202 
HLGT PT In trials In 
SPC 
Very 
common 
Common Uncommon Rare Very 
rare 
Not 
known 
Comment 
Vaccine breakthrough 
infection 
  x           x SPC: (after in utero 
exposure to 
infliximab) 
Mycobacterial 
infectious 
disorders 
Tuberculosis x x     x         
Viral infectious 
disorders 
Cytomegalovirus infection x               Listed as example 
of opportunistic 
infection in SPC 
Hepatitis B   x       x     SPC: listed as 
hepatitis B 
reactivation 
Hepatitis C x                 
Herpes virus infection x               SPC: listed as 
example of viral 
infection 
Influenza x               SPC: listed as 
example of viral 
infection 
Viral infection   x x           SPC: (e.g. 
influenza, herpes 
virus infection) 
Note: SOC – System Organ Classification; PT – preferred term; HLGT – higher-level group term; LRTI – lower respiratory tract infection 
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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4.7. Discussion 2 
4.7.1. Summary of evidence 
The work in this chapter builds upon both the systematic review in Chapter 2 and the outcomes 
classification hierarchy in Chapter 3.  The aim was to examine potential methods of fully 
characterising the harms that are incompletely described in RCTs due to the factors discussed in 
Section 4.1, including the limited population involved, length of trials and evidence of reporting 
bias.  The data source used was the summary of product characteristics (SPC).  The initial 
methodology involved organising the drugs into classes and comparing RCT adverse events against 
adverse reactions from the SPCs.  14 therapies were included in the analysis, which grouped into 
five drug classes.  The SPCs were found for 69 studies identified in the systematic review, 38.1% 
of the total.  Corticosteroids were the drug class with most trials for which an SPC could be 
matched, followed by anti-TNFα inhibitors, and budesonide was the active ingredient with the 
most trials for which an SPC could be matched.   
Based upon the known issue that RCTs fail to characterise rare events and the selective reporting 
which may introduce bias and prevent the identification of all risks, the intention was to identify 
common and very common and rare and very rare adverse reactions that were not reported in 
trials.  However, difficulties arose from this method due to a number of reasons.  The grouping of 
drugs into classes, some of which were much older and had been developed under different 
reporting protocols for adverse reactions, meant there was potential bias in the data in both trials 
and SPCs.  Identifying important harms was potentially compromised due to the use of therapies 
for other more common conditions that may have a different risk profile, such as rheumatoid 
arthritis, and the ability to code events in different way using MedDRA. 
A new approach sought to refine the analysis and reduce the noise by focusing on one treatment, 
infliximab (Remicade®), using the evidence base to identify the key harms from that treatment.  
Standardised MedDRA queries (SMQs) grouped preferred terms to overcome the difficulties 
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caused by multiple ways to code the same reaction in MedDRA and the potential for trials to 
identify earlier symptoms of longer-term adverse reactions.  The narrow definition SMQs were 
deemed most relevant to the aims of the chapter as summary data is being used, and the narrow 
terms maximise specificity rather than sensitivity.  Ten trials were included for infliximab, with a 
median treatment sample size of 65 (interquartile range: 31-125 participants).  It might therefore 
be expected that trials would identify very common (affecting at least one in ten) and perhaps 
common events (affecting at least one in 100).  The capture of uncommon harms (affecting more 
than or equal to one in 1,000, but fewer than one in 100 patients), rare or very rare harms 
(affecting fewer than one in 1,000 patients) would not be expected.  Analysing trials in aggregate 
gives improved power for detecting rarer adverse events and, as described in Section 4.1.3, is the 
approach taken by spontaneous reporting systems to establish the frequency of occurrence of 
adverse reactions.  Indeed, a rule of three calculation359 for the 10 trials  combined (total 937 
participants receiving infliximab) suggests that any adverse reactions not identified in trials have 
a 95% confidence interval upper limit of occurrence of three in 1,000 patients, which is within the 
rare category. This is a much-improved potential for detection of adverse reactions than based on 
any single trials alone. 
The use of harm categories and SMQs greatly reduced the number of preferred terms identified.  
Only six adverse reactions in the SPC matched directly to adverse events recorded in the RCTs.  
Using the SMQs, 29 adverse reactions were identified from the SPC that were not reported in the 
RCTs (four preferred terms under the infections and infestations SOC for which there was no 
SMQ).  17 of these were rarely occurring adverse reactions, and offer the strongest potential as 
additional data on the harms of Remicade therapy in Crohn’s disease.  This is a significant 
improvement on 52 rare and very rare adverse reactions that were identified for anti-TNFα 
therapies using the initial methodology. 
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This leaves 12 non-rare adverse reactions that deserve further consideration.  Three of these were 
reported as frequency not known (hepatic failure, hepatosplenic T-cell lymphoma and 
neuroendocrine carcinoma of the skin) which are likely to be signals that have been identified 
through spontaneous reporting.  However, two are common or very common in occurrence 
according to the SPC, which should appear in the trials unless they are adverse events that occur 
through extended use.  Hepatic function abnormal was a commonly occurring adverse reaction in 
the hepatic events harms category that was unreported in RCTs.  However, three preferred terms 
within the drug-related hepatic disorders SMQ that indicate abnormal liver function were 
reported in trials: alanine aminotransferase abnormal, hepatic enzyme increased and 
transaminases increased.  It is conceivable that these are similar but coded differently and the 
SMQ has succeeded in pulling them together.  Similarly, allergic respiratory symptom is reported 
as a common adverse reaction but is not reported in trials.  However, hypersensitivity was 
reported as an adverse reaction in trials and is grouped within the hypersensitivity SMQ, which 
may again signal a success in the grouping of different codes for similar events. 
Uncommon adverse reactions could not be expected to occur in trials given their size as the rule 
of three (as derived in Equation 4 to Equation 7) would put the estimates of missing adverse events 
outside of this frequency grouping (Table 13).  There are seven preferred terms that fall into this 
category of uncommon events not reported in RCTs, and whilst six of these offer no immediate 
explanation, but would be of interest because of their potential seriousness (cardiac failure, 
hepatitis, hepatocellular injury, periorbital oedema, dermatitis bullous and anaphylactic reaction), 
the remaining one potentially highlights another SMQ linking.  Neuropathy peripheral is an 
uncommon adverse reaction recorded in the SPC, but is not recorded in trials. However, sensory 
loss is recorded in trials and is within the peripheral neuropathy SMQ. Given that sensory loss is 
an initial symptom of peripheral neuropathy, this might reflect a coding variation or it could reflect 
the time course differences in adverse events identified in RCTs versus post-marketing 
surveillance.  Sensory loss is likely to be a short-term observation of peripheral neuropathy, the 
206 
 
former of which could be identified in RCTs, whilst the latter would almost certainly not be.  The 
use of SMQs allows for the initial symptoms and final outcomes to be identified together. 
4.7.2. Strengths and limitations 
A key strength of this approach is the ability to make use of existing data to characterise more 
completely the harms from a specific therapy in Crohn’s disease.  Harms reporting is complex and 
there is a high volume of data to incorporate from both trials and SPCs. This method enabled the 
vast amounts of data to be summarised and interpreted.  The results in Section 4.3.2 show that 
up to 91.5% of rare and very rare adverse events reported in the SPCs are not reported in trials, 
which gives an indication of the potential value of this approach.   
A search of the literature to identify important harms for Crohn’s disease and then matching the 
SMQ and trials data allowed for 17 rare harms to be identified, some of which are very serious.  
Narrow SMQ searches were used to ensure specificity of the preferred terms, but research 
suggests the choice of narrow or broad makes little difference probably because medical coders 
are trained to code the most important events, which are in the narrow search360.  Knowing the 
very serious adverse events, even if they are very rare, is an important consideration for those 
involved in health technology assessment and can have a significant impact upon the benefit-risk 
balance of a drug. This method has the potential to add value to such processes. 
The ability to understand the risk associated with this smaller number of most relevant harms 
could help to systematically and comprehensively characterise harms and support clinical 
decision-making.  Assessing harms requires a different paradigm to assessing efficacy, where the 
hierarchy of evidence is not relevant but instead there is a need to consider all available evidence 
on harms and explore different methods in order to reach a conclusion on risk334,347,361.   The 
approach taken in this chapter attempts to work within the altered paradigm in an efficient way 
to maximise the value of existing data.   This approach is in line with research into other sources 
of harms data, which included observational studies, unpublished work and, more recently, social 
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media334,336,343,346,362. It may be useful in contributing important harms to a core outcome set 
development process by identifying a list of harms that can be included in the outcomes to be 
prioritised as part of consensus methods. 
The CONSORT statement makes clear how trials should report harm and a joint response by 
industry and journal editors emphasises a key problem is in identifying those harms that are most 
clinically significant as this is what supports decision-making363.  The authors argue for clinical trials 
to filter reported harms to help identify key harms. This could be based upon the mechanism of 
action, or consideration of previous agents in the class, but they suggest it could also come from 
clinical experience or a systematic review to identify other harms.  In essence, the methods 
described here have applied a clinical filter using a literature review and SMQs, but to the 
pharmacovigilance information from the SPCs, rather than RCT adverse events.  This is a novel 
approach. 
However, the method is not without limitations.  Many of the difficulties relate to the general 
processes involved in generating data in SPCs (and trials), and are not specific to this method 
alone.  One issue of vital importance is the limited consideration of seriousness or causation of 
adverse events in clinical trials.  Results in Chapter 2 highlight that few trials record serious adverse 
events and serious treatment-related adverse events are even less likely to be reported.  Of the 
69 trials included in this chapter, only 69.1% assessed causation of adverse events and even fewer 
(59%) reported individual adverse events that were assessed as possibly treatment related.  The 
CONSORT statement extension identifies poor reporting as the summation of adverse events 
without reference to seriousness and made suggestions that have improved reporting, but it 
remains a current issue333,363.  In addition, competing risks and the independence of adverse 
reactions need to be assessed and their impact understood.   
The guidance for SPCs states that within each frequency grouping in the table of undesirable 
events, adverse reactions should be presented in the order of decreasing seriousness15. However, 
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this does little to quantify the seriousness of each event, especially if attempting to compare 
between different system organ classifications, and the preferred terms do not indicate it either.  
As an example, cardiac failure sounds very serious, but is actually graded from Class I where it 
causes no limitations at all, to Class IV where patients are unable to carry on any physical activity 
and have symptoms at rest, although there is risk of progression364.  Therefore even where a list 
of preferred terms is identified using this method, it would need further investigation to 
understand seriousness. 
Whilst spontaneous reporting systems represent a cost-effective method of monitoring drug 
safety, there are issues with under-reporting of adverse reactions, poor quality reporting and the 
absence of a clear denominator to quantify risk334,365,366.  Significant under-reporting of adverse 
reactions is a well-understood limitation of spontaneous reporting systems.  Estimates of 
underreporting from one systematic review range from 82% to 96%, with little improvement in 
the reporting of serious adverse reactions, and this can delay the identification of signals and 
create difficulties in quantifying risk365,367.  Reasons for under-reporting by health professionals 
are multiple.  They include a lack of knowledge about the reporting system (including mistaken 
beliefs that the system is only for monitoring severe reactions or conversely that all adverse 
reactions are known about when the drug comes to market), worry about correctly identifying 
adverse reactions and attributing causation, and administration reasons such as a lack of time or 
inability to locate forms365–367. 
Further limitations exist at the point of identifying signals from the spontaneous reports.  
Disproportionality methods are quick, inexpensive, and able to identify previously unknown 
harms, which is especially useful in the case of rare events347.  However, when a drug is used for a 
variety of conditions there is the chance for signals in one condition to be diluted, or for the 
opposite and one to be identified that doesn’t hold for all conditions.  This could be a factor in our 
case study of Remicade, as Crohn’s disease is much less common than rheumatoid arthritis, and 
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the drug is used in both.  However, an analysis of two spontaneous databases found that 
significant masking was in fact rare in large databases368.  In addition, there is a risk of false positive 
signals of adverse reactions due to multiplicity, if appropriate statistical techniques are not 
used334,352. 
SMQs are designed to reduce the problem of signal dilution and there is evidence that both 
applicants and the FDA increasingly use them in the applications for market review, and that the 
results impact the decisions made369.  This is a significant change from a survey of MedDRA users 
in 2007 which suggested that they were not well used370, and indicates a growing acceptance of 
the tools.  Caution should be paid though, as an analysis of one year of data from the French 
spontaneous reporting database indicated variable performance across different SMQs in terms 
of their ability to correctly detect cases with fairly low positive predictive value360.  Although the 
use of SMQ here is on data that should already have been through this process and have been 
validated against other data, in the case of FDA market approvals, 26% of SMQ searches used at 
the point of labelling did not mention validation369. If the same finding applied in the EU, this would 
still have implications for the accuracy of the data in our results.   
When signals are detected, reference will be made to the clinical trial data.  Underreporting may 
not be as great a concern in clinical trials as in spontaneous reporting systems (although selective 
reporting is still a concern as discussed in Chapter 3), but quality and completeness are an issue, 
even for serious adverse events.  One study found that adverse events were reported incorrectly 
in 15.1% of investigator reports and clinical or laboratory findings were not included in 30% of 
reports371.  Even where cases are reported correctly, a study estimates that 12% of reports were 
coded differently by 2 different coders in clinical trials and that 8% of investigator reports were 
coded incorrectly353.  This reduces the usefulness of pharmacovigilance at each stage of the 
lifecycle of a drug. 
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Frequency reporting within the SPC is flawed, as it does not report on the duration of treatment, 
which can often increase the risk of adverse reactions334.  Further, it does not consider the 
different indications, unless there is a great deal of evidence in support of an adverse reaction 
that is particular to one indication.  Alternative systems of adverse event classification have been 
proposed to overcome these flaws.  One such system, discussed in Chapter 1 is the DoTs system, 
which classifies adverse reactions according to dose, time and susceptibility factors56.   
In addition, the use of the rule of three can lead to estimates of adverse reaction frequency in 
SPCs higher than adverse events that were actually reported in trials372.  This is best illustrated by 
example, such as where adverse reactions that did not appear in the trials would be recorded as 
rare in the SPC, but some adverse events that did occur within trials were reported as very rare.  
Greater clarity in reporting is proposed by Crowe et al372 who recommend that incidence rates 
should be included (as well as comparator incidence rates for alternative treatments) and that 
frequencies estimated using the rule of 3 should be recorded separately.  Additionally, evidence 
points to under-reporting in SPCs of drug interaction information, with only 33% of SPCs reporting 
drug interaction information equivalent to that published in the literature373.    Accounting for 
such measures within SPCs would help to identify the data with most uncertainty.  
The faults of the two data sources, RCTs and SPCs, are on opposite sides of the denominator and 
population sides of a risk calculation, which may result in differences in absolute risk values (or 
even the ability to calculate absolute risk values). However, research by Zink et al (2018) 
demonstrated similarities in the ranking of adverse reactions taken from the two sources334.  This 
supports the use of both sources to improve the safety profile of medicines, despite the biases 
involved in both. 
A final, limitation specific to the methods in this chapter, is the failure to include harms data from 
observational studies, which arguably would include the longer-term harms.  The work on this 
chapter built upon the systematic review in Chapter 2, which was of both harm and efficacy 
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outcomes.  Work by Golder et al339 has demonstrated that more comprehensive information on 
harms can be obtained by a review focused on adverse events and with consideration of both 
published and unpublished work.  The differences between the harms identified in the SPCs and 
the trials might have been less had this approach been taken, although it would be a very complex 
undertaking for the grouping of trials in the first methods section, 4.2.  The approach taken was 
pragmatic in light of the restricted time of a PhD project, and the ability to build upon the work 
from an earlier chapter, but does bear consideration regardless. 
4.7.3. Conclusions 
This chapter presents a novel method for triangulating the literature on key harms, the adverse 
events reported in randomised controlled trials and the adverse reactions recorded in SPCs.  The 
use of SMQs provides the opportunity to group initial symptoms, which are more likely to be 
identified in RCTs, with the longer-term outcomes identified through post-marketing surveillance.  
Whilst spontaneous reporting systems are undoubtedly flawed, the design of trials to estimate 
benefit and their short-term nature, particularly for chronic conditions like Crohn’s disease, means 
that pharmacovigilance relies upon such reports.   Methods to bring together a variety of harms 
data must be considered efficient research, especially where they allow for the identification and 
quantification (albeit in broad frequency groups) of harms.  Methods that help to identify the most 
rare and serious harms from drugs add value by supporting a better understanding of the benefit-
risk balance of a therapy, which is useful for a range of decision-makers from clinical to health-
care payer and could also potentially support the inclusion of harms in core outcome set 
development.  Other methods would be needed for non-drug therapies, such as polymeric diet 
and surgery, and for widely used drug therapies such as mercaptopurine and prednisolone for 
which no randomised clinical trial evidence was found in the systematic review in Chapter 2. 
Further research would be valuable to validate the findings in this chapter and could involve an 
analysis of the performance of standardised MedDRA queries on a sample of Yellow Card 
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spontaneous reports.  Additionally, the research could be repeated as new SMQs are developed, 
particularly those for opportunistic infections, infusion-related reactions and autoimmune 
diseases and immune mediated conditions, which were all identified as important harm categories 
for infliximab. 
The work in Chapter 5 continues the focus on infliximab as a case study and seeks to estimate the 
benefit-risk balance of a biosimilar where there is no direct evidence of harm and efficacy in 
Crohn’s disease patients.  
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Chapter 5: Value assessment and quantitative benefit-risk 
modelling: a case study of infliximab in Crohn’s disease 
5.1. Introduction 
Biosimilars offer the opportunity for less expensive treatment of chronic conditions, while 
achieving comparable health outcomes to reference medical products (RMP), enabling reduced 
expenditure on the therapies or the extension of treatment to allow more patients to benefit 
within the same budget.  Medicine regulators seek assurance that there are no clinically 
meaningful differences in efficacy and safety to the RMP81,374 using processes described in detail 
in Section 1.3.2.  This normally requires a clinical trial in a population sensitive to potential 
differences in efficacy, safety, or immunogenicity between the biosimilar and originator.  Evidence 
of similarity in one clinical indication is assumed to extrapolate to other indications for which the 
medicine is approved based on a qualitative assessment of the totality of the evidence, including 
the structural, physicochemical, functional, and non-clinical data in addition to clinical studies81,374.  
Biosimilars are not intended to be superior to the originator (these would be biobetters375), 
although advances in technology and improved manufacturing processes over time may in fact 
mean that biosimilars could become more efficacious and less harmful than their originator 
products.  However, they may be less efficacious and there is also is a risk that they carry an 
inferior safety profile (if only marginally).  Uncertainties regarding the safety of biosimilars at the 
point of marketing authorisation are inherently related to the use of non-inferiority trials to justify 
near-equivalence of efficacy, the absence of trial evidence for all indications due to the process of 
extrapolation and the lack of long-term experience and data.  These uncertainties were discussed 
further in Section 1.3.3.2.  The primary reason for adopting biosimilars and acceptance of the 
potential risks with no improved health benefits is the opportunity for cost savings.  With each 
new biosimilar, heath care payers therefore face the question of whether the cost savings can 
justify the increased uncertainty in their clinical performance.   
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At the point of launch, and for a long period after, the biosimilar will have less safety data than 
the originator and therefore there will always be uncertainty about the net health benefit (NHB).  
As explained in Section 1.1.2.2, the NHB is the net benefit of investing resources in a given 
intervention, rather than in investing the same resources in another marginally cost-effective 
intervention37.  In other words, in the presence of budget constraints, spending on this biosimilar 
means forgoing the health benefits of investing in another drug.   
Biological therapies have improved the quality of life of patients with Crohn’s disease, but they 
are expensive and are linked to serious adverse events376.  The first Crohn’s disease (CD) biological 
treatment patent to expire was for originator infliximab (IFX) (Remicade, Merck Sharp & Dohme 
Limited, Hertfordshire, UK).  As discussed in Section 1.3.3, the pattern of regulatory approvals, 
with some countries initially rejecting the drugs or limiting their approved indications, highlights 
the difficulties arising from the subjective nature of benefit-risk balance assessment and 
extrapolation from evidence in rheumatoid arthritis (RA)68,86,377.  A key concern was that CD 
patients are more likely than other patients to develop antibodies to infliximab (ATI), which trials 
in other indications are unable to rule out94,378.  The consequences of developing ATI, known as 
immunogenicity, include reduced efficacy and increased likelihood of adverse events, particularly 
infusion reactions, which are rare but can be severe. Even minor differences between the 
biosimilar and originator have the potential to cause significant harm for patients379. 
With each new biosimilar, heath care payers therefore face the question of whether the cost 
savings can justify the increased uncertainty in their clinical performance.  A  range of quantitative 
methods for benefit-risk assessment are available, but to date, there has been no quantitative 
benefit-risk analysis of biosimilars, which may reflect the further challenge of assumed 
equivalence in benefits with the RMP.  Health economic modelling can be used as part of the 
health technology assessment to evaluate the benefit-risk balance by pooling the available 
evidence and reflecting uncertainty in inputs, to estimate the likelihood of a biosimilar providing 
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a net health gain39.  The INHB between the biosimilar and originator represents the added value 
of the biosimilar considering both the reduced costs and the increased uncertainty surrounding 
its clinical performance given societal resource constraints37 and, in effect, represents a 
quantitative approach to the benefit-risk assessment of biosimilars. 
The work presented in this chapter aimed to quantitatively assess the benefit-risk balance of 
biosimilar versus originator, using IFX as an exemplar, to determine whether the cost savings 
justify the increased uncertainties in efficacy and safety and to assess the value of conducting 
further trials in CD to reduce uncertainty in key parameters. The results of the model were 
discussed in the context of emerging evidence from clinical use and ongoing trials in CD. 
5.2. Methods 
5.2.1. Literature review 
The model was developed as a proof-of-concept rather than to inform clinical decision-making 
and therefore a pragmatic approach was taken to literature review.  A search of MEDLINE was 
used to identify economic models used to evaluate infliximab.  Where possible, parameter values 
were guided by previous economic models and included parameters from clinical trials, 
observational studies, meta-analyses and data generated by authors of previous economic 
models.  However, the focus on the development and consequences of ATI necessitated additional 
targeted searches of MEDLINE to obtain parameter values.  Given the assumption of biosimilarity, 
and the lack of clinical trial data for Inflectra in CD, the parameter values were obtained for the 
originator drug, and assumed equivalent in the base case. 
The following section discusses the evidence from the clinical trials of originator IFX and the 
implications of their use in modelling. 
5.2.1.1. Pivotal infliximab monotherapy trials 
The pivotal IFX trials were identified by the systematic review reported in Chapter 2. Two trials 
were used to evidence the efficacy of originator infliximab in patients with moderate to severe 
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Crohn’s disease, in order to obtain regulatory approval from the EMA380.  The pivotal induction 
therapy trial was a double-blinded randomised controlled trial (RCT) of 108 patients by Targan et 
al (1997)129.  This RCT included 108 patients with moderate to severe CD, defined as 220 ≤ Crohn’s 
disease activity index (CDAI) score ≤ 400.  Patients were randomised to receive a single infusion of 
IFX at a dose of 5, 10 or 20 mg / kg body weight, or placebo.  The primary endpoint was response 
at week 4, which was defined as a 70-point reduction in CDAI score.  The response rate at 4 weeks 
was 81% (22/27) in the 5mg/kg infusion group, 50% (14/28) in the 10mg/kg group, and 64% 
(18/28) in the 20mg/kg group, compared to 16% (4/24) in the placebo arm.  The authors concluded 
that a single infusion of IFX was effective for short-term treatment in patients with moderate-to-
severe CD. 
Hanauer et al (2002)240 conducted the pivotal IFX maintenance therapy RCT in 523 patients with a 
CDAI score ≥ 220.  The ACCENT I trial aimed to assess the efficacy and safety of repeated infusions 
of IFX over 1 year, in patients who responded to an initial infusion.  All patients received an initial 
5mg/kg dose infusion of IFX at week 0.  Response was defined as a reduction in CDAI by ≥ 25% and 
≥ 70 points, and was checked at week 2.  Responders were randomised to placebo (group I), IFX 
5mg/kg (group II) and IFX 10mg/kg (group III).  Maintenance infusions were received at weeks 2 
and 6, and every 8 weeks afterwards.  The co-primary endpoint was remission (CDAI < 150) at 
week 30 and time to loss of response up to week 54.  Remission at week 30 was achieved by 20.9% 
(23/110) of patients in group I (placebo), 38.9% (44/113) of patients in group II (5mg/kg) and 45.5% 
(51/112) of patients in group III (10mg/kg).  The median time to loss of response was 19 weeks in 
group I, 38 weeks in group II and more than 54 weeks in group III. 
The ACCENT I trial informed the EMA approved dosing strategy for Crohn’s disease, but does not 
provide the appropriate data for modelling efficacy and harm as it does not contain an assessment 
of induction therapy.  As with Targan et al, the initial response is tested after a single dose.  IFX 
was initially developed as a single dose drug, with retreatment to be given once the condition 
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flared.  However, over time it became clear that episodic treatment resulted in a greater risk of 
ATI (45.8%, 95% CI: 41.7-50.0%) compared to maintenance schedules (12.4%, 95% CI: 10.8-14.1%), 
demonstrated by systematic review and meta-analysis381.  Consequently, the current 
recommended treatment pathway for IFX does not reflect the early clinical trials and necessitates 
the use of other data sources in modelling. 
5.2.2. Model structure 
A decision analytic model was constructed, to compare the benefits and risks of IFX biosimilar and 
originator.  The model was adapted from a published one-year cost-effectiveness analysis of IFX 
dose escalation versus initiation of adalimumab by Kaplan et al (2007)382 by the inclusion of 
adverse events.   
A hypothetical cohort of 100,000 biologic-naïve 35-year-old 70-kg patients with moderate-to-
severe CD was simulated through the model (Figure 19), which was structured over 4-weekly 
intervals to capture costs and outcomes.  The perspective of the analysis was that of the National 
Health Service (NHS) in the UK following marketing authorisation for Inflectra in 2013.  For the 
purposes of the economic analysis, which requires a single payer perspective, costs were 
restricted to those of the NHS in the UK.  Although CD is a chronic condition, a one-year time-
horizon was justified, as this was a proof-of-concept model with a focus on short-term outcomes.       
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Figure 19: Partial schematic representation of the decision-analysis model comparing Inflectra and Remicade. (Abbreviations: ATI – antibodies to infliximab; LOR – loss 
of response) 
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Due to the concern regarding immunogenicity of the biosimilar, the development of ATI is an 
important modifier in the model, influencing the rate of primary and secondary non-response383, 
and the likelihood of infusion reaction.  Acute or severe infusion reactions take place within 24 
hours of infusion and delayed infusion reactions take place between 24 hours to 14 days after 
infusion384.  In line with common practice59, the disease states were defined by the CDAI: 
moderate-to-severe disease equates to a CDAI score ≥220, remission to a score <150 and response 
to a reduction in CDAI score ≥70 points, resulting in mild disease (≥150 CDAI score <220). 
All patients enter the model in period 1 in moderate-to-severe disease state and received IFX 
therapy of 5mg/kg at weeks 0, 2 (period 1) and 6 (period 2), in accordance with the summary of 
product characteristics (SPC)380,385.  Initial response and the development of ATI are measured at 
week 12 (period 4). Those with no initial response ceased treatment with IFX, moved to standard 
care therapy in period 4, initially remaining in moderate-to-severe disease state.  Standard care 
includes all other possible therapies and surgeries, as outlined in NICE clinical management 
guidance62. 
Patients with primary response were in a mild disease state during periods 2 and 3 and entered 
ATI status-dependent remission or mild disease states in period 4.  IFX maintenance therapy 
continued every 8 weeks unless they experienced secondary non-response (loss of response), or 
a severe infusion reaction, upon which they moved to standard care (or died).  Patients who 
experience secondary non-response do so from a mild disease state.  Acute and delayed infusion 
reactions were managed in the same period and IFX was not withdrawn.  Patients could only 
experience one infusion reaction over the year and all were assumed to be in period 4, following 
the 4th infusion, consistent with the findings of the pivotal trial of IFX maintenance therapy in 
Crohn’s disease, ACCENT I240. 
At the end of one year, patients who remained on IFX could be in remission or experiencing mild 
disease or had moved to standard care or died.  Patients receiving standard care could end the 
220 
 
year in a moderate-to-severe disease state or post-surgical remission as it seems clinically 
unrealistic that patients who have failed standard care, then failed anti-TNFα therapy, could 
return to standard care and achieve remission or mild disease.  Death in the model could result 
from age-specific, all-cause mortality, severe infusion reaction, surgery or disease flare.  Age-
specific, all-cause mortality386 was applied during week 12, meaning none had experienced 
maintenance therapy. 
Moves to alternative treatment or surgery take place at the end of each period to allow for 
benefits, harms and costs to be allocated in whole periods. Benefits and harms took the form of 
utility values, health state preferences measured as quality adjusted life years (QALYs).  The effects 
of IFX treatment occur within the period of treatment. SC is assumed to take two periods to have 
effect 382.  Secondary non-response is assumed to take place at 38 weeks in line with the median 
in patients receiving the standard therapy of 5mg/kg of infliximab from ACCENT I (group II)240. The 
effect of IFX is assumed to wash out 19 weeks after stopping IFX due to a severe infusion reaction, 
in line with the median time to offset of response during placebo maintenance in ACCENT I240.  
The model was constructed in Microsoft Excel using visual basic language for probabilistic 
sensitivity analysis (PSA). 
5.2.3. Model parameters 
Parameter estimates for ATI development, efficacy, adverse events, health utilities and costs were 
obtained from targeted MEDLINE literature reviews of infliximab cost-effectiveness models and 
meta-analyses of infliximab immunogenicity and its impacts as discussed in Section 5.2.1.  
Parameters were selected purposively for methodological convenience, rather than through 
systematic review and evidence grading as the model intended to act as a proof of concept, rather 
than produce answers for clinical decision-making.  Model inputs are shown in Table 35.
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Table 35: Clinical event rates, health state utility values assigned to clinical events, and costs included in the model 
Parameter estimate Base Range for univariate 
sensitivity analysis 
Distribution for 
probabilistic 
sensitivity analysis 
Ref. Type of source data 
low high 
Antibodies to infliximab (ATI) probability       
ATI development during maintenance use+ 0.124 0.108 0.141 Beta_R(95,19) 
Beta_I(6,1) 
381 Meta-analysis 
Efficacy transition probabilities           
Initial response to infliximab at 12 weeks** 0.833 0.667 1 Beta_R(195,1383) 
Beta_I(84,594) 
387 Observational 
ATI+ responders in remission at 12 months 0.21 N/A N/A Dir(30) 388,389 Meta-analysis and cost-effectiveness 
study 
ATI+ responders in response at 12 months 0.121 N/A N/A Dir(18) 388,389 Meta-analysis and cost-effectiveness 
study 
ATI+ responders lost response at 12 months** 0.669 0.535 0.803 Dir(97) 389 Meta-analysis 
ATI- responders in remission at 12 months 0.482 N/A N/A Dir(187) 388,389 Meta-analysis and cost-effectiveness 
study 
ATI- responders in response at 12 months 0.278 N/A N/A Dir(108) 388,389 Meta-analysis and cost-effectiveness 
study 
ATI- responders lost response at 12 months** 0.24 0.192 0.288 Dir(93) 389 Meta-analysis 
Adverse event transition probabilities          
ATI+ responders experience acute IR** 0.315 0.252 0.378 Beta(78.170) 390 Systematic review and meta-analysis 
ATI+ responders experience delayed IR** 0.054 0.043 0.065 Beta(7,122) 390 Systematic review and meta-analysis 
ATI+ responders experience severe IR** 0.094 0.075 0.113 Beta(10,96) 390 Systematic review and meta-analysis 
ATI- responders experience acute IR** 0.142 0.114 0.17 Beta(133,804) 390 Systematic review and meta-analysis 
ATI- responders experience delayed IR** 0.021 0.017 0.025 Beta(12,569) 390 Systematic review and meta-analysis 
ATI- responders experience severe IR** 0.061 0.049 0.073 Beta(3,46) 390 Systematic review and meta-analysis 
Death from severe IR~ 0.004 0 0.01 Beta(2,609) 391 Systematic review and meta-analysis 
Age-specific all-cause mortality~ 0.001 0 0.005 Beta(1,630) 386 UK life tables 
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Parameter estimate Base Range for univariate 
sensitivity analysis 
Distribution for 
probabilistic 
sensitivity analysis 
Ref. Type of source data 
low high 
Adalimumab therapy       
12 week remission rate 0.29 N/A N/A N/A 392 Open label trial 
12 week response rate 0.39 N/A N/A N/A 392 Open label trial 
12 week no response rate 0.41 N/A N/A N/A 392 Open label trial 
Ustekinumab therapy       
Initial response at week 16 0.474 N/A N/A N/A 393 Post-hoc analysis 
Responders in remission at week 44 0.386 N/A N/A N/A 394 Randomised controlled trial 
Responders in response at week 44 0.312 N/A N/A N/A 394 Randomised controlled trial 
Responders lost response at week 44  0.302 N/A N/A N/A 394 Randomised controlled trial 
Vedolizumab therapy       
Initial response at week 10 0.478 N/A N/A N/A 395 Randomised controlled trial 
Responders in remission at week 52 0.280 N/A N/A N/A 395,396 Randomised controlled trials 
Responders in response at week 52 0.213 N/A N/A N/A 395,396 Randomised controlled trials 
Responders lost response at week 52 0.507 N/A N/A N/A 395,396 Randomised controlled trials 
Standard care therapy & 
 
       
Remain moderate-to-severe disease 0.680  0.544 0.816 Dir(30) 382 Cost-effectiveness study 
Require surgery** 0.312 0.250 0.375 Dir(14) 382 Cost-effectiveness study 
Death from surgery 0.002 N/A N/A Beta(96,63831) 382 Cost-effectiveness study 
Death from Crohn's disease flare 0.008 N/A N/A Dir(0.3) 382 Cost-effectiveness study 
Quality of life utilities          
Medical remission# 0.89 0.67 1 Beta(11,1) 397 Cost-effectiveness study 
Mild disease# 0.81 0.61 1 Beta(12,3) 397 Cost-effectiveness study 
Moderate-to-severe disease# 0.74 0.56 0.93 Beta(15,5) 397 Cost-effectiveness study 
Surgery# 0.4 0.3 0.5 Beta(36,55) 398 Cost-effectiveness study 
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Parameter estimate Base Range for univariate 
sensitivity analysis 
Distribution for 
probabilistic 
sensitivity analysis 
Ref. Type of source data 
low high 
Surgical remission# 0.8 0.6 1 Beta(11,3) 397 Cost-effectiveness study 
Severe infusion reaction# 0.4 0.3 0.5 Beta(36,55) 398 Cost-effectiveness study 
Utility decrement per acute or delayed IR~ 0.01 0 0.1 Beta(0.1,14) 399 Cost-effectiveness study 
Death 0 N/A N/A    
Costs (GBP)          
Inflectra vial cost* 378 189 420 N/A   
Remicade vial cost 420 N/A N/A N/A 400 NICE technology appraisal 
Adalimumab subcutaneous injection cost 358 N/A N/A N/A 400 NICE technology appraisal 
Ustekinumab vial & subcutaneous injection 
cost 
2,147 N/A N/A N/A 75 NICE technology appraisal 
Vedolizumab vial cost 2,050 N/A N/A N/A 76 NICE technology appraisal 
Infusion (day case hospital attendance) 697 N/A N/A N/A 401 UK NHS data 
Remission therapy (4 weeks)# 58 43 72 Lognormal(4.1,0.1) 401,402 Cost effectiveness study and NHS data 
Mild disease therapy (4 weeks)# 165 123 206 Gamma(61.5,2.7) 401,402 Cost effectiveness study and NHS data 
Moderate-to-severe disease therapy (4 weeks)# 257 193 321 Gamma(61.5,4.2) 401,402 Cost effectiveness study and NHS data 
Post-surgery therapy (4 weeks)## 257 129 386 Gamma(15.4,16.7) 401,402 Cost effectiveness study and NHS data 
Surgery# 11,116 8,337 13,894 Gamma(61.5,180.9) 401,402 Cost effectiveness study and NHS data 
Delayed IR (outpatient hospital attendance) 135 N/A N/A N/A 401 UK NHS data 
Severe IR (non-elective long stay admission) 2,581 N/A N/A N/A 401,403 Clinical review and UK NHS data 
Note: Parameter values are identical in the base case for both treatments due to the assumption of biosimilarity.   _R indicates distribution for Remicade parameter 
and _I for Inflectra parameter.  Abbreviations: IR - infusion reaction; ATI+ patients who developed antibodies to infliximab; ATI- patients who did not develop 
antibodies to infliximab; NHS – National Health Service; N/A – not applicable.  Key: + reported confidence interval used as range;  ** reported mean +/-20% used as 
range; ~ range determined by authors; & Silverstein standard care outcomes with remission and response parameters shared proportionately between moderate to 
severe disease and surgery outcomes to reflect more severe disease pathway; # reported mean +/- 25% used as range; * BNF reported prices, range of 50% to 100% 
of Remicade price; ## reported mean +/- 50% used as range, to account for uncertainty in costs 
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An explanation of the sources of the parameter values follows in Section 5.2.3.1 to Section 5.2.3.6.  
Section 5.2.5 discusses how the ranges and distributions were identified. 
5.2.3.1. ATI development 
The rate of ATI development for Remicade (ATI_R) during maintenance use were taken from a 
meta-analysis381 as ACCENT I had 46% inconclusive samples and were considered potentially 
biased240.  In the base case, this is also the ATI development rate for Inflectra (ATI_I). 
5.2.3.2. Efficacy 
Early clinical trials focused on single infusions, and the pivotal maintenance trial, ACCENT I, 
contained only patients who had responded to the initial infusion, as discussed in Section 5.2.1.1.  
To provide an estimate of the induction phase response, the probability of response at 12 weeks 
was taken from an observational study387 identified from a previous economic model388.   
The limited availability of data by ATI status for maintenance therapy necessitated that we derive 
some parameter values.  The rates of secondary non-response (LOR) by ATI status were derived 
from a meta-analysis of the impact of ATIs on clinical outcomes389.  Rates of remission and 
response by ATI status at 1 year were calculated by adjusting the rates for IFX monotherapy 
calculated by Saito et al388 proportionately by our calculated LOR probabilities.  
Standard care probabilities were based upon the results of a Markov analysis of the natural history 
of Crohn’s disease before the introduction of biologics by Silverstein et al (1999), who reported 
two-month transition probabilities across 8 states404.  We used the figures derived by Kaplan et al, 
who reported probabilities of six states from non-anti-TNF management (referred to as standard 
care in this model)382.  Remission and mild disease states were not considered clinically realistic 
and were not included as pathways from standard care as explained in Section 5.2.2 (Figure 19). 
Therefore, all patients who moved to standard care were split between the surgery and moderate-
to-severe disease states in proportion to the ratio between the probabilities in Kaplan et al382. 
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5.2.3.3. Adverse events 
The probabilities of acute and delayed infusion reactions by ATI status were calculated from a 
meta-analysis of the impact of antibodies on the risk of infusion reactions, with supplementary 
data on severe infusion reactions provided by the corresponding author390.  Data on mortality 
from serious adverse events was taken from Siegel et al (2006)391 and was used for the risk of 
death from severe infusion reaction. The risk of death from age-specific, all-cause mortality was 
taken from UK life tables for the period of 2012-14386. 
5.2.3.4. Utilities 
Utility values for disease states and surgery were taken from two published cost-effectiveness 
models where they had been derived for the appropriate disease states397,398. They adapted utility 
estimates reported in an evaluation of methods used to measure utility in Crohn’s disease by 
Gregor et al (1997)405.  The utility value for non-responding active disease in Lindsay et al (2008) 
was assumed for the surgery state.  Acute and delayed infusion reactions do not affect disease 
activity but a 0.01 utility decrement was applied per event399. In the absence of other utility 
estimates, the following assumptions were made: utility for a severe infusion reaction is the same 
as that for surgery due to the need for hospitalisation in both; and post-surgical utility equalled 
moderate-to-severe disease for one period, then surgical remission for the remainder of the year. 
5.2.3.5. Resource use 
Patients receiving IFX (and other biologics) also receive standard care.  Vial sharing was not 
assumed so each infusion required four vials and an NHS day case hospital attendance.  Acute 
infusion reactions were managed at the time of infusion within the day case hospital 
attendance401.  Delayed infusion reactions required an additional outpatient clinical visit.  Severe 
infusion reactions were assumed to require a 4 night hospital stay, based upon a study of another 
biologic agent406, which aligns with a long stay non-elective NHS hospital admission.  Post-surgical 
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therapy was assumed to be in line with standard care resource use for moderate-to-severe 
disease. 
5.2.3.6. Costs 
Standard care costs were taken from a previous Markov model by Bodger, Kikuchi and Hughes 
(2009), inflated using the retail price index401,402. IFX vial prices were from the British National 
Formulary (BNF), as reported in NICE technical appraisals75,76,400. Costs of day case hospital 
attendances, outpatient clinic visits and long stay non-elective admissions were from 
contemporary NHS reference costs401. 
5.2.4. Outcomes 
Estimates of efficacy, ATI risk and adverse events for Inflectra were assumed equivalent to 
Remicade in the base case analysis, in line with the assumption of biosimilarity.  The outcomes of 
the analyses were one-year costs and QALYs for treatment, and the proportion of patients who 
experienced: sustained remission for 12 months, sustained response for 12 months, remission, 
response, no adverse events following IFX treatment for 12 months, moved to standard care, 
developed ATIs, non-response (primary and secondary), infusion reactions (acute, delayed and 
serious), surgeries and death.   
Assuming biosimilarity implies equal outcomes.  Given the effect that this has on the outcomes 
(equal expected QALY), comparative value was determined from the Incremental Net Health 
Benefit (INHB) rather than the incremental cost-effectiveness ratio (ICER) as the ICER is a ratio of 
the difference in expected costs against the difference in expected benefit and this presents 
mathematical difficulties.  INHB is the difference in Net Health Benefit (NHB) between each 
intervention37.  INHB was calculated as the incremental benefit (in QALYs) of the biosimilar 
compared with the originator, minus the incremental cost divided by the threshold for cost-
effectiveness:   
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Equation 8: Incremental net health benefit (INHB) 
𝐼𝑁𝐻𝐵 = (𝐸𝐼 − 𝐸𝑅) − (𝐶𝐼 − 𝐶𝑅)/λ 
Where E and C are the expected benefit (QALY) and costs for Inflectra (I) and Remicade (R), 
respectively, and λ is the cost-effectiveness threshold for a QALY (assumed £30,000)27.   
A positive INHB means that the intervention of interest provides a health gain and is cost effective 
at the given threshold37. It is a clearer statistic than the ICER, where the same value can have two 
different interpretations.  It also has analytical strength in terms of sensitivity analysis where it 
can add in understanding the point at which Inflectra is no longer the preferred option, i.e. when 
INHB is equal to 0. 
5.2.5. Sensitivity analyses 
One-way deterministic analyses were performed for all variables to determine the thresholds over 
which the risks associated with biosimilar therapy outweigh the benefits, indicated by a negative 
INHB.  Where available, ranges were based on confidence intervals provided in the literature, 
otherwise plausible ranges were assumed (for example, +/- 20%) around the mean.  The results 
were presented in a tornado plot to examine the impact on INHB.  Extreme value analysis was also 
conducted to identify the impact of each variable in the model. Percentages and utilities were 
varied from 0-1 and costs from £1 to twice the deterministic value. 
A two-way sensitivity analysis was conducted to assess the interaction between the development 
of ATI_I and the price differential between the two drugs.  This identifies the discount in vial price 
required to compensate for a higher rate of antibodies to Inflectra.  
A probabilistic sensitivity analysis (PSA) with 10,000 Monte Carlo draws from distributions was 
conducted. All parameters were included in the PSA except fixed costs: Inflectra and Remicade 
vial costs and NHS costs for short-stays, long-stays and day cases, which affected the costs of 
infusions, serious infusion reactions and delayed infusion reactions.  Efficacy, adverse event and 
utility parameters were drawn from beta distributions as a beta distribution is constrained to lie 
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between zero and one, which fits for our probability and utility parameters.  A beta distribution 
can be estimated from two parameters (α, β), which are the observed number of events in a 
known population size.   
Dirichlet distributions were used for related probability parameters (i.e. disease state and 
outcomes of standard care) as these allow for the sampling of multiple parameters, which must 
all sum to one to represent the total population.  To fit a Dirichlet distribution, a series of Gamma 
distributions are used to estimate the individual outcome events, based upon two parameters (α, 
β).  The first parameter, α, is the observed number of events and the second parameter, β, is set 
to unity.  The Dirichlet draw for each parameter is obtained by dividing the draw for the outcome 
of interest by the sum of the draws for all the parameters in the distribution.  
Costs were drawn from gamma or lognormal distributions as these distributions are strictly 
positive and allow for extreme outliers (Table 35).  Lognormal was used for the smaller costs 
associated with standard care remission therapy, as the Lognormal distribution tends to cluster 
more around the mode, than the gamma distribution.  The necessary parameters for the draws 
were obtained through the mean and ranges of each cost variable. 
The ranges used for deterministic sensitivity analysis (described earlier in this section) were used 
for the PSA.  It was assumed that the unknown biosimilar standard deviations for the rate of initial 
response and development of ATI were 50% higher than the originator drug to reflect the 
uncertainty in efficacy and immunogenicity. 
5.2.6. Scenario analyses 
To consider the robustness of the assumptions in the base case, seven scenarios with alternative 
structural assumptions were tested: 
Scenario (i) tested the impact of a 25% reduction in the price of Remicade® in response to the 
biosimilar entrance to the market.   
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Scenario (ii) tested the clinical likelihood that patients with secondary non-response may be 
reluctant to stop therapy with IFX in the hope that they regain response.  Patients with secondary 
non-response who experienced no adverse events continued with IFX, remaining in the moderate-
to-severe disease state.   
Scenario (iii) tested a shorter washout period (8 weeks, based upon clinical opinion of KB) in those 
who experienced a severe infusion reaction and stopped IFX therapy. 
Scenario (iv) tested a shorter time to LOR in patients who developed ATIs (15 weeks, in line with 
the lower quartile of the interquartile range from ACCENT I)240 to reflect the potential for 
increased clearance of the drug due to antibodies.  
Scenario (v) assumed patients switch to adalimumab (ADA) upon IFX failure.  Therapy begins with 
an 80mg subcutaneous injection in week 0, followed by 40mg in week 2 and every other week as 
per the product label407.  Initial response is checked at week 12 and patients transition to standard 
care if no response.   
Scenario (vi) assumed patients switch to ustekinumab (UST) upon IFX failure.  UST is infused at an 
initial dose of 6mg/kg, with further therapy (90mg) administered subcutaneously at week 8 and 
every subsequent 12 weeks408.  Initial response is checked at week 16 and patients transition to 
standard care if no response.   
Scenario (vii) assumed patients switch to vedolizumab (VED) upon IFX failure.  VED is administered 
as 300mg infusions at weeks 0, 2 and 6, followed by maintenance infusions at week 14 and every 
8 weeks after409.  Initial response is checked at week 14 and patients transition to standard care if 
no response.   
Patients in scenarios (v) to (vii) all have a washout period of six weeks prior to starting a second 
biologic whereupon they receive standard care.  Standard care continued when starting the new 
therapy, under the same assumptions as the base case.  Patients who switch following a severe 
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infusion reaction continue their response to IFX until it is lost at week 33.   However, an 
improvement in disease course prompted by the second biologic will override the IFX response.  
Patients who change biologic following primary or secondary non-response experience moderate-
to-severe disease during the washout period and until the new therapy takes effect.  LOR for UST 
and VED was assumed to take place in line with IFX for model simplicity and an absence of other 
evidence.  Adverse events were not modelled for the second-line biologics. 
Initial response to ADA at week 12 in the IFX failure population was taken from an open label trial 
as the best match for the dose and timing of outcomes392.  No LOR was assumed over the year, 
based upon the results of a systematic review of adalimumab use after IFX failure410.   
The initial response for UST at 16 weeks was taken from a follow-on analysis of a key trial for UST 
in the IFX failure population (UNITI-1)393.  Sustained remission at  44 weeks in the UNITI-1 
population was taken from the long term safety follow up study, and response was calculated by 
applying the ratio of response to remission at 8 weeks in the same study394. 
The initial response for VED was taken from GEMINI-3, a pivotal study of induction therapy in anti-
TNFα failure patients395.  The week 10 response rate was used, as a week 14 rate was unavailable 
in the literature.  Sustained remission in anti-TNFα failure patients at week 52 was from a RCT of 
maintenance therapy in line with the dosing pattern from the SPC396.  The GEMINI-3 ratio of week 
10 response to remission was applied to the long-term remission to calculate long-term response. 
UST and VED infusions use single vials and require a day case hospital attendance.  ADA and UST 
subcutaneous injections are patient-administered and are assumed to require no additional 
resource. 
ADA, UST and VED vial and subcutaneous injection prices were from the British National Formulary 
(BNF), as reported in NICE technical appraisals75,76,400. 
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5.2.7. Value of information analysis 
As discussed in Chapter 1,  value of information (VOI) methods expose the costs of uncertainty by 
quantifying the probability that the decision is wrong and the (cost) consequences if it is wrong57. 
The VOI method calculates the net benefit that is lost over all the PSA simulations as a result of 
choosing the intervention based on expected net benefit over all simulations, rather than being 
able to choose the optimal intervention in each simulation58.  This value, known as the Expected 
Value of Perfect Information (EVPI) is the difference between the maximum possible expected net 
health benefit (NHB) that would be attained if the optimal intervention was chosen in each 
individual simulation, minus the expected NHB from the PSA, and is shown in Equation 9. 
Equation 9: Expected value of perfect information (EVPI) 
𝐸𝑉𝑃𝐼 = 𝐸𝜃𝑚𝑎𝑥𝑖𝑁𝐻𝐵(𝑖, 𝜃) − 𝑚𝑎𝑥𝑖𝐸𝜃𝑁𝐻𝐵(𝑖, 𝜃) 
Where the first part expresses the expected NHB from treatment i given current information θ, 
and the second part expresses the expected NHB from the same treatment given perfect 
information411. 
Given that there is more uncertainty in some parameters than others, especially those related to 
the biosimilar, it is useful to calculate the EVPI for individual parameters in the model, the 
expected value of perfect parameter information (EVPPI).  This is achieved by running the 
simulation for each possible value of the parameter of interest and averaging the maximum NHB 
for each run to obtain the expected NHB with certainty for the parameter of interest.  The 
difference between this and the expected NHB is the EVPPI. 
A VOI analysis was conducted by inputting the results of the PSA into the Sheffield Accelerated 
Value of Information (SAVI)412 tool to identify the value of conducting further research to reduce 
uncertainty.  This was used to assess the value of conducting further clinical research.  The annual 
Expected Value of Perfect Information (EVPI) per patient was calculated, and the annual and 10-
year population EVPI estimated based on the number of patients affected by Crohn’s disease and 
likely to benefit from the treatment each year in England.  The population number was taken from 
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the costing template made available by NICE to support NHS organisations to plan for the financial 
implications of implementing the infliximab technical appraisal guidance413. To examine the effect 
of vial price differentials, a second base case scenario was explored where the price of Remicade 
falls to match Inflectra.     A partial EVPI (EVPPI) analysis was conducted to examine the value in 
reducing the uncertainty around individual model parameters. 
5.2.8. Discounting 
The model did not extend beyond a year so the results were not discounted. A discount rate of 
3.5% per annum was applied to the population EVPI. 
5.2.9. Reporting 
The analysis is reported in line with the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) guidelines41. 
5.3. Results 
5.3.1. Base case 
The decision analytic model base case results in expected one-year quality-adjusted life-years 
(QALYs) of 0.803 for both Inflectra and Remicade, with expected one-year costs of £18,087 and 
£19,176, respectively (Table 36).  The additional benefit of Inflectra to society, based solely on the 
reduced cost of Inflectra, is represented in the 0.04 (95% Central Range 0.00-0.09) incremental 
net health benefit (INHB) versus Remicade.     
For both treatments, 48.9% of patients are in remission at the end of the year in the base case, 
35% of whom have sustained remission since IFX induction therapy.  The model predicts that 
44.8% of patients treated with IFX would experience a full year without adverse events, and an 
equal percentage would move to standard care at some point during the year.  10.3% of the cohort 
developed ATI.  16.6% experienced primary non-response to IFX, and 24.4% experienced 
secondary non-response.  13.6%, 2.1% and 5.4% of the cohort had acute, delayed or severe 
infusion reactions, respectively, and 14.0% of the cohort had surgery (Table 37). 
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Table 36: Model results for base case and scenarios – expected costs and QALYS and net health benefit 
    Base case (i) 
Remicade 
price drop 
(ii) 
LOR and 
no AEs 
continue 
IFX 
(iii) 
8 week 
wash-out 
after SIR 
ends IFX 
(iv) 
quicker 
LOR in 
patients 
with ATI 
(v) switch 
to ADA 
upon IFX 
failure 
(vi) 
switch to 
UST upon 
IFX failure 
(vii) 
switch to 
VED upon 
IFX failure 
Vial cost Inflectra  £  378   £  378  £  378  £  378  £  378  £  378   £  378  £  378 
Remicade  £  420   £  315   £  420  £  420  £  420  £  420   £ 420   £  420 
Expected QALY Inflectra 0.803 0.803 0.803 0.802 0.801 0.816 0.811 0.813 
Remicade 0.803 0.803 0.803 0.802 0.801 0.816 0.811 0.813 
Expected cost Inflectra  £  18,087   £  18,087  £  18,729   £  18,097   £  17,821   £ 18,166   £ 19,421   £ 21,366  
Remicade  £  19,176   £  16,453   £  19,867   £  19,187   £  18,890   £ 19,255   £ 20,511   £ 22,455  
Net health 
benefit 
Inflectra 0.200 0.200 0.179 0.199 0.207 0.211  0.164  0.101  
Remicade 0.164 0.254 0.141 0.162 0.172 0.174  0.128  0.064  
Incremental QALY 0.000  0.000  0.000  0.000  0.000  0.000  0.000  0.000  
Cost -£  1,089   £  1,634  -£ 1,138  -£ 1,089  -£ 1,069  -£  1,089  -£  1,089  -£  1,089  
NHB 0.036 -0.054 0.038 0.036 0.036 0.036  0.036  0.036  
Vial cost -£  42   £   63  -£  42  -£  42  -£  42  -£  42  -£  42  -£  42  
ICER Dominant Dominated Dominant Dominant Dominant Dominant Dominant Dominant 
Note: Scenarios: (i), 25% reduction in Remicade price; (ii), patients with LOR but no AEs continue IFX; (iii), 8 week IFX wash out; (iv), LOR at 15 weeks with ATIs; 
(v), switch to adalimumab; (vi), switch to ustekinumab; (vii),switch to vedolizumab.   
Abbreviations: QALY - quality adjusted life year, NHB - net health benefit, ICER - incremental cost effectiveness ratio, IFX - infliximab, AEs - adverse events, ATI - 
antibodies to infliximab; SIR – severe infusion reaction 
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Table 37: Model results for base case and scenarios - clinical outcomes 
    Base case (i) Remicade 
price drop 
(ii) 
LOR and 
no AEs 
continue 
IFX 
(iii) 
8 week 
wash-out 
after SIR 
ends IFX 
(iv) 
quicker 
LOR in 
patients 
with ATI 
(v) switch 
to ADA 
upon IFX 
failure 
(vi) 
switch to 
UST upon 
IFX failure 
(vii) 
switch to 
VED upon 
IFX failure 
Clinical 
outcomes 
Sustained remission 35.0% 35.0% 35.0% 35.0% 35.0% 35.7% 35.4% 35.7% 
Remission 48.9% 48.9% 48.9% 48.9% 48.9% 50.1% 43.2% 51.3% 
IFX for 12 months with no AEs 44.8% 44.8% 62.2% 44.8% 44.8% 44.8% 44.8% 44.8% 
Standard care 44.8% 44.8% 27.5% 44.8% 44.8% 18.4% 29.9% 27.7% 
Developed ATIs 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 
Primary non-response 16.6% 16.6% 16.6% 16.6% 16.6% 16.6% 16.6% 16.6% 
Secondary non-response 24.4% 24.4% 24.4% 24.4% 24.4% 24.4% 24.4% 24.4% 
Deaths 0.5% 0.5% 0.5% 0.5% 0.5% 0.2% 0.2% 0.2% 
Acute infusion reactions 13.6% 13.6% 13.6% 13.6% 13.6% 13.6% 13.6% 13.6% 
Severe infusion reactions 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 
Delayed infusion reactions 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 2.1% 
Surgeries 14.0% 14.0% 14.0% 14.0% 14.0% 2.8% 3.6% 3.6% 
Note: Scenarios: (i), 25% reduction in Remicade price; (ii), patients with LOR but no AEs continue IFX; (iii), 8 week IFX wash out; (iv), LOR at 15 weeks with 
ATIs; (v), switch to adalimumab; (vi), switch to ustekinumab; (vii),switch to vedolizumab.   
Abbreviations: QALY - quality adjusted life year, NHB - net health benefit, ICER - incremental cost effectiveness ratio, IFX - infliximab, AEs - adverse events, 
ATI - antibodies to infliximab; SIR – severe infusion reaction 
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5.3.2. Base case sensitivity analyses 
5.3.2.1. One-way sensitivity analysis 
One-way sensitivity analyses demonstrated that the model was most sensitive to the Inflectra vial 
price and initial response rates of Inflectra and Remicade (Figure 20).  The INHB was stable for 
most model parameters, which were able to take extreme values without altering the result that 
Inflectra has a positive benefit-risk profile.  The INHB advantage of Inflectra was outweighed in 
the model only when the vial price exceeded that of Remicade. 
Figure 20: Tornado plot of the univariate analysis. 
 
NOTE: PANEL PRESENTS THE TEN PARAMETERS THAT LED TO THE GREATEST CHANGE IN OVERALL INCREMENTAL NET 
HEALTH BENEFITS (INMB).  INFLECTRA PARAMETERS (SUFFIXED _I), REMICADE PARAMETERS (SUFFIXED _R).  L/H 
REFER TO LOWER AND HIGHER LIMITS OF PARAMETER ESTIMATES.   
ABBREVIATIONS: ATI – ANTIBODIES TO INFLIXIMAB, LOR – LOSS OF RESPONSE, IR – INFUSION REACTION 
 
5.3.2.2. Two-way sensitivity analysis of vial price versus ATI development 
A two-way sensitivity analysis shows how the Inflectra vial price would need to adjust in response 
to increasing rates of developing ATI in order to remain the preferred choice.  Based on a cost-
effectiveness threshold of £30,000 per QALY27, and assuming 50% of patients develop ATI for 
Inflectra (ATI_I), compared with 12.4% who develop ATI from Remicade (ATI_R), then 57.7% of 
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patients would switch to standard care after experiencing a serious infusion reaction or secondary 
non-response and, within that, 18% of patients would have a surgery.  Inflectra remained the 
preferred option provided it is priced below £410 per vial (compared with £420 for Remicade).  
Even in a worst case scenario where all Inflectra patients develop ATI, resulting in 75% of patients 
moving to standard care and 23% having surgeries, a vial of Inflectra could be priced up to £395 
and it would remain the treatment of choice with a positive INHB (Figure 21). 
Figure 21: Results of the base case two-way analysis of risk of Inflectra antibodies (ATI) against 
incremental vial price.   
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5.3.2.3. Probabilistic sensitivity analysis 
The net-benefit plane414 illustrating the joint distribution of incremental costs and QALYs (Figure 
22) shows the clustering of simulations on the vertical axis due to the minimal differences in QALYs 
between the two interventions.  Inflectra had the better benefit-risk balance, illustrated by a 
positive INHB, in 97.6% of simulations.  
Figure 22: Net-benefit plane resulting from base case probabilistic sensitivity analysis. 
 
NOTE: THE LINE REPRESENTS THE COST-EFFECTIVENESS THRESHOLD OF £30,000 PER QUALITY-ADJUSTED LIFE YEAR 
(QALY).   
 
This result was robust over a range of threshold values for λ, as shown in the cost-effectiveness 
acceptability curve (Figure 23).  Inflectra dominated Remicade in 50.3% of simulations and was 
less effective but less costly in 45.5% of simulations.  Inflectra was more effective but more costly 
in 3.3% and was dominated by Remicade in 0.8% of simulations.  
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Figure 23: Cost-effectiveness acceptability curve resulting from the base case probabilistic sensitivity 
analysis 
 
 
5.3.3. Scenario analyses 
Inflectra is associated with a positive INHB across the scenarios tested, with the exception of 
scenario (i) where Remicade is the preferred option due to the reduced price (Table 36).  Changes 
in INHB overall were minimal and, in fact, there was no change in INHB in scenarios involving a 
shorter wash-out of IFX following a SIR (iii), a shorter time to loss of response in patients with ATI 
(iv) and a switch to another biologic before standard care, (v), (vi) and (vii), as changes affected 
both biologics equivalently.  
The results of the two-way sensitivity analysis reveal the value-based price for Inflectra as they 
identify the price at which the biosimilar could be marketed based upon the development of ATI 
and downstream consequences415.  Most scenarios follow a similar pattern to the base case 
analysis (Figure 24). The price of Inflectra must reduce as ATI_I increases, to remain the optimal 
choice, but remains below the current market price at all risks of ATI development.  Only in 
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scenario (vii), where patients switch to vedolizumab after IFX failure, is a reduction to below the 
current market price necessary to remain the optimal choice, and it does so when 60% of Inflectra 
patients develop ATI. 
The relationship is reversed in scenario (iv) and the price of Inflectra can increase as ATI_I risk 
increases, due to the expected cost savings from the earlier movement to standard care. The cost 
reduction outweighs the QALY reduction, giving Inflectra an even greater net benefit than in the 
base case.  For illustration, when all Inflectra patients develop ATI (ATI_I=100%), the expected 
QALY gain is 0.03 less than for Remicade whilst resulting in a cost saving of £1,029.  A similar 
pattern is seen for scenario (v) when patients switch to ADA after IFX failure.  In this case, the 
introduction of a second biologic reduces costs, as it is cheaper than IFX, but also reduces the 
number of patients moving to standard care in the model and therefore limits the number of 
expensive surgeries as ATI_I increases. 
 
  
240 
 
Figure 24: Results of the two-way analysis of risk of Inflectra antibodies (ATI) against incremental vial 
price. 
 
NOTE: EACH FIGURE REPRESENTS A SCENARIO. SCENARIO (I), 25% REDUCTION IN VIAL COST OF REMICADE; SCENARIO (II), PATIENTS WITH 
SECONDARY NON-RESPONSE BUT NO ADVERSE EVENTS CONTINUE IFX; SCENARIO (III), 8 WEEK INFLIXIMAB WASH OUT PERIOD; SCENARIO (IV), 
SECONDARY NON-RESPONSE AT 15 WEEKS FOR THOSE DEVELOPING ATI; SCENARIO (V), SWITCH TO ADALIMUMAB AFTER IFX FAILURE; SCENARIO 
(VI), SWITCH TO USTEKINUMAB AFTER IFX FAILURE; SCENARIO (VII), SWITCH TO VEDOLIZUMAB AFTER IFX FAILURE 
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5.3.4. Value of information analysis 
Using the results of the PSA, the expected value of perfect information (EVPI) in the base model is 
£7.56 per patient.  Based on the number of patients expected to be eligible for Inflectra in England 
(7,912)413, the value of removing the decision uncertainty is £59,775 for one year and £807,332 
for the assumed 20-year therapeutic lifetime of the drug. This represents the upper limit on the 
investment of conducting further research to eliminate uncertainty in model parameters. A more 
informative expected value of partial perfect information (EVPPI) indicates that there would be 
no gain from any research to reduce uncertainty in any individual parameters, including the ATI 
rate of Inflectra.  The decision certainty for Inflectra as the optimal choice is so high that there is 
no value to further researching any individual parameters. 
The result of the second VOI analysis, where the price of Remicade is reduced to match that of 
Inflectra, provides a different result.  In this case, the EVPI is now £220.51 per person, equivalent 
to £25.4 million (discounted) for the assumed 20-year therapeutic lifespan.  The EVPPI is now 
relevant and the highest value is for the initial response rate of Inflectra, where the expected value 
of reducing uncertainty around the parameter is £196.42 per patient, which is £1.6 million per 
year, or £22.6 million over 20 years.  There is greater value in reducing uncertainty from a range 
of parameters, including the initial response rate of Remicade, and the rates of sustained 
remission, sustained response and loss of response in patients who do not develop ATI, than in 
reducing uncertainty in ATI_I, which has an EVPPI of £7.00 per patient (Table 38).      
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Table 38: Ten parameters with highest EVPPI when the Remicade price reduces to match Inflectra. 
  Per Person 
EVPPI (£) 
Standard 
Error 
Indexed to 
Overall 
EVPI = 1.00 
Initial response_I 196.42 2.47 0.89 
Initial response_R 51.54 3.17 0.23 
ATI negative sustained remission_I 23.14 3.65 0.1 
ATI negative sustained remission_R 20.69 3.02 0.09 
ATI negative sustained response_I 13.36 3.15 0.06 
ATI negative sustained response_R 11.37 3.08 0.05 
ATI negative LOR_I 11.16 3.07 0.05 
ATI negative LOR_R 10.64 2.99 0.05 
ATI positive delayed IR_I 7.89 2.86 0.04 
ATI_I 7 2.83 0.03 
Note: _I/_R suffix indicates Inflectra/Remicade parameter.  ATI – antibodies to 
infliximab. LOR – loss of response. 
 
5.4. Discussion 
5.4.1. Summary of evidence 
This is the first study to explicitly consider the trade-off between the risk of development of ATI 
(which is largely unknown at the time of marketing authorisation) and cost advantages, and the 
value of obtaining further evidence.  It positions the problem of assessing the benefit-risk of 
biosimilars in the context of an economic evaluation framework.  For Inflectra, the results align 
with those found in the extrapolation process of regulators which deemed the new drug biosimilar 
to the originator86,90,91,377,416.  Non-inferiority of the biosimilar to the originator infliximab was 
demonstrated in a phase III trial for rheumatoid arthritis417 and extrapolation assumes equivalence 
in efficacy for Crohn’s disease. Preliminary results from a post-marketing trial of Inflectra and 
Remicade indicate there is no significant difference between the efficacy and safety of the two 
drugs at 6 weeks418.  Observational studies and clinical case series have confirmed that Inflectra 
appears to be safe and efficacious, especially in infliximab-naïve patients419–425. A study of cross 
immunogenicity identified that ATI developed in patients treated with Remicade react to the 
biosimilar, further supporting the case that the two drugs are biosimilar426. 
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In the base case analysis, Inflectra dominated Remicade because the outcomes from both 
therapies are equivalent, so the advantage is purely based on the lower cost.  This was robust to 
sensitivity analyses, with all parameters – except the drug vial price– having little or no impact on 
the INHB and the decision outcome.  Given the concern and uncertainty around the development 
of ATIs, the results of the two-way sensitivity analyses of the trade-off between ATIs and the vial 
price of Inflectra are important.  In the base model, increasing the development of ATI would 
necessitate a reduction in the vial price of Inflectra to remain cost-effective, but even if all patients 
were to develop ATI_I, the price at which Remicade becomes the preferable option still exceeds 
the current vial price by £17.21.  The only scenarios where the price of Inflectra would fall below 
the current price to remain the optimal choice as the risk of ATI increases are scenario (i) where 
the price of Remicade reduces by 25% and scenario (vii) where patients who fail IFX move to 
vedolizumab.  The price of Inflectra would have to be below the current market point at all levels 
of risk of ATI in scenario (i) and would fall below current market price once the risk of ATI exceeded 
60% in scenario (vii). 
The PSA highlighted almost no decision uncertainty in the base case and therefore the VOI analysis 
suggests no value in further research to reduce uncertainty. Inflectra appears to be the most cost-
effective with such high probability that there is little value in learning about the parameters, even 
ATI_I. However, if the price of the originator fell in line with the biosimilar as it entered the market 
the parameter most worthy of additional research would be the initial response rate of Inflectra, 
with the expected value of reducing uncertainty around the parameter of £22.6 million over the 
20-year lifetime of the drug patent. 
5.4.2. Strengths and limitations 
A major strength of the work in this chapter is the transparency the approach provides for 
assessing the value of biosimilars by considering the incremental net health benefit, taking into 
account both benefits (in terms of cost savings) and the uncertainty of potential harms.  Given the 
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increasing use of biological therapies and the need to restrain costs whilst allowing patients access 
to these therapies, biosimilars are a rational choice as they open up the opportunity for cost 
savings or extension of treatment, and given technological advances and improved manufacturing 
processes they may even result in greater efficacy and less harm.  HTA of biosimilars presents a 
significant challenge due to the assumption of equivalence in outcomes and the lack of 
comprehensive data at the time of market authorisation.  All of this adds to uncertainty in results, 
but this model overcomes some of these difficulties by making explicit reference to, and 
characterising the uncertainty of, ATI development as the driver for differences in treatment 
outcomes. This addresses potential areas of concern relating to the extrapolation exercise while 
allowing for the uncertainty to be quantified – both in terms of identifying whether the cost 
savings are sufficient for a health-care payer to accept a potentially inferior product, and the value 
of conducting further research427. 
Modelling the potential impacts using the available evidence and theoretical risks against what is 
known of the originator could help prevent the rejection of equivalent (or better) biosimilars by 
health care-payers, which would restrict the opportunity to make cost savings and extend 
treatment to more patients.  Further, having a model which acknowledges and quantifies the 
uncertainties, explores the risks and identifies key areas requiring further research (or not) could 
support increased adoption of biosimilars into health care practice by reassuring clinicians and 
patients427.  This is especially relevant in the UK system where biosimilars do not prompt a HTA, 
but instead existing guidance for originator drugs is applied to the biosimilar once they have 
gained marketing approval428. 
By their nature, models that draw from multiple sources of evidence require many assumptions, 
which can be considered limitations.    Shaping the model to the HTA perspective forced an 
idealised view of the clinical situation with full adherence to treatment assumed.  Further, whilst 
NICE clinical guidance is to prescribe for only severe disease (CDAI above 300)62, the model was 
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aligned with the population approved by the EMA.  Building the model on the basis of previous 
models382,388 and the availability of data for an initial response at 12 weeks shaped the model 
contrary to UK clinical guidance, which advocates that response should be checked after two 
doses (week 2) and therapy stopped if there is none62.  The UK NHS cost framework may eliminate 
the sensitivity of the model to increased acute infusion reactions as they are managed within the 
day case cost.  Studies in other countries have suggested that infusion costs managed in the 
outpatient setting could increase the infusion cost by as much as 40%429. 
Whilst the one-year timescale was appropriate for simplicity in this proof of concept model, it 
does not reflect the chronic disease course and fails to capture costs and utilities consequences 
of long-term outcomes.  It is likely that patients who experience LOR are at higher risk of serious 
infection, due to their active disease, but we could not identify any evidence to support an 
increased risk due to ATI development.  Similarly, we were unable to locate evidence to support 
modified cancer risk from ATI development.  In  the interest of parsimony, serious infections and 
cancers were removed38. However, these are important events with significant costs and health 
utility impacts and should ideally be incorporated with appropriate methodology.  
By necessity, the model is a simplification of reality. All-age, all-cause mortality was applied at 
week 12 but deaths would take place across the year. Similarly, infusion reactions were all 
assumed to take place in once period, and on the fourth infusion, occurring only in those who 
experience a response to treatment.  Evidence from studies by Duron et al and Cheiftez el al 
suggest that infusion reactions take place in the first four infusions384,430, although it is unclear 
whether this holds for all types of infusion reactions. 
Assigning QALYs by 4-week period may fail to reflect the changing condition of patients with 
Crohn’s disease.  For instance, the occurrence of a serious infusion reaction is assumed to place a 
patient in hospital for four days431, but causes a detriment to quality of life lasting an entire period.  
Similarly, the two IFX infusions received in the first period of the model are likely to take effect 
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before the end of the period, but the quality of life improvement, where experienced, only takes 
place in period 2.   
Sourcing parameter values for the model was a challenge, as was expected. Estimates for ATIs 
were based on the episodic use of infliximab or were complicated by the absence of a standard 
definition of ATI, the many factors that can affect ATI test result94 and the increasing recognition 
of transient ATI, which are idiosyncratic and have little impact on outcomes432.  More accurate 
measures of ATI in research would support more accurate modelling of their impact.   
Further limitations stemmed from the data available on “standard care” for Crohn’s disease, which 
do not accurately reflect current clinical management of CD and which we attempted to overcome 
by including scenarios with other biologics (adalimumab, vedolizumab and ustekinumab)59,62,433. 
However, more clinically accurate scenarios might include dose escalation or shortening the 
interval between infusions prior to switching to another drug or a switch to the originator drug59.  
Further, modelling of second line biologics should consider their harms so as not to overstate their 
benefits. Addressing some of these points might address some of the counterintuitive results in 
the scenarios where increasing risk of immunogenicity in Inflectra can be accompanied by an 
increase in price because switching to alternative therapies is seen as more cost-effective.  
However, accepting these limitations may be appropriate for a model, which is focused not on 
predicting outcomes, but rather to offer a transparent and structured way to examine a complex 
decision problem434. 
5.4.3. Conclusions 
Biosimilars are generally less expensive than originators but achieve similar outcomes.  They have 
been given regulatory approval on the basis of extrapolated evidence with the use of qualitative 
benefit-risk frameworks, which has led to uncertainty about equivalence in benefits and risks.  To 
date, there has been no attempt to quantitatively assess the benefit-risk balance.  This chapter 
presents a novel framework for the quantitative benefit-risk assessment of biosimilars, the results 
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of which support the conclusion reached by the regulators of Inflectra through their qualitative 
approaches.  The model is not without limitations in terms of structure and inputs. However, the 
robustness of the results was tested by identifying potential areas of concern relating to the 
extrapolation exercise, and conducting a variety of sensitivity and scenario analyses, each of which 
supported the main findings.  It would be appropriate to refine the model to more closely reflect 
clinical reality and follow the treatment pathway in the UK. 
Using knowledge of theoretical risks of biosimilars, the model could be adapted to other therapies.  
As well as indicating the limits of biosimilarity, the method could help to identify the value of 
further research and offer reassurance that the extrapolation process is justified. In the absence 
of trial evidence, the model provides a basis for the quantitative evaluation of biosimilars to 
support health technology assessment.  Value-based pricing using this methodology would be 
possible to protect health systems such as the NHS in the UK from the potential risks of biosimilars 
where they are untested in the populations for which they have been approved. 
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Chapter 6: Discussion and conclusions 
All health care interventions carry risk alongside benefit and the availability of good data is vital 
to allow all decision-makers to assess whether the balance is favourable.  Randomised controlled 
trials (RCTs) remain the gold standard for efficacy data, but they have well understood difficulties 
in identifying real-world effectiveness, and being able to identify slight increases in common risks 
and rarer risks occurring, especially with longer-term treatment.  Benefit-risk decisions are often 
at the margin and therefore slight differences in effectiveness, versus efficacy, can alter the 
benefit-risk balance substantially.  Arguably, the greatest uncertainties are in the risks of 
therapies, which are only well understood long after a drug has been approved for marketing.  
Even where risks are identified through post-marketing pharmacovigilance, uncertainties remain 
due to the flaws in spontaneous reporting systems, including the under-reporting of adverse 
reactions and the difficulties in assigning causation to particular indications or drug-indication 
combinations. 
Further challenges arise from the entrance of biosimilars into market, which introduce additional 
uncertainty due to the complex manufacturing processes involved and the belief of enough 
similarity to the originator drug to allow a reduced approval process and extrapolation to a 
number of indications based upon clinical trial evidence from a single ‘sensitive’ population.  As 
such, some biosimilars are approved for indications without ever having been tested on patients 
with those diseases.   
These conditions require new approaches to fully characterise the benefit and risks of therapies, 
which must account for unavailable or uncertain data.  As such, this thesis examined methods for 
understanding what is being measured in clinical trials and what should be measured, additional 
sources of harms data and the development of a quantitative framework for assessing whether 
cost savings of biosimilar justify the increased uncertainties regarding efficacy and safety. 
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6.1. Summary of the main findings from the thesis 
The first study of this thesis was a systematic review of RCTS of treatments for Crohn’s disease 
trials in adults.  The aim was to identify the outcomes and adverse events reported in RCTs for 
Crohn’s disease, including the measurement tools used and changes over time.  The results 
demonstrate that trialists have adopted a wide and variable approach to outcome measurement 
with all types of efficacy and safety outcomes increasingly measured over time, with the exception 
of safety withdrawals reporting, which has reduced.  What is clear from the work of this chapter 
is that clinical and composite-clinical outcomes continue to be the most commonly reported 
primary and secondary trial endpoints, findings that are confirmed by other recently published 
reviews of outcomes in Crohn’s disease and patients with fistula103,104.  In particular, the Crohn’s 
Disease Activity Index (CDAI) is the single most commonly used outcome measurement tool, but 
its fall from favour with the EMA68, alongside increasing interest in objective measures of 
inflammation and patient reported outcome measures, highlights the need for new outcome 
measurement tools.  The review confirmed the challenge of measuring and categorising harms 
where it can be difficult to distinguish lack of treatment efficacy from treatment side effects.  The 
results provide a comprehensive inventory of outcomes and adverse events that can support the 
development of a core outcome set (COS) for Crohn’s disease. 
The shift towards objective measures of inflammation and patient reported outcomes measures 
rather than clinical-composite tools requires the design and validation of new measurement tools.  
Chapter 3 presented a method for disaggregating the discrete outcomes captured within 
composite outcome measurement tools to make it transparent what is being measured.  
Overlapping and differential naming of outcomes within the measures necessitated an outcomes 
classification method, which applied a conceptual framework for developing COS and other 
validated theoretical frameworks for classifying outcomes.  Mapping the categorised data against 
both a proposed COS for Inflammatory Bowel Disease (IBD) and the commonly used outcome 
measurement tools identified some inconsistencies between the outcomes identified through 
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consensus methods with patients and clinicians, and those measured in trials.  The method 
developed in this chapter could be used both to assess which measurement tools currently used 
in the literature address current COS, but also allows for the indirect assessment of the uptake of 
COS through the inclusion of the measurement tools.   
Chapter 4 examined how to make use of established pharmacovigilance systems to characterise 
harms that are not captured well in RCTs, such as rare harms or those associated with long-term 
exposure to treatment.  All adverse reactions are recorded in a drug’s summary of product 
characteristics (SPC), which supports benefit-risk assessments that take place beyond the 
marketing approval of the drug.  The initial method in this chapter compared the adverse reactions 
from the SPCs and adverse events from the trials by drug classes.  Whilst there were some findings 
of interest, overall the complexities of harms data required a more focused method, as there was 
too much uncertainty in the results. Further, it seemed clear that some of the differences might 
simply reflect differences in coding of adverse events with the medical dictionary for regulatory 
activities (MedDRA). An alternative approach was developed to focus on one drug and a limited 
set of harms. 
A literature review identified important and serious harms that result from, or could plausibly 
result from, the use of the case study drug, Remicade.  Grouping queries (SMQs) from the MedDRA 
data dictionary were used to overcome any risk of inter-coder variability and ensure all terms for 
the same harm were grouped so that any differences identified did not simply reflect coding 
differences.  This approach identified 17 rare adverse reactions that were not reported in trials 
but featured in the SPC.  Two common or very common adverse events were identified from the 
SPCs that were not reported by trials: hepatic function abnormal and allergic respiratory 
symptom.  Events occurring with such high frequency would be expected to be detected in trials, 
but the SMQs helped to identify that similar adverse events had been reported in the trials.  This 
appears to confirm a potential validity to this approach.  As up to 91.5% of adverse reactions in 
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SPCs were not captured in Crohn’s disease trials, there is large potential value of approaches to 
making use of SPC data to characterise harms. 
Benefit-risk assessment under conditions of uncertainty was considered further in Chapter 5.  A 
decision-analytic model was constructed to investigate whether the cost savings from biosimilars 
are sufficient to outweigh the additional uncertainties related to shortened regulatory processes 
and extrapolation of evidence.  The construction of this model extended the theoretical approach 
to identifying risks that was used in Chapter 4 with a literature search to identify the potential 
harms from infliximab biosimilars in Crohn’s disease.  Incremental net health benefit (INHB) was 
measured to represent the added value of the biosimilar considering both the reduced costs and 
the increased uncertainty surrounding its clinical performance given societal resource 
constraints37 and, in effect, represents a quantitative approach to the benefit-risk assessment of 
biosimilars.  This novel approach is the first attempt to quantitatively measure the benefit-risk 
balance of biosimilar versus originator, to determine whether the cost savings justify the increased 
uncertainty in efficacy and safety and to assess the value of conducting further trials in CD to 
reduce uncertainty in parameters.  The results of the model support the regulatory decision to 
approve the infliximab biosimilar.  A range of post-marketing studies have provided evidence that 
supports the drug being biosimilar418–426.  The results of the model were robust across a range of 
sensitivity analyses and even found that the cost reduction was sufficient to outweigh even very 
high levels of risk of immunogenicity from the drug.  Probabilistic sensitivity analysis highlighted 
almost no decision uncertainty and therefore found no value in further research to reduce 
uncertainty. 
6.2. Implications for practice and research 
6.2.1. Implications for practice 
The work of this thesis adds to the evidence base on the poor quality of adverse event reporting.  
The extension to the CONSORT statement requires that all adverse events are reported, but 
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research suggests this continues to be poor333,335,337,339–341,363.  Under-reporting is a significant issue 
in spontaneous systems too, with estimates as high as 96% of adverse reactions under-
reported365.  Causality assessment is flawed  with incorrect investigator reports estimated at 
15.1% and even where correctly reported, 12% of reports coded differently by two coders and 8% 
were coded incorrectly353.  Improved reporting of adverse events would create a much better data 
set that would be applicable to benefit-risk assessment at all stages.  Current systems for adverse 
event reporting appear overly simplistic with the result that the outcome data is of little use to 
fully characterise risk.  The results, in common with those in the SPC, are only considered in terms 
of the drug, but there may be other factors, such as drug-drug and drug-indication interactions 
that should be considered, especially when supporting patients to take decisions on treatments.  
Chapter 4 highlights the lack of transparency in the adverse reactions reported in SPCs as it is not 
clear where the reports come from, as demonstrated when a treatment related adverse event is 
reported in trials, but is not captured as an adverse reaction in the SPC.  To support the richer 
dataset of harms, ADRs could be identified by source, for example, rule of three calculations or 
trials in particular indications372.  Given the move towards personalised medicine to improve 
outcomes217,435, it would seem appropriate to begin to personalise harms information.   
The hierarchy of evidence is less relevant to harms and pluralist methods are needed that take 
account of all available evidence to maximise the value of existing data347,361.  Adverse events 
require contextual information, such as the dose taken, how long the drug was taken for, which 
population is affected, if they are to be a useful source of risk to be included in benefit-risk 
assessment.  However, RCTs deliberately decontextualize information by ensuring that patients, 
interventions and settings are as similar as possible to remove bias361.  Risk assessment needs a 
richer dataset and the triangulation of a variety of sources.   Use of systems such as DoTS (dose-
time-susceptibility) to incorporate measures of treatment duration and susceptibility factors 
would support an improved data set on risk56.   
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The evidence from Chapter 3 highlights another issue, selective reporting.  Trials and current 
outcome measurement tools in Crohn’s disease appear not to capture some “softer” outcomes 
such as body image issues, despite them clearly being of enough importance to be included in an 
IBD COS.  The omission of other outcomes and adverse events, related to sexual function and 
procreation function may reflect both an unwillingness of patients to report these types of adverse 
events, and a limited focus on trialists on immediate efficacy over wider life impacts.  There may 
be a need for trials to create better guidelines on what should be measured and reported, which 
would be supported by the development of a COS for Crohn’s disease.  There may also be value 
in improving trialists’ and patients’ understanding of what should be reported as an adverse event.   
Trialists could adopt methods developed within this thesis.  The results of the mapping exercise in 
Chapter 3 would help to guide choice of measurement tools by considering which outcomes of 
the wider life impacts of Crohn’s disease they consider the most important to measure in trials.  
The method in Chapter 4 could help to develop a clinical filter that could be applied to harms 
reporting in clinical trials as suggested by Lineberry et al363, and this would be especially useful for 
drugs in the same class.  Such an approach would help to focus reporting on the important known 
and potential harms and ensure that the information provided in publications can help to 
accurately characterise harms. 
A quantitative benefit-risk model, as developed in Chapter 5, could help to inform regulatory 
decision processes as well as health technology assessment in the case of biosimilars.  Regulators 
face a difficult path, attempting to allow early access to drugs, whilst ensuring they are safe 
enough to prevent harm4.  Being able to explore and quantify key risks via a quantitative model 
could help prevent the rejection of biosimilars through HTA, but could also support uptake by 
clinicians and patients by offering reassurance that the extrapolation process was justified, 
something which is especially important in the UK where biosimilars do not prompt a new 
HTA427,436.  
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There is an increasing willingness to consider quantitative approaches to benefit-risk assessment 
by some organisations13,21, but as yet, there has been no attempt at a regulatory level.  There are 
fundamental difficulties in using economic value for optimising a regulatory decision problem, as 
regulators cannot consider costs, but it would be possible to strip back the model to remove costs 
and consider a benefit-risk outcome. The same model could then be passed to HTA organisations 
following regulatory approval and costs considered within it, as was done in Chapter 5.  This would 
support alignment of the regulatory and HTA processes, as is envisaged in the partnership 
between the EMA and the European network of health technology assessors (EuNetHTA)26. 
6.2.2. Implications for research 
The development of a COS for Crohn’s disease is a clear research need identified from this thesis 
as the work in Chapter 2 demonstrates that there is no consensus on what outcome to measure 
and how to measure them.  Whilst there are proposals to develop a COS for inflammatory bowel 
diseases as a whole102, Crohn’s disease is sufficiently different to other forms of IBD to warrant a 
separate COS, or at least disease-specific parts to the COS.  The first step of any COS is to identify 
what to measure, that is, which outcomes the key stakeholders consider the most important 
elements of the disease that should (or should not) be impacted by treatment49.   
The results in Chapter 2 offer comprehensive listing of both efficacy and safety outcomes to 
support future COS development, and the lists are supported by recent publications, which adds 
validity103,104.  Adverse event reporting and categorisation is difficult, but the data provided should 
support attempts to identify disease- and intervention-specific adverse events to standardise 
safety outcomes as discrete endpoints, within a COS process. 
Once a list of outcomes has been generated, consensus methods are used to prioritise the most 
important outcomes.  When agreement is reached on this list of core outcomes, appropriate ways 
of measuring those outcomes can be identified.  The identification of the outcome measurement 
tools in Chapter 2, and the categorisation of the components of those measurement tools in 
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Chapter 3 will support these later processes.  In particular, the results in Chapter 3 provide a 
comprehensive and transparent list of the discrete outcomes measured in Crohn’s disease trials 
and highlight the gaps that are apparent, based upon the ICF IBD COS, which has been through a 
rigorous development process.  This list should inform the beginning of the development of new 
outcome measurement tools to meet the requirements set down by the EMA. A new outcome 
measurement tool should seek to identify those patients who face a more severe disease pathway 
and who would benefit from more intensive earlier treatment.  This would support benefit-risk 
assessment and better decision making at the level of clinicians and patients.  Understanding the 
importance of some of the gaps and the importance (or otherwise) of historical outcomes 
incorporated in the CDAI will be necessary at part of this work – specifically, body image, digestive 
functions and uveitis outcomes. 
The range of harms experienced by a patient is dependent on the treatment. However, as part of 
a COS development process for Crohn’s disease, it would be necessary to consider the harms 
which are common to all treatments, which could be measured and reported in all trials.  The 
methods in Chapter 4 could provide a refined list of harms that could be prioritised as part of 
consensus methods in a COS.  The approach of linking SPCs and adverse events from trials using 
evidence of important known and potential risks identified from the literature is efficient research.  
It could support the inclusion of harms into COS and ensure that clinically important risks are 
measured and reported.  
The complexities involved in recording and categorising harms means that there are a number of 
areas requiring further research.  Chapter 2 highlighted a reduction in study withdrawals over time 
in Crohn’s disease trials. It is hoped that this reflects improved trial management and drug safety, 
but it could reflect an improvement in patient follow up and this should be understood.  The 
potential selective reporting identified in Chapter 3 indicated that there may be issues for patients 
and investigators in reporting embarrassing or less clinical issues, or simply bias as investigators 
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may not report events that appear detrimental to the efficacy found.  This should be investigated 
with trial participants and investigators and inform guidelines for reporting of adverse events.  
Discrepancies were found in Chapter 4 between adverse events reported as treatment-related in 
trials and those reported as adverse reactions in SPCs. However, there is a wider issue of causation 
reporting in general as only 69.1% of trials assessed causation and only 59% reported individual 
events deemed potential ADRs.  An understanding of the causes of these issues is needed to 
identify methods to improve them. 
The methods of characterising harms in Chapter 4 appear to have highlighted some additional 
serious adverse events that were not reported in trials for infliximab.  It would be useful to validate 
this approach by triangulating the findings with a sample of yellow card spontaneous reports for 
Crohn’s disease, whilst ensuring that methods to deal with multiplicity are used352.  Further 
application of the methods in Chapter 4 should take place when the additional SMQs relevant to 
infliximab are available – opportunistic infections, autoimmune diseases / autoimmune mediated 
conditions, and infusion-related reactions358.     
There is a need to refine the quantitative benefit-risk model in Chapter 5 to be more clinically 
realistic and over a longer term due to chronic nature of the disease. Other methodologies might 
be considered including Multi-Criteria Decision Analysis (MCDA) which is favoured by the IMI-
Protect project and the EMA benefit-risk methodology project6,21.  It is limited by the need for 
clinical trial data, which were not available for the biosimilar in Chapter 5.  Methods for dealing 
with uncertainty might support the use of the method in the context of missing clinical data. 
6.3. Limitations 
The limitations of each area of work have been addressed in each chapter.  This section will focus 
on the overall limitations of the thesis. 
A fundamental difficulty for the consideration of harms within economic models is that benefit 
outcomes are usually specified as primary outcomes in the trial and the power calculation is based 
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on this. It is therefore possible to obtain a carefully monitored and reasonably precise estimate 
for benefit, but the harms are always imprecise and uncertain. Added to this, is the fact that there 
are a small number of major benefits, but the potential risks can run into dozens of possibilities. 
The selection of which harms to include can be determined using consensus methods, but health 
economic modelling methods will need to develop to tackle this situation. 
A limitation of this thesis is the consideration of trial outcomes and harms, which did not go 
beyond RCTs.  Observational studies contain an array of outcomes and harm information that 
would be useful to characterise the effects of a product more comprehensively.  Given the need 
for pluralist methods for identifying harms, consideration of observational studies would add 
another layer to the benefit-risk profile of a drug. 
Much of the methodological work in this thesis focused on improving transparency including what 
is being measured within outcome measurement tools used in trial, alignment of the trials adverse 
events with adverse reactions in SPCs and the quantification of the uncertainties present in the 
benefit-risk assessment of biosimilar drugs approved through extrapolation of trial data in other 
indications.  What this has highlighted in many cases, is the clear uncertainties involved in all the 
sources of information, which can undermine the results.  However, novel approaches are 
required to tackle the issues and the work in this thesis has attempted to do so in an efficient way 
by making use of existing sources of information. 
6.4. Conclusions 
The work presented in this thesis is timely as there is a range of work taking place to streamline 
regulator and HTA processes, to ensure patients are given access to newer forms of biologics, and 
to ensure that the outcomes of treatments for Crohn’s disease are being adequately captured.   
A key strength of this thesis is the focus throughout on harms from interventions.  Difficulties are 
extensive in measuring harms – understanding what is caused purely by the intervention, what is 
related to the drug combined with the indication or other therapies, what is related to treatment 
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failure.  Problems begin at the reporting of causation in trials, where there is evidence that it is 
not always correct and is prone to variation between investigators and coders.  The reporting of 
adverse events as causally related in trials, which do not appear in the SPC suggest that those 
reports are either incorrect, or that the grouping of trial data and spontaneous reports with other 
indications masks an effect that is specific to Crohn’s disease.  The work in this thesis makes a 
novel contribution to the literature through methods to triangulate theoretical harms from the 
literature, adverse events data from trials and adverse reactions data from the SPCs.   
A novel contribution is made in Chapter 5, as it is the first attempt to provide a transparent 
framework for assessing the value of biosimilars by considering the incremental net health 
benefit, taking into account both benefits and harms.  Value-based pricing using this methodology 
would be possible to protect health systems such as the NHS in the UK from the potential risks of 
biosimilars where they are untested in the populations for which they have been approved.  
Future developments on this work could allow a single model to be developed and utilised in both 
regulatory and health technology assessment decisions. 
6.4.1. Recommendations for practice 
 The results of the mapping exercise in Chapter 3 should guide trialists in their choice of 
outcome measurement tools by transparently deciding which wider impacts of the 
disease are important. 
 Trials should have clear guidelines on what should be reported as an adverse event, 
ensuring that wider life impact adverse events are captured, and patients and 
investigators are supported to identify such events. 
 Improved reporting of adverse events in trials requires more contextual information.  
Trials should consider the use of the DoTs classification. 
 The clinical filter approach to identifying important harms in Chapter 4 could be used by 
trials in reporting harms. 
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 SPCs should be more transparent and identify the source of information for each 
adverse reaction, specifically whether the assessment of frequency is via a rule of three 
calculation of trials, and if the latter, in which indication. 
 Quantitative models, such as in Chapter 5, should be developed to measure a benefit-
risk value for regulators, with the ability to add costs in so that they can be passed onto 
health technology assessors in the post-marketing period.  This will support the 
alignment of regulatory and HTA processes. 
6.4.2. Recommendations for future research 
 The reduction in study withdrawals found over time should be researched, specifically, 
whether this reflects a change in the withdrawal from treatment rather than from trial, 
or whether there has been a change in definition over time due to greater clarity on the 
requirements of analysis in the CONSORT guidelines. 
 Research should be conducted to understand issues around causality of harms 
assessment, i.e. the absence of causality assessment in trials and the differences in 
causality between trials and SPCs. 
 The outcomes and adverse events data in Chapter 2 should be used as the first stage of a 
COS in Crohn’s disease, to be prioritised through consensus methods. 
 Intervention-specific harms should be developed as add-ons to COS.  The clinical filter 
approach to identifying important harms in Chapter 4 might provide a list of 
intervention-specific harms to include in a consensus process. 
 New outcome measurement tools for Crohn’s disease should be developed using the 
results of the categorisation process in Chapter 3.   
 Repeat methods in Chapter 4, comparing harms in trials and SPCs to identify new harms 
as relevant SMQs are made available. 
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 Validate Chapter 4 results with a sample of MHRA Yellow Card spontaneous reporting 
data for Crohn’s disease using infliximab. 
 The quantitative model for benefit-risk assessment of infliximab biosimilar should be 
refined for a more clinically realistic model, with a longer time horizon to reflect the 
chronic nature of the disease.  MCDA methods should be investigated for the model. 
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Appendices 
Appendix 1: Full list of benefit-risk methodologies for Chapter 1 
Appendix table 1: Full list of benefit-risk methodologies reviewed by Mt-Isa et al (2014) and the 
abbreviations17 
Methodology Description Category 
AE-NNT Adverse event adjusted number 
needed to treat 
Metric indices – threshold indices 
ASF Ashby and Smith Framework Descriptive framework 
BLRA Benefit-less-risk analysis Quantitative framework 
Beckmann Beckmann model (AKA evidence 
based model) 
Metric indices – trade-off indices 
BRAFO Benefit-risk analysis for foods Descriptive framework 
BRAT Benefit-Risk Action Team Descriptive framework 
BRR Benefit-risk ratio Metric indices – trade-off indices 
CA Conjoint analysis Utility survey techniques 
CDS Cross-design synthesis Estimation techniques 
CMR CASS CMR Health Canada, Australia’s 
Therapeutic Goods Administration, 
SwissMedic and Singapore Health 
Science Authority 
Descriptive framework 
COBRA Consortium on benefit-risk 
assessment 
Descriptive framework 
CPM Confidence profile method Estimation techniques 
CUI Clinical utility index Quantitative framework 
CV Contingent valuation Utility survey techniques 
DAG Directed acyclic graphs Estimation techniques 
DALY Disability-adjusted life years Metric indices – health indices 
DCE Discrete choice experiment Utility survey techniques 
Decision tree Decision tree Quantitative framework 
DI Desirability index Quantitative framework 
FDA BRF FDA benefit-risk framework Descriptive framework 
GBR Global benefit-risk Metric indices – trade-off indices 
HALE Health-adjusted life years Metric indices – health indices 
Impact numbers Impact numbers Metric indices – threshold indices 
INHB Incremental net health benefit Metric indices – trade-off indices 
ITC Indirect treatment comparison Estimation techniques 
MAR Maximum acceptable risk Metric indices – threshold indices 
MCDA Multicriteria decision analysis Quantitative framework 
MCE Minimum clinical efficacy Metric indices – threshold indices 
MDP Markov decision process Quantitative framework 
MTC  Mixed treatment comparison Estimation techniques 
NCB Net clinical benefit Quantitative framework 
NEAR Net efficacy adjusted for risk Metric indices – threshold indices 
NNH Number needed to harm Metric indices – threshold indices 
NNT Number needed to treat Metric indices – threshold indices 
OMERACT 3x3 Omeract Measures in Rheumatology 
3x3 
Descriptive framework 
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Methodology Description Category 
Principle of 3s Principle of threes Metric indices – trade-off indices 
PrOACT-URL Problem, objectives, alternatives, 
consequences, trade-offs, 
uncertainty risk, and linked decisions 
framework 
Descriptive framework 
PSM Probabilistic simulation model Estimation techniques 
QALY Quality-adjusted life years Metric indices – health indices 
Q-TWIST Quality-adjusted time without 
symptoms and toxicity 
Metric indices – health indices 
RV-MCE Relative value-adjusted minimum 
clinical efficacy 
Metric indices – threshold indices 
RV-NNH Relative value-adjusted number 
needed to (treat to) harm 
Metric indices – threshold indices 
SABRE Southeast Asia benefit-risk evaluation Descriptive framework 
SBRAM Sarac’s benefit-risk assessment Quantitative framework 
SMAA Stochastic multicriteria acceptability 
analysis 
Quantitative framework 
SPM Stated preference method Utility survey techniques 
TURBO Transparent uniform risk-benefit 
overview 
Metric indices – trade-off indices 
UMBRA Unified methodologies for benefit-
risk assessment 
Descriptive framework 
UT-NNT Utility-adjusted and time-adjusted 
number needed to treat 
Metric indices – trade-off indices 
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Appendix 2: Systematic review registered protocol for Chapter 2 
Appendix figure 1: PROSPERO Systematic Review Registered Protocol 
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Appendix 3: Systematic review search strategies for Chapter 2 
Appendix table 2: Cochrane search strategy for Crohn's disease outcomes in adults (search completed 3rd 
November 2015) 
# Searches Results Search description 
1 MeSH descriptor: [Inflammatory 
Bowel Diseases] explode all trees 
2,092 Inflammatory bowel disease 
2 Inflammatory bowel disease* 1,865 Inflammatory bowel disease 
3 #1 or #2 3,240 Inflammatory bowel disease 
4 MeSH descriptor: [Crohn disease] 
explode all trees 
1,034 Crohn’s disease 
5 Crohn* 2,137 Crohn’s disease 
6 #4 or #5 2,137 Crohn’s disease 
7 #3 or #6 3,905 Inflammatory bowel disease or Crohn’s disease 
8 Outcome* 241,924 Outcomes 
9 #7 and #8 1,794 Inflammatory bowel disease or Crohn’s disease 
and outcomes 
10 Not possible to limit on age   
 
Appendix table 3: Cumulative Index to Nursing and Allied Health Literature search strategy for Crohn's 
disease outcomes in adults (search completed 3rd November 2015) 
# Searches Results Search description 
1 (MH “Inflammatory Bowel 
Diseases+”)  
8,376 Inflammatory bowel disease 
2 Inflammatory bowel disease* 4,881 Inflammatory bowel disease 
3 S1 OR S2 9,322 All inflammatory bowel disease 
4 (MH “Crohn Disease”) 4,017 Crohn’s disease 
5 Crohn* 4,884 Crohn’s disease 
6 S4 or S5 4,884 All Crohn’s disease 
7 S3 or S6 9,769 Inflammatory bowel disease or Crohn’s disease 
8 Outcome* 477,077 Outcomes 
9 S7 AND S8 1,310 Inflammatory bowel disease or Crohn’s disease 
and outcomes 
10 S9 with restriction for adults 529 Inflammatory bowel disease or Crohn’s disease 
and outcomes for adults 
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Appendix table 4: EMBASE search strategy for Crohn's disease outcomes in adults (search completed 3rd 
November 2015) 
# Searches Results Search description 
1 exp INFLAMMATORY BOWEL 
DISEASE/ 
98,256 Inflammatory bowel disease 
2 Inflammatory AND bowel AND 
disease.mp 
54,886 Inflammatory bowel disease 
3 1 OR 2 119,712 Inflammatory bowel disease 
4 Exp CROHN DISEASE/ 64,317 Crohn’s disease 
5 Crohn*.mp 72,296 Crohn’s disease 
6 4 OR 5 72,296 Crohn’s disease 
7 3 OR 6 123,434 Inflammatory bowel disease or Crohn’s disease 
8 Outcome*.mp 215,869 Outcomes 
9 7 AND 8 16,198 Inflammatory bowel disease or Crohn’s disease and 
outcomes 
10 9 [Limit to: (Human Age Groups 
Adult 18 to 64 years or Aged 
64+ years) 
6,394 Inflammatory bowel disease or Crohn’s disease and 
outcomes for adults 
 
Appendix table 5: MEDLINE search strategy for Crohn's disease outcomes in adults (search completed 3rd 
November 2015) 
# Searches Results Search description 
1 exp Inflammatory Bowel 
Diseases/ 
65,723 Inflammatory bowel disease 
2 Inflammatory bowel 
disease*.mp 
32,235 Inflammatory bowel disease 
3 1 or 2 73,709 Inflammatory bowel disease 
4 exp Crohn disease/ 33,044 Crohn's disease 
5 Crohn*.mp 41,633 Crohn's disease 
6 4 or 5 41,633 Crohn's disease 
7 3 or 6 77,739 Inflammatory bowel disease or Crohn’s disease 
8 outcome*.mp 1,539,674 Outcomes 
9 7 and 8 9,153 Inflammatory bowel disease or Crohn’s disease 
and outcomes 
10 Limit 9 to “all adult (19 plus 
years)” 
5,710  Inflammatory bowel disease or Crohn’s disease 
and outcomes for adults 
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Appendix 4: Characteristics of randomised controlled trials identified by the systematic review in Chapter 2 
Appendix table 6: Characteristics of Randomised Controlled Trials in Crohn's Disease 
Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Induction (n=110) 
Medical induction (n=104) 
Greenberg 1988 USA and 
Canada 
51 CDAI >150, refractory 52 Parenteral versus defined formula 
nutrition 
Wright 1990 USA and 
Canada 
11 Patients requiring hospitalisation for acute exacerbation of 
Crohn's 
2 Parenteral versus enteral nutrition 
Rigaud 1991 UK and 
Europe 
30 CDAI >150 52 Enteral nutrition: elemental vs 
polymeric 
Ewe 1993 UK and 
Europe 
42 CDAI >150 16 AZA and prednisolone 
Singleton 1993 USA and 
Canada 
310 CDAI 150-400 16 Mesalamine  
Wright 1993 Rest of world 356 Mild to moderate Crohn's, judged to need oral corticosteroids 4 Fluticasone propionate 
Rutgeerts 1994 UK and 
Europe 
176 CDAI >200 10 Budesonide and prednisolone 
Tremaine 1994 USA and 
Canada 
38 CDAI 150-450 17 Mesalamine  
Royall 1994 USA and 
Canada 
40 CDAI >250 52 Amino acid based defined formula 
Greenberg 1994 USA and 
Canada 
258 CDAI >200 10 Budesonide 
Jewell 1994 UK and 
Europe 
147 Chronically active Crohn's despite steroid treatment  52 Cyclosporine 
Gross 1995 UK and 
Europe 
31 CDAI 150-350 8 5-ASA 
302 
 
Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Mansfield 1995 UK and 
Europe 
44 One symptom of active disease, CDAI >150 and one abnormal 
lab measurement 
4 Amino acid versus oligopeptide diet 
Middleton 1995 UK and 
Europe 
76 HBI >=6 and elevated ESR, CRP and alpha-1-antichymotrypsin 3 Enteral feeds 
Feagan 1995 USA and 
Canada 
141 Chronically active Crohn's despite steroid treatment  16 Methotrexate 
Targan 1997 USA and 
Canada 
108 CDAI 220-400 12 Infliximab 
Frascio 1997 UK and 
Europe 
14 CDAI >150 2 Enteral and parenteral nutrition 
Bar-Meir 1998 Rest of world 201 CDAI 150-350 8 Budesonide and prednisolone 
Colombel 1999 UK and 
Europe 
40 CDAI 150-300 6 Ciprofloxacin and mesalazine 
Hond 1999 UK and 
Europe 
14 Crohn's with increased intestinal permeability 4 Oral glutamine 
D’Haens 1999 UK and 
Europe 
22 CDAI 220-400, refractory 4 infliximab 
**Present 1999 USA and 
Canada 
94 Crohn's with single or multiple draining or abdominal fistulas 
of at least three months' duration 
34 infliximab 
Sandborn 1999 USA and 
Canada 
96 CDAI 150-450, steroid treated 18 Azathioprine 
Verma 2000 UK and 
Europe 
21 CDAI >150, presence of bowel symptoms, at least one raised 
inflammatory marker and increased bowel activity on 
leukocyte bowel imaging 
4 Elemental versus polymeric diet 
Fedorak 2000 USA and 
Canada 
95 CDAI 200-350 24 rhuIL-10 
Schreiber 2000 UK and 
Europe 
329 CDAI 200-400 8 Tenovil 
Leiper 2001 UK and 
Europe 
54 CDAI >200 and serum C-reactive protein 10mg/l 3 Whole protein feed with long chain 
triglyceride content 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Gordon 2001 UK and 
Europe 
30 CDAI 150-450 12 natalizumab 
Schreiber 2001 UK and 
Europe 
78 CDAI 200-400, steroid dependent 26 ISIS-2302 
Sandborn 2001 USA and 
Canada 
193 CDAI 220-450 24 CDP571 
Lomer 2001 UK and 
Europe 
20 CDAI >150 17.3 Low micro particle diet 
Hawkes 2001 UK and 
Europe 
70 CDAI 150-450 12 Glyceryl trinitate (GTN) 
Sandborn 2001 USA and 
Canada 
43 CDAI 220-450 8 Etanercept 
Carty 2001 UK and 
Europe 
85 CDAI 200-400 12 Ridrogel 
Goodgame 2001 USA and 
Canada 
31 Crohn's disease 52 Ethambutol and clarithromycin 
Tremaine 2002 USA and 
Canada 
200 CDAI 200-450 10 Budesonide 
Steinhart 2002 USA and 
Canada 
134 CDAI 200-400 8 Ciprofloxacin and metronidazole 
Yacyshyn 2002 USA and 
Canada 
22 CDAI >220 52 Alicaforsen 
Hommes 2002 UK and 
Europe 
12 CDAI 220-450 4 CNI-1493, a guanylhydrazone 
Arnold 2002 USA and 
Canada 
47 CDAI >150 CDAI 26 Ciprofloxacin 
Sakurai 2002 Rest of world 36 CDAI >150 6 Enteral nutrition with low or high 
medium-chain triglycerides  
Ardizzone 2003 UK and 
Europe 
54 CDAI >200 26 Methotrexate and azathioprine 
304 
 
Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Bamba 2003 Rest of world 36 International Organisation of Inflammatory Bowel Disease 
(IOIBD) rating >=2 and at least one abnormal inflammatory 
marker 
4 Different fat-dose levels of enteral 
nutrition 
Ghosh 2003 UK and 
Europe 
244 CDAI 220-450 12 natalizumab 
Ito 2004 Rest of world 36 CDAI >150 and abnormal levels of serum C-reactive protein 12 anti-IL-6R mAb MRA 
Joos 2004 UK and 
Europe 
51 CDAI 150-350 12 Traditional acupuncture 
Herfarth 2004 UK and 
Europe 
104 CDAI >150 6 Budesonide 
Mannon 2004 UK and 
Europe 
79 CDAI 220-450 25 anti-interleukin-12 
Sandborn 2004 USA and 
Canada 
396 CDAI 220-450 28 CDP571 
**West 2004 UK and 
Europe 
24 Crohn's disease complicated by single or multiple draining 
perianal fistulae 
18 Ciprofloxacin and infliximab 
Winter 2004 USA and 
Canada 
92 CDAI 220-450 12 CDP870 
Schreiber 2005 UK and 
Europe 
291 CDAI 220-450 20 certolizumab pegol 
Lomer 2005 UK and 
Europe 
83 CDAI >150 52 Low microparticle diet 
Korzenik 2005 USA and 
Canada 
124 CDAI 220-475 34.3 Granulocyte-macrophage colony-
stimulating factor (GM-CSF) 
Reinsich 2006 UK and 
Europe 
45 CDAI 250-450 25.1 fontolizumab 
Margalit 2006 USA and 
Canada 
31 CDAI 220-400 27 Autologous colonic proteins 
Prantera 2006 UK and 
Europe 
83 CDAI 220-400 16 Rifaximin 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Schroder 2006 UK and 
Europe 
19 Refractory to or dependent on corticosteroids 48 infliximab and methotrexate 
Hommes 2006 UK and 
Europe 
133 CDAI 250-450 26 fontolizumab 
Hanauer 2006 USA and 
Canada 
299 CDAI 220-450 4 Adalimumab 
Lemann 2006 UK and 
Europe 
115 CDAI >150, steroid dependent 52 infliximab 
Rutgeerts 2006 UK and 
Europe 
207 CDAI 250-400 20 onercept 
Schreiber 2006 USA and 
Canada 
284 CDAI 220-450 8 BIRB 796 
Herrlinger 2006 UK and 
Europe 
52 CDAI >220 12 rhIL-11 and prednisolone 
Reinshagen 2007 UK and 
Europe 
58 CDAI 150-450 24 Azathioprine and azathioprine dose 
adaption 
Mansfield 2007 UK and 
Europe 
84 CDAI 200-400 12 Lenalidomide 
Sandborn 2007 USA and 
Canada 
325 CDAI 220-450 4 Adalimumab 
Hafer 2007 UK and 
Europe 
31 Active Crohn's 17.3 lactulose syrup 
Targan 2007 USA and 
Canada 
509 CDAI 220-450  and elevated CRP 12 natalizumab 
Omer 2007 UK and 
Europe 
40 CDAI >170 20 Wormwood 
**Hart 2007 UK and 
Europe 
19 Patients with single or multiple draining perianal fistulas or 
perianal or anal ulcerating disease without fistulas 
24 Tacrolimus 
Sandborn 2008 USA and 
Canada 
104 CDAI 220-450 28 ustekinumab 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Leiper 2008 UK and 
Europe 
41 CDAI >200 12 Clarithromycin 
D’Haens 2008 UK and 
Europe 
133 CDAI >200 104 Immunosuppressives and Infliximab 
**Fukuda 2008 Rest of world 62 At least one intractable active anal fistula 8 Spherical carbon adsorbent 
Feagan 2008 USA and 
Canada 
185 CDAI 220-400 25.7 vedolizumab 
**Thia 2009 USA and 
Canada 
27 Perianal Crohn's with 1 or more open actively draining 
perianal fistula 
10 Ciprofloxacin and metronidazole 
Dotan 2010 Rest of world 152 CDAI 250-400 8.1 Semapimod 
Steed 2010 UK and 
Europe 
35 CDAI 150-450 26 Synbiotic B.longum and Synergy 1 
Van der Woude 
2010 
UK and 
Europe 
40 CDAI 220-450, elevated CRP and endoscopic confirmation 27.9 NI-0401 
Maeda 2010 UK and 
Europe 
74 PCDAI score of >=5 4 Metronidazole 
Sands 2010 USA and 
Canada 
220 CDAI 220-450 30.1 Apilimod mesylate 
Buchman 2010 USA and 
Canada 
100 CDAI 220-450 24 Teduglutide 
Krebs 2010 UK and 
Europe 
20 CDAI >200 6 Wormwood 
Tromm 2011 UK and 
Europe 
311 CDAI 200-400 8 Budesonide and mesalamine 
Sandborn 2011 USA and 
Canada 
439 CDAI 220-450 6 certolizumab pegol 
Benjamin 2011 UK and 
Europe 
103 CDAI >220 and an additional marker of inflammation 4 Prebiotic fructo-oligosaccharides (FOS) 
Smith 2011 USA and 
Canada 
34 CDAI >220 24 naltrexone 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Prantera 2012 UK and 
Europe 
402 CDAI 220-400 24 Rifaximin 
Hueber 2012 UK and 
Europe 
59 CDAI 220-450 16 Secukinumab 
Sands 2013 USA and 
Canada 
235 CDAI 220-450 24 Granulocyte / monocyte apheresis 
Naftali 2013 Rest of world 21 CDAI 200-450 10 Cannabis 
Suzuki 2013 Rest of world 77 CDAI >200 10 Budesonide 
Sandborn 2013 USA and 
Canada 
36 Confirmed diagnosis of Crohn's 26 Trichuris suis ova 
Brotherton 2014 USA and 
Canada 
7 partial Harvey Bradshaw Index >=3 4 Whole wheat fibre diet 
Sandborn 2014 USA and 
Canada 
139 CDAI 220-450 8 Tofacitinib 
**Dewint 2014 UK and 
Europe 
76 Active perianal fistulising Crohn's 24 Adalimumab and ciprofloxacin 
**Reinisch 2014 UK and 
Europe 
249 At least one draining perianal fistula, CDAI <400 24 Spherical carbon adsorbant 
Sands 2014 USA and 
Canada 
416 CDAI 220-400 and one of the following: elevated C-reactive 
protein, endoscopy documented ulcerations or elevated 
faecal calprotectin and features of clinical activity 
22 vedolizumab 
Dignass 2014 UK and 
Europe 
471 CDAI 200-400 10 Budesonide 
Bao 2014 Rest of world 92 CDAI 150-350 24 Acupuncture and moxibustion 
D’Haens 2015 UK and 
Europe 
180 CDAI 220-450 12 Laquinimod 
Monteleone 2015 UK and 
Europe 
166 CDAI 220-400 12 Mongerson 
Vande Casteele 
2015 
UK and 
Europe 
251 treated with infliximab for at least 14 weeks and in a stable 
clinical response 
52 infliximab 
308 
 
Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Surgical induction (n=6) 
Maartense 2006 UK and 
Europe 
60 Patients undergoing elective ilocolonic resection 13 Laparascopic versus open resection 
East 2007 UK and 
Europe 
13 Symptomatic strictures suitable for colonscopic dilation 52 Intrastricture steroid after balloon 
dilatation of strictures 
Mcleod 2009 USA and 
Canada 
170 Patients undergoing elective ilocolonic resection 52 End to end and side to side 
anastomosis 
**Grimaud 2010 UK and 
Europe 
77 CDAI <250 and at least one draining perianal fistula 16 Fibrin glue 
Zurbuchen 2013 UK and 
Europe 
67 Crohn's patients with ileitis terminalis who underwent 
elective ileocecal resection 
0 End to end and side to side 
anastomosis 
**Molendijk 2015 UK and 
Europe 
21 Actively draining fistulising Crohn's with 1-2 internal openings 
and 1-3 fistula tracts and CDAI <250 
24 Mesenchymal stromal cells (MSC) 
Maintenance (n=71) 
Maintenance studies of medically induced maintenance (n=52) 
Singleton 1979 USA and 
Canada 
89 CDAI >150 26 Prednisone and sulfasalazine 
Malchow 1984 UK and 
Europe 
452 Active Crohn's or quiescent 104 Sulfasalazine and / or 
methylprednisolone 
Levenstein 1985 UK and 
Europe 
58 Non-stenoising Crohn's 104 Low residue or normal diet 
Bresci 1994 UK and 
Europe 
66 CDAI <150 208 5-ASA 
Feagan 1994 USA and 
Canada 
305 Active crohn's with symptoms requiring treatment with 
steroids or 5-ASA 
78 Cyclosporine 
Schreiber 1994 UK and 
Europe 
60 CDAI <150 for at least two months 52 4-ASA and 5-ASA 
Stange 1995 UK and 
Europe 
182 Stratified: CDAI <200 and CDAI >200 65 Cyclosporine 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Belluzzi 1996 UK and 
Europe 
78 CDAI <150 for 3 months - 2 years plus elevated inflammation 
marker 
52 Fish oil 
Greenberg 1996 USA and 
Canada 
105 CDAI <150 52 Budesonide 
Sutherland 1997 USA and 
Canada 
293 CDAI <150 with no symptoms for the past 30 days 48 Mesalamine  
Ferguson 1998 UK and 
Europe 
75 CDAI <150 52 Budesonide 
Arora 1999 USA and 
Canada 
33 Steroid dependent for at least 6 months 52 Methotrexate 
Guslandi 2000 UK and 
Europe 
32 CDAI <150 for at least three months 26 Probiotic Saccharomyces boulardii 
Green 2001 UK and 
Europe 
141 In remission for at least 1 month (exhibiting no or mild 
symptoms) 
52 Flexible dose budesonide 
Mahmud 2001 UK and 
Europe 
328 CDAI <150 for at least one month 52 Olsalazine 
Cortot 2001 UK and 
Europe 
120 CDAI <200 22 Budesonide 
Hanauer 2002 USA and 
Canada 
335 CDAI 220-400 54 infliximab 
Mantzaris 2003 UK and 
Europe 
57 CDAI <150, steroid dependent 52 Budesonide and mesalamine 
Keller 2004 UK and 
Europe 
108 At least one active episode of disease in the last 2 years 104 Psychotherapy and relaxation therapy 
**Sands 2004 USA and 
Canada 
282 Crohn's with single or multiple draining or abdominal fistulas 
of at least three months' duration 
54 infliximab 
Schultz 2004 USA and 
Canada 
11 CDAI 150-300 26 Probiotic Lactobacillus GG 
Vilien 2004 UK and 
Europe 
29 Crohn's in remission and on AZA for at least 2 years 52 Azathioprine 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Lemann 2005 UK and 
Europe 
83 In clinical remission induced by azathioprine for >=42 months 78 Azathioprine 
Feagan 2005 USA and 
Canada 
71 CDAI <150 and receiving corticosteroid therapy 16 CDP571 
Hanauer 2005 USA and 
Canada 
110 CDAI <150 52 Budesonide 
Sandborn 2005 USA and 
Canada 
905 CDAI 220-450 60 natalizumab 
Feagan 2006 USA and 
Canada 
271 CDAI <150, steroid dependent 34 CDP571 
Takagi 2006 Rest of world 51 CDAI <150 104 Half elemental diet 
Colombel 2007 UK and 
Europe 
778 CDAI 220-450 60 Adalimumab 
Sandborn 2007 USA and 
Canada 
55 CDAI <150 52 Adalimumab 
Ng 2007 USA and 
Canada 
32 Mildly active or disease in remission 13 Exercise: walking 
Schreiber 2007 UK and 
Europe 
425 CDAI 220-450 26 certolizumab pegol 
De Jong 2007 UK and 
Europe 
157 CDAI <150 for 3-18 months 52 Budesonide 
Selby 2007 Rest of world 213 CDAI >200 52 Clarithromycin, Rifabutin and 
Clofazimine 
Garcia 2008 Rest of world 34 CDAI <150 13 Probiotic Saccharomyces boulardii 
Feagan 2008 USA and 
Canada 
363 CDAI <150 58 Omega 3 free fatty acids 
Mantzaris 2009 UK and 
Europe 
77 CDAI <150, steroid dependent 52 Azathioprine and budesonide 
Rossi 2009 UK and 
Europe 
67 CDAI <150 56 IFN beta-la 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Takagi 2009 Rest of world 51 CDAI <150 104 Half elemental diet 
Valentine 2009 USA and 
Canada 
156 CDAI 150-450 26 Granulocyte-macrophage colony-
stimulating factor (GM-CSF) 
Sandborn 2010 USA and 
Canada 
329 CDAI 220-450 26 certolizumab pegol 
Jorgensen 2010 UK and 
Europe 
94 CDAI <150 and biochemical signs of quiescent CD 52 Vitamin D3 
Prantera 2011 UK and 
Europe 
73 CDAI <150 24 Beclomethasone dipropionate (BDP) 
Holtmeier 2011 UK and 
Europe 
82 CDAI <150 64 Boswellia serrata 
Watanabe 2012 Rest of world 90 CDAI 220-450 52 Adalimumab 
Keefer 2012 USA and 
Canada 
28 CDAI <150 6 Project management 
Keshav 2013 UK and 
Europe 
436 CDAI 250-450 and elevated C-reactive protein 52 Vercinon 
Bourreile 2013 UK and 
Europe 
165 CDAI <150 after induction therapy 65 Probiotic Saccharomyces boulardii 
Jigaranu 2014 UK and 
Europe 
168 CDAI 220-400 48 Rifaximin 
Feagan 2014 USA and 
Canada 
126 Active Crohn's being treated with prednisone 50 Methotrexate and infliximab 
Piche 2014 UK and 
Europe 
37 Normal global assessment by a clinician, normal C-reactive 
protein, erythrocyte sedimentation rate, platelet count and 
white cell count, no use of corticiosteroids in the past 12 
months, CDAI <150 and normal mucosa 
8.6 Osteopathy 
Wenzl 2015 UK and 
Europe 
52 CDAI <150 and azathioprine therapy >= 4 years 104 Azathioprine 
Maintenance studies of surgically induced remission (n=19) 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Brignola 1995 UK and 
Europe 
87 Post curative resection 52 Mesalamine  
McLeod 1995 USA and 
Canada 
163 Post-surgical resection 312 Mesalamine  
Ewe 1999 UK and 
Europe 
83 Post curative resection for ileal, ileo-colonic or colonic 
Crohn's 
52 budesonide 
Hellers 1999 UK and 
Europe 
129 Patients scheduled for resection surgery for ileocolonic 
Crohn's 
52 Budesonide 
Lochs 2000 UK and 
Europe 
324 Post-surgical resection 78 Mesalamine  
Colombel 2001 UK and 
Europe 
65 First resectional surgery for ileal or ileocolonic Crohn's 16 Tenovil 
Prantera 2002 UK and 
Europe 
55 Undergone recent curative resection 52 Probiotic Lactobacillus rhamnosus GG 
Caprilli 2003 UK and 
Europe 
206 Post-surgical resection 52 Mesalazine 
Hanauer 2004 USA and 
Canada 
131 Patients schedules for resection 104 6-mercaptopurine or mesalamine 
Marteau 2006 UK and 
Europe 
98 Undergone recent curative resection 26 Probiotic Lactobacillus johnsonii LA1 
D’Haens 2008 UK and 
Europe 
81 Post ileal or ileocolonic resection with ileocolonic 
anastomosis 
52 Metronidazole and azathioprine 
Regueiro 2009 USA and 
Canada 
24 Patients with ileal or ileocolonic Crohn's undergoing resection 60 infliximab 
Reinisch 2010 UK and 
Europe 
78 CDAI <200 and endoscopic recurrence Rutgeerts grade >=2 52 Azathioprine 
Savarino 2013 UK and 
Europe 
51 Undergoing resection  104 Adalimumab 
Herfarth 2013 USA and 
Canada 
33 Ileal or ileocolonic resection with ileocolonic anastomosis 26 Ciprofloxacin 
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Reference Country of 
study or lead 
author 
Sample 
size 
Disease behaviour Follow 
up 
(weeks) 
Intervention 
Ren 2013 Rest of world 39 CDAI <150 since resection 52 Tripterygium wilfordii polyglycoside 
Armuzzi 2013 UK and 
Europe 
22 Post curative resection 52 Azathioprine and infliximab 
Fedorak 2015 USA and 
Canada 
120 Post resection with margins macroscopically free of disease 52 Probiotic VSL#3 
Zhu 2015 Rest of world 90 Crohn's undergoing macroscopic disease resection 52 Tripterygium wilfordii Hook f. 
Note: CDAI, Crohn’s disease activity index; IOIBD, International Organisation of Inflammatory Bowel Disease; HBI, Harvey Bradshaw Index; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; PDAI, perianal disease activity index; **, study involved only patients with fistula. 
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Appendix 5: Additional tables for Chapter 2 
Appendix table 7: Primary and Secondary Clinical and Composite-Clinical Efficacy Outcomes in Crohn's Disease Randomised Controlled Trials 
Reference Outcome Outcome measurement Measurement tool 
Induction (n=101) 
Medical induction 
(n=95) 
   
Greenberg 1988 Disease relapse or worsening Need for additional therapy or surgery    
Disease relapse or worsening CDAI >250 CDAI 
Wright 1990 Remission CDAI <150 CDAI 
Ewe 1993 Response Change in CDAI score CDAI 
 Response Change in Dutch index score Dutch index 
 Response Change in SAI score SAI 
 Corticosteroid sparing Steroid dose   
 Remission CDAI <150 CDAI 
Singleton 1993 Response CDAI decrease by >=50 points CDAI 
 Response Mean CDAI score CDAI 
 Response Mean HBI score HBI 
 Response Mean PGA of degree of illness on a Visual Analogue Scale PGA 
 Response Mean VHAI score VHAI 
 Remission CDAI <150 and a reduction of >=50 CDAI 
Wright 1993 Remission PGA of disease severity PGA 
Rutgeerts 1994 Remission CDAI <150 CDAI 
 Response CDAI <150 or CDAI 100 CDAI 
Tremaine 1994  Response CDAI <150 or CDAI 70 CDAI 
 Disease relapse or worsening CDAI increase of >=100 from baseline CDAI 
 Remission CDAI <150 and CDAI 70 CDAI 
Greenberg 1994 Remission CDAI <150 CDAI 
Jewell 1994 Corticosteroid-free response Clinician grades response as clinically significant improvement and 
steroid withdrawal 
PGA 
 Disease relapse or worsening Development of new fistula or abscess   
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Reference Outcome Outcome measurement Measurement tool 
 Disease relapse or worsening Need for additional therapy or surgery   
 Remission Clinician grades response as freedom from clinical symptoms PGA 
Gross 1995 Remission CDAI <150 and a reduction of >=60 CDAI 
Middleton 1995 Remission HBI <=3 HBI 
Feagan 1995 Response Mean CDAI score CDAI 
 Corticosteroid sparing Mean daily prednisone dose   
 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
Targan 1997 Response CDAI 70 CDAI 
Bar-Meir 1998  Response CDAI <150 or decrease of >=60 with no steroid side effects CDAI 
 Response CDAI <150 or decrease of >=60 with steroid side effects CDAI 
Colombel 1999  Remission CDAI <150 and a reduction of >75 CDAI 
Present 1999**  Response Change in CDAI score CDAI 
 Response Change in PDAI score PDAI 
 Fistula remission Closure of all active draining anal fistulas at baseline   
 Fistula response Reduction of 50% in draining fistula   
Sandborn 1999  Response CDAI 70 CDAI 
 Corticosteroid sparing Mean daily prednisone dose   
 Corticosteroid sparing Withdrawal of steroids   
 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
 Response Mean CDAI score CDAI 
 Remission CDAI <150 CDAI 
Verma 2000  Remission CDAI <150 or CDAI 100, no bowel symptoms and normal CRP CDAI 
Fedorak 2000  Combined clinical and endoscopic 
remission 
CDAI <150 and improvement or resolution in endoscopic appearance CDAI and PGA 
Schreiber 2000 Response CDAI 100 CDAI 
 Remission CDAI <150 and CDAI 100 CDAI 
Leiper 2001 Remission CDAI <150 CDAI 
 Response CDAI 70 CDAI 
 Response HBI <=3 HBI 
 Response Change in VHAI score VHAI 
Gordon 2001 Remission CDAI <150 CDAI 
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Reference Outcome Outcome measurement Measurement tool 
 Disease relapse or worsening Need for additional therapy   
 Response Change in CDAI score CDAI 
Schreiber 2001 Remission CDAI <150 and low dose corticosteroids CDAI 
 Corticosteroid sparing Changes from baseline in daily steroids consumed   
 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
Sandborn 2001143  Fistula response Reduction of 50% in draining fistula   
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Remission CDAI <150 CDAI 
Lomer 2001  Corticosteroid sparing Median corticosteroid usage    
Response Mean CDAI score CDAI 
Hawkes 2001 Response Change in CDAI score CDAI 
Sandborn 2001146  Fistula remission Closure of all draining fistulas   
 Fistula response Reduction of 50% in draining fistula   
 Response CDAI <150 or CDAI 70 CDAI 
 Response CDAI score CDAI 
 Remission CDAI <150 CDAI 
Carty 2001  Response Mean CDAI score CDAI 
 Response Mean HBI score HBI 
 Response PGA of change in clinical condition PGA 
 Remission CDAI <150 CDAI 
Goodgame 2001  Disease relapse or worsening Need for hospitalisation due to worsening Crohn's   
 Disease relapse or worsening Need for surgery   
 Response Change in HBI HBI 
Tremaine 2002  Response CDAI 100 CDAI 
 Remission CDAI <150 CDAI 
 Response Change in CDAI score CDAI 
Steinhart 2002 Response Change in CDAI score CDAI  
Remission CDAI <150 CDAI 
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Reference Outcome Outcome measurement Measurement tool 
Yacyshyn 2002  Corticosteroid sparing Corticosteroid use over time   
 Corticosteroid-free remission CDAI <150 and no need for corticosteroids or immunosuppressives CDAI 
 Disease relapse or worsening Withdrawal rates for disease progression or lack of efficacy   
 Response CDAI 70 CDAI 
 Response Change in CDAI score CDAI 
 Remission CDAI <150 and no increased or new corticosteroids, 
immunosuppressives or surgery 
CDAI 
Hommes 2002 Response CDAI 70 and reduction of >=25% from baseline score CDAI  
Remission CDAI <150 CDAI 
Arnold 2002 Remission CDAI <150 CDAI 
Sakurai 2002 Remission CDAI 100 or reduction of 40% from baseline score CDAI 
Ardizzone 2003 Corticosteroid sparing Mean cumulative steroid dose   
 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
 Fistula remission Closure of draining enterocutaneous and perianal fistulas   
 Response Change in CDAI score CDAI 
Ghosh 2003  Response CDAI 70 CDAI  
Remission CDAI <150 CDAI 
Ito 2004 Remission CDAI <150 CDAI  
Response CDAI 70 CDAI 
Joos 2004 Remission CDAI <150 CDAI  
Response CDAI 150-160 (near remission) CDAI 
Herfarth 2004  Remission CDAI <150 CDAI  
Response Change in CDAI score CDAI 
Mannon 2004 Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Sandborn 2004  Remission CDAI <150 CDAI 
 Fistula remission Closure of all draining fistulas   
 Fistula response Reduction of 50% in draining fistula   
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response Mean CDAI score CDAI 
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Reference Outcome Outcome measurement Measurement tool 
West 2004**  Response Change in PDAI score PDAI 
 Fistula response Improvement on 3D-HPUS 3D-diagnostic ultrasound 
system (3D-HPUS) 
 Fistula response 50% reduction in draining fistula   
Winter 2004 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response CDAI score CDAI 
 Remission CDAI <150 CDAI 
Schreiber 2005 Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Lomer 2005  Response CDAI decrease >=60 from baseline CDAI 
 Response CDAI score CDAI 
 Response Change in VHAI score VHAI 
 Remission CDAI <150 CDAI 
Korzenik 2005  Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Remission CDAI <150 CDAI 
Reinsich 2006  Remission CDAI <150 CDAI 
Margalit 2006  Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Prantera 2006  Remission CDAI <150 CDAI 
 Disease relapse or worsening Need for additional therapy or surgery   
 Disease relapse or worsening CDAI increase of >100 CDAI 
 Response CDAI 70 CDAI 
Schroder 2006  Remission CDAI <150 CDAI 
 Corticosteroid sparing Mean daily prednisolone dose   
Hommes 2006 Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Hanauer 2006  Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
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Reference Outcome Outcome measurement Measurement tool 
Lemann 2006 Corticosteroid sparing Median cumulative dose of prednisone    
Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
Rutgeerts 2006 Disease relapse or worsening Need for additional therapy   
 Response Mean CDAI score CDAI 
 Remission CDAI <150 CDAI 
Screiber 2006  Fistula response Reduction of 50% in draining fistula   
 Response CDAI 70 CDAI 
 Response Change in CDAI from baseline CDAI 
 Remission CDAI <150 CDAI 
Herrlinger 2006 Response CDAI 100 CDAI 
 Remission CDAI <150 CDAI 
Reinshagen 2007 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
Mansfield 2007 Remission CDAI <150 and CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response Mean change in CDAI score CDAI 
Sandborn 2007  Remission CDAI <150 CDAI 
 Fistula response 50% reduction in draining fistula   
 Fistula remission Closure of all active draining fistulas at baseline   
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response Change in CDAI from baseline CDAI 
Hafer 2007  Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response Change in SAI score SAI 
Targan 2007 Sustained remission CDAI <150 over a four week period CDAI 
 Sustained response CDAI decrease of >=70 for a four week period CDAI 
 Remission CDAI <150 CDAI 
 Response CDAI 70 CDAI 
Omer 2007  Corticosteroid sparing Average dose of corticosteroids    
Response CDAI 70 or reduction of  >=30% from baseline score CDAI 
Hart 2007**  Response Physician assessment of improvement of ulcers   
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Reference Outcome Outcome measurement Measurement tool 
 Fistula response 50% reduction in draining fistula   
 Sustained fistula remission Maintenance of fistula remission for at least 4 weeks   
 Complete response Physician assessment of complete resolution of all ulcers   
Sandborn 2008  Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 or >=25% CDAI 
Leiper 2008 Remission CDAI <150 and CDAI 70 CDAI 
 Remission HBI <=4 HBI 
 Response Change in VHAI score VHAI 
D’Haens 2008 Corticosteroid sparing Daily dose of methylprednisolone   
 Corticosteroid-free remission CDAI <150, withdrawal of corticosteroids and no surgery CDAI 
 Disease relapse or worsening proportion given infliximab, methylprednisolone and antimetabolites   
 Disease relapse or worsening CDAI increase of >=50 points CDAI 
 Response Mean CDAI score CDAI 
Fukuda 2008** Fistula response 50% reduction in draining fistula    
Fistula remission Closure of all active draining fistulas at baseline   
Feagan 2008 Disease relapse or worsening Worsening clinical status and need for additional therapy PGA 
 Disease relapse or worsening Worsening clinical status and CDAI increase of >=100 CDAI and PGA 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Remission CDAI <150 CDAI 
Thia 2009**  Response Change in CDAI score CDAI 
 Response Change in PDAI score PDAI 
 Fistula remission Closure of all active draining anal fistulas at baseline   
 Fistula response Reduction of 50% in draining fistula   
 Fistula response Change in mean PGA score of fistula activity PGA 
 Sustained fistula remission Maintenance of fistula remission for at least 4 weeks   
Dotan 2010  Remission CDAI <150 CDAI 
 Response CDAI 70 CDAI 
 Response Change in Median CDAI CDAI 
 Response Mean CDAI score CDAI 
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Reference Outcome Outcome measurement Measurement tool 
 Response Median CDAI score CDAI 
Steed 2010  Remission CDAI <150 or a reduction of >=75 CDAI 
Van der Woude 2010  Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Maeda 2010  Response Change in component of PDAI from baseline: degree of induration PDAI  
Response Change in component of PDAI from baseline: discharge PDAI 
 Response Change in component of PDAI from baseline: pain / restriction of 
activities 
PDAI 
 Response Change in component of PDAI from baseline: type of perianal disease PDAI 
 Response Perianal Disease Activity Index (PDAI) - restriction of sexual activity PDAI 
 Response Change in PDAI score PDAI 
Sands 2010  Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Buchman 2010  Response CDAI 100 CDAI 
 Response CDAI 100 CDAI 
 Remission CDAI <150 CDAI 
 Remission CDAI <150 CDAI 
Krebs 2010  Response CDAI 70 or reduction of  >=30% from baseline score CDAI 
Tromm 2011  Remission CDAI <150 CDAI 
 Remission PGA of therapeutic success PGA 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response PGA of therapeutic benefit (category 1, 2, 3 or 4) PGA 
Sandborn 2011  Remission CDAI <150 CDAI 
 Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response CDAI score CDAI 
 Response Change in HBI from baseline HBI 
Benjamin 2011  Remission CDAI <150 CDAI 
 Response CDAI 70 CDAI 
 Response Change in CDAI score CDAI 
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Reference Outcome Outcome measurement Measurement tool 
Smith 2011  Response CDAI 70 CDAI 
Prantera 2012  Disease relapse or worsening Need for additional therapy or surgery   
 Disease relapse or worsening CDAI fail to decrease by at least 70 points from baseline CDAI 
 Disease relapse or worsening CDAI increase of >100 from baseline CDAI 
 Sustained remission CDAI <150 sustained for the length of the study CDAI 
 Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
Hueber 2012 Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response Change in CDAI score CDAI 
Sands 2013  Remission CDAI <150 CDAI  
Response CDAI 100 CDAI  
Response Change in CDAI from baseline CDAI 
Naftali 2013 Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Suzuki 2013 Remission CDAI <150 CDAI  
Response Change in CDAI score CDAI 
Brotherton 2014 Response Mean pHBI score pHBI 
Sandborn 2014  Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
Dewint 2014** Fistula remission 100% reduction in draining fistula    
Fistula response 50% reduction in draining fistula   
Reinisch 2014**  Response Change in CDAI score CDAI 
 Fistula remission Closure of all draining fistulas   
 Fistula response Reduction of 50% in draining fistula   
Sands 2014  Remission CDAI <150 CDAI  
Response CDAI 100 CDAI 
Dignass 2014 Remission CDAI <150 CDAI 
 Response Mean CDAI score CDAI 
 Response Change in PGA score PGA 
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Reference Outcome Outcome measurement Measurement tool 
Bao 2014  Remission CDAI <150 CDAI 
 Disease relapse or worsening CDAI decreased by <70 or increased CDAI CDAI 
 Response CDAI 70 CDAI 
D’Haens 2015 Remission CDAI <150 and no treatment failures CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
Monteleone 2015 Remission CDAI <150 CDAI 
 Sustained remission CDAI <150 maintained for at least 2 weeks CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response Change in median CDAI CDAI 
 Response Mean CDAI score CDAI 
Vande Casteele 2015 Disease relapse or worsening Need for additional therapy   
 Sustained remission HBI <=4 and CRP concentration of <=5mg/L throughout study HBI 
 Remission HBI <=4 and CRP of <=5mg/L HBI 
Surgical induction 
(n=6) 
   
Maartense 2006 Post-operative recovery Duration of hospital stay (days)    
Post-operative recovery Morphine requirement   
East 2007  Disease relapse or worsening Time to repeat dilation or surgery   
Mcleod 2009 Combined clinical and endoscopic 
recurrence 
RES >=2 and need for additional therapy or surgery Rutgeerts endoscopic 
score 
Grimaud 2010**  Response Occurrence of perianal abscess   
 Fistula remission Absence of draining fistula, absence of perianal pain and absence of 
perianal abscess 
  
 Fistula response Closure of 50% or more of draining anal fistulas   
Zurbuchen 2013 Recurrence Need for additional surgery   
 Post-operative recovery Duration of hospital stay (days)   
 Post-operative recovery Time (days) to first postoperative stool   
Molendijk 2015** Fistula response Reduced number of draining fistulas   
 Response MRI evaluation of fistula tracts   
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Reference Outcome Outcome measurement Measurement tool 
 Response Change in CDAI score CDAI 
 Response Change in PDAI score PDAI 
Maintenance (n=65) 
Maintenance studies of medically induced remission (n=47) 
Singleton 1979 Response Change in CDAI score CDAI 
 Disease relapse or worsening Withdrawn early for severe exacerbation or drug toxicity   
 Disease relapse or worsening Withdrawn early for surgery   
 Disease relapse or worsening CDAI > 150 or >40% of initial CDAI CDAI 
 Sustained remission CDAI <150 for the length of the study CDAI 
 Treatment compliance Pill count   
 Remission CDAI <150 CDAI 
Malchow 1984 Disease relapse or worsening Development of a new abscess   
 Disease relapse or worsening Pending surgery for complication of Crohn's   
 Disease relapse or worsening CDAI >150 requiring repetition of acute phase treatment CDAI 
 Disease relapse or worsening CDAI increase of >100, no change or minimal reduction <60 CDAI 
Bresci 1994 Disease relapse or worsening CDAI >150 or increase >=100 CDAI 
Feagan 1994 Response Mean CDAI score CDAI 
 Corticosteroid sparing Mean dose of prednisone and 5-aminosalicylates   
 Disease relapse or worsening CDAI increase of >=100 CDAI 
Schreiber 1994 Disease relapse or worsening CDAI >150 and an increase of >=100 points CDAI  
Sustained remission CDAI <150 maintained for 12 months CDAI 
Stange 1995 Response CDAI between 150 and 200 CDAI 
 Response HBI score HBI 
 Response Change in Present score Present score  
 Response Change in VHAI score VHAI 
 Disease relapse or worsening CDAI >200 CDAI 
 Remission CDAI <150 CDAI 
Belluzzi 1996  Disease relapse or worsening CDAI >150 and an increase of >=100 points CDAI 
Greenberg 1996 Disease relapse or worsening Need for additional therapy or surgery    
Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
Sutherland 1997 Disease relapse or worsening Investigator opinion of relapse   
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Reference Outcome Outcome measurement Measurement tool 
 Disease relapse or worsening Need for hospitalisation due to worsening Crohn's   
 Disease relapse or worsening Need for introduction of corticosteroids   
 Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
Ferguson 1998  Response Mean CDAI score CDAI  
Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
Arora 1999 Disease relapse or worsening Withdrew from study due to disease flare or failure to reduce 
prednisone dose 
  
Guslandi 2000  Disease relapse or worsening CDAI >150 and an increase of >=100 points CDAI 
Green 2001  Disease relapse or worsening Moderate to severe symptoms with either high steroid dose or CDAI 
>200 
  
Mahmud 2001 Disease relapse or worsening Need for additional therapy or surgery    
Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
Cortot 2001 Response Change in CDAI score CDAI  
Disease relapse or worsening Crohn's Disease Activity Index (CDAI) CDAI 
Hanauer 2002 Disease relapse or worsening CDAI score >175 and an increase of >=70 points or >=35% CDAI 
 Remission CDAI <150 CDAI 
Mantzaris 2003 Response Change in CDAI score CDAI 
Mantzaris 2003 Disease relapse or worsening CDAI >150 and an increase of >=100 points CDAI 
Keller 2004 Disease relapse or worsening Failure of any drug treatment including immunosuppressants, with or 
without surgery 
ECCDS 
 Disease relapse or worsening Failure of standard drug therapy, but effective immunosuppressive 
therapy 
ECCDS 
 Remission Relapse-free course ECCDS 
Sands 2004**  Response CDAI 70 or by 25% from start of >220 CDAI 
 Response CDAI score CDAI 
 Disease relapse or worsening Study discontinuation due to perceived inefficacy   
 Disease relapse or worsening Need for additional therapy or surgery   
 Disease relapse or worsening Recurrence of draining fistula   
Schultz 2004 Disease relapse or worsening CDAI increased by >100 points CDAI  
Sustained remission CDAI <150 sustained for the length of the study CDAI 
Vilien 2004 Disease relapse or worsening Need for additional therapy or surgery   
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Reference Outcome Outcome measurement Measurement tool  
Disease relapse or worsening CDAI >150 or an increase of >=75 points CDAI 
Lemann 2005 Disease relapse or worsening Need for surgery    
Disease relapse or worsening CDAI >250 or CDAI 150-250 and an increase of >=75 points from 
baseline 
CDAI 
Feagan 2005 Response Median CDAI score CDAI 
 Corticosteroid sparing Withdrawal of corticosteroids, no flare (CDAI >=220) and no study 
withdrawal 
CDAI 
 Disease relapse or worsening CDAI >=220 CDAI 
 Response Mean CDAI score CDAI 
Hanauer 2005  Response Change in CDAI score CDAI  
Disease relapse or worsening CDAI >150 and an increase of >=60 points or clinical deterioration CDAI 
Sandborn 2005  Sustained remission CDAI <150 sustained for the length of the study CDAI 
 Sustained response CDAI 70 sustained for the length of the study CDAI 
 Remission CDAI <150 CDAI 
Feagan 2006 Response Mean CDAI score CDAI 
 Corticosteroid sparing Withdrawal of corticosteroids and no flare (CDAI >220) CDAI 
 Disease relapse or worsening Increase in steroids, total steroids taken   
 Fistula remission Closure of all draining fistulas   
 Fistula response Reduction of 50% in draining fistula   
Takagi 2006 Disease relapse or worsening Need for additional therapy    
Disease relapse or worsening CDAI >200 CDAI 
Colombel 2007  Remission CDAI <150 CDAI  
Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
 Sustained corticosteroid-free 
remission 
CDAI<150 and able to discontinue corticosteroid use for >=90days CDAI 
 Fistula remission Closure of all fistulas that were draining at screening and baseline visits   
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
Sandborn 2007  Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
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Reference Outcome Outcome measurement Measurement tool 
 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
Ng 2007  Response HBI score HBI 
Schreiber 2007 Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
De Jong 2007  Remission CDAI <150 CDAI 
 Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
Selby 2007  Disease relapse or worsening Need for additional therapy   
 Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
 Remission CDAI <150 CDAI 
Feagan 2008 Response Change in CDAI score CDAI 
 Disease relapse or worsening Need for additional therapy or surgery   
 Disease relapse or worsening CDAI >150 and an increase of >=70 points CDAI 
Mantzaris 2009 Response Mean CDAI score CDAI  
Disease relapse or worsening CDAI >150 and an increase of >=100 points CDAI 
Rossi 2009  Response Change in CDAI from baseline CDAI 
 Response Number of fistulas including new ones and closure of existing ones   
 Disease relapse or worsening CDAI >220 and increase of >=70 and need for additional therapy CDAI 
Valentine 2009 Corticosteroid-free response CDAI  decrease of >=100 points and withdrawal of corticosteroids CDAI 
 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
 Corticosteroid-free remission CDAI score <150 and >=25% decrease and withdrawal of corticosteroids CDAI 
 Corticosteroid-free remission CDAI score <150 and 100 point decrease and withdrawal of 
corticosteroids 
CDAI 
 Disease relapse or worsening Mean daily corticosteroid use at study withdrawal   
 Disease relapse or worsening Study withdrawal   
 Response CDAI 100 CDAI 
 Response Change in mean CDAI CDAI 
 Remission CDAI <150 CDAI 
Sandborn 2010  Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response Mean CDAI score CDAI 
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Reference Outcome Outcome measurement Measurement tool 
Jorgensen 2010 Disease relapse or worsening CDAI >150 and an increase of >=70 points CDAI 
Prantera 2011  Response Change in CDAI score CDAI 
 Disease relapse or worsening Study withdrawal due to disease deterioration   
 Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
Holtmeier 2011 Response Mean change in CDAI score CDAI 
 Disease relapse or worsening Clinical need for introduction of corticosteroid therapy or 
hospitalisation for flare-up 
  
 Disease relapse or worsening Investigator opinion of relapse   
 Disease relapse or worsening Surgical intervention for stenosis, fistula or abscesses   
 Disease relapse or worsening CDAI >150 and an increase of >=70 points CDAI 
 Sustained remission CDAI <150 maintained for 12 months CDAI 
 Treatment compliance Pill count   
Watanabe 2012  Remission CDAI <150 CDAI 
 Response CDAI 100 CDAI 
 Response CDAI 70 CDAI 
 Response Change in CDAI from baseline CDAI 
 Response Change in IOIBD from baseline IOIBD 
Keshav 2013 Remission CDAI <150 CDAI 
 Sustained remission CDAI <150 sustained for the length of the study CDAI 
 Response CDAI 100 CDAI 
 Sustained response CDAI 70 sustained for the length of the study CDAI 
 Response CDAI 70 CDAI 
Bourreile 2013 Response Mean CDAI score CDAI 
 Disease relapse or worsening Need for additional therapy or surgery   
 Disease relapse or worsening Crohn's Disease Activity Index (CDAI) CDAI 
Jigaranu 2014  Sustained remission CDAI <150 sustained for the length of the study CDAI  
Sustained response  CDAI 100 sustained for the length of the study CDAI 
Feagan 2014 Sustained corticosteroid-free 
remission 
CDAI  <150 and withdrawal of prednisone for length of trial CDAI 
 Corticosteroid-free remission CDAI <150 and withdrawal of corticosteroids CDAI 
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Reference Outcome Outcome measurement Measurement tool 
 Disease relapse or worsening Failure to achieve CDAI<150 and total withdrawal of prednisone or 
failure to maintain CDAI <150 until the end of the study 
CDAI 
 Disease relapse or worsening Failure to achieve CDAI<150 and total withdrawal of prednisone or 
failure to maintain CDAI <150 until the end of the study 
CDAI 
 Response Mean change in CDAI score CDAI 
Wenzl 2015  Disease relapse or worsening Development of one or more new fistula   
 Disease relapse or worsening Need for additional surgery   
 Disease relapse or worsening Need for steroids or anti-TNF   
 Disease relapse or worsening CDAI >150 and an increase of >=60 points CDAI 
 Disease relapse or worsening PDAI increase of >4 points PDAI 
 Response CDAI score CDAI 
Maintenance studies of surgically induced remission (n=18) 
McLeod 1995 Combined clinical and endoscopic 
recurrence 
Investigator assessment of disease activity and radiological or 
endoscopic evidence 
  
Ewe 1999  Response Median CDAI score CDAI 
 Recurrence Signs and symptoms characteristic of Crohn's   
 Recurrence CDAI >200 and rise of 60 points CDAI 
Hellers 1999  Response Mean CDAI score CDAI  
Response Change in PGA score PGA 
Lochs 2000  Recurrence Development of one or more new fistula or septic complication   
 Recurrence Need for additional surgery   
 Recurrence CDAI >250 CDAI 
 Recurrence CDAI >200 and rise of 60 points CDAI 
Colombel 2001  Recurrence Need for additional therapy   
Prantera 2002  Recurrence CDAI >150 CDAI 
Caprilli 2003  Recurrence CDAI >150 CDAI 
Hanauer 2004  Recurrence Clinical recurrence grading scale   
Marteau 2006  Recurrence CDAI >=200 CDAI 
D’Haens 2008  Recurrence CDAI >250 CDAI 
Regueiro 2009  Recurrence CDAI >200 CDAI 
Reinisch 2010  Response Mean CDAI change from baseline CDAI 
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Reference Outcome Outcome measurement Measurement tool  
Recurrence CDAI >=200 and an increase of >=60 CDAI 
Savarino 2013  Recurrence CDAI >200 CDAI 
Herfarth 2013  Recurrence HBI score >=5 or an increase of 3 points since previous visit HBI 
Ren 2013  Response Change in CDAI score CDAI  
Combined clinical and endoscopic 
recurrence 
RES >=2 and either symptoms and symptoms of Crohn's or CDAI >150, 
needing therapy or surgery 
Rutgeerts endoscopic 
score and CDAI 
Armuzzi 2013  Recurrence HBI >=8 HBI 
Fedorak 2015  Response Mean CDAI score CDAI 
Zhu 2015  Recurrence Need for additional therapy or surgery   
Note: CDAI, Crohn’s disease activity index; IOIBD, International Organisation of Inflammatory Bowel Disease; HBI, Harvey Bradshaw Index; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; PDAI, perianal disease activity index; **, study involved only patients with fistula. 
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Appendix table 8: Primary and Secondary Endoscopic Efficacy Outcomes in Crohn's Disease Randomised Controlled Trials 
Reference Outcome Outcome measure Outcome measurement tool 
Induction (n=13) 
   
Medical induction (n=10) 
Schreiber 2000 Endoscopic response Change in CDEIS score from baseline CDEIS 
Reinsich 2006 Endoscopic response Change in CDEIS score from baseline CDEIS 
Lemann 2006 Endoscopic response Change in CDEIS score from baseline CDEIS 
Schreiber 2006 Endoscopic response Change in CDEIS score from baseline CDEIS 
D’Haens 2008 Endoscopic mucosal healing No ulcers identified SES-CD 
 
Endoscopic response Mean SES-CD severity score SES-CD 
Van der Woude 2010 Endoscopic response Mean change in CDEIS score CDEIS 
Sands 2010 Endoscopic response Change in CDEIS score from baseline CDEIS 
 
Endoscopic response Change in SES-CD score from baseline SES-CD 
Smith 2011 Endoscopic remission CDEIS score <6 CDEIS 
 Endoscopic response CDEIS score <3 CDEIS 
 Endoscopic response CDEIS score decrease by >=5 CDEIS 
 Endoscopic response Change in CDEIS score CDEIS 
Dignass 2014 Endoscopic mucosal healing Complete mucosal healing: SES-CD score of 0 SES-CD 
Bao 2014 Endoscopic response CDEIS score CDEIS 
Surgical induction (n=3) 
Mcleod 2009 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Zurbuchen 2013 Endoscopic recurrence Rate of endoscopic recurrence Rutgeerts endoscopic score 
Molendijk 2015** Endoscopic response Change in CDEIS score CDEIS 
 
Endoscopic response Change in SES-CD score SES-CD 
Maintenance (n=22) 
   
Maintenance studies of medically induced remission (n=3) 
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Reference Outcome Outcome measure Outcome measurement tool 
Malchow 1984 Endoscopic recurrence Endoscopic or radiological results document a worsening of condition   
Selby 2007 Endoscopic response Change in CDEIS score CDEIS 
Mantzaris 2009 Endoscopic mucosal healing Change in endoscopic category of mucosal healing D'Haens endoscopic categories 
 
Endoscopic response Change in CDEIS score CDEIS 
Maintenance studies of surgically induced remission (n=19) 
Brignola 1995 Endoscopic recurrence Rutgeerts endoscopic score >2 Rutgeerts endoscopic score 
 Endoscopic recurrence Rutgeerts endoscopic score >2 or radiological documentation of 
recurrence 
Rutgeerts endoscopic score 
 Endoscopic response Mean Rutgeerts endoscopic score Rutgeerts endoscopic score 
McLeod 1995 Endoscopic recurrence Rate of endoscopic or radiological recurrence   
Ewe 1999 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Hellers 1999 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Lochs 2000 Endoscopic recurrence Rutgeerts score >=2 Rutgeerts endoscopic score 
Colombel 2001 Endoscopic recurrence Rutgeerts endoscopic score >0 Rutgeerts endoscopic score 
Prantera 2002 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
 
Endoscopic recurrence Rutgeerts endoscopic score >2 Rutgeerts endoscopic score 
Caprilli 2003 Endoscopic recurrence Rutgeerts endoscopic score >0 Rutgeerts endoscopic score 
 
Endoscopic recurrence Rutgeerts endoscopic score >2 Rutgeerts endoscopic score 
Hanauer 2004 Endoscopic recurrence Radiographic recurrence grading scale >=2 Radiographic grading scale 
 
Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Marteau 2006 Endoscopic recurrence Colonic lesions endoscopic score >1   
 Endoscopic recurrence Rutgeerts endoscopic score >1 Rutgeerts endoscopic score 
 Endoscopic response Maximum colonic lesions endoscopic score   
 Endoscopic response Maximum Rutgeerts endoscopic score Rutgeerts endoscopic score 
D’Haens 2008 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
 
Endoscopic recurrence Rutgeerts endoscopic score >2 Rutgeerts endoscopic score 
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Reference Outcome Outcome measure Outcome measurement tool 
Regueiro 2009 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Reinisch 2010 Endoscopic mucosal healing Median improvement in CDEIS score CDEIS 
 
Endoscopic response >=1 point improvement in Rutgeerts score Rutgeerts endoscopic score 
Savarino 2013 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Herfarth 2013 Endoscopic recurrence Marteau score >= c2 Marteau endoscopic score 
 
Endoscopic recurrence Rutgeerts score >=2 Rutgeerts endoscopic score 
Ren 2013 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Ren 2013 Endoscopic response Change in Rutgeerts endoscopic score Rutgeerts endoscopic score 
Armuzzi 2013 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Fedorak 2015 Endoscopic recurrence Rutgeerts endoscopic score >0 Rutgeerts endoscopic score 
 
Endoscopic recurrence Rutgeerts endoscopic score >2 Rutgeerts endoscopic score 
Zhu 2015 Endoscopic recurrence Rutgeerts endoscopic score >=2 Rutgeerts endoscopic score 
Note: CDEIS, Crohn's Disease Endoscopic Index of Severity; SES-CD, Simple Endoscopic Score for Crohn's disease;**, study involved only patients with fistula. 
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Appendix table 9: Primary and Secondary Histology Efficacy Outcomes in Crohn's Disease Randomised Controlled Trials 
Reference Outcome Outcome measure Outcome measurement tool 
Induction (n=5) 
Medical induction (n=5) 
Schreiber 2000 Tissue cytokine, leukocyte, receptor or gene 
expression 
Total concentration of NFκB and  IκBα cytokine 
 
Mannon 2004 Histologic response D'Haens histologic score D'Haens histological activity 
score 
Mannon 2004 Tissue cytokine, leukocyte, receptor or gene 
expression 
Mononuclear cell secretion of Interferon-γ cytokine 
 
Steed 2010 Tissue cytokine, leukocyte, receptor or gene 
expression 
Change in mucosal TNF-alpha cytokines 
 
Smith 2011 Histologic response Dieleman histological score Dieleman histological score 
Bao 2014 Histologic response D'Haens histological activity score of biopsy D'Haens histological activity 
score 
Maintenance (n=6) 
Maintenance studies of medically induced remission (n=1) 
Mantzaris 2009 Histologic remission Average histology score (AHS) Average histology score (AHS) 
Maintenance studies of surgically induced remission (n=5) 
Ewe 1999 Histologic recurrence Histological score of 2 or 1 in conjunction with special 
findings 
Histological Activity Score 
Colombel 2001 Histologic recurrence D'Haens histological activity score of biopsy D'Haens histological activity 
score 
Regueiro 2009 Histologic recurrence D'Haens histological activity score and presence of 
neutrophils 
D'Haens histological activity 
score 
Armuzzi 2013 Histologic recurrence Regueiro histology score of moderate to severe activity Regueiro histology score 
Fedorak 2015 Tissue cytokine, leukocyte, receptor or gene 
expression 
Mucosal inflammatory cytokines expression 
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Appendix table 10: Primary and Secondary Biomarker Outcomes in Crohn's Disease Randomised 
Controlled Trials 
Reference Outcome Outcome measure 
Induction studies (n=39) 
Medical induction (n=38) 
Ewe 1993 Serum albumin Serum albumin 
 Serum C-reactive protein C-reactive protein 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
 Serum full blood count and subsets Haematocrit 
 Serum full blood count and subsets Haemoglobin 
 Serum full blood count and subsets Platelet count 
 Serum full blood count and subsets White blood cell count 
Greenberg 1994 Serum cortisol level Plasma cortisol levels 
 Serum C-reactive protein Mean serum C-reactive protein 
concentration 
 Serum protein concentrations Mean serum orosomucoid concentration 
Feagan 1995 Serum protein concentrations Mean serum orosomucoid concentration 
Hond 1999 Intestinal permeability % of orally administered Cr-EDTA dose 
permeability 
Sandborn 1999 Drug concentration and 
pharmacokinetics 
Mean RBC 6TGN concentrations 
 Serum full blood count and subsets White blood cell count 
Verma 2000 Serum C-reactive protein C-reactive protein 
Sandborn 2001 Antidrug antibodies Presence of anti-drug antibodies  
Autoantibodies Presence of other antibodies 
Hawkes 2001 Serum C-reactive protein Change in mean C-reactive protein 
concentrations  
Serum erythrocyte sedimentation rate Change in mean erythrocyte 
sedimentation rate 
Carty 2001 Serum C-reactive protein Change in C-reactive protein 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
 Serum full blood count and subsets Change in platelet count 
 Serum protein concentrations Change in orosomucoid concentration 
Goodgame 
2001 
Intestinal permeability Lactulose-mannitol test change from 
baseline 
Tremaine 2002 Serum cortisol level Plasma cortisol levels 
Yacyshyn 2002 Drug concentration and 
pharmacokinetics 
Plasma ISIS 2302 concentrations 
Ardizzone 2003 Serum C-reactive protein Decrease in C-reactive protein  
Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Ghosh 2003 Serum C-reactive protein Mean change in C-reactive protein from 
baseline 
Ito 2004 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
 Serum lymphocyte count and subset 
expression 
Change in fibrinogen concentration from 
baseline 
 Serum protein concentrations Change in serum amyloid A protein from 
baseline 
Sandborn 2004 Antidrug antibodies Presence of anti-drug antibodies  
Serum C-reactive protein Mean C-reactive protein concentrations 
Winter 2004 Serum C-reactive protein Mean C-reactive protein concentrations 
Lomer 2005 Faecal calprotectin Faecal calprotectin 
 Intestinal permeability % of intestinal permeability 
 Serum C-reactive protein C-reactive protein 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
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Reference Outcome Outcome measure 
Reinsich 2006 Antidrug antibodies Presence of anti-drug antibodies  
Serum C-reactive protein Median serum C-reactive protein change 
from baseline 
Hommes 2006 Antidrug antibodies Presence of anti-drug antibodies 
 Drug concentration and 
pharmacokinetics 
Serum fontolizumab concentrations 
 Serum C-reactive protein Mean C-reactive protein concentration 
change from baseline 
Rutgeerts 2006 Serum C-reactive protein C-reactive protein 
Schreiber 2006 Serum C-reactive protein Change in C-reactive protein 
concentration from baseline 
Sandborn 2007 Serum C-reactive protein Change in C-reactive protein 
Leiper 2008 Serum C-reactive protein Median serum C-reactive protein 
D’Haens 2008 Serum C-reactive protein Median serum C-reactive protein 
Feagan 2008 Serum C-reactive protein Change in serum C-reactive protein 
concentrations 
Dotan 2010 Serum C-reactive protein Mean change in C-reactive protein from 
baseline 
Van der Woude 
2010 
Serum lymphocyte count and subset 
expression 
T-cell receptor (TCR) modulation 
Buchman 2010 Serum C-reactive protein Mean change in serum C-reactive protein 
from baseline 
 Serum full blood count and subsets Mean change in peripheral blood WBC 
 Serum full blood count and subsets Mean change in platelet count from 
baseline 
Sandborn 2011 Antidrug antibodies Presence of anti-drug antibodies 
 Drug concentration and 
pharmacokinetics 
Serum certolizumab pegol concentrations 
 Serum C-reactive protein Change in C-reactive protein from 
baseline 
Benjamin 2011 Faecal calprotectin Change in faecal calprotectin  
Serum C-reactive protein Change in C-reactive protein 
Hueber 2012 Drug concentration and 
pharmacokinetics 
Serum secukinumab concentrations 
Naftali 2013 Serum C-reactive protein Reduction of >= 0.5mg C-reactive protein 
Suzuki 2013 Serum cortisol level Plasma cortisol levels 
Brotherton 
2014 
Serum C-reactive protein C-reactive protein 
 
Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Bao 2014 Serum C-reactive protein C-reactive protein  
Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Monteleone 
2015 
Serum C-reactive protein Change in C-reactive protein 
 
Serum cytokine or immunoglobulin 
levels 
Complement activation 
Vande Casteele 
2015 
Antidrug antibodies Presence of anti-drug antibodies 
 
Drug concentration and 
pharmacokinetics 
Serum infliximab concentrations 
Surgical induction (n=1) 
Molendijk 
2015** 
Serum C-reactive protein Changes in C-reactive protein 
Maintenance studies (n=22) 
Maintenance studies of medically induced remission (n=16) 
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Reference Outcome Outcome measure 
Bresci 1994 Disease relapse or worsening Laboratory index >=100 
Stange 1995 Serum C-reactive protein C-reactive protein 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
 Serum full blood count and subsets Platelet count 
 Serum protein concentrations Serum orosomucoid concentration 
Greenberg 1996 Serum cortisol level Plasma cortisol levels  
Serum C-reactive protein Serum C-reactive protein concentration 
Ferguson 1998 Serum cortisol level Plasma cortisol levels 
Cortot 2001 Serum cortisol level Plasma cortisol levels 
Schultz 2004 Serum C-reactive protein C-reactive protein 
Vilien 2004 Serum albumin Serum albumin  
Serum C-reactive protein C-reactive protein 
Feagan 2005 Antidrug antibodies Presence of anti-drug antibodies 
 Autoantibodies Presence of other antibodies 
 Serum C-reactive protein Median C-Reactive protein 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Hanauer 2005 Serum cortisol level Change in plasma cortisol level 
Feagan 2006 Serum C-reactive protein Median serum C-reactive protein 
concentration 
Selby 2007 Serum C-reactive protein Change in C-reactive protein  
Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Garcia 2008 Intestinal permeability Median urinary lactulose excretion 
Rossi 2009 Antidrug antibodies Presence of anti-drug antibodies 
 Serum C-reactive protein Change in C-reactive protein 
concentration from baseline 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Bourreile 2013 Serum C-reactive protein Change in C-reactive protein 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
 Serum full blood count and subsets Full blood count 
Feagan 2014 Antidrug antibodies Presence of anti-drug antibodies 
 Drug concentration and 
pharmacokinetics 
Median serum infliximab concentration 
 Serum C-reactive protein Median change in serum C-reactive 
protein concentration 
Wenzl 2015 Serum C-reactive protein Median C-reactive protein 
 Serum full blood count and subsets Mean serum haemoglobin 
 Serum full blood count and subsets Platelet count 
Maintenance studies of surgically induced remission (n=5) 
Hellers 1999 Serum albumin Change in serum albumin level 
 Serum cortisol level Plasma cortisol levels 
 Serum C-reactive protein Change in C-reactive protein 
 Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
 Serum protein concentrations Change in orosomucoid level 
Colombel 2001 Antidrug antibodies Presence of anti-drug antibodies 
Regueiro 2009 Serum C-reactive protein C-reactive protein  
Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Reinisch 2010 Drug concentration and 
pharmacokinetics 
TPMT and thiopurine metabolites activity 
 
Serum C-reactive protein Mean C-reactive protein change from 
baseline 
Ren 2013 Serum C-reactive protein Change in C-reactive protein  
Serum erythrocyte sedimentation rate Erythrocyte sedimentation rate 
Note: Laboratory index: -26+(1.3xerythrocyte sedimentation rate)+(0.03xwhite blood cell 
count)+(5.5*C-reactive protein)+(0.08xα1-antitrypsin) 
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Appendix table 11: Primary and Secondary Patient Reported Outcomes in Crohn's Disease Randomised Controlled Trials 
Reference Outcome Outcome measure Outcome measurement tool 
Induction studies (n=47) 
Medical induction (n=45) 
Singleton 1993 Defecation functions Patient diary score of diarrhoea 
 
 Pain Mean patient assessment of abdominal pain, diarrhoea and overall 
well-being 
 
 Quality of life Mean patient assessment of abdominal pain, diarrhoea and overall 
well-being 
 
Greenberg 1994 Quality of life Mean IBDQ score IBDQ 
Feagan 1995 Quality of life Mean IBDQ score IBDQ 
Sandborn 1999 Quality of life Mean IBDQ score IBDQ 
Verma 2000 Bowel symptoms Patient report of bowel symptoms such as diarrhoea, rectal bleeding or 
pain 
 
Fedorak 2000 Quality of life IBDQ score IBDQ 
Schreiber 2000 Quality of life Change in IBDQ from baseline IBDQ  
Quality of life Change in SF-36 physical scale score SF-36 
Leiper 2001 Quality of life Improvement in IBDQ score IBDQ 
Schreiber 2001 Quality of life Change in IBDQ from baseline IBDQ 
 Quality of life Median IBDQ score IBDQ 
Hawkes 2001 Defecation functions Change in stool frequency 
 
 Pain Change in abdominal pain 
 
 Quality of life Change in Short-IBDQ score Short-IBDQ 
Sandborn 2001 Quality of life IBDQ score IBDQ 
Carty 2001 Quality of life Patient global assessment of changes in clinical condition Patient Global Assessment 
Tremaine 2002 Quality of life Change in IBDQ from baseline IBDQ 
 Quality of life Change in SF-36 from baseline SF-36 
 Quality of life Change in SF-36 mental component summary score from baseline SF-36 MCS 
 Quality of life Change in SF-36 physical component summary score from baseline SF-36 PCS 
Steinhart 2002 Quality of life Change in IBDQ from baseline IBDQ 
Ghosh 2003 Quality of life Median IBDQ score IBDQ 
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Reference Outcome Outcome measure Outcome measurement tool 
Ito 2004 Quality of life Change in IBDQ from baseline IBDQ 
Joos 2004 Quality of life Change in IBDQ from baseline IBDQ  
Quality of life VAS measure of general wellbeing score Visual analogue scale 
Sandborn 2004 Quality of life Mean IBDQ score IBDQ 
Lomer 2005 Quality of life IBDQ score IBDQ 
Korzenik 2005 Quality of life Change in IBDQ from baseline IBDQ 
Reinsich 2006 Quality of life Mean IBDQ score IBDQ 
Margalit 2006 Quality of life Mean IBDQ score IBDQ 
Prantera 2006 Quality of life Mean IBDQ score IBDQ 
Hanauer 2006 Quality of life Change in IBDQ from baseline IBDQ 
Schreiber 2006 Quality of life Change in IBDQ from baseline IBDQ 
Reinshagen 2007 Quality of life Mean IBDQ score IBDQ 
Sandborn 2007 Quality of life Change in IBDQ from baseline IBDQ 
Omer 2007 Quality of life Decrease in HAMD score from baseline Hamilton Depression Scale 
Fukuda 2008** Defecation functions Patient diary score of faecal consistency 
 
 Pain Change in symptom scores for perianal pain 
 
 Quality of life Change in symptom scores for drainage amount (patient diary) 
 
Leiper 2008 Quality of life Decrease in inflammatory bowel specific Quality of Life Index IBD Quality of Life Index 
D’Haens 2008 Quality of life Mean IBDQ score IBDQ 
Feagan 2008 Quality of life Change in IBDQ from baseline IBDQ 
Thia 2009** Quality of life Change in IBDQ from baseline IBDQ 
 Quality of life Change in mean Patient Global Assessment score Patient Global Assessment 
Dotan 2010 Quality of life Change in median IBDQ IBDQ 
 Quality of life Mean IBDQ score IBDQ 
 Quality of life Median IBDQ IBDQ 
Maeda 2010 Pain Change in perianal pain (VA-Scale) from baseline Visual analogue scale 
 Quality of life Change in SF12 scores from baseline SF-12 
 Treatment acceptability Patient global assessment of improvement (Likert scale) Patient Global Assessment 
Sands 2010 Quality of life Change IBDQ score from baseline IBDQ 
Buchman 2010 Defecation functions Mean change in number of liquid bowel movements 
 
 
Treatment compliance Patient diary and pill count 
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Reference Outcome Outcome measure Outcome measurement tool 
Krebs 2010 Quality of life Decrease in HAMD score from baseline Hamilton Depression Scale 
Sandborn 2011 Quality of life IBDQ score >170 IBDQ 
Benjamin 2011 Quality of life Change in IBDQ from baseline IBDQ 
Naftali 2013 Quality of life Improvement in SF-36 score of at least 50 points SF-36 
Brotherton 2014 Quality of life Mean IBDQ score IBDQ 
Dignass 2014 Quality of life SHS value Short Health Scale  
Quality of life Total GIQLI score GIQLI 
Bao 2014 Quality of life IBDQ score IBDQ 
Surgical induction (n=2) 
Maartense 2006 Pain Pain VAS score Visual analogue scale 
 Pain SF-36 bodily pain score SF-36 bodily pain score 
 Quality of life SF-36 emotional score SF-36 
 Quality of life SF-36 General health perception score SF-36 general health perception score 
 Quality of life SF-36 mental component scale score SF-36 MCS 
 Quality of life SF-36 mental health score SF-36 mental health score 
 Quality of life SF-36 physical component scale score SF-36 
 Quality of life SF-36 physical function score SF-36 physical function score 
 Quality of life SF-36 physical role score SF-36 
 Quality of life SF-36 Social function score SF-36 social function score 
 Quality of life SF-36 vitality score SF-36 vitality score 
 Quality of life Total GIQLI score GIQLI 
Molendijk 2015** Defecation functions Changes in adapted Vaizey faecal incontinence score Adapted Vaizey faecal incontinence score 
 Quality of life Change in SF-36 from baseline SF-36 
 
 
Changes in short IBDQ score Short-IBDQ 
Maintenance studies (n=28) 
Maintenance studies of medically induced remission (n=24) 
Feagan 1994 Quality of life Mean IBDQ score IBDQ 
Greenberg 1996 Quality of life Mean IBDQ score IBDQ 
Sutherland 1997 Quality of life Mean IBDQ score IBDQ 
Cortot 2001 Quality of life Change in IBDQ from baseline IBDQ 
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Reference Outcome Outcome measure Outcome measurement tool 
Mantzaris 2003 Quality of life Change in IBDQ from baseline IBDQ 
Sands 2004** Quality of life IBDQ score IBDQ 
Keller 2004 Quality of life Mean depression BDI score BDI - depression score 
 Quality of life Mean PSKB score PSKB 
 Quality of life Mean QL score Quality of Life instrument 
 Quality of life Mean Trait anxiety STAI-X2 score STAI-X2 - trait anxiety score 
Feagan 2005 Quality of life Median IBDQ score IBDQ 
Feagan 2006 Quality of life Mean IBDQ score IBDQ 
Colombel 2007 Quality of life Change in IBDQ from baseline IBDQ 
Sandborn 2007 Quality of life Change in IBDQ from baseline IBDQ 
Ng 2007 Quality of life IBD Stress Index Score IBD Stress Index  
Quality of life IBDQ score IBDQ 
Selby 2007 Quality of life Change in Assessment of Quality of Life score Assessment of Quality of Life 
Questionnaire 
 Quality of life Change in IBDQ from baseline IBDQ 
 Quality of life Change in SF-36 score SF-36 
Feagan 2008 Quality of life Change in SF-36 from baseline SF-36 
Mantzaris 2009 Quality of life Change in IBDQ from baseline IBDQ 
Rossi 2009 Quality of life Change in IBDQ from baseline IBDQ 
Takagi 2009 Quality of life Mean IBDQ score IBDQ 
Valentine 2009 Quality of life Change in IBDQ from baseline IBDQ 
 Quality of life Change in SF-36 score SF-36 
 Quality of life Change in VAS score EuroQOL-derived visual analogue scale 
Holtmeier 2011 Quality of life Change in IBDQ from baseline IBDQ 
Watanabe 2012 Quality of life Change in SF-36 mental component summary score from baseline SF-36 MCS 
 Quality of life Change in SF-36 physical component summary score from baseline SF-36 
 Quality of life IBDQ score IBDQ 
Keefer 2012 Quality of life Mean IBDQ score IBDQ 
 Quality of life Mean IBD-SES score IBD-SES 
 Quality of life Mean PSQ-R score PSQ-R 
 Treatment compliance Mean MAS score Medical Adherence Scale 
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Reference Outcome Outcome measure Outcome measurement tool 
Feagan 2014 Quality of life Change in SF-36 from baseline SF-36 
Piche 2014 Bowel symptoms IBS severity scoring system IBS severity scoring system 
 Quality of life BDI severity of depression score BDI 
 Quality of life FIS severity of fatigue score Fatigue Impact Scale 
 Quality of life HAD severity of anxiety score Hospital Anxiety and Depression Scale 
 Quality of life IBDQ score IBDQ 
Wenzl 2015 Quality of life IBDQ score IBDQ 
Maintenance studies of surgically induced remission (n=4) 
Ewe 1999 Quality of life Patient global assessment of wellbeing Patient Global Assessment 
Reinisch 2010 Quality of life Mean IBDQ change from baseline IBDQ 
Savarino 2013 Quality of life Mean IBDQ score IBDQ 
Fedorak 2015 Quality of life Mean IBDQ score IBDQ 
Note: IBDQ, Inflammatory Bowel Disease Questionnaire; SF-36, Short-Form 36; SF-36 MCS, SF-36 mental component summary score; SF-36 PCS, SF-36 physical 
component summary score; SF-12, Short-Form 12; GIQLI, Gastrointestinal Quality of Life Index;  STAI-X2 State trait Anxiety Inventory instrument; PSKB, Psychiatric and 
Socio-communicative finding standardised clinical interview; BDI, Beck's Depression Inventory instrument; IBD-SES, Inflammatory Bowel Disease Self-Efficacy Scale; 
PSQ-R, Perceived Stress Questionnaire-Recent 
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Appendix table 12: Primary and Secondary Safety Outcomes in Crohn's Disease Randomised Controlled 
Trials 
Reference Outcome Outcome measure 
Induction studies (n=42) 
Medical induction (n=38) 
Wright 1993 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Corticosteroid-associated side effects 
Rutgeerts 1994 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Corticosteroid-associated side effects 
Greenberg 1994 Adverse events Adverse events 
Jewell 1994 Adverse events Study withdrawal due to adverse events  
Death Death due to Crohn's 
Gross 1995 Adverse events Adverse events 
Bar-Meir 1998 Adverse events Steroid side effects 
Sandborn 1999 Adverse events Adverse events 
Fedorak 2000 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Schreiber 2000 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters 
 Adverse events Adverse events 
Schreiber 2001 Adverse events Adverse events 
Sandborn 2001 (1737) Adverse events Adverse events 
Steinhart 2002 Adverse events Adverse drug reactions 
Yacyshyn 2002 Adverse events Adverse events 
Hommes 2002 Adverse events Adverse events  
Adverse events Stopping medication because of adverse 
events 
Ardizzone 2003 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory or ECG parameters 
 
Adverse events Adverse events 
Herfarth 2004 Adverse events Steroid-associated side effects 
Mannon 2004 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Sandborn 2004 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Winter 2004 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters 
Winter 2004 Adverse events Adverse events, serious adverse events, 
infusion reactions and treatment related 
adverse events 
Reinsich 2006 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Prantera 2006 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory or ECG parameters 
Schroder 2006 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Hommes 2006 Adverse events Adverse events 
Lemann 2006 Adverse events Adverse events 
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Reference Outcome Outcome measure 
 Adverse events Steroid side effect score 
Reinshagen 2007 Adverse events AZA related side effects 
Feagan 2008 Adverse events Adverse events 
Van der Woude 2010 Adverse events Adverse events 
Buchman 2010 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Tromm 2011 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Prantera 2012 Adverse events Adverse events 
Sands 2013 Adverse events Adverse events 
Suzuki 2013 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters 
Sandborn 2013 Adverse events Adverse events 
Reinisch 2014** Adverse events Treatment-related adverse events 
Dignass 2014 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Bao 2014 Abnormal laboratory or ECG 
parameters 
Haemoglobin 
D’Haens 2015 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Monteleone 2015 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Surgical induction (n=4) 
Maartense 2006 Adverse events Post-operative complications: minor and 
major 
 Complications of surgery Mean blood loss 
 Complications of surgery Mean operating time (min) 
 Complications of surgery Number of conversions to open surgery 
 Death Mortality 
Mcleod 2009 Adverse events Post-operative complications: minor and 
major  
Complications of surgery Mean time to complete anastomosis (min) 
Grimaud 2010** Adverse events Adverse events 
Molendijk 2015** Adverse events Incidence of surgical interventions and 
infections  
Adverse events Serious adverse events 
Maintenance studies (n=22) 
Maintenance studies of medically induced remission (n=17) 
Malchow 1984 Adverse events Adverse events 
 Adverse events Prolonged fever 
 Death Death due to Crohn's 
Greenberg 1996 Adverse events Adverse events 
Ferguson 1998 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse corticosteroid-associated effects 
Arora 1999 Adverse events Withdrew from study due to side effects 
Cortot 2001 Adverse events Corticosteroid-associated side effects 
Hanauer 2002 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters 
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Reference Outcome Outcome measure  
Adverse events Adverse events, serious adverse events 
and infections 
Mantzaris 2003 Adverse events Time to discontinuation of study drug 
Schultz 2004 Adverse events Possible side effects of the study 
medication 
De Jong 2007 Adverse events Adverse events and corticosteroid-
associated side effects 
Selby 2007 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Feagan 2008 Adverse events Adverse events 
Mantzaris 2009 Adverse events Adverse events 
Rossi 2009 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events and serious adverse 
events 
Valentine 2009 Adverse events Adverse events 
Prantera 2011 Adverse events Adverse events 
Keshav 2013 Adverse events Adverse events, serious adverse events 
and withdrawals due to adverse events 
Feagan 2014 Adverse events Adverse events 
Maintenance studies of surgically induced remission (n=5) 
Hellers 1999 Adverse events Corticosteroid-associated side effects 
Colombel 2001 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
D’Haens 2008 Adverse events Adverse events 
Reinisch 2010 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
Herfarth 2013 Abnormal laboratory or ECG 
parameters 
Abnormal laboratory parameters or ECG 
parameters  
Adverse events Adverse events 
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Appendix table 13: Reporting of Safety Outcomes in Crohn's Disease Randomised Controlled Trials 
Reference Adverse 
events 
Serious adverse 
events 
Treatment 
related 
adverse events 
Treatment 
related serious 
adverse events 
Discontinuation due to:   
Adverse 
events 
Treatment 
failure 
Various 
reasons 
Induction studies        
Medical induction studies 
Greenberg 1988 x 
 
x 
  
x 
 
Wright 1990 
       
Rigaud 1991 
     
x 
 
Ewe 1993 x 
   
x x 
 
Singleton 1993 x 
 
x 
 
x x x 
Wright 1993 x 
 
x 
 
x x x 
Greenberg 1994 x 
 
x 
 
x x x 
Jewell 1994 x x x 
 
x x x 
Royall 1994 
       
Rutgeerts 1994 
 
x x 
 
x x x 
Tremaine 1994 x 
   
x x 
 
Feagan 1995 x 
 
x 
 
x x 
 
Gross 1995 x 
   
x x x 
Mansfield 1995 
     
x x 
Middleton 1995 
      
x 
Frascio 1997 
     
x x 
Targan 1997 x x x 
    
Bar-Meir 1998 
 
x x 
 
x x x 
Colombel 1999 x 
   
x x x 
D’Haens 1999 x 
      
Hond 1999 
       
Present 1999** x x x 
 
x x x 
Sandborn 1999 x x x 
 
x x x 
Fedorak 2000 x x x 
 
x x x 
Schreiber 2000 x x x 
 
x 
 
x 
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Reference Adverse 
events 
Serious adverse 
events 
Treatment 
related 
adverse events 
Treatment 
related serious 
adverse events 
Discontinuation due to:   
Adverse 
events 
Treatment 
failure 
Various 
reasons 
Verma 2000 
       
Carty 2001 x x 
  
x x x 
Goodgame 2001 x 
      
Gordon 2001 x 
   
x 
 
x 
Hawkes 2001 
  
x 
 
x 
 
x 
Leiper 2001 
     
x x 
Lomer 2001 x 
   
x 
 
x 
Sandborn 2001 x x x 
 
x x x 
Sandborn 2001 x x x 
 
x x x 
Schreiber 2001 x x 
 
x x 
  
Arnold 2002 x 
   
x 
 
x 
Hommes 2002 x 
 
x 
 
x x 
 
Sakurai 2002 
       
Steinhart 2002 x x x 
 
x x x 
Tremaine 2002 x x x 
 
x x x 
Yacyshyn 2002 x x x x x x 
 
Ardizzone 2003 x 
 
x 
 
x 
  
Bamba 2003 x 
    
x x 
Ghosh 2003 x x x x x x x 
Herfarth 2004 
 
x x 
    
Ito 2004 x x 
 
x x x x 
Joos 2004 x x 
  
x x x 
Mannon 2004 x x x 
 
x 
  
Sandborn 2004 x x x 
 
x 
  
West 2004** x 
 
x 
 
x 
  
Winter 2004 x x x 
 
x x x 
Korzenik 2005 x x x x x x x 
Lomer 2005 
      
x 
Schreiber 2005 x x x x x x 
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Reference Adverse 
events 
Serious adverse 
events 
Treatment 
related 
adverse events 
Treatment 
related serious 
adverse events 
Discontinuation due to:   
Adverse 
events 
Treatment 
failure 
Various 
reasons 
Hanauer 2006 x x x 
 
x 
  
Herrlinger 2006 x x x 
 
x x x 
Hommes 2006 x x 
     
Lemann 2006 x x x x 
   
Margalit 2006 
  
x 
  
x x 
Prantera 2006 x x x x x 
  
Reinsich 2006 x x x 
    
Rutgeerts 2006 x 
 
x 
    
Schreiber 2006 x x 
 
x 
 
x x 
Schroder 2006 x x x 
 
x x 
 
Hafer 2007 x 
 
x 
    
Hart 2007** x 
 
x 
 
x 
  
Mansfield 2007 x x x x x x x 
Omer 2007 
       
Reinshagen 2007 x 
      
Sandborn 2007 x x x x x 
 
x 
Targan 2007 x x x x x 
  
D’Haens 2008 x x x 
 
x 
 
x 
Feagan 2008 x x x x 
   
Fukuda 2008** x x 
  
x 
 
x 
Leiper 2008 x 
   
x x x 
Sandborn 2008 x x x 
 
x 
  
Thia 2009** x 
 
x 
 
x 
 
x 
Buchman 2010 x x x x x x x 
Dotan 2010 x 
 
x 
 
x 
  
Krebs 2010 
     
x 
 
Maeda 2010 x x 
     
Sands 2010 x x x 
 
x x x 
Steed 2010 x 
     
x 
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Reference Adverse 
events 
Serious adverse 
events 
Treatment 
related 
adverse events 
Treatment 
related serious 
adverse events 
Discontinuation due to:   
Adverse 
events 
Treatment 
failure 
Various 
reasons 
Van der Woude 2010 x x x x x 
  
Benjamin 2011 x x 
   
x 
 
Sandborn 2011 x x x x x 
  
Smith 2011 x 
 
x 
    
Tromm 2011 x 
 
x x x 
  
Hueber 2012 x x 
 
x x x x 
Prantera 2012 x x x x x 
  
Naftali 2013 x 
    
x 
 
Sandborn 2013 x x x 
 
x 
 
x 
Sands 2013 x x x x x 
  
Suzuki 2013 x x x x x 
  
Bao 2014 x x x 
  
x x 
Brotherton 2014 
       
Dewint 2014** x x 
  
x x x 
Dignass 2014 x x x x x 
  
Reinisch 2014** x x 
  
x x 
 
Sandborn 2014 x x x x x 
  
Sands 2014 x x x x x 
  
D’Haens 2015 x x 
  
x x x 
Monteleone 2015 x x 
     
Vande Casteele 2015 x x x 
 
x x x 
Surgical induction studies 
Maartense 2006 x 
 
x 
    
East 2007 
       
Mcleod 2009 
       
Grimaud 2010** x x 
     
Zurbuchen 2013 
  
x 
    
Molendijk 2015** x 
 
x 
    
Maintenance studies        
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Reference Adverse 
events 
Serious adverse 
events 
Treatment 
related 
adverse events 
Treatment 
related serious 
adverse events 
Discontinuation due to:   
Adverse 
events 
Treatment 
failure 
Various 
reasons 
Maintenance studies of medically induced remission  
Singleton 1979 x 
 
x 
 
x x x 
Malchow 1984 x x x 
 
x 
 
x 
Levenstein 1985 x 
      
Bresci 1994 x 
     
x 
Feagan 1994 x 
   
x 
 
x 
Schreiber 1994 x 
   
x 
 
x 
Stange 1995 x x 
  
x x x 
Belluzzi 1996 x 
   
x 
 
x 
Greenberg 1996 x 
 
x 
 
x x 
 
Sutherland 1997 x 
 
x 
 
x 
  
Ferguson 1998 x 
 
x 
 
x x x 
Arora 1999 x 
   
x x x 
Guslandi 2000 
       
Cortot 2001 x x x x x x x 
Green 2001 x x x x x x x 
Mahmud 2001 x 
 
x x x x x 
Hanauer 2002 x x x x x x x 
Mantzaris 2003 x 
 
x 
 
x x 
 
Keller 2004 
      
x 
Sands 2004** x x x 
 
x 
  
Schultz 2004 x 
 
x 
 
x 
  
Vilien 2004 
       
Feagan 2005 x x x 
 
x 
  
Hanauer 2005 
  
x 
 
x x x 
Lemann 2005 x 
      
Sandborn 2005 x x x x x 
  
Feagan 2006 x x x 
 
x 
  
Takagi 2006 x 
     
x 
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Reference Adverse 
events 
Serious adverse 
events 
Treatment 
related 
adverse events 
Treatment 
related serious 
adverse events 
Discontinuation due to:   
Adverse 
events 
Treatment 
failure 
Various 
reasons 
Colombel 2007 x x x 
 
x 
  
De Jong 2007 x x x x 
 
x x 
Ng 2007 
       
Sandborn 2007 x x x 
 
x 
  
Schreiber 2007 x x x x x 
  
Selby 2007 x x 
  
x 
 
x 
Feagan 2008 x 
   
x x x 
Garcia 2008 x 
   
x 
  
Mantzaris 2009 x 
 
x 
    
Rossi 2009 x x x x x 
  
Takagi 2009 
       
Valentine 2009 x x x x x x 
 
Jorgensen 2010 x 
 
x 
    
Sandborn 2010 x x x x x x 
 
Holtmeier 2011 x x x 
    
Prantera 2011 x 
 
x 
 
x x x 
Keefer 2012 
       
Watanabe 2012 x x x 
 
x 
  
Bourreile 2013 x x x x 
   
Keshav 2013 x x 
  
x x x 
Feagan 2014 x x x 
    
Jigaranu 2014 
      
x 
Piche 2014 x 
 
x 
    
Wenzl 2015 x 
 
x 
 
x 
 
x 
Maintenance studies of surgically induced remission  
Brignola 1995 x 
   
x 
  
McLeod 1995 
  
x 
 
x 
  
Ewe 1999 
 
x x 
 
x 
  
Hellers 1999 x x x 
 
x x x 
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Reference Adverse 
events 
Serious adverse 
events 
Treatment 
related 
adverse events 
Treatment 
related serious 
adverse events 
Discontinuation due to:   
Adverse 
events 
Treatment 
failure 
Various 
reasons 
Lochs 2000 x x 
 
x 
   
Colombel 2001 x x 
  
x 
  
Prantera 2002 x 
 
x 
 
x x x 
Caprilli 2003 x 
   
x x x 
Hanauer 2004 x x 
  
x x x 
Marteau 2006 x 
 
x 
 
x 
 
x 
D’Haens 2008 x 
   
x x x 
Regueiro 2009 x 
 
x 
 
x 
  
Reinisch 2010 x x x x x x 
 
Armuzzi 2013 x 
 
x 
 
x 
  
Herfarth 2013 x x x 
 
x 
 
x 
Ren 2013 x x 
  
x 
 
x 
Savarino 2013 x 
    
x 
 
Fedorak 2015 x x x 
 
x 
 
x 
Zhu 2015 x 
 
x 
 
x x x 
Note: Discontinuation of treatment due to treatment failure, insufficient therapeutic effect, exacerbation of Crohn's, development of complications 
of Crohn's, need for additional therapy or surgery, etc.; Discontinuation of treatment due to various reasons, Protocol non-compliance, lost to follow 
up, prohibited medication use, withdrawal of consent, etc. 
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Appendix table 14: Safety-related outcomes in Crohn's disease Randomised Controlled Trials, by most commonly reported MedDRA SOCs 
Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Induction studies 
Medical induction studies 
Greenberg 
1988 
x 
  
x 
    
x 
   
Wright 1990 
            
Rigaud 1991 
            
Ewe 1993 x 
  
x 
 
x x 
     
Singleton 
1993 
x x x x 
 
x x x 
 
x 
  
Wright 1993 x 
  
x 
  
x 
  
x 
  
Greenberg 
1994 
x x x 
 
x 
 
x 
  
x 
  
Jewell 1994 x x 
 
x x 
 
x 
 
x 
   
Royall 1994 
            
Rutgeerts 
1994 
x x x 
 
x x x x 
 
x 
  
Tremaine 
1994 
x x x 
 
x 
 
x 
  
x 
  
Feagan 1995 x x x x x x x 
     
Gross 1995 x 
   
x 
       
Mansfield 
1995 
            
Middleton 
1995 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Frascio 1997 
            
Targan 1997 x x x x x x x 
 
x 
   
Bar-Meir 
1998 
x x 
  
x 
 
x x x x 
  
Colombel 
1999 
x 
           
D’Haens 
1999 
x 
  
x 
    
x 
   
Hond 1999 
            
Present 
1999** 
x x x x x x 
      
Sandborn 
1999 
x x x x x x x x 
    
Fedorak 2000 x x x x x x x x 
 
x x 
 
Schreiber 
2000 
x x x x x x 
 
x 
    
Verma 2000 
            
Carty 2001 x 
     
x 
     
Goodgame 
2001 
x 
       
x 
   
Gordon 2001 x x 
   
x 
 
x x 
   
Hawkes 2001 x x x 
   
x 
     
Leiper 2001 
            
Lomer 2001 x 
      
x 
 
x 
  
Sandborn 
2001 
x x x x x x x 
   
x x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Sandborn 
2001 
x x x 
   
x x 
    
Schreiber 
2001 
x x x 
 
x 
 
x 
 
x 
   
Arnold 2002 x 
  
x x 
 
x x x 
   
Hommes 
2002 
x x x x 
 
x x x 
    
Sakurai 2002 
            
Steinhart 
2002 
x x x x x x x 
     
Tremaine 
2002 
x x x x x 
 
x x 
 
x 
  
Yacyshyn 
2002 
x x x x x x x 
   
x 
 
Ardizzone 
2003 
x x x 
  
x 
 
x 
    
Bamba 2003 
            
Ghosh 2003 x x x x x x x 
 
x 
 
x 
 
Herfarth 
2004 
    
x 
       
Ito 2004 x x x x 
 
x 
   
x 
  
Joos 2004 x x x 
 
x 
  
x x 
   
Mannon 
2004 
x x x x x x 
  
x x 
 
x 
Sandborn 
2004 
x x x x x x x 
   
x x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
West 2004** x x 
 
x x 
 
x 
   
x 
 
Winter 2004 x x x x x 
 
x 
   
x 
 
Korzenik 
2005 
x x x x x x 
 
x 
 
x 
  
Lomer 2005 
            
Schreiber 
2005 
x x x x x x x x 
   
x 
Hanauer 
2006 
x x x x 
 
x 
     
x 
Herrlinger 
2006 
x x x x x 
 
x x 
    
Hommes 
2006 
x x x x x x 
  
x 
  
x 
Lemann 2006 x x x x x x x 
   
x 
 
Margalit 
2006 
            
Prantera 
2006 
x x x x x x x 
 
x x 
  
Reinsich 
2006 
x x x 
 
x x 
      
Rutgeerts 
2006 
x x x x x x 
 
x 
   
x 
Schreiber 
2006 
x x x x x x x 
     
Schroder 
2006 
 
x x x 
 
x x 
    
x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Hafer 2007 x 
           
Hart 2007** 
  
x x 
  
x 
     
Mansfield 
2007 
x x x 
  
x x x 
    
Omer 2007 
            
Reinshagen 
2007 
x 
 
x 
 
x 
       
Sandborn 
2007 
x x x x x x 
   
x 
 
x 
Targan 2007 x x x x 
 
x x 
   
x x 
D’Haens 
2008 
x x x x x x x x x x 
  
Feagan 2008 x x x x 
 
x 
 
x 
   
x 
Fukuda 
2008** 
x 
 
x 
  
x 
      
Leiper 2008 x x 
 
x 
        
Sandborn 
2008 
x x x x x x x 
   
x x 
Thia 2009** x x 
 
x x 
       
Buchman 
2010 
x x x x x x 
 
x 
 
x 
 
x 
Dotan 2010 x x x x x x x x 
    
Krebs 2010 
            
Maeda 2010 x x x x 
    
x 
  
x 
Sands 2010 x x x x x 
    
x 
  
Steed 2010 
 
x x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Van der 
Woude 2010 
x x x x x x x 
  
x 
 
x 
Benjamin 
2011 
x 
         
x 
 
Sandborn 
2011 
x x x x x x 
 
x 
  
x x 
Smith 2011 x x x x 
 
x x 
  
x 
  
Tromm 2011 x x x x x x x 
  
x 
  
Hueber 2012 x x x x x x 
 
x 
 
x 
  
Prantera 
2012 
x x x x 
 
x 
      
Naftali 2013 x x x 
         
Sandborn 
2013 
x x 
 
x x 
   
x x x 
 
Sands 2013 x x x x 
 
x 
  
x 
 
x 
 
Suzuki 2013 x 
 
x x 
 
x x x 
 
x x 
 
Bao 2014 
  
x 
       
x 
 
Brotherton 
2014 
            
Dewint 
2014** 
x x x x 
      
x 
 
Dignass 2014 x x 
 
x 
        
Reinisch 
2014** 
x x x x x 
 
x 
     
Sandborn 
2014 
x x x x 
 
x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Sands 2014 x x x x x x 
 
x 
   
x 
D’Haens 
2015 
x x x 
 
x x 
      
Monteleone 
2015 
x x x x x x 
  
x 
 
x 
 
Vande 
Casteele 
2015 
x x x x x x x 
 
x 
 
x 
 
Surgical induction studies 
Maartense 
2006 
x 
 
x x 
    
x 
 
x 
 
East 2007 
            
Mcleod 2009 
            
Grimaud 
2010** 
   
x 
        
Zurbuchen 
2013 
   
x 
    
x 
 
x 
 
Molendijk 
2015** 
x x x x x x x 
 
x x x x 
Maintenance studies 
Maintenance studies of medically induced remission 
Singleton 
1979 
x x 
 
x x 
 
x x 
 
x 
  
Malchow 
1984 
x x x x x 
 
x x 
 
x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Levenstein 
1985 
x 
 
x 
 
x 
   
x 
 
x 
 
Bresci 1994 x 
 
x 
     
x 
   
Feagan 1994 
 
x x 
  
x x 
    
x 
Schreiber 
1994 
  
x 
         
Stange 1995 x x 
 
x x x x 
     
Belluzzi 1996 x 
           
Greenberg 
1996 
x x x 
   
x x 
 
x 
  
Sutherland 
1997 
x x x x x x 
      
Ferguson 
1998 
x 
   
x x x x x x 
  
Arora 1999 
  
x x 
 
x 
      
Guslandi 
2000 
            
Cortot 2001 x x x 
 
x x x 
 
x 
   
Green 2001 x x x x x x x 
     
Mahmud 
2001 
x 
   
x 
       
Hanauer 
2002 
x x x x x x x 
 
x 
 
x x 
Mantzaris 
2003 
x x 
 
x x 
 
x 
     
Keller 2004 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Sands 
2004** 
x x x x x x 
  
x 
  
x 
Schultz 2004 x 
  
x 
    
x 
   
Vilien 2004 
            
Feagan 2005 x x x x x x x 
 
x 
  
x 
Hanauer 
2005 
 
x 
  
x 
 
x x 
 
x 
  
Lemann 2005 
  
x 
   
x x 
   
x 
Sandborn 
2005 
x x x x x x x 
   
x 
 
Feagan 2006 x x x x x x x x x 
 
x x 
Takagi 2006 x 
         
x 
 
Colombel 
2007 
x x x x x 
      
x 
De Jong 2007 x x x x x 
 
x 
 
x x x 
 
Ng 2007 
            
Sandborn 
2007 
x x x x x x 
     
x 
Schreiber 
2007 
x x x x x x 
 
x 
  
x x 
Selby 2007 x 
  
x x x 
      
Feagan 2008 x x x x x x 
      
Garcia 2008 x 
           
Mantzaris 
2009 
x x 
 
x 
 
x x x 
    
Rossi 2009 x x x x x x x x 
 
x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Takagi 2009 
            
Valentine 
2009 
x x x x x x x 
 
x x 
  
Jorgensen 
2010 
x 
        
x 
  
Sandborn 
2010 
x x x x x 
      
x 
Holtmeier 
2011 
x x x x x x x x 
 
x 
  
Prantera 
2011 
x x x x x x x x 
    
Keefer 2012 
            
Watanabe 
2012 
x x x x x x 
   
x 
 
x 
Bourreile 
2013 
x 
  
x x 
       
Keshav 2013 x x x x x x 
      
Feagan 2014 x x x x x x x x x 
 
x x 
Jigaranu 
2014 
            
Piche 2014 
  
x 
         
Wenzl 2015 x x x x x x 
 
x x x x x 
Maintenance studies of surgically induced remission 
Brignola 
1995 
x 
    
x x 
     
McLeod 1995 x x 
    
x 
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Reference Gastro-
intestinal 
disorders 
Nervous 
system 
disorders 
General 
disorders 
and 
adminis-
tration 
conditio
ns 
Infections 
and infest-
ations 
Musculo-
skeletal 
and 
connective 
tissue 
disorders 
Invest-
igations 
Skin and 
sub-
cutaneous 
tissue 
disorders 
Blood and 
lymphatic 
system 
disorders 
Surgical 
and 
medical 
proced
ures 
Metabolis
m and 
nutrition 
disorders 
Injury, 
poisoni
ng and 
proced
ural 
compli
cations 
Neopla
sms 
benign, 
malign
ant and 
unspec
ified  
Ewe 1999 x x 
   
x x 
 
x 
   
Hellers 1999 x x 
 
x x x x x 
 
x 
  
Lochs 2000 x x x x 
  
x 
   
x x 
Colombel 
2001 
x x x 
 
x x 
 
x x 
 
x 
 
Prantera 
2002 
x 
  
x 
 
x x 
     
Caprilli 2003 x 
 
x 
 
x x 
  
x 
  
x 
Hanauer 
2004 
x x 
  
x x x x x 
   
Marteau 
2006 
x 
 
x 
        
x 
D’Haens 
2008 
x x 
 
x x x x 
     
Regueiro 
2009 
x 
 
x x x x x 
     
Reinisch 
2010 
x x x x x x 
 
x x x x 
 
Armuzzi 2013 x 
       
x 
 
x 
 
Herfarth 
2013 
   
x 
    
x 
 
x 
 
Ren 2013 x 
    
x 
 
x 
    
Savarino 
2013 
x x x x x x x 
 
x 
   
Fedorak 2015 x 
 
x x 
    
x 
 
x 
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Appendix 6:  Additional tables for Chapter 3 
Appendix table 15: Outcomes measured in Crohn’s disease trials in adults identified by systematic review, 
listed by frequency of reporting 
Outcome Studies measuring 
outcome 
No. % (of 181) 
Abdominal pain 169 93.4% 
Faecal consistency 169 93.4% 
Fistula / fissure / abscess 168 92.8% 
Frequency of defecation 168 92.8% 
Abdominal mass 164 90.6% 
Wellbeing 164 90.6% 
Arthralgia 163 90.1% 
Extra-intestinal lesions 163 90.1% 
Fever 163 90.1% 
Arthritis 162 89.5% 
Need for additional steroids, therapy or surgery 162 89.5% 
Uveitis 162 89.5% 
Body mass 157 86.7% 
Blood abnormalities 156 86.2% 
Inflammation 100 55.2% 
Depression 83 45.9% 
Energy levels 82 45.3% 
Happy 82 45.3% 
Relaxed 82 45.3% 
Condition affects attending events 82 45.3% 
Condition affects leisure or sports activities 82 45.3% 
Condition prevents going out 82 45.3% 
Activities limited due to health problems (education) 82 45.3% 
Activities limited due to health problems (work and employment) 82 45.3% 
Appetite 78 43.1% 
Blood with stool 78 43.1% 
Faecal continence 78 43.1% 
Flatulence 78 43.1% 
Nausea 78 43.1% 
Abdominal bloating 77 42.5% 
Angry 77 42.5% 
Embarrassment 77 42.5% 
Feel lack of sympathy 77 42.5% 
Feeling generally well 77 42.5% 
Frustration 77 42.5% 
Irritable 77 42.5% 
Needing to keep close to a toilet 77 42.5% 
Needing to rush to the toilet 77 42.5% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Sex life affected 77 42.5% 
Unable to sleep 77 42.5% 
Upset 77 42.5% 
Wanting to go back to the toilet 77 42.5% 
Worries about being admitted to hospital 77 42.5% 
Worry 77 42.5% 
Lesions / ulcers 63 34.8% 
Perceived tolerability of treatment 57 31.5% 
Disease activity 25 13.8% 
Withdrawal or tapered steroids 22 12.2% 
Steroid dose 19 10.5% 
Anxiety 16 8.8% 
Bodily pain 15 8.3% 
Absorption of nutrients 14 7.7% 
Bathing or dressing yourself 14 7.7% 
Bending, kneeling or stooping 14 7.7% 
Climbing stairs 14 7.7% 
Condition interferes with social life 14 7.7% 
Lifting or carrying groceries 14 7.7% 
Moderate activities 14 7.7% 
Patient perception of health 14 7.7% 
Vigorous activities 14 7.7% 
Walking 14 7.7% 
Perianal pain 12 6.6% 
Fistula discharge 10 5.5% 
General quality of life 10 5.5% 
Perianal disease 10 5.5% 
Perianal induration 10 5.5% 
Restriction of sexual activity 10 5.5% 
Resection 7 3.9% 
Temperature 7 3.9% 
Intestinal permeability 6 3.3% 
Need for hospitalisation 6 3.3% 
Prolonged fever 4 2.2% 
Calorie intake 3 1.7% 
Costs of health care 3 1.7% 
Faecal output 3 1.7% 
Death due to Crohn's 2 1.1% 
Liver function 2 1.1% 
Maintenance of full oral diet 2 1.1% 
Pancreas function 2 1.1% 
Utility 2 1.1% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Ability to cope with the disease 1 0.6% 
Acid reflux 1 0.6% 
Defecation functions 1 0.6% 
Diarrhoea 1 0.6% 
Improvement in psychological status 1 0.6% 
Influence on interpersonal relationships 1 0.6% 
Perceived credibility of treatment 1 0.6% 
Perceived efficacy of treatment 1 0.6% 
Perceived stress 1 0.6% 
Return to full diet 1 0.6% 
Return to liquid diet 1 0.6% 
Rumbling gut 1 0.6% 
Vomiting 1 0.6% 
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Appendix table 16: Adverse events reported in Crohn’s disease trials in adults identified by systematic 
review, listed by frequency of reporting 
Outcome Studies measuring 
outcome 
No. % (of 181) 
Discrete adverse events 
Abdominal pain 102 56.4% 
Headache 96 53.0% 
Crohn's disease 89 49.2% 
Nausea 88 48.6% 
Vomiting 67 37.0% 
Diarrhoea 59 32.6% 
Arthralgia 58 32.0% 
Pyrexia 56 30.9% 
Infection 53 29.3% 
Death 48 26.5% 
Fatigue 37 20.4% 
Nasopharyngitis 35 19.3% 
Drug specific antibody present 33 18.2% 
Anal abscess 33 18.2% 
Rash 31 17.1% 
Dizziness 29 16.0% 
Acne 28 15.5% 
Upper respiratory tract infection 27 14.9% 
Back pain 24 13.3% 
Intestinal obstruction 22 12.2% 
Urinary tract infection 21 11.6% 
Hospitalisation 21 11.6% 
Injection site reaction 20 11.0% 
Cushingoid 20 11.0% 
Pneumonia 20 11.0% 
Myalgia 19 10.5% 
Dyspepsia 18 9.9% 
Asthenia 18 9.9% 
Insomnia 17 9.4% 
Flatulence 17 9.4% 
Influenza 17 9.4% 
Pain 16 8.8% 
Abdominal distension 16 8.8% 
Abscess 16 8.8% 
Anaemia 15 8.3% 
Opportunistic infection  15 8.3% 
Pancreatitis 14 7.7% 
Injection site pain 13 7.2% 
Infusion related reaction 13 7.2% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Leukopenia 13 7.2% 
Pruritus 13 7.2% 
Surgery 13 7.2% 
Depression 12 6.6% 
Cough 12 6.6% 
Alopecia 12 6.6% 
Neoplasm malignant 12 6.6% 
Tuberculosis 12 6.6% 
Decreased appetite 11 6.1% 
Abdominal pain upper 11 6.1% 
Hypersensitivity 11 6.1% 
Alanine aminotransferase increased 11 6.1% 
Chills 11 6.1% 
Fistula 11 6.1% 
Double stranded DNA antibody 10 5.5% 
Transaminases increased 10 5.5% 
Hirsutism 10 5.5% 
Sinusitis 10 5.5% 
Viral infection 10 5.5% 
Influenza like illness 10 5.5% 
C-reactive protein increased 9 5.0% 
Thrombocytopenia 9 5.0% 
Ileus 9 5.0% 
Constipation 9 5.0% 
Lipohypertrophy 9 5.0% 
Skin striae 9 5.0% 
Paraesthesia 9 5.0% 
Abdominal abscess 9 5.0% 
Dysgeusia 8 4.4% 
Proctalgia 8 4.4% 
Antinuclear antibody positive 8 4.4% 
Lupus-like syndrome 8 4.4% 
Flushing 8 4.4% 
Pharyngitis 8 4.4% 
Sepsis 8 4.4% 
Oedema 8 4.4% 
Chest pain 7 3.9% 
Laryngeal pain 7 3.9% 
Increased tendency to bruise 7 3.9% 
Lymphoma 7 3.9% 
Gastroenteritis 7 3.9% 
Respiratory tract infection 7 3.9% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Oedema peripheral 7 3.9% 
Hypertension 6 3.3% 
Weight decreased 6 3.3% 
Liver function test abnormal 6 3.3% 
Blood creatinine increased 6 3.3% 
Dehydration 6 3.3% 
Cushing's syndrome 6 3.3% 
Pregnancy 6 3.3% 
Joint swelling 6 3.3% 
Urticaria 6 3.3% 
Intestinal resection 6 3.3% 
Injection site erythema 5 2.8% 
Post procedural complication 5 2.8% 
Tachycardia 5 2.8% 
Hypotension 5 2.8% 
Haemoglobin decreased 5 2.8% 
Platelet count decreased 5 2.8% 
Systematic lupus erythematosus 5 2.8% 
Demyelination 5 2.8% 
Dyspnoea 5 2.8% 
Abdominal mass 5 2.8% 
Small intestinal obstruction 5 2.8% 
Aspartate aminotransferase increased 5 2.8% 
Liver function test increased 5 2.8% 
Blood cortisol decreased 5 2.8% 
Nephrolithiasis 5 2.8% 
Arthritis 5 2.8% 
Muscle spasms 5 2.8% 
Hypertrichosis 5 2.8% 
Aphthous ulcer 5 2.8% 
Rectal haemorrhage 5 2.8% 
Anal fistula 5 2.8% 
Adenocarcinoma 5 2.8% 
Clostridium difficile infection 5 2.8% 
Bronchitis 5 2.8% 
Gastroenteritis viral 5 2.8% 
Injection site bruising 4 2.2% 
Injection site irritation 4 2.2% 
Injection site pruritus 4 2.2% 
Overdose 4 2.2% 
Malaise 4 2.2% 
Cataract 4 2.2% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Vision blurred 4 2.2% 
Pulmonary embolism 4 2.2% 
Deep vein thrombosis 4 2.2% 
Lymphopenia 4 2.2% 
Neutropenia 4 2.2% 
Type IV hypersensitivity reaction 4 2.2% 
White blood cell count decreased 4 2.2% 
White blood cell count increased 4 2.2% 
Weight increased 4 2.2% 
Blood alkaline phosphatase increased 4 2.2% 
Hepatic enzyme increased 4 2.2% 
Renal impairment  4 2.2% 
Tremor 4 2.2% 
Gastrointestinal haemorrhage 4 2.2% 
Squamous cell carcinoma 4 2.2% 
Vulvovaginal candidiasis 4 2.2% 
Conjunctivitis 4 2.2% 
Peritonitis 4 2.2% 
Rhinitis 4 2.2% 
Herpes zoster 4 2.2% 
Injection site inflammation 3 1.7% 
Drug intolerance 3 1.7% 
Syncope 3 1.7% 
Confusional state 3 1.7% 
Mood swings 3 1.7% 
Completed suicide 3 1.7% 
Vertigo 3 1.7% 
Migraine 3 1.7% 
Chest discomfort 3 1.7% 
Musculoskeletal pain 3 1.7% 
Oropharyngeal pain 3 1.7% 
Bone pain 3 1.7% 
Haematocrit decreased 3 1.7% 
Subileus 3 1.7% 
Diarrhoea haemorrhagic 3 1.7% 
Gastrointestinal sounds abnormal 3 1.7% 
Amylase increased 3 1.7% 
Lipase increased 3 1.7% 
Hyperglycaemia 3 1.7% 
Adrenal disorder 3 1.7% 
Muscular weakness 3 1.7% 
Dermatitis 3 1.7% 
371 
 
Outcome Studies measuring 
outcome 
No. % (of 181) 
Eczema 3 1.7% 
Erythema 3 1.7% 
Skin disorder 3 1.7% 
Hyperhidrosis 3 1.7% 
Hair growth abnormal 3 1.7% 
Anal fissure 3 1.7% 
Haematochezia 3 1.7% 
Enteritis 3 1.7% 
Intestinal perforation 3 1.7% 
Hepatotoxicity 3 1.7% 
Basal cell carcinoma 3 1.7% 
Stenosis 3 1.7% 
Oral candidiasis 3 1.7% 
Gastrointestinal infection 3 1.7% 
Peritoneal abscess 3 1.7% 
Vaginal infection 3 1.7% 
Herpes simplex 3 1.7% 
Herpes virus infection 3 1.7% 
Oral herpes 3 1.7% 
Progressive multifocal leukoencephalopathy 3 1.7% 
Fistula repair 3 1.7% 
Infusion site reaction 2 1.1% 
Injection site haemorrhage 2 1.1% 
Injection site rash 2 1.1% 
Thermal burn 2 1.1% 
Anastomic leak 2 1.1% 
Procedural pain 2 1.1% 
Serum sickness 2 1.1% 
Increased appetite 2 1.1% 
Amnesia 2 1.1% 
Affect lability 2 1.1% 
Mood altered 2 1.1% 
Psychotic disorder 2 1.1% 
Oral pain 2 1.1% 
Pain in extremity 2 1.1% 
Palpitations 2 1.1% 
Myocardial infarction 2 1.1% 
Cardiac failure congestive 2 1.1% 
Venous thrombosis 2 1.1% 
Hot flush 2 1.1% 
Phlebitis 2 1.1% 
Iron deficiency anaemia 2 1.1% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Thrombocytosis 2 1.1% 
Red blood cell sedimentation rate increased 2 1.1% 
Hypersensitivity vasculitis 2 1.1% 
Leukocytosis 2 1.1% 
Eosinophil count increased 2 1.1% 
Lymphocyte count decreased 2 1.1% 
Lymphocyte count increased 2 1.1% 
Monocyte count increased 2 1.1% 
Neutrophil count increased 2 1.1% 
Interleukin level increased 2 1.1% 
Multiple sclerosis 2 1.1% 
Pneumothorax 2 1.1% 
Dry mouth 2 1.1% 
Ileus paralytic 2 1.1% 
Abdominal tenderness 2 1.1% 
Gamma-glutamyltransferase increased 2 1.1% 
Blood albumin decreased  2 1.1% 
Hyperamylasasemia 2 1.1% 
Bone density decreased 2 1.1% 
Blood calcium decreased 2 1.1% 
Hypokalaemia 2 1.1% 
Iron deficiency 2 1.1% 
Body temperature increased 2 1.1% 
Hyperthyroidism 2 1.1% 
Blood cortisol abnormal 2 1.1% 
Dysmenorrhoea 2 1.1% 
Menstrual disorder 2 1.1% 
Skin lesion 2 1.1% 
Erythema nodosum 2 1.1% 
Rosacea 2 1.1% 
Night sweats 2 1.1% 
Tooth disorder 2 1.1% 
Pulmonary mass  2 1.1% 
Gastric ulcer 2 1.1% 
Anorectal swelling 2 1.1% 
Anal fistula 2 1.1% 
Melaena 2 1.1% 
Intestinal stenosis 2 1.1% 
Haemorrhoids thrombosed 2 1.1% 
Colon cancer 2 1.1% 
Nephropathy toxic 2 1.1% 
Breast cancer 2 1.1% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Prostate cancer 2 1.1% 
Anogenital warts 2 1.1% 
Face oedema 2 1.1% 
Neoplasm 2 1.1% 
Furuncle 2 1.1% 
Candida infection 2 1.1% 
Oral fungal infection 2 1.1% 
Abdominal wall abscess 2 1.1% 
Appendicitis 2 1.1% 
Ear infection 2 1.1% 
Pelvic abscess 2 1.1% 
Postoperative wound infection 2 1.1% 
Psoas abscess 2 1.1% 
Pyelonephritis 2 1.1% 
Skin infection 2 1.1% 
Tonsillitis 2 1.1% 
Wound infection 2 1.1% 
Anogenital warts 2 1.1% 
Hepatitis C 2 1.1% 
Colectomy 2 1.1% 
Ileostomy 2 1.1% 
Abscess drainage 2 1.1% 
Antibiotic therapy 2 1.1% 
Elective surgery 2 1.1% 
Contusion 2 1.1% 
Road traffic accident 2 1.1% 
Stab wound 2 1.1% 
Infusion site erythema 1 0.6% 
Infusion site irritation 1 0.6% 
Infusion site pain 1 0.6% 
Infusion site phlebitis 1 0.6% 
Injection site haematoma 1 0.6% 
Vessel puncture site bruise 1 0.6% 
Subcutaneous haematoma 1 0.6% 
Feeding tube complication 1 0.6% 
Intestinal anastomosis complication 1 0.6% 
Post procedural haematoma 1 0.6% 
Post procedural haemorrhage 1 0.6% 
Postoperative ileus 1 0.6% 
Procedural complication 1 0.6% 
Procedural intestinal perforation 1 0.6% 
Stomal hernia 1 0.6% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Sudden cardiac death 1 0.6% 
Feeling abnormal 1 0.6% 
Diabetic coma 1 0.6% 
Loss of consciousness 1 0.6% 
Seizure 1 0.6% 
Hyperphagia 1 0.6% 
Substance abuse 1 0.6% 
Lethargy 1 0.6% 
Somnolence 1 0.6% 
Abnormal dreams 1 0.6% 
Sleep disorder 1 0.6% 
Disturbance in attention 1 0.6% 
Agitation 1 0.6% 
Ataxia 1 0.6% 
Anxiety 1 0.6% 
Nervousness 1 0.6% 
Depression suicidal 1 0.6% 
Irritability 1 0.6% 
Suicide attempt 1 0.6% 
Photophobia 1 0.6% 
Amblyopia 1 0.6% 
Visual acuity reduced 1 0.6% 
Visual impairment 1 0.6% 
Dry eye 1 0.6% 
Tinnitus 1 0.6% 
Facial pain 1 0.6% 
Biliary colic 1 0.6% 
Musculoskeletal chest pain 1 0.6% 
Renal colic 1 0.6% 
Breast pain 1 0.6% 
Neuralgia 1 0.6% 
Post herpetic neuralgia 1 0.6% 
Sciatica 1 0.6% 
Tendon pain 1 0.6% 
Sensory loss 1 0.6% 
Sinus tachycardia 1 0.6% 
Ventricular extrasystoles 1 0.6% 
Ventricular fibrillation 1 0.6% 
Cyanosis 1 0.6% 
Angina pectoris 1 0.6% 
Coronary artery disease 1 0.6% 
Myocardial ischaemia 1 0.6% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Cardiac failure 1 0.6% 
Electrocardiogram QT prolonged 1 0.6% 
Cerebrovascular accidents 1 0.6% 
Superior sagittal sinus thrombosis 1 0.6% 
Peripheral coldness 1 0.6% 
Circulatory collapse 1 0.6% 
Thrombosis 1 0.6% 
Flushing 1 0.6% 
Haematoma 1 0.6% 
Haemorrhage 1 0.6% 
Blood pressure diastolic decreased 1 0.6% 
Blood pressure diastolic increased 1 0.6% 
Blood pressure increased 1 0.6% 
Orthostatic hypotension 1 0.6% 
Hypertensive crisis 1 0.6% 
Hyperbilirubinaemia 1 0.6% 
Anaemia macrocytic 1 0.6% 
Cytopenia 1 0.6% 
Pancytopenia 1 0.6% 
Hypercoagulation 1 0.6% 
Blood disorder 1 0.6% 
Haemolytic anaemia 1 0.6% 
Splenomegaly 1 0.6% 
Eosinophilia 1 0.6% 
Granulocytopenia 1 0.6% 
Activated partial thromboplastin time prolonged 1 0.6% 
Prothrombin time shortened 1 0.6% 
Reticulocyte count increased 1 0.6% 
Myelodysplastic syndrome 1 0.6% 
Natural killer-cell lymphoblastic lymphoma 1 0.6% 
Rhinitis allergic 1 0.6% 
Lymphoedema 1 0.6% 
Lymphocytosis 1 0.6% 
Neutrophilia 1 0.6% 
Drug hypersensitivity 1 0.6% 
Seasonal allergy 1 0.6% 
Autoimmune disorder 1 0.6% 
Cytokine release syndrome 1 0.6% 
T-lymphocyte count decreased 1 0.6% 
Optic neuritis 1 0.6% 
Multiple sclerosis relapse 1 0.6% 
Central nervous system lesion 1 0.6% 
376 
 
Outcome Studies measuring 
outcome 
No. % (of 181) 
Asthma 1 0.6% 
Bronchospasm 1 0.6% 
Acute pulmonary oedema 1 0.6% 
Pneumonitis 1 0.6% 
Dyspnoea exertional 1 0.6% 
Retching 1 0.6% 
Megacolon 1 0.6% 
Large intestinal obstruction 1 0.6% 
Abdominal adhesions 1 0.6% 
Frequent bowel movements 1 0.6% 
Rectal tenesmus 1 0.6% 
Abnormal faeces 1 0.6% 
Mucous stools 1 0.6% 
Abnormal loss of weight 1 0.6% 
Malnutrition 1 0.6% 
Obesity 1 0.6% 
Gastrooesophageal disease 1 0.6% 
Gastrooesophageal reflux disease 1 0.6% 
Abdominal symptom 1 0.6% 
Blood creatine phosphokinase increased 1 0.6% 
Pancreatic enzymes increased 1 0.6% 
Alanine aminotransferase abnormal 1 0.6% 
Blood bilirubin increased 1 0.6% 
Hepatic enzyme abnormal 1 0.6% 
Blood triglycerides decreased  1 0.6% 
Low density lipoprotein 1 0.6% 
Blood glucose abnormal  1 0.6% 
Retinol binding protein decreased 1 0.6% 
Protein total decreased 1 0.6% 
Hyperlipidaemia 1 0.6% 
Hyperuricaemia 1 0.6% 
Blood potassium decreased 1 0.6% 
Serum ferritin decreased 1 0.6% 
Hyperphosphataemia 1 0.6% 
Hypocalcaemia 1 0.6% 
Fluid retention 1 0.6% 
Apoptosis 1 0.6% 
Vitamin D deficiency 1 0.6% 
Osteoporosis 1 0.6% 
Adrenal suppression 1 0.6% 
Hypoglycaemia 1 0.6% 
Chromaturia 1 0.6% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Haematuria 1 0.6% 
Libido decreased 1 0.6% 
Sexual dysfunction 1 0.6% 
Metrorrhagia 1 0.6% 
Abortion spontaneous 1 0.6% 
Ectopic pregnancy 1 0.6% 
Unintended pregnancy 1 0.6% 
Joint stiffness 1 0.6% 
Polyarthritis 1 0.6% 
Muscle atrophy 1 0.6% 
Muscle contractions involuntary 1 0.6% 
Neurological symptom 1 0.6% 
Dermatitis atopic 1 0.6% 
Dry skin 1 0.6% 
Lichen planus 1 0.6% 
Photosensitivity reaction 1 0.6% 
Rash erythematous 1 0.6% 
Rash generalised 1 0.6% 
Rash maculo-papular 1 0.6% 
Skin ulcer 1 0.6% 
Ecchymosis 1 0.6% 
Purpura 1 0.6% 
Anal pruritus 1 0.6% 
Anorectal discomfort 1 0.6% 
Paraesthesia oral 1 0.6% 
Glossodynia 1 0.6% 
Burning sensation 1 0.6% 
Skin burning sensation 1 0.6% 
Parkinson's disease 1 0.6% 
Ependymoma 1 0.6% 
Neuropathy peripheral 1 0.6% 
Polyneuropathy 1 0.6% 
Eyelid oedema 1 0.6% 
Laryngeal oedema 1 0.6% 
Nasal mucosal ulcer 1 0.6% 
Sinus congestion 1 0.6% 
Tooth discolouration 1 0.6% 
Gingival hyperplasia 1 0.6% 
Glossitis 1 0.6% 
Mouth ulceration 1 0.6% 
Lung neoplasm malignant 1 0.6% 
lung cyst 1 0.6% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Haematological malignancy 1 0.6% 
Gastritis 1 0.6% 
Peptic ulcer 1 0.6% 
Peptic ulcer haemorrhage 1 0.6% 
Stomatitis 1 0.6% 
Anal inflammation 1 0.6% 
Colonic fistula 1 0.6% 
Anal haemorrhage 1 0.6% 
Haematemesis 1 0.6% 
Lower gastrointestinal haemorrhage 1 0.6% 
Colitis 1 0.6% 
Anal stenosis 1 0.6% 
Large intestinal stenosis 1 0.6% 
Small intestinal stenosis 1 0.6% 
Duodenal ulcer 1 0.6% 
Ileal ulcer 1 0.6% 
Small intestinal ulcer haemorrhage 1 0.6% 
Colorectal cancer 1 0.6% 
Rectal adenocarcinoma 1 0.6% 
Rectal cancer 1 0.6% 
Pancreatitis acute 1 0.6% 
Hepatitis acute 1 0.6% 
Hepatomegaly 1 0.6% 
Cholelithiasis 1 0.6% 
Papillary thyroid cancer 1 0.6% 
Renal cell carcinoma 1 0.6% 
Glomerulonephritis 1 0.6% 
Renal infarct 1 0.6% 
Ureteric obstruction 1 0.6% 
Bladder cancer 1 0.6% 
Ovarian cancer 1 0.6% 
Ovarian cyst 1 0.6% 
Cervix carcinoma 1 0.6% 
Breast hyperplasia 1 0.6% 
Bartholin's cyst 1 0.6% 
Benign neoplasm of epididymis 1 0.6% 
Testis cancer 1 0.6% 
Scrotal oedema 1 0.6% 
Prostatitis 1 0.6% 
Inguinal hernia 1 0.6% 
Hernia 1 0.6% 
Melanocytic naevus 1 0.6% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Neoplasm skin 1 0.6% 
Skin cancer 1 0.6% 
Multiple organ dysfunction syndrome 1 0.6% 
Adenoma benign 1 0.6% 
Carcinoma in situ 1 0.6% 
Campylobacter infection 1 0.6% 
Cellulitis 1 0.6% 
Clostridia infection 1 0.6% 
Escherichia infection 1 0.6% 
Legionella infection 1 0.6% 
Listeriosis 1 0.6% 
Nocardiosis 1 0.6% 
Staphylococcal sepsis 1 0.6% 
Aspergillus infection 1 0.6% 
Blastomycosis 1 0.6% 
Coccidioidomycosis 1 0.6% 
Fungal infection 1 0.6% 
Histoplasmosis 1 0.6% 
Histoplasmosis disseminated 1 0.6% 
Mucocutaneous candidiasis 1 0.6% 
Oesophageal candidiasis 1 0.6% 
Onychomycosis 1 0.6% 
Pneumocystis jirovecii pneumonia 1 0.6% 
Abdominal infection 1 0.6% 
Abscess intestinal  1 0.6% 
Abscess jaw 1 0.6% 
Appendiceal abscess 1 0.6% 
Bacteraemia 1 0.6% 
Catheter site infection 1 0.6% 
Device related sepsis 1 0.6% 
Ear lobe infection 1 0.6% 
Eye infection 1 0.6% 
Hordeolum 1 0.6% 
Infectious colitis 1 0.6% 
Liver abscess 1 0.6% 
Mesenteric abscess 1 0.6% 
Otitis media 1 0.6% 
Pelvic inflammatory disease 1 0.6% 
Perirectal abscess 1 0.6% 
Pilonidal cyst 1 0.6% 
Pyuria 1 0.6% 
Rectal abscess 1 0.6% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Scrotal infections 1 0.6% 
Subcutaneous abscess 1 0.6% 
Urosepsis 1 0.6% 
Vaginal infections 1 0.6% 
Vulval abscess 1 0.6% 
Pulmonary tuberculosis 1 0.6% 
Cytomegalovirus hepatitis 1 0.6% 
Cytomegalovirus infection 1 0.6% 
Epstein-Barr virus 1 0.6% 
HIV infection 1 0.6% 
Lower respiratory tract infection viral 1 0.6% 
Meningitis viral 1 0.6% 
Respiratory tract infection viral 1 0.6% 
Varicella zoster pneumonia 1 0.6% 
Abdominal hernia repair 1 0.6% 
Appendicectomy 1 0.6% 
Hernia repair 1 0.6% 
Ileostomy closure 1 0.6% 
Small intestinal resection 1 0.6% 
Transfusion 1 0.6% 
Dental operation 1 0.6% 
Tooth extraction 1 0.6% 
Toothache 1 0.6% 
Adhesiolysis 1 0.6% 
Bed rest 1 0.6% 
Drain placement 1 0.6% 
Vasodilation procedure 1 0.6% 
Swelling 1 0.6% 
Swelling face 1 0.6% 
Concomitant disease aggravated 1 0.6% 
Fracture 1 0.6% 
Hand fracture 1 0.6% 
Spinal compression fracture 1 0.6% 
Arthropod sting 1 0.6% 
Adverse event categories 
Discontinuation of treatment due to adverse events 102 56.4% 
Total adverse events 93 51.4% 
Discontinuation of treatment due to various reasons (Protocol non-
compliance, lost to follow up, prohibited medication use, 
withdrawal of consent) 
83 45.9% 
Total serious adverse events 76 42.0% 
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Outcome Studies measuring 
outcome 
No. % (of 181) 
Discontinuation of treatment due to treatment failure (insufficient 
therapeutic effect, exacerbation of Crohn's, development of 
complications of Crohn's, need for additional therapy or surgery) 
75 41.4% 
Total treatment related adverse events 66 36.5% 
Total treatment related serious adverse events 31 17.1% 
Discontinuation of treatment due to treatment related adverse 
events 
25 13.8% 
Discontinuation of treatment due to serious adverse events 7 3.9% 
Discontinuation of treatment due to treatment related serious 
adverse events 
2 1.1% 
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Appendix table 17: Crohn’s disease activity index constituent outcomes and mapped Filter 2.0 domains 
Item 
no. 
Item description ICF outcome code 
level 
Outcome Domain 
1st 2nd  3rd 
1 No. of liquid or very soft stools per day (liquid or very 
soft stools) 
  b5251 Faecal consistency ICF b525: Defecation functions 
1 No. of liquid or very soft stools per day (frequency of 
stools) 
  b5252 Frequency of defecation ICF b525: Defecation functions 
1-A Adjustment if using diarrhoea-control medications    Need for additional 
therapy 
Individual resource use 
2 Abdominal pain rating (0-3)   b28012 Pain in stomach or 
abdomen 
ICF b28012: Pain in stomach 
or abdomen 
3 General well-being rating (0-4)    Wellbeing Quality of life 
4 No. of 6 
types, other 
occasional 
Crohn's 
findings 
The presence of joint pains 
(arthralgia) or frank arthritis 
  b28016 Pain in joints ICF b28016: Pain in joints 
 s770  Additional musculoskeletal 
structures related to 
movement 
ICF s770: Additional 
musculoskeletal structures 
related to movement 
Inflammation of the iris or uveitis   s2202 Iris ICF s220: Structure of eyeball 
Presence of erythema nodosum, 
pyoderma gangrenosum or aphthous 
ulcers 
 s810  Structure of areas of skin ICF s810: Structure of areas of 
skin 
Anal fissures, fistulae or abscesses  s540  Structure of intestine ICF s540: Structure of intestine 
Other fistulae  s540  Structure of intestine ICF s540: Structure of intestine 
Fever during the previous week   b5500 Body temperature ICF b5500: Body temperature 
5 Abdominal mass (CDAI = 0, 2, 5; HBI = 1-4)  s540  Structure of intestine ICF s540: Structure of intestine 
6 Haematocrit, % decrease from expected  b430  Haematological system 
functions 
ICF b430: Haematological 
system functions 
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Item 
no. 
Item description ICF outcome code 
level 
Outcome Domain 
1st 2nd  3rd 
7 Body weight, % decrease from expected  b530  Weight maintenance 
functions 
ICF b530: Weight maintenance 
functions 
 
  
384 
 
Appendix table 18: Inflammatory Bowel Disease Questionnaire constituent outcomes and mapped Filter 2.0 domains 
Item 
no. 
Item description IBDQ 
score 
ICF code level Outcome Domain 
1st 2nd  3rd 
1 Runny bowel movements Bowel   b5251 Faecal consistency ICF b525: Defecation functions 
5 Frequent bowel movements Bowel    b5252 Frequency of defecation ICF b525: Defecation functions 
9 Bowels open accidentally Bowel   b5253 Faecal continence ICF b525: Defecation functions 
13 Abdominal pain Bowel   b28012 Pain in stomach or abdomen ICF b28012: Pain in stomach or abdomen 
17 Problems with wind Bowel   b5254 Flatulence ICF b525: Defecation functions 
20 Bloated abdomen Bowel   b5351 Feeling bloated ICF b535: Sensations associated with the 
digestive system 
22 Notice blood with bowel 
movement 
Bowel  b525  Defecation functions ICF b525: Defecation functions 
24 Want to go back to the toilet 
immediately after emptying 
bowel 
Bowel   d5301 Regulating defecation ICF d5301: Regulating defecation 
26 Have to rush to toilet Bowel   d5301 Regulating defecation ICF d5301: Regulating defecation 
29 Feeling sick Bowel   b5350 Sensation of nausea ICF b535: Sensations associated with the 
digestive system 
3 Feeling frustrated Emotion  b152  Emotional functions ICF b152: Emotional functions 
7 Worried about being admitted 
to hospital 
Emotion  b152  Emotional functions ICF b152: Emotional functions 
11 Need to keep close to a toilet Emotion   d5301 Regulating defecation ICF d5301: Regulating defecation 
15 Feeling depressed Emotion  b152  Emotional functions ICF b152: Emotional functions 
19 Feeling worried Emotion  b152  Emotional functions ICF b152: Emotional functions 
21 Feeling relaxed Emotion  b152  Emotional functions ICF b152: Emotional functions 
23 Feeling embarrassed by bowel 
problem 
Emotion  b152  Emotional functions ICF b152: Emotional functions 
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Item 
no. 
Item description IBDQ 
score 
ICF code level Outcome Domain 
1st 2nd  3rd 
25 Feeling upset Emotion  b152  Emotional functions ICF b152: Emotional functions 
27 Feeling angry Emotion  b152  Emotional functions ICF b152: Emotional functions 
30 Feeling irritable Emotion  b152  Emotional functions ICF b152: Emotional functions 
31 Feeling lack of sympathy from 
others 
Emotion  b152  Emotional functions ICF b152: Emotional functions 
32 Feeling happy Emotion  b152  Emotional functions ICF b152: Emotional functions 
4 Unable to attend school or work Social  d810-
d839 
d840-
d859 
 Education 
Work and employment 
ICF d810-d839: Education 
ICF d840-d859: Work and employment 
8 Prevent going out Social  d920  Recreation and leisure ICF d9: Community, social and civic life 
12 Leisure or sports activities 
affected 
Social  d920  Recreation and leisure ICF d9: Community, social and civic life 
16 Avoid attending events Social  d910  Community life ICF d9: Community, social and civic life 
28 Sex life affected Social  d640  Sexual functions ICF d640: Sexual functions 
2 Feeling tired Systemic   b1300 Energy level ICF b130: Energy and drive functions 
6 Feeling full of energy Systemic   b1300 Energy level ICF b130: Energy and drive functions 
10 Feeling generally unwell Systemic    Feeling generally well Patient perception of health 
14 Unable to sleep Systemic  b134  Sleep functions ICF b134: Sleep functions 
18 Feeling off food Systemic   b1302 Appetite ICF b130: Energy and drive functions 
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Appendix table 19: Short Form-36 constituent outcomes and mapped Filter 2.0 domains 
Item 
no. 
Item description ICF code level Outcome Domain 
1st 2nd  3rd 
GENERAL HEALTH 
1 In general, how would you rate your health?    Perception of health Patient perception of health 
2 Compared to one year ago, how would you rate 
your health in general now? 
   Perception of health Patient perception of health 
LIMITATIONS OF ACTIVITIES 
Does your health limit you in these activities? If so, how much? 
3 Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
  d9201 Sports ICF d9: Community, social and civic life 
 d430  Lifting and carrying objects ICF d4: Mobility 
4 Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing 
golf 
  d9201 Sports ICF d9: Community, social and civic life 
 d640 
 
 Doing housework ICF d640: Doing housework 
5 Lifting or carrying groceries  d430  Lifting and carrying objects ICF d4: Mobility 
6 Climbing several flights of stairs   d4551 Climbing ICF d4: Mobility 
7 Climbing one flight of stairs   d4551 Climbing ICF d4: Mobility 
8 Bending, kneeling, or stooping  d410  Changing basic body position ICF d4: Mobility 
9 Walking more than a mile   d4501 Walking long distances ICF d4: Mobility 
10 Walking several blocks  d450  Walking ICF d4: Mobility 
11 Walking one block   d4500 Walking short distances ICF d4: Mobility 
12 Bathing or dressing yourself (bathing)  d510  Washing oneself ICF d5: Self care 
Bathing or dressing yourself (dressing)  d540  Dressing ICF d5: Self care 
PHYSICAL HEALTH PROBLEMS 
Have you had any of the following problems with your work or other regular daily activities as a result of your physical health? 
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Item 
no. 
Item description ICF code level Outcome Domain 
1st 2nd  3rd 
13 Cut down the amount of time you spent on work 
or other activities 
 d810-
d839 
d840-
d859 
 Education 
Work and employment 
ICF d810-d839: Education  
ICF d840-d859: Work and employment 
14 Accomplished less than you would like 
15 Were limited in the kind of work or other 
activities 
16 Had difficulty performing the work or other 
activities (for example, it took extra effort) 
EMOTIONAL HEALTH PROBLEMS 
Have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
17 Cut down the amount of time you spent on work 
or other activities 
 d810-
d839 
d840-
d859 
 Education 
Work and employment 
ICF d810-d839: Education  
ICF d840-d859: Work and employment 
18 Accomplished less than you would like 
19 Didn't do work or other activities as carefully as 
usual 
SOCIAL ACTIVITIES 
20 Emotional problems interfered with your normal 
social activities with family, friends, neighbours, 
or groups? 
d9 
 
  Community, social and civic 
life 
Community, social and civic life 
PAIN 
21 How much bodily pain have you had during the 
past 4 weeks? 
 b280 
 
 Sensation of pain ICF b280: Sensation of pain 
22 During the past 4 weeks, how much did pain 
interfere with your normal work (including both 
work outside the home and housework)? 
 b280 
 
 Sensation of pain ICF b280: Sensation of pain 
ENERGY AND EMOTIONS 
23 Did you feel full of pep?   b1300 Energy level ICF b130: Energy and drive functions 
388 
 
Item 
no. 
Item description ICF code level Outcome Domain 
1st 2nd  3rd 
24 Have you been a very nervous person?  b152  Emotional functions Emotional functions 
25 Have you felt so down in the dumps that nothing 
could cheer you up? 
 b152  Emotional functions Emotional functions 
26 Have you felt calm and peaceful?  b152  Emotional functions Emotional functions 
27 Did you have a lot of energy?   b1300 Energy level ICF b130: Energy and drive functions 
28 Have you felt downhearted and blue?  b152  Emotional functions Emotional functions 
29 Did you feel worn out?   b1300 Energy level ICF b130: Energy and drive functions 
30 Have you been a happy person?  b152  Emotional functions Emotional functions 
31 Did you feel tired?   b1300 Energy level ICF b130: Energy and drive functions 
SOCIAL ACTIVITIES 
32 During the past 4 weeks, how much of the time 
has your physical health or emotional problems 
interfered with your social activities (like visiting 
with friends, relatives, etc.)? 
d9 
 
  Community, social and civic 
life 
Community, social and civic life 
GENERAL HEALTH 
33 I seem to get sick a little easier than other people    Perception of health Patient perception of health 
34 I am as healthy as anybody I know    Perception of health Patient perception of health 
35 I expect my health to get worse    Perception of health Patient perception of health 
36 My health is excellent    Perception of health Patient perception of health 
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Appendix table 20: Harvey Bradshaw Index (HBI) constituent outcomes and mapped Filter 2.0 domains 
Item 
no. 
Item description ICF outcome code 
level 
Outcome Domain 
1st 2nd  3rd 
1 No. of liquid or very soft stools per day (liquid or very 
soft stools) 
  b5251 Faecal consistency ICF b525: Defecation functions 
1 No. of liquid or very soft stools per day (frequency of 
stools) 
  b5252 Frequency of defecation ICF b525: Defecation functions 
1-A Adjustment if using diarrhoea-control medications    Need for additional therapy Individual resource use 
2 Abdominal pain rating (0-3)   b28012 Pain in stomach or abdomen ICF b28012: Pain in stomach or 
abdomen 
3 General well-being rating (0-4)    Wellbeing Quality of life 
4 No. of 6 
types, other 
occasional 
Crohn's 
findings 
The presence of joint pains 
(arthralgia) or frank arthritis 
  b28016 Pain in joints ICF b28016: Pain in joints 
 s770  Additional musculoskeletal 
structures related to 
movement 
ICF s770: Additional musculoskeletal 
structures related to movement 
Inflammation of the iris or uveitis   s2202 Iris ICF s220: Structure of eyeball 
Presence of erythema nodosum, 
pyoderma gangrenosum or aphthous 
ulcers 
 s810  Structure of areas of skin ICF s810: Structure of areas of skin 
Anal fissures, fistulae or abscesses  s540  Structure of intestine ICF s540: Structure of intestine 
Other fistulae  s540  Structure of intestine ICF s540: Structure of intestine 
Fever during the previous week   b5500 Body temperature ICF b5500: Body temperature 
5 Abdominal mass (CDAI = 0, 2, 5; HBI = 1-4)  s540  Structure of intestine ICF s540: Structure of intestine 
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Appendix table 21: Perianal Disease Activity Index (PDAI) constituent outcomes and mapped Filter 2.0 domains 
Item 
no. 
Item description ICF code level Outcome Domain 
1st 2nd  3rd 
1 Discharge  b525  Defecation functions ICF b525: Defecation functions 
2 Pain /restriction of activities  b280  Sensation of pain ICF b280: Sensation of pain 
3 Restriction of sexual activities  b640  Sexual functions ICF b640: Sexual functions 
4 Type of perianal disease  s540  Structure of the intestine ICF s540: Structure of the intestine 
5 Degree of induration  S810  Structure of areas of skin ICF s810: Structure of areas of skin 
 
Appendix table 22: Van-Hees Activity Index (VHAI) constituent outcomes and mapped Filter 2.0 domains 
Item 
no. 
Item description ICF code level Outcome Domain 
1st 2nd  3rd 
1 Albumin  b430  Haematological system functions ICF b430: Haematological system functions 
2 ESR    Inflammation Biomarker 
3 BMI  b530  Weight maintenance functions ICF b530: Weight maintenance functions 
4 Abdominal mass  s540  Structure of intestine ICF s540: Structure of intestine 
5 Sex      
6 Temperature   b5500 Body temperature ICF b5500: Body temperature 
7 Stool consistency   b5251 Faecal consistency ICF b525: Defecation functions 
8 Resection    Need for surgery Individual resource use 
9 Extraintestinal lesion  s810  Structure of areas of skin ICF s810: Structure of areas of skin 
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Appendix table 23: Filter 2.0 domains, outcomes and outcome measures within the endpoints of 181 trials in adults with Crohn’s disease  
Outcome domain 
Studies measuring 
outcomes in domain 
Outcomes Outcome measures 
Indivi
dually 
Within 
an 
index Total 
CONCEPT: IMPACT OF HEALTH CONDITIONS; CORE AREA: DEATH 
Death 2  2 Death due to Crohn's Death due to Crohn's 
CONCEPT: IMPACT OF HEALTH CONDITIONS; CORE AREA: ECONOMIC IMPACT 
Individual resource use 83 156 163 
Disease activity, need for additional 
steroids, therapy or surgery, need for 
hospitalisation, steroid dose, withdrawal 
or tapered steroids and resection. 
CDAI, VHAI and physician assessment. 
Physician global assessments of disease 
activity, partial Harvey Bradshaw index, 
Severity and Activity index, Present score 
and European cooperative Crohn's 
Disease Study (ECCDS) based grading. 
Patient global ratings, impressions and 
evaluations of disease activity. 
Health care cost 3  3 Costs of health care 
Drug cost per patient, monthly cost of 
medical treatment, overall cost of 
surgery, Cost per QALY, cost to utility 
ratio of treatment, incremental cost 
effectiveness ratio (ICER) 
CONCEPT: IMPACT OF HEALTH CONDITIONS; CORE AREA: LIFE IMPACT 
Quality of life 16 163 167 Wellbeing and general quality of life 
VAS assessment, CDAI, HBI, diary card 
assessments and patient global 
assessments of wellbeing. Assessment of 
Quality of Life Questionnaire, 
Gastrointestinal Quality of Life Index, IBD 
392 
 
Outcome domain 
Studies measuring 
outcomes in domain 
Outcomes Outcome measures 
Indivi
dually 
Within 
an 
index Total 
Quality of Life questionnaires, 
Inflammatory Bowel Disease Self-Efficacy 
Scale, Inflammatory Bowel Disease Stress 
Index, Quality of Life instrument, Short 
Form 12 Health Survey, Short Health 
Scale and Short Inflammatory Bowel 
disease Questionnaire (short-IBDQ) 
ICF d9: Community, social and civic 
life 1 82 82 
Condition interferes with social life, 
education, work and employment, 
prevents going out, attending social 
events and leisure and sports affected. SF-36, IBDQ 
Patient perception of health 2 82 82 
Perception of health and feeling 
generally well 
EuroQOL visual analogue scale, SF-36 and 
IBDQ 
ICF d5301: Regulating defecation  77 77 
Wanting to go back to the toilet, needing 
to rush to the toilet and needing to keep 
close to a toilet. IBDQ 
Utility of treatment 71  71 
Perceived credibility, efficacy and 
tolerability of treatment, perceived 
disease activity and utility. 
Pill counts, patient diaries, duration of 
therapy, stool pH test, Patient ratings, 
Investigator / physician assessment, 
changes in laboratory values deemed 
serious, EQ-5D, EuroQOL derived VAS, 
QALY. 
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Outcome domain 
Studies measuring 
outcomes in domain 
Outcomes Outcome measures 
Indivi
dually 
Within 
an 
index Total 
ICF d4: Mobility  14 14 
Bending, kneeling or stooping, climbing 
stairs, lifting or carrying groceries, 
vigorous activities and walking SF-36 
ICF d5: Self-care  14 14 Bathing or dressing yourself SF-36 
ICF d640: Doing housework  14 14 Moderate activities SF-36 
ICF d810-d839: Education  14 14 
Activities limited due to emotional or 
physical health problems SF-36 
ICF d840-d859: Work and 
employment 1 14 14 
Activities limited due to emotional or 
physical health problems Work limitation questionnaire and SF-36 
ICF d240: Handling stress and other 
psychological demands 2  2 
Ability to cope with the disease, 
perceived stress and improvement in 
psychological status. 
Patient self-rating and perceived stress 
questionnaire 
ICF d7: Interpersonal interactions 
and relationships 1  1 Influence on interpersonal relationships 
Patient self-rating and Psychiatric and 
Socio-communicative finding (PSKB) 
standardised clinical interview 
CONCEPT: PATHOPHYSIOLOGICAL MANIFESTATIONS; CORE AREA: PATHOPHYSIOLOGICAL MANIFESTATIONS 
ICF s540: Structure of intestine 85 166 174 
Fistulae, fissures, abscesses, abdominal 
masses, lesions, ulcers and perianal 
disease. 
CDAI, HBI, VHAI, PDAI, Crohn's disease 
Endoscopic Index of Severity (CDEIS), 
D'Haens endoscopic scores, Rutgeerts 
scores, Simple Endoscopic Score for 
Crohn's disease (SES-CD), Marteau 
endoscopic score, other endoscopic 
classifications and scores,  endoscopic 
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Outcome domain 
Studies measuring 
outcomes in domain 
Outcomes Outcome measures 
Indivi
dually 
Within 
an 
index Total 
visual analogue scales, Dieleman 
histological score, Regueiro histology 
score, other histology scores and grading, 
barium x-ray appearance, 3D ultrasound 
and physician assessments. 
ICF b525: Defecation functions 19 170 172 
Faecal output, faecal consistency, 
frequency of defecation, faecal 
continence, flatulence, diarrhoea, blood 
with stool and fistula discharge. 
CDAI, HBI, VHAI, IBDQ, PDAI, adapted 
Vaizey faecal incontinence score, IBS 
severity scoring system and diary card 
assessments. 
ICF b28012: Pain in abdomen or 
stomach 7 168 169 Abdominal pain CDAI, HBI and IBDQ. 
ICF s810: Structure of areas of skin 2 166 166 
Extra intestinal lesions and perianal 
induration. CDAI, HBI, VHAI and PDAI. 
ICF b28012: Pain in joints  163 163 Arthralgia CDAI and HBI. 
ICF b5500: Body temperature 4 163 163 Fever and prolonged fever CDAI, HBI and VHAI. 
ICF s220: Structure of eyeball  162 162 Uveitis CDAI and HBI. 
ICF s770: Additional 
musculoskeletal structures related 
to movement  162 162 Arthritis CDAI and HBI. 
ICF b530: Weight maintenance 
functions 15 156 157 Body mass 
CDAI, VHAI, body weight, BMI, creatinine-
height index, mid-arm muscle 
circumference and triceps skinfold 
thickness. 
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Outcome domain 
Studies measuring 
outcomes in domain 
Outcomes Outcome measures 
Indivi
dually 
Within 
an 
index Total 
ICF b430: Haematological system 
functions 23 156 156 Blood abnormalities 
CDAI, VHAI, albumin, abnormal blood cell 
count, complete blood count, full blood 
count, haematocrit, haemoglobin, 
platelet count, red blood cell count, white 
blood cell count. 
Biomarkers 102 7 102 Inflammation and intestinal permeability 
VHAI, C-reactive protein, erythrocyte 
sedimentation rate, faecal calprotectin, 
serum orosomucoid concentration, α-1 
acid glycoprotein and presence of 
cytokines and bacteria in mucosal tissues 
and plasma. Urine permeability tests and 
stool α1-antitrypsin clearance. 
ICF b152: Emotional functions 6 82 83 
Depression, frustration, anxiety, worry, 
embarrassment, upset, angry, irritable, 
happy, relaxed, feel lack of sympathy and 
worries about being admitted to hospital. 
Beck's depression inventory, Hamilton 
Depression Scale, Hospital Anxiety and 
Depression Scale, SF-36, State trait 
Anxiety Inventory instrument and IBDQ. 
ICF b640: Sexual functions 1 83 83 
Restriction of sexual activity and sex life 
affected. IBDQ and PDAI. 
ICF b130: Energy and drive 
functions 3 82 82 Energy levels and appetite. 
Fatigue impact scale, side effect 
questionnaire, IBDQ and SF-36. 
ICF b535: Sensations associated 
with the digestive system 2 77 78 
Nausea, abdominal bloating, rumbling 
gut and acid reflux. IBDQ and patient diary. 
ICF b134: Sleep functions  77 77 Unable to sleep IBDQ 
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Outcome domain 
Studies measuring 
outcomes in domain 
Outcomes Outcome measures 
Indivi
dually 
Within 
an 
index Total 
ICF b280: Sensation of pain 8 23 25 Bodily pain and perianal pain. 
Clinical scales, patient diary, PDAI, 
Physician assessment, SF-36, side effect 
questionnaire and visual analogue scale. 
ICF b515: Digestive functions 14  14 Absorption of nutrients 
Important outcomes include albumin 
(also an indicator of inflammation), 
transferrin and retinol-binding protein.  
Numerous other outcome measures 
including fatty acid fractions, linoleic acid 
and phospholipids 
ICF b510: Ingestion functions 6  6 
Vomiting, calorie intake, maintenance of 
full diet, return to full diet and return to 
liquid diet Patient diary scores. 
ICF b540: General metabolic 
functions 2  2 Liver or kidney function 
Abnormal alkaline phosphatase, AST, 
amylase, lipase or serum creatinine levels 
and elevated liver enzyme 
Note: CDAI – Crohn’s disease activity index; VHAI – Van Hees activity index; VAS – visual analogue scale; HBI – Harvey Bradshaw index; SF-36 – Short form 36; IBDQ – inflammatory 
bowel disease questionnaire; QALY – quality-adjusted life-years; PDAI – perianal disease activity index; BMI – body mass index; AST – aspartate aminotransferase 
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 Appendix table 24: Filter 2.0 domains and adverse events reported in the 181 trials in adults with Crohn’s disease 
ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
CONCEPT: IMPACT OF HEALTH CONDITIONS; CORE AREA: DEATH 
 Death 49 2 Fatal outcomes Death, sudden cardiac death 
CONCEPT: IMPACT OF HEALTH CONDITIONS; CORE AREA: ECONOMIC IMPACT 
 
Individual resource 
use 38 15 
Gastrointestinal therapeutic procedures, 
Haematological and lymphoid tissue 
therapeutic procedures, Therapeutic 
procedures and supportive care NEC 
Hospitalisation, surgery, intestinal repaid, 
colectomy, ileostomy, abscess drainage, 
antibiotic therapy, elective surgery, ileostomy 
closure, small intestinal resection, 
transfusion, adhesiolysis, bed rest, drain 
placement 
CONCEPT: IMPACT OF HEALTH CONDITIONS; CORE AREA: LIFE IMPACT 
 Utility of treatment 160 43 
Administration site reactions, Injuries by 
physical agents, Injuries NEC, Procedural 
related injuries and complications NEC, 
Product use issues, Therapeutic and 
nontherapeutic effects (excl. toxicity),  
Injection site reaction, injection site pain, 
infusion related reaction, injection site 
erythema, post-procedural complication, 
injection site bruising, injection site irritation, 
injection site pruritus, overdose, injection site 
inflammation, drug intolerance, infusion site 
reaction, injection site haemorrhage, 
injection site rash, infusion site erythema, 
infusion site irritation, infusion site pain, 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
infusion site phlebitis, injection site 
haematoma 
 
Patient perception of 
health 5 2 General system disorders NEC Malaise, feeling abnormal 
CONCEPT: PATHOPHYSIOLOGICAL MANIFESTATIONS; CORE AREA: PATHOPHYSIOLOGICAL MANIFESTATIONS 
 Infections 106 100 
Bacterial infectious disorders, Fungal 
infectious disorders, General system 
disorders NEC, Infections - pathogen 
unspecified, Mycobacterial infectious 
disorders, Viral infectious disorders,  
Infection, nasopharyngitis, anal abscess, 
upper respiratory tract infection, urinary tract 
infection, urinary tract infection, pneumonia, 
influenza, abscess, opportunistic infection, 
tuberculosis, sinusitis, viral infection, 
influenza like illness 
b280 Sensation of pain 105 24 
Anal and rectal conditions NEC, bile duct 
disorders, Bone disorders (excl congenital 
and fractures), Breast disorders, General 
system disorders NEC, Headaches, Muscle 
disorders, Musculoskeletal and connective 
tissue disorders NEC, Neurological 
disorders NEC, Oral soft tissue conditions, 
Respiratory disorders NEC, Spinal cord and 
nerve root disorders, Tendon, ligament 
Headache, back pain, myalgia, pain, 
proctalgia, chest pain, laryngeal pain, bone 
pain, chest discomfort, migraine, 
musculoskeletal pain, oropharyngeal pain, 
oral pain, pain in extremity, biliary colic, 
breast pain, facial pain, musculoskeletal chest 
pain, neuralgia, post herpetic neuralgia, renal 
colic, sciatica, sensory loss, tendon pain 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
and cartilage disorders, Urinary tract signs 
and symptoms 
s540 Structure of intestine 96 62 
Anal and rectal conditions NEC, 
Gastrointestinal conditions NEC, 
Gastrointestinal haemorrhages NEC, 
Gastrointestinal inflammatory conditions, 
Gastrointestinal neoplasms malignant and 
unspecified, Gastrointestinal stenosis and 
obstruction, Gastrointestinal ulceration 
and perforation, Gastrointestinal vascular 
conditions, General system disorders NEC, 
Musculoskeletal and connective tissue 
disorders NEC 
Crohn's disease, fistula, rectal haemorrhage, 
anal fistula, gastrointestinal haemorrhage, 
anal fissure, haematochezia, enteritis, 
intestinal perforation, stenosis, anorectal 
swelling, melaena, intestinal stenosis, 
haemorrhoids thrombosed, colon cancer, anal 
inflammation, colonic fistula, anal 
haemorrhage, haematemesis, lower 
gastrointestinal haemorrhage, colitis, anal 
stenosis, large intestinal stenosis, small 
intestinal stenosis, duodenal ulcer, ileal ulcer, 
small intestinal ulcer haemorrhage, colorectal 
cancer, rectal adenocarcinoma, rectal cancer 
b28012 
Pain in stomach or 
abdomen 90 2 Gastrointestinal signs and symptoms Abdominal pain, abdominal pain upper 
b535 
Sensations associated 
with the digestive 
system 90 8 
Gastrointestinal motility and defaecation 
conditions, Gastrointestinal signs and 
symptoms 
Nausea, dyspepsia, abdominal distension, 
gastrointestinal sounds abnormal, abdominal 
tenderness, gastrooesophageal disease, 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
gastrooesophageal reflux disease, abdominal 
symptom 
b8 
Functions of the skin 
and related structures 76 35 
Anal and rectal conditions NEC, 
Angioedema and urticaria, Cornification 
and dystrophic skin disorders, Epidermal 
and dermal conditions, General system 
disorders NEC, Neurological disorders NEC, 
Oral soft tissue conditions, Skin and 
subcutaneous tissue disorders NEC, Skin 
appendage conditions, Skin vascular 
abnormalities, Tongue conditions 
Rash, acne, pruritus, alopecia, skin striae, 
paraesthesia, flushing, urticaria, 
hypertrichosis, dermatitis, eczema, erythema, 
skin disorder, hyperhidrosis, hair growth 
abnormal, skin lesion, erythema nodosum, 
rosacea, night sweats, dermatitis atopic, dry 
skin, lichen planus, photosensitivity reaction, 
rash erythematous, rash generalised, rash 
maculo-papular, skin ulcer, ecchymosis, 
purpura, anal pruritus, anorectal discomfort, 
paraesthesia oral, glossodynia, burning 
sensation, skin burning sensation 
b435 
Immunological 
system functions 65 36 
Allergic conditions, Autoimmune 
disorders, Connective tissue disorders 
(excl congenital), Cranial nerve disorders 
(excl neoplasms), Demyelinating disorders, 
Haematology investigations (incl blood 
groups), Immune disorders NEC, 
Immunology and allergy investigations, 
Drug specific antibody present, leukopenia, 
hypersensitivity, double stranded DNA 
antibody, antinuclear antibody present, 
lupus-like syndrome, lymphoma, systematic 
lupus erythematosus, demyelination, 
lymphopenia, neutropenia, type IV 
hypersensitivity reaction, white blood cell 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
Lymphomas NEC, Lymphomas non-
Hodgkin's T-cell, Neurological disorders 
NEC, Skin vascular abnormalities, Spleen, 
lymphatic and reticuloendothelial system 
disorders, Toxicology and therapeutic drug 
monitoring, Upper respiratory tract 
disorders (excl infections), White blood 
cell disorders 
count decreased / increased, hypersensitivity 
vasculitis, leucocytosis, eosinophil count 
increased, lymphocyte count increased / 
decreased, monocyte count increased, 
neutrophil count increased, interleukin level 
increased, multiple sclerosis / MS relapse, 
rhinitis allergic, natural killer-cell 
lymphoblastic lymphoma, lymphoedema, 
lymphocytosis, neutrophilia, drug 
hypersensitivity, seasonal allergy, 
autoimmune disorder, cytokine release 
syndrome, T-lymphocyte count decreased, 
optic neuritis, central nervous system lesion 
b525 Defecation functions 65 8 
Anal and rectal conditions NEC, 
Gastrointestinal motility and defaecation 
conditions, Gastrointestinal signs and 
symptoms 
Diarrhoea, flatulence, constipation, diarrhoea 
haemorrhagic, frequent bowel movements, 
rectal tenesmus, abnormal faeces, mucous 
stools 
b510 Ingestion functions 59 3 
Gastrointestinal signs and symptoms, 
Salivary gland conditions Vomiting, dry mouth, retching 
b28016 Pain in joints 58 1 Joint disorders Arthralgia 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
b540 
General metabolic 
functions 50 26 
Enzyme investigations, Enzyme 
investigations NEC, Gastrointestinal 
investigations, Hepatobiliary 
investigations, Lipid analyses, Lipid 
metabolism disorders, Metabolic, 
nutritional and blood gas investigations, 
Metabolism disorders NEC, Protein and 
chemistry analyses NEC, Purine and 
pyrimidine metabolism disorders, Renal 
and urinary tract investigations and 
urinalyses 
Alanine aminotransferase increased / 
abnormal, transaminases increased, 
lipohypertrophy, liver function test abnormal 
/ increased, blood creatinine increased, 
aspartate aminotransferase increased. Blood 
alkaline phosphatase increased, hepatic 
enzyme abnormal / increased, amylase 
increased, lipase increased, gamma-
glutamyltransferase increased, blood albumin 
decreased, hyperamylasasemia, blood 
creatine phosphokinase increased, pancreatic 
enzymes increased, blood bilirubin increased, 
blood triglycerides decreased, low density 
lipoprotein, blood glucose abnormal, retinol 
binding protein decreased, protein total 
decreased, hyperlipidaemia, hyperuricemia 
b130 
Energy and drive 
functions 47 6 
Appetite and general nutrition disorders, 
general system disorders NEC, 
neurological disorders NEC, psychiatric 
disorders NEC 
Fatigue, decreased / increased appetite, 
lethargy, substance abuse, hyperphagia 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
b5500 Body temperature 47 3 
Body temperature conditions, General 
system disorders NEC, Physical 
examination and organ system status 
topics Pyrexia, chills, body temperature decreased 
b430 
Haematological 
system functions 39 23 
Anaemias nonhaemolytic and marrow 
depression, Coagulopathies and bleeding 
diatheses (excl thrombocytopenic), 
Haematological disorders NEC, 
Haematology investigations (incl blood 
groups), Haemolyses and related 
conditions, Hepatic and hepatobiliary 
disorders, Leukaemias, Platelet disorders, 
Spleen, lymphatic and reticuloendothelial 
system disorders, White blood cell 
disorders 
Anaemia, thrombocytopenia, increased 
tendency to bruise, haemoglobin decreased, 
platelet count decreased, haematocrit 
decreased, iron deficiency anaemia, 
thrombocytosis, red blood cell sedimentation 
rate increased, hyperbilirubinaemia, anaemia 
macrocytic, cytopenia, pancytopenia, 
hypercoagulation, blood disorder, haemolytic 
anaemia, splenomegaly, eosinophilia, 
granulocytopenia, activated partial 
thromboplastin time prolonged, prothrombin 
time shortened, reticulocyte count increased, 
myelodysplastic syndrome 
b515 Digestive functions 35 9 
Gastrointestinal motility and defaecation 
conditions, Gastrointestinal signs and 
symptoms, Gastrointestinal stenosis and 
Intestinal obstruction, ileus, abdominal mass, 
small intestinal obstruction, subileus, ileus 
paralytic, megacolon, large intestinal 
obstruction, abdominal adhesions 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
obstruction, Peritoneal and 
retroperitoneal conditions 
b7 
Neuromusculoskeletal 
and movement-
related functions 33 11 
General system disorders NEC, Joint 
disorders, Movement disorders (incl 
parkinsonism), Muscle disorders, 
Neurological disorders NEC, 
Neuromuscular disorders 
Asthenia, joint swelling, arthritis, muscle 
spasms, tremor, muscular weakness, joint 
stiffness, polyarthritis, muscle atrophy, 
muscle contractions involuntary, neurological 
symptom 
b240 
Sensations associated 
with hearing and 
vestibular function 31 3 
Inner ear and VIIIth cranial nerve 
disorders, Neurological signs and 
symptoms NEC Dizziness, tinnitus, vertigo 
b555 
Endocrine gland 
functions 25 9 
Adrenal gland disorders, Endocrine 
disorders of gonadal function, Endocrine 
investigations (incl sex hormones), Glucose 
metabolism disorders (incld diabetes 
mellitus), Thyroid gland disorders 
Cushingoid, hirsutism, Cushing's syndrome, 
blood cortisol decreased / abnormal, adrenal 
disorder / suppression, hyperthyroidism, 
hypoglycaemia 
b415 Blood vessel functions 24 13 
Arteriosclerosis, stenosis, vascular 
insufficiency and necrosis, Central nervous 
system vascular disorders, Decreased and 
nonspecific blood pressure disorders and 
shock, Embolism and thrombosis, 
Pulmonary vascular disorders, Vascular 
Pulmonary embolism, deep vein thrombosis, 
venous thrombosis, hot flush, phlebitis, 
cerebrovascular accidents, superior sagittal 
sinus thrombosis, peripheral coldness, 
circulatory collapse, thrombosis, flushing, 
haematoma, haemorrhage 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
disorders NEC, Vascular haemorrhagic 
disorders, Vascular inflammations 
b152 Emotional functions 22 11 
Anxiety disorder and symptoms, 
Depressed mood disorders and 
disturbances, Mood disorders and 
disturbances NEC, Schizophrenia and other 
psychotic disorders, Suicidal and self-
injurious behaviours NEC 
Depression, mood swings, completed suicide, 
affect lability, mood altered, psychotic 
disorder, anxiety, nervousness, depression 
suicidal, irritability, suicide attempt 
b6 
Genitourinary and 
reproductive 
functions 22 13 
Abortions and stillbirths, Maternal 
complications of pregnancy, Menstrual 
cycle and uterine bleeding disorders, 
Pregnancy, labour, delivery and 
postpartum conditions, Renal disorders 
(excl nephropathies), Sexual dysfunctions, 
disturbances and gender identity 
disorders, Sexual function and fertility 
disorders, Urinary tract signs and 
symptoms, Urolithiases 
Pregnancy, nephrolithiasis, renal impairment, 
dysmenorrhoea, menstrual disorder, 
chromaturia, haematuria, libido decreased, 
sexual dysfunction, metrorrhagia, abortion 
spontaneous, ectopic pregnancy, unintended 
pregnancy 
 Unspecified: cancer 20 5 
Miscellaneous and site unspecified 
neoplasms malignant and unspecified 
Neoplasm malignant, adenocarcinoma, 
neoplasm, adenoma benign, carcinoma in situ 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
b440-
b460 Respiratory functions 20 8 
Bronchial disorders (excl neoplasms), 
Lower respiratory tract disorders (excl 
obstruction and infection), Pleural 
disorders, Respiratory disorders NEC 
Cough, dyspnoea, pneumothorax, asthma, 
bronchospasm, acute pulmonary oedema, 
pneumonitis, dyspnoea exertional 
s6 
Structures related to 
the genitourinary and 
reproductive systems 20 18 
Breast disorders, Breast neoplasms 
malignant and unspecified (incl nipple), 
Cutaneous neoplasms benign, Male 
reproductive tract infections and 
inflammations, Nephropathies, Ovarian 
and fallopian tube disorders, Penile and 
scrotal disorders (excl infections and 
inflammations), Renal and urinary tract 
neoplasms malignant and unspecified, 
Renal disorders (excl nephropathies), 
Reproductive neoplasms female malignant 
and unspecified, Reproductive neoplasms 
male malignant and unspecified, Ureteric 
disorders, Vulvovaginal disorders (excl 
infections and inflammations) 
Nephropathy toxic, breast cancer, prostate 
cancer, anogenital warts, renal cell 
carcinoma, glomerulonephritis, renal infarct, 
ureteric obstruction, bladder cancer, ovarian 
cancer, ovarian cyst, cervix carcinoma, breast 
hyperplasia, Bartholin's cyst, benign 
neoplasm of epididymis, testis cancer, scrotal 
oedema, prostatitis 
b134 Sleep functions 19 4 
Neurological disorders NEC, sleep 
disorders and disturbances 
Insomnia, sleep disorder, somnolence and 
abnormal dreams 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
b410 Heart functions 18 13 
Cardiac and vascular investigations (excl 
enzyme tests), Cardiac arrhythmias, 
Cardiac disorders signs and symptoms, 
Coronary artery disorders, Heart failures 
Tachycardia, palpitations, myocardial 
infarction, cardiac failure congestive, sinus 
tachycardia, ventricular extrasystoles, 
ventricular fibrillation, cyanosis, angina 
pectoris, coronary artery disease, myocardial 
ischaemia, cardiac failure, electrocardiogram 
QT prolonged 
b545 
Water, mineral and 
electrolyte balance 
functions 18 14 
Bone disorders (excl congenital and 
fractures), Bone, calcium, magnesium and 
phosphorus metabolism disorders, 
Electrolyte and fluid balance conditions, 
Glucose metabolism disorders (incld 
diabetes mellitus), Iron and trace metal 
metabolism, Metabolism disorders NEC, 
Musculoskeletal and soft tissue 
investigations (excl enzyme tests), Vitamin 
related disorders, Water, electrolyte and 
mineral investigations 
Dehydration, hyperglycaemia, bone density 
decreased, blood calcium decreased, 
hypokalaemia, iron deficiency, blood 
potassium decreased, serum ferritin 
decreased, hyperphosphataemia, 
hypocalcaemia, fluid retention, apoptosis, 
vitamin D deficiency, osteoporosis 
 
Unspecified: general 
system conditions 18 5 
Angioedema and urticaria, General system 
disorders NEC 
Oedema, oedema peripheral, multiple organ 
dysfunction syndrome, swelling, swelling face 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
b420 
Blood pressure 
functions 16 7 
Cardiac and vascular investigations (excl 
enzyme tests), Decreased and nonspecific 
blood pressure disorders and shock, 
Vascular hypertensive disorders 
Hypertension, hypotension, blood pressure 
diastolic increased / decreased, blood 
pressure increased, orthostatic hypotension, 
hypertensive crisis 
s550-
580 
Structures related to 
the metabolic and 
endocrine systems 16 7 
Endocrine neoplasms malignant and 
unspecified, Exocrine pancreas conditions, 
Gallbladder disorders, Hepatic and 
hepatobiliary disorders 
Pancreatitis, hepatotoxicity, pancreatitis 
acute, hepatitis acute, hepatomegaly, 
cholelithiasis, papillary thyroid cancer 
b530 
Weight maintenance 
functions 13 5 
Appetite and general nutritional disorders, 
Physical examination and organ system 
status topics 
Weight decreased / increased, abnormal loss 
of weight, malnutrition, obesity 
s3 
Structures involved in 
voice and speech 12 9 
Dental and gingival conditions, Oral soft 
tissue conditions, Tongue conditions, 
Upper respiratory tract disorders (excl 
infections) 
Aphthous ulcer, tooth disorder, laryngeal 
oedema, nasal mucosal ulcer, sinus 
congestion, tooth discolouration, gingival 
hyperplasia, glossitis, mouth ulceration 
b210-
b220 
Seeing functions and 
sensations associated 
with the eye 11 7 
Anterior eye structural change, deposit 
and degeneration, eye disorders NEC, 
ocular sensory symptoms NEC, Vision 
disorders 
Cataract, vision blurred, photophobia, 
amblyopia, visual acuity reduced, visual 
impairment, dry eye 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
b110-
b147 
Other mental 
functions 10 9 
Deliria (incl confusion), Mental impairment 
disorders, Neurological disorders NEC, 
Seizures (incl subtypes) 
Syncope, confusional state, amnesia, diabetic 
coma, loss of consciousness, seizure, 
disturbance in attention, agitation, ataxia 
s8 
Skin and related 
structures 10 6 
Cutaneous neoplasms benign, General 
system disorders NEC, Miscellaneous and 
site unspecified neoplasms malignant and 
unspecified, Skin neoplasms malignant and 
unspecified 
Squamous cell carcinoma, basal cell 
carcinoma, face oedema, melanocytic naevus, 
neoplasm skin, skin cancer 
 Biomarkers 9 1 Protein and chemistry analyses NEC C-reactive protein increased 
b250 Taste function 8 1 Neurological disorders NEC Dysguesia 
s4 
Structures of the 
cardiovascular, 
immunological and 
respiratory systems 5 4 
Haematopoietic neoplasms (excl 
leukaemias and lymphomas), Lower 
respiratory tract disorders (excl 
obstruction and infection), Respiratory 
and mediastinal neoplasms malignant and 
unspecified, Respiratory disorders NEC 
Pulmonary mass, haematological malignancy, 
lung cyst, lung neoplasm malignant 
s530 Structure of stomach 5 5 
Gastrointestinal inflammatory conditions, 
Gastrointestinal ulceration and 
perforation, Oral soft tissue conditions 
Gastric ulcer, gastritis, peptic ulcer, peptic 
ulcer haemorrhage, stomatitis 
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ICF 
code Domain 
Number 
of trials 
reporting 
adverse 
events in 
domain 
Number 
of 
adverse 
events 
reported 
in 
domain 
MedDRA Higher Level Group Terms for 
adverse events reported 
(in alphabetical order) 
MedDRA Preferred Terms for adverse events 
reported  
(in order of frequency reported) 
s1 
Structures of the 
nervous system 4 4 
Movement disorders (incl parkinsonism), 
Nervous system neoplasms malignant and 
unspecified NEC, Peripheral neuropathies 
Parkinson's disease, ependymoma, 
neuropathy peripheral, polyneuropathy 
s7 
Structures related to 
movement 2 2 
Abdominal hernias and other abdominal 
wall conditions, General system disorders 
NEC Inguinal hernia, hernia 
s2 
The eye, ear and 
related structures 1 1 
Ocular infections, irritations and 
inflammations Eyelid oedema 
Note: NEC – not elsewhere classified 
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Appendix table 25: Filter 2.0 domains and key outcome measurement tools mapped against the ICF comprehensive core set for IBD 
Comprehensive set Brief 
set?  
Filter 2.0?  CDAI? 
  
IBDQ? 
  
SF-36? 
  
HBI? 
  
PDAI? 
  
VHAI? 
  
Adverse 
events? Code Name Code Domains 
b130 Energy and drive functions yes yes     yes yes       yes 
b134 Sleep functions yes yes     yes         yes 
b152 Emotional functions yes yes     yes yes       yes 
b1801 Body image yes                  
b28012 Pain in stomach or abdomen yes yes Plus b280- 
sensation of 
pain 
yes yes b280 - 
sensation 
of pain 
yes b280 - 
sensation 
of pain 
  yes 
b28016 Pain in joints   yes yes   yes   yes 
b430 Haematological system 
functions 
  yes   yes         yes yes 
b435 Immunological system 
functions 
                  yes 
b515 Digestive functions yes yes               yes 
b525 Defecation functions yes yes   yes yes   yes yes yes yes 
b530 Weight maintenance 
functions 
  yes   yes         yes yes 
b535 Sensations associated with 
the digestive system 
  yes     yes         yes 
b545 Water, mineral and 
electrolyte balance functions 
                  Yes 
b640 Sexual functions   yes     yes     yes    
b660 Procreation functions                    
b810 Protective functions of the 
skin 
  s810 Structures of 
areas of skin 
yes - 
s810 
    yes - 
s810 
yes - s810 yes - 
s810 
 
s540 Structure of intestine yes yes   yes     yes yes yes yes 
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Comprehensive set Brief 
set?  
Filter 2.0?  CDAI? 
  
IBDQ? 
  
SF-36? 
  
HBI? 
  
PDAI? 
  
VHAI? 
  
Adverse 
events? Code Name Code Domains 
s770 Additional musculoskeletal 
structures related to 
movement 
yes yes   yes     yes      
d230 Carrying out daily routine   
 
    
 
         
d5301 Regulating defecation yes yes     yes          
d570 Looking after one's health yes d5 Quality of life 
Self-care 
yes - 
quality 
of life 
  yes - self 
care 
yes - 
quality 
of life 
     
d7 Interpersonal interactions 
and relationships 
yes yes     yes          
d810-
d839 
Education yes yes      yes yes        
d840-
d859 
Work and employment yes yes      yes yes        
d920 Recreation and leisure   d9 Community, 
social and civic 
life 
  Yes yes        
Additional domains not in the ICF core set   Patient 
perception of 
health 
  yes yes        
d4 Mobility     yes        
d640 Doing 
housework 
    yes        
d240 Handling stress 
and other 
psychological 
demands 
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Comprehensive set Brief 
set?  
Filter 2.0?  CDAI? 
  
IBDQ? 
  
SF-36? 
  
HBI? 
  
PDAI? 
  
VHAI? 
  
Adverse 
events? Code Name Code Domains 
  Utility              
  Surrogate: 
disease activity 
yes     yes   yes  
b5500 Body 
temperature 
yes     yes   yes  
s220 Structure of 
eyeball 
yes     yes      
  Biomarkers              
  Surrogate: 
treatment 
acceptability 
             
b510 Ingestion 
functions 
             
b540 General 
metabolic 
function 
             
Note: CDAI – crohn’s disease activity index; IBDQ – inflammatory bowel disease questionnaire; SF-36 – short form 36; HBI – Harvey Bradshaw Index; 
PDAI – perianal disease activity index; VHAI – van Hees activity index 
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Appendix 7: Additional tables for Chapter 4 
Appendix table 26: Very common and common adverse reactions recorded in summary of product characteristics (SPCs) - antibiotics: macrolides 
SOC HLGT PT Frequency Not 
reported 
in trials 
Gastrointestinal disorders Gastrointestinal motility and defaecation conditions Diarrhoea Common   
Gastrointestinal signs and symptoms Abdominal pain Common   
Dyspepsia Common x 
Nausea Common   
Vomiting Common   
Investigations Hepatobiliary investigations Liver function test abnormal Common   
Nervous system disorders Headaches Headache Common x 
Neurological disorders NEC Dysgeusia Common   
Sleep disturbances (incl subtypes) Insomnia Common x 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Rash Common x 
Skin appendage conditions Hyperhidrosis Common X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: VERY COMMON, affecting more than or equal to one in ten patients exposed to the drug; COMMON, affecting more than or equal to one 
in 100, but fewer than one in ten patients. 
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Appendix table 27: Very common and common adverse reactions recorded in SPCs - antibiotics: quinolones 
SOC HLGT PT Frequency Not 
reported 
in trials 
Gastrointestinal disorders Gastrointestinal motility and defecation conditions Diarrhoea Common 
 
Gastrointestinal signs and symptoms Nausea Common 
 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: VERY COMMON, affecting more than or equal to one in ten patients exposed to the drug; COMMON, affecting more than or equal to one in 
100, but fewer than one in ten patients. 
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Appendix table 28: Very common and common adverse reactions recorded in summary of product characteristics (SPCs) – corticosteroids 
SOC HLGT PT Frequency Not 
reported 
in trials 
Cardiac disorders Cardiac disorders signs and symptoms Palpitations Common 
 
Endocrine disorders Adrenal gland disorders Cushingoid Common 
 
Cushing's syndrome Common 
 
Eye disorders Anterior eye structural change, deposit and 
degeneration 
Cataract subcapsular Common X 
Vision disorders Vision blurred Common 
 
Gastrointestinal disorders Gastrointestinal signs and symptoms Dyspepsia Common 
 
Gastrointestinal ulceration and perforation Peptic ulcer Common X 
General disorders and administration 
site conditions  
Tissue disorders NEC Impaired healing Common X 
Infections and infestations Infections - pathogen unspecified Infection Common 
 
Infection susceptibility 
increased 
Common X 
Investigations Water, electrolyte and mineral investigations Blood potassium decreased Common 
 
Metabolism and nutrition disorders Electrolyte and fluid balance conditions Fluid retention Common 
 
Hypokalaemia Common 
 
Sodium retention Common X 
Musculoskeletal and connective tissue 
disorders 
Bone disorders (excl congenital and fractures) Osteoporosis Common X 
Joint disorders Arthralgia Common X 
Muscle disorders Muscle spasms Common 
 
Muscle twitching Common X 
Muscular weakness Common  
Myalgia Common X 
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SOC HLGT PT Frequency Not 
reported 
in trials 
Musculoskeletal and connective tissue disorders NEC Growth retardation Common 
 
Nervous system disorders Headaches Headache Common 
 
Sleep disturbances (incl subtypes) Insomnia Common 
 
Psychiatric disorders Anxiety disorders and symptoms Nervousness Common X 
Depressed mood disorders and disturbances Depression Common 
 
Mood disorders and disturbances NEC Affective disorder Common X 
Euphoric mood Common X 
Irritability Common X 
Mood swings Common 
 
Reproductive system and breast 
disorders 
Menstrual cycle and uterine bleeding disorders Menstrual disorder Common 
 
Skin and subcutaneous tissue disorders Cornification and dystrophic skin disorders Skin atrophy Common X 
Epidermal and dermal conditions Allergic exanthema Common X 
Dermatitis contact Common X 
Skin reaction Common X 
Skin appendage conditions Acne Common 
 
Ecchymosis Common X 
Petechiae Common X 
Vascular disorders Vascular hypertensive disorders Hypertension Common 
 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – not 
elsewhere classified     
Frequency: VERY COMMON, affecting more than or equal to one in ten patients exposed to the drug; COMMON, affecting more than or equal to one in 
100, but fewer than one in ten patients. 
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Appendix table 29: Very common and common adverse reactions recorded in summary of product characteristics (SPCs) - immunosuppressives: methotrexate 
SOC HLGT PT Frequency Not 
reported 
in trials 
Blood and lymphatic system disorders Anaemias nonhaemolytic and marrow depression Anaemia Common x 
Platelet disorders Thrombocytopenia Common   
White blood cell disorders Leukopenia Common   
Gastrointestinal disorders Gastrointestinal motility and defaecation conditions Diarrhoea Common   
Gastrointestinal signs and symptoms Abdominal pain Very common   
Dyspepsia Very common   
Nausea Very common   
Vomiting Very common   
Oral soft tissue conditions Stomatitis Very common x 
General disorders and administration 
site conditions  
General system disorders NEC Fatigue Common   
Infections and infestations Viral infectious disorders Herpes zoster Common x 
Investigations Hepatobiliary investigations Hepatic enzyme increased Very common   
Metabolism and nutrition disorders Appetite and general nutritional disorders Decreased appetite Very common x 
Nervous system disorders Headaches Headache Common   
Neurological disorders NEC Somnolence Common x 
Respiratory, thoracic and mediastinal 
disorders 
Lower respiratory tract disorders (excl obstruction and 
infection) 
Alveolitis Common x 
Interstitial lung disease Common x 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Erythema Common x 
Pruritus Common x 
Rash Common X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – not 
elsewhere classified     
419 
 
Frequency: VERY COMMON, affecting more than or equal to one in ten patients exposed to the drug; COMMON, affecting more than or equal to one in 
100, but fewer than one in ten patients. 
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Appendix table 30: Rare and very rare adverse reactions recorded in summary of product characteristics (SPCs) - 5-ASAs 
SOC HLGT PT Frequency Not 
reported in 
trials 
Blood and lymphatic system disorders Anaemias nonhaemolytic and marrow depression Anaemia very rare  
Aplastic anaemia rare X 
Aplastic anaemia very rare X 
Pancytopenia very rare  
Platelet disorders Thrombocytopenia Rare X 
Thrombocytopenia very rare X 
White blood cell disorders agranulocytosis Rare X 
agranulocytosis very rare X 
Eosinophilia very rare X 
Leukopenia Rare X 
Leukopenia very rare X 
Neutropenia Rare X 
Neutropenia very rare X 
Cardiac disorders Myocardial disorders Myocarditis rare X 
Pericardial disorders Pericarditis rare X 
Ear and labyrinth disorders Inner ear and VIIIth cranial nerve disorders Vertigo rare X 
Gastrointestinal disorders Exocrine pancreas conditions Pancreatitis Rare  
Pancreatitis acute very rare X 
Gastrointestinal inflammatory conditions Colitis very rare X 
Gastrointestinal motility and defaecation conditions Diarrhoea Rare  
Gastrointestinal signs and symptoms Abdominal pain Rare  
Flatulence Rare X 
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SOC HLGT PT Frequency Not 
reported in 
trials 
Nausea Rare  
Vomiting Rare  
General disorders and administration 
site conditions  
Body temperature conditions Pyrexia rare  
Pyrexia very rare  
Fatal outcomes Death very rare  
Hepatobiliary disorders Hepatic and hepatobiliary disorders Cholestasis very rare X 
Hepatic function abnormal rare X 
Hepatitis rare X 
Hepatitis very rare X 
Hepatitis cholestatic very rare X 
Hepatotoxicity Rare X 
Immune system disorders Allergic conditions Hypersensitivity very rare X 
Autoimmune disorders Systemic lupus 
erythematosus 
Rare X 
Investigations Gastrointestinal investigations Amylase increased Rare X 
Hepatobiliary investigations Blood bilirubin increased very rare X 
Hepatic enzyme increased very rare X 
Liver function test abnormal rare X 
Transaminases increased very rare  
Musculoskeletal and connective tissue 
disorders 
Joint disorders Arthralgia very rare  
Muscle disorders Myalgia very rare  
Nervous system disorders Headaches Headache Rare  
Neurological disorders NEC Dizziness Rare  
Peripheral neuropathies Neuropathy peripheral rare X 
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SOC HLGT PT Frequency Not 
reported in 
trials 
Neuropathy peripheral very rare X 
Renal and urinary disorders Nephropathies Nephropathy toxic rare  
Nephrotic syndrome rare X 
Tubulointerstitial nephritis rare X 
Tubulointerstitial nephritis very rare X 
Renal disorders (excl nephropathies) Renal failure rare X 
Renal failure very rare X 
Renal impairment Rare  
Urinary tract signs and symptoms Chromaturia Rare X 
Reproductive system and breast 
disorders 
Sexual function and fertility disorders Oligospermia very rare X 
Respiratory, thoracic and mediastinal 
disorders 
Bronchial disorders (excl neoplasms) Bronchospasm rare X 
Bronchospasm very rare X 
Lower respiratory tract disorders (excl obstruction and 
infection) 
allergic alveolitis Rare X 
Alveolitis very rare X 
Eosinophilic pneumonia rare X 
Lung infiltration Rare X 
Lung infiltration very rare X 
Pneumonitis Rare X 
Pneumonitis very rare X 
Pulmonary eosinophilia Rare X 
Pulmonary eosinophilia very rare X 
Respiratory disorders NEC Cough Rare X 
Cough very rare X 
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SOC HLGT PT Frequency Not 
reported in 
trials 
Dyspnoea Rare X 
Dyspnoea very rare X 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Dermatitis bullous rare X 
Erythema multiforme very rare X 
Rash rare  
Stevens-Johnson syndrome very rare  
Skin appendage conditions Alopecia rare  
Alopecia very rare  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – not 
elsewhere classified     
Frequency: RARE, affecting more than or equal to one in 10,000 patients, but fewer than one in 1,000; VERY RARE, affecting less than one in 10,000. 
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Appendix table 31: Rare and very rare adverse reactions recorded in summary of product characteristics (SPCs) - antibiotics: nitroimidazole derivatives 
SOC HLGT PT Frequency Not in 
trials 
Blood and lymphatic system 
disorders 
Anaemias nonhaemolytic and marrow depression Pancytopenia Very rare x 
Platelet disorders Thrombocytopenia Very rare x 
White blood cell disorders Agranulocytosis Very rare x 
Neutropenia Very rare x 
Eye disorders Vision disorders Diplopia Very rare x 
Myopia Very rare x 
Gastrointestinal disorders Exocrine pancreas conditions Pancreatitis Very rare 
 
Hepatobiliary disorders Hepatic and hepatobiliary disorders Hepatitis cholestatic Very rare x 
Jaundice Very rare x  
Immune system disorders Allergic conditions Anaphylactic reaction Rare x 
Investigations Hepatobiliary investigations Liver function test abnormal Very rare x 
Musculoskeletal and connective 
tissue disorders 
Joint disorders Arthralgia Very rare 
 
Muscle disorders Myalgia Very rare 
 
Nervous system disorders Encephalopathies Encephalopathy Very rare x  
Headaches Headache Very rare 
 
Neurological disorders NEC Cerebellar syndrome Very rare x  
Dizziness Very rare 
 
Somnolence Very rare x  
Seizures (incl subtypes) Seizure Very rare x  
Psychiatric disorders Schizophrenia and other psychotic disorders Psychotic disorder Very rare x  
Renal and urinary disorders Urinary tract signs and symptoms Chromaturia Very rare x  
Skin and subcutaneous tissue 
disorders 
Epidermal and dermal conditions Pruritus Very rare x  
Rash Very rare 
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SOC HLGT PT Frequency Not in 
trials 
Rash pustular Very rare x  
Skin vascular abnormalities Flushing Very rare x  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: RARE, affecting more than or equal to one in 10,000 patients, but fewer than one in 1,000; VERY RARE, affecting less than one in 10,000. 
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Appendix table 32: Rare and very rare adverse reactions recorded in summary of product characteristics (SPCs) - antibiotics: quinolones 
SOC HLGT PT Frequency Not in 
trials 
Blood and lymphatic system disorders Anaemias nonhaemolytic and marrow depression Anaemia rare   
Bone marrow failure very rare x 
Pancytopenia very rare x 
Haemolyses and related conditions Haemolytic anaemia very rare x 
Platelet disorders Thrombocytopenia rare x 
Thrombocytosis rare x 
White blood cell disorders agranulocytosis very rare x 
Leukocytosis rare x 
Leukopenia rare x 
Neutropenia rare x 
Cardiac disorders Cardiac arrhythmias Tachycardia rare x 
Ear and labyrinth disorders Hearing disorders Hypoacusis rare x 
Inner ear and VIIIth cranial nerve disorders Tinnitus rare x 
Vertigo rare x 
Eye disorders Vision disorders Visual impairment rare x 
Gastrointestinal disorders Exocrine pancreas conditions Pancreatitis very rare   
General disorders and administration 
conditions 
General system disorders NEC Oedema rare   
Hepatobiliary disorders Hepatic and hepatobiliary disorders Hepatic necrosis very rare x 
Hepatitis rare x 
Jaundice cholestatic rare x 
Liver disorder rare x 
Immune system disorders Allergic conditions Allergic oedema rare x 
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SOC HLGT PT Frequency Not in 
trials 
Anaphylactic reaction very rare x 
Anaphylactic shock very rare x 
Hypersensitivity rare x 
Infections and infestations Bacterial infectious disorders Clostridium difficile colitis rare   
Injury, poisoning and procedural 
complications 
Injuries NEC Tendon rupture very rare x 
Procedural related injuries and complications NEC Serum sickness very rare x 
Investigations Gastrointestinal investigations Amylase increased rare x 
Metabolism and nutrition disorders Glucose metabolism disorders (incld diabetes 
mellitus) 
Hyperglycaemia rare x 
Hypoglycaemia rare x 
Musculoskeletal and connective tissue 
disorders 
Joint disorders Arthritis rare x 
Muscle disorders Hypertonia rare x 
Muscle spasms rare x 
Muscular weakness very rare x 
Myalgia rare   
Myasthenia gravis very rare x 
Tendon, ligament and cartilage disorders Tendonitis very rare x 
Nervous system disorders Cranial nerve disorders (excl neoplasms) Olfactory nerve disorder very rare x 
Headaches Migraine very rare x 
Increased intracranial pressure and hydrocephalus  Intracranial pressure 
increased  
very rare x 
Benign intracranial 
hypertension 
very rare x 
Movement disorders (incl parkinsonism) Tremor rare x 
Neurological disorders NEC Coordination abnormal very rare x 
Dysaesthesia rare x 
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SOC HLGT PT Frequency Not in 
trials 
Gait disturbance very rare x 
Hypoaesthesia rare x 
Paraesthesia rare x 
Seizures (incl subtypes) Seizure rare x 
Psychiatric disorders Anxiety disorders and symptoms Anxiety rare x 
Deliria (incl confusion) Confusional state rare x 
Depressed mood disorders and disturbances Depression rare x 
Disturbances in thinking and perception Hallucination rare x 
Schizophrenia and other psychotic disorders Psychotic disorder very rare x 
Sleep disorders and disturbances Abnormal dreams rare x 
Renal and urinary disorders Nephropathies Tubulointerstitial nephritis rare x 
Renal disorders (excl nephropathies) Renal failure rare x 
Urinary tract signs and symptoms Crystalluria rare x 
Haematuria rare x 
Respiratory, thoracic and mediastinal 
disorders 
Respiratory disorders NEC Dyspnoea rare x 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Photosensitivity reaction rare   
Stevens-Johnson syndrome very rare x 
Toxic epidermal necrolysis very rare x 
Skin and subcutaneous tissue disorders NEC Erythema nodosum very rare x 
Skin appendage conditions Hyperhidrosis rare x 
Skin vascular abnormalities Petechiae very rare x 
Epidermal and dermal conditions Erythema multiforme very rare x 
Surgical and medical procedures Vascular therapeutic procedures Vasodilation procedure rare x 
Vascular disorders Hypotension rare x 
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SOC HLGT PT Frequency Not in 
trials 
Decreased and nonspecific blood pressure disorders 
and shock 
Syncope rare x 
Vascular inflammations Vasculitis very rare X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – not 
elsewhere classified     
Frequency: RARE, affecting more than or equal to one in 10,000 patients, but fewer than one in 1,000; VERY RARE, affecting less than one in 10,000. 
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Appendix table 33: Rare and very rare adverse reactions recorded in summary of product characteristics (SPCs) – corticosteroids 
SOC HLGT PT Frequency Not in 
trials 
Blood and lymphatic system disorders White blood cell disorders Granulocytosis Rare X 
Lymphopenia Rare X 
Monocytopenia Rare X 
Endocrine disorders Adrenal gland disorders Adrenal suppression Rare 
 
Cushingoid Rare 
 
Cushing's syndrome very rare 
 
Eye disorders Anterior eye structural change, deposit and 
degeneration 
Cataract Rare X 
Cataract very rare X 
Glaucoma and ocular hypertension Glaucoma Rare X 
Glaucoma very rare X 
Gastrointestinal disorders Exocrine pancreas conditions Pancreatitis very rare 
 
Gastrointestinal motility and defaecation conditions Constipation very rare 
 
Gastrointestinal signs and symptoms Dyspepsia very rare 
 
Gastrointestinal ulceration and perforation Gastroduodenal ulcer very rare X 
General disorders and administration site 
conditions  
General system disorders NEC Asthenia very rare X 
Fatigue very rare X 
Malaise very rare X 
Oedema peripheral very rare X 
Immune system disorders Allergic conditions Anaphylactic reaction very rare X 
Infections and infestations Fungal infectious disorders Oropharyngeal candidiasis Rare X 
Metabolism and nutrition disorders Appetite and general nutritional disorders Obesity Rare 
 
Musculoskeletal and connective tissue 
disorders 
Bone disorders (excl congenital and fractures) Osteonecrosis very rare X 
Osteoporosis Rare X 
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SOC HLGT PT Frequency Not in 
trials 
Osteoporosis very rare X 
Muscle disorders Myalgia very rare X 
Nervous system disorders Increased intracranial pressure and hydrocephalus Benign intracranial 
hypertension 
Rare X 
Benign intracranial 
hypertension 
very rare X 
Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders NEC Lipodystrophies Rare X 
Skin appendage conditions Rosacea Rare 
 
Vascular disorders Vascular inflammations Vasculitis very rare X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – not 
elsewhere classified     
Frequency: RARE, affecting more than or equal to one in 10,000 patients, but fewer than one in 1,000; VERY RARE, affecting less than one in 10,000. 
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Appendix table 34: Rare and very rare adverse reactions recorded in summary of product characteristics (SPCs) - immunosuppressives: methotrexate 
SOC HLGT PT Frequency Not in 
trials 
Blood and lymphatic system disorders Anaemias nonhaemolytic and marrow depression Anaemia megaloblastic Rare x 
Aplastic anaemia Very rare x 
Bone marrow failure Very rare x 
Haematopoietic neoplasms (excl leukaemias and 
lymphomas) 
Lymphoproliferative disorder Very rare x 
Spleen, lymphatic and reticuloendothelial system 
disorders 
Lymphadenopathy Very rare x 
White blood cell disorders Eosinophilia Very rare x 
Neutropenia Very rare   
Cardiac disorders Pericardial disorders Cardiac tamponade Rare x 
Pericardial effusion Rare x 
Pericarditis Rare x 
Eye disorders Eye disorders NEC Lacrimation increased Very rare x 
Periorbital oedema Very rare x 
Ocular infections, irritations and inflammations Blepharitis Very rare x 
Conjunctivitis Very rare x 
Ocular sensory symptoms NEC Photophobia Very rare x 
Retina, choroid and vitreous haemorrhages and 
vascular disorders 
Retinopathy Very rare x 
Vision disorders Blindness Very rare x 
Vision blurred Rare   
Visual impairment Rare x 
Gastrointestinal disorders Dental and gingival conditions Gingivitis Rare x 
Gastrointestinal haemorrhages NEC Haematemesis Very rare x 
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SOC HLGT PT Frequency Not in 
trials 
Melaena Rare x 
Gastrointestinal inflammatory conditions Enteritis Rare x 
Gastrointestinal motility and defaecation conditions Megacolon Very rare x 
General disorders and administration 
site conditions  
Body temperature conditions Pyrexia Very rare   
General system disorders NEC Pain Very rare   
Tissue disorders NEC Impaired healing Very rare x 
Hepatobiliary disorders Hepatic and hepatobiliary disorders Acute hepatic failure Very rare x 
Chronic hepatitis Very rare x 
Hepatic failure Very rare x 
Hepatitis acute Rare   
Hepatotoxicity Rare x 
Herpes simplex hepatitis Very rare x 
Immune system disorders Immunodeficiency syndromes Hypogammaglobulinaemia Very rare x 
Immunosuppression Very rare x 
Infections and infestations Bacterial infectious disorders Furuncle Very rare x 
Nocardiosis Very rare x 
Fungal infectious disorders Pneumocystis jirovecii 
pneumonia 
Very rare x 
Infections - pathogen unspecified Opportunistic infection  Very rare x 
Pharyngitis Rare x 
Pneumonia Very rare   
Sepsis Very rare x 
Viral infectious disorders Cytomegalovirus infection Very rare   
Investigations Renal and urinary tract investigations and urinalyses Blood creatinine increased Rare x 
Blood urea increased Rare x 
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SOC HLGT PT Frequency Not in 
trials 
Metabolism and nutrition disorders Glucose metabolism disorders (incl diabetes 
mellitus) 
Diabetes mellitus Rare x 
Purine and pyrimidine metabolism disorders Hyperuricaemia Rare x 
Musculoskeletal and connective tissue 
disorders 
Fractures Stress fracture Rare x 
Muscle disorders Muscular weakness Very rare x 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Neoplasm related morbidities Tumour lysis syndrome Very rare x 
Nervous system disorders Movement disorders (incl parkinsonism) Paresis Rare x 
Neurological disorders NEC Dysgeusia Very rare x 
Meningism Very rare x 
Paraesthesia Very rare x 
Sleep disturbances (incl subtypes) Insomnia Very rare   
Central nervous system infections and 
inflammations 
Meningitis aseptic Very rare x 
Psychiatric disorders Cognitive and attention disorders and disturbances Cognitive disorder Very rare x 
Mood disorders and disturbances NEC Mood altered Rare x 
Sexual dysfunctions, disturbances and gender 
identity disorders 
Loss of libido Very rare x 
Renal and urinary disorders Renal disorders (excl nephropathies) Anuria Rare x 
Azotaemia Rare x 
Oliguria Rare x 
Renal failure Rare x 
Urinary tract signs and symptoms Proteinuria Very rare x 
Reproductive system and breast 
disorders 
Breast disorders Gynaecomastia Very rare x 
Menstrual cycle and uterine bleeding disorders Menstrual disorder Very rare x 
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SOC HLGT PT Frequency Not in 
trials 
Sexual function and fertility disorders Erectile dysfunction Very rare x 
Infertility Very rare x 
Oligospermia Very rare x 
Vulvovaginal disorders (excl infections and 
inflammations) 
Vaginal discharge Very rare x 
Respiratory, thoracic and mediastinal 
disorders 
Bronchial disorders (excl neoplasms) Asthma Rare x 
Chronic obstructive 
pulmonary disease 
Very rare x 
Pleural disorders Pleural effusion Very rare x 
Respiratory disorders NEC Apnoea Rare x 
Dyspnoea Very rare x 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Erythema multiforme Rare x 
Rash erythematous Rare x 
Pigmentation disorders Pigmentation disorder Rare x 
Skin and subcutaneous tissue infections and 
infestations 
Paronychia Very rare x 
Skin appendage conditions Acne Rare   
Skin vascular abnormalities Ecchymosis Rare x 
Petechiae Rare x 
Telangiectasia Very rare x 
Vascular disorders Decreased and nonspecific blood pressure disorders 
and shock 
Hypotension Rare x 
Embolism and thrombosis Embolism Rare X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: RARE, affecting more than or equal to one in 10,000 patients, but fewer than one in 1,000; VERY RARE, affecting less than one in 10,000. 
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Appendix table 35: All adverse reactions reported in the summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category - 5-ASAs 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Blood and 
lymphatic 
system 
disorders 
Anaemias nonhaemolytic and 
marrow depression 
Anaemia megaloblastic           x 
Aplastic anaemia       x x x 
Pancytopenia           x 
Coagulopathies and bleeding 
diatheses (excl thrombocytopenic) 
Hypoprothrombinaemia           x 
Haematological disorders NEC Methaemoglobinaemia           x 
Haemoglobinopathies Anaemia Heinz body           x 
Haemolyses and related conditions Haemolytic anaemia           x 
Platelet disorders Thrombocytopenia     x x x   
Red blood cell disorders Macrocytosis           x 
Spleen, lymphatic and 
reticuloendothelial system 
disorders 
Lymphadenopathy           x 
White blood cell disorders agranulocytosis       x x x 
Eosinophilia         x x 
Leukopenia   x   x x x 
Neutropenia       x x x 
Cardiac 
disorders 
Cardiac disorders signs and 
symptoms 
Cyanosis           x 
Palpitations           x 
Myocardial disorders Allergic myocarditis           x 
Myocarditis       x   x 
Pericardial disorders Pericarditis       x   x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Ear and 
labyrinth 
disorders 
Inner ear and VIIIth cranial nerve 
disorders 
Vertigo     x x     
Eye disorders Eye disorders NEC Periorbital oedema           x 
Ocular infections, irritations and 
inflammations 
Scleritis   x         
Gastrointestinal 
disorders 
Anal and rectal conditions NEC Anorectal disorder   x         
Exocrine pancreas conditions Pancreatitis acute         x   
Gastrointestinal inflammatory 
conditions 
Colitis         x   
Colitis ulcerative           x 
Gastrointestinal signs and 
symptoms 
Flatulence   x   x     
Oral soft tissue conditions Stomatitis   x         
Salivary gland conditions Parotitis           x 
Hepatobiliary 
disorders 
Hepatic and hepatobiliary 
disorders 
Cholestasis         x   
Hepatic failure           x 
Hepatic function 
abnormal 
      x     
Hepatitis       x x x 
Hepatitis cholestatic         x   
Hepatitis fulminant           x 
Hepatotoxicity       x     
Immune system 
disorders 
Allergic conditions Anaphylactic reaction           x 
Hypersensitivity         x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Autoimmune disorders Systemic lupus 
erythematosus 
      x     
Immune disorders NEC Polyarteritis nodosa           x 
Infections and 
infestations 
Bacterial infectious disorders Pseudomembranous 
colitis 
          x 
Infections - pathogen unspecified Respiratory tract 
infection 
  x         
Rhinitis   x         
Sinusitis   x         
Injury, 
poisoning and 
procedural 
complications 
Procedural related injuries and 
complications NEC 
Serum sickness           x 
Investigations Gastrointestinal investigations Amylase increased       x     
Hepatobiliary investigations Blood bilirubin increased         x x 
Hepatic enzyme 
increased 
    x   x   
Liver function test 
abnormal 
      x     
Immunology and allergy 
investigations 
Autoantibody positive           x 
Musculoskeletal 
and connective 
tissue disorders 
Connective tissue disorders (excl 
congenital) 
Systematic lupus 
erythematosus 
          x 
Nervous system 
disorders 
Central nervous system infections 
and inflammations 
Meningitis aseptic           x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Cranial nerve disorders (excl 
neoplasms) 
Parosmia           x 
Encephalopathies Encephalopathy           x 
Neurological disorders NEC Ataxia           x 
Dysgeusia   x         
Peripheral neuropathies Neuropathy peripheral       x x x 
Psychiatric 
disorders 
Disturbances in thinking and 
perception 
Hallucination           x 
Renal and 
urinary 
disorders 
Nephropathies Nephrotic syndrome       x   x 
Tubulointerstitial 
nephritis 
      x x x 
Renal disorders (excl 
nephropathies) 
Renal failure       x x   
Urinary tract signs and symptoms Chromaturia       x     
Crystalluria           x 
Haematuria           x 
Proteinuria   x         
Reproductive 
system and 
breast disorders 
Sexual function and fertility 
disorders 
Oligospermia         x x 
Respiratory, 
thoracic and 
mediastinal 
disorders 
Bronchial disorders (excl 
neoplasms) 
Bronchospasm       x x   
Lower respiratory tract disorders 
(excl obstruction and infection) 
allergic alveolitis       x     
Alveolitis         x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Eosinophilic pneumonia       x     
Idiopathic pulmonary 
fibrosis 
          x 
Interstitial lung disease x         x 
Lung infiltration       x x   
Pneumonitis       x x   
Pulmonary eosinophilia       x x x 
Respiratory disorders NEC Cough   x   x x   
Dyspnoea     x x x   
Skin and 
subcutaneous 
tissue disorders 
Angioedema and urticaria Angioedema           x 
Urticaria     x       
Epidermal and dermal conditions Acute generalised 
exanthematous 
pustulosis 
          x 
Dermatitis bullous       x     
Dermatitis exfoliative           x 
Drug reaction with 
eosinophilia and systemic 
symptoms 
          x 
Erythema           x 
Erythema multiforme         x   
Lichen planus           x 
Photosensitivity reaction     x     x 
Skin discolouration           x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Toxic epidermal 
necrolysis 
          x 
Vascular 
disorders 
Vascular inflammations Vasculitis     x       
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – not 
elsewhere classified     
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 36: All adverse reactions recorded in summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category - antibiotics: 
macrolides 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Blood and 
lymphatic system 
disorders 
Platelet disorders Thrombocytosis     x       
White blood cell disorders agranulocytosis           x 
Eosinophilia     x       
Leukopenia     x       
Neutropenia     x       
Cardiac disorders Cardiac arrhythmias Torsade de pointes           x 
Ventricular tachycardia           x 
Cardiac disorders signs and 
symptoms 
Palpitations     x       
Ear and labyrinth 
disorders 
Hearing disorders Deafness           x 
Hypoacusis     x       
Inner ear and VIIIth cranial 
nerve disorders 
Tinnitus     x       
Vertigo     x       
Gastrointestinal 
disorders 
Anal and rectal conditions NEC Proctalgia     x       
Exocrine pancreas conditions Pancreatitis acute           x 
Gastrointestinal inflammatory 
conditions 
Gastritis     x       
Gastrointestinal motility and 
defaecation conditions 
Constipation     x       
Gastrooesophageal reflux 
disease 
    x       
Gastrointestinal signs and 
symptoms 
Dyspepsia   x         
Eructation     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Flatulence     x       
Oral soft tissue conditions Stomatitis     x       
Salivary gland conditions Dry mouth     x       
Tongue conditions Glossitis     x       
Tongue discolouration           x 
General disorders 
and 
administration 
site conditions  
General system disorders NEC Asthenia     x       
Chest pain     x       
Chills     x       
Fatigue     x       
Malaise     x       
Hepatobiliary 
disorders 
Hepatic and hepatobiliary 
disorders 
Cholestasis     x       
Hepatic failure           x 
Hepatitis     x       
Jaundice hepatocellular           x 
Immune system 
disorders 
Allergic conditions Anaphylactic reaction           x 
Hypersensitivity     x       
Infections and 
infestations 
Bacterial infectious disorders Erysipelas           x 
Pseudomembranous colitis           x 
Fungal infectious disorders Candida infection     x       
Infections - pathogen 
unspecified 
Gastroenteritis     x       
Vaginal infection     x       
Investigations Cardiac and vascular 
investigations (excl enzyme 
tests) 
Electrocardiogram QT 
prolonged 
    x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Enzyme investigations NEC Blood alkaline phosphatase 
increased 
    x       
Blood lactate 
dehydrogenase increased 
    x       
Haematology investigations 
(incl blood groups) 
 International normalised 
ratio increased 
          x 
Prothrombin time 
prolonged 
          x 
Hepatobiliary investigations Alanine aminotransferase 
increased 
    x       
Aspartate 
aminotransferase 
increased 
    x       
Gamma-
glutamyltransferase 
increased 
    x       
Metabolism and 
nutrition 
disorders 
Appetite and general nutrition 
disorders 
Decreased appetite     x       
musculoskeletal 
and connective 
tissue disorders 
Muscle disorders Myopathy           x 
Rhabdomyolysis           x 
Nervous system 
disorders 
Cranial nerve disorders (excl 
neoplasms) 
Anosmia           x 
Parosmia           x 
Headaches Headache   x         
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Movement disorders (incl 
parkinsonism) 
Tremor     x       
Neurological disorders NEC Dizziness     x       
Paraesthesia           x 
Somnolence     x       
Seizures (incl subtypes) Seizure           x 
Sleep disturbances (incl 
subtypes) 
Insomnia   x         
Neurological disorders NEC Ageusia           x 
Psychiatric 
disorders 
Anxiety disorders and 
symptoms 
Anxiety     x       
Deliria (incl confusion) Confusional state           x 
Disorientation           x 
Depressed mood disorders and 
disturbances 
Depression           x 
Dissociative disorders Depersonalisation/ 
derealisation disorder 
          x 
Disturbances in thinking and 
perception 
Hallucination           x 
Schizophrenia and other 
psychotic disorders 
Psychotic disorder           x 
Sleep disorders and 
disturbances 
Abnormal dreams           x 
Nephropathies Tubulointerstitial nephritis           x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Renal and urinary 
disorders 
Renal disorders (excl 
nephropathies) 
Renal failure           x 
Respiratory, 
thoracic and 
mediastinal 
disorders 
Upper respiratory tract 
disorders (excl infections) 
Epistaxis     x       
Skin and 
subcutaneous 
tissue disorders 
Angioedema and urticaria Angioedema           x 
Urticaria     x       
Epidermal and dermal 
conditions 
Drug reaction with 
eosinophilia and systemic 
symptoms 
          x 
Pruritus     x       
Rash   x         
Stevens-Johnson syndrome           x 
Toxic epidermal necrolysis           x 
Skin appendage conditions Acne           x 
Hyperhidrosis   x         
Vascular 
disorders 
Vascular haemorrhagic 
disorders 
Haemorrhage           X 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC 
– not elsewhere classified     
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 37: All adverse reactions recorded in summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category - antibiotics: 
nitroimidazole derivatives 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Blood and lymphatic 
system disorders 
Anaemias nonhaemolytic 
and marrow depression 
Bone marrow failure           x 
Pancytopenia         x   
Platelet disorders Thrombocytopenia         x   
White blood cell disorders agranulocytosis         x   
Leukopenia           x 
Neutropenia         x   
Eye disorders Vision disorders Diplopia         x   
Vision disorders Myopia         x   
Gastrointestinal 
disorders 
Gastrointestinal conditions 
NEC 
Gastrointestinal 
disorder 
          x 
Gastrointestinal signs and 
symptoms 
Abdominal pain           x 
Vomiting           x 
Oral soft tissue conditions Stomatitis           x 
Tongue conditions Dysgeusia           x 
Tongue coated           x 
Hepatobiliary disorders Hepatic and hepatobiliary 
disorders 
Hepatitis cholestatic         x   
Jaundice         x   
Immune system 
disorders 
Allergic conditions Anaphylactic reaction       x     
Investigations Hepatobiliary investigations Liver function test 
abnormal 
        x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Metabolism and 
nutrition disorders 
Appetite and general 
nutrition disorders 
Decreased appetite           x 
Nervous system 
disorders 
Encephalopathies Encephalopathy         x   
Neurological disorders NEC Cerebellar syndrome         x   
Somnolence         x   
Peripheral neuropathies Peripheral sensory 
neuropathy 
          x 
Seizures (incl subtypes) Epilepsy           x 
Seizure         x   
Psychiatric disorders Depressed mood disorders 
and disturbances 
Depression           x 
Schizophrenia and other 
psychotic disorders 
Psychotic disorder         x   
Renal and urinary 
disorders 
Urinary tract signs and 
symptoms 
Chromaturia         x   
Skin and subcutaneous 
tissue disorders 
Angioedema and urticaria Angioedema           x 
Urticaria           x 
Epidermal and dermal 
conditions 
Pruritus         x   
Rash pustular         x   
Erythema multiforme           x 
Skin vascular abnormalities Flushing         x   
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified.  Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 
1/1,000; VERY RARE, < 1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 38: All adverse reactions recorded in summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category - antibiotics: 
quinolones 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not known 
Blood and lymphatic 
system disorders 
Anaemias nonhaemolytic and 
marrow depression 
Bone marrow failure         x   
Pancytopenia         x   
Haemolyses and related 
conditions 
Haemolytic anaemia         x   
Platelet disorders Thrombocytopenia       x     
Thrombocytosis       x     
White blood cell disorders agranulocytosis         x   
Eosinophilia     x       
Leukocytosis       x     
Leukopenia       x     
Neutropenia       x     
Cardiac disorders Cardiac arrhythmias Tachycardia       x     
Torsade de pointes           x 
Ventricular arrhythmia           x 
Ear and labyrinth 
disorders 
Hearing disorders Hypoacusis       x     
Inner ear and VIIIth cranial 
nerve disorders 
Tinnitus       x     
Vertigo       x     
Eye disorders Vision disorders Visual impairment       x     
Gastrointestinal 
disorders 
Gastrointestinal signs and 
symptoms 
Dyspepsia     x       
Flatulence     x       
Vomiting     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not known 
General disorders and 
administration site 
conditions  
General system disorders NEC Asthenia     x       
Hepatobiliary 
disorders 
Hepatic and hepatobiliary 
disorders 
Hepatic necrosis         x   
Hepatitis       x     
Jaundice cholestatic       x     
Liver disorder       x     
Immune system 
disorders 
Allergic conditions Allergic oedema       x     
Anaphylactic reaction         x   
Anaphylactic shock         x   
Hypersensitivity       x     
Infections and 
infestations 
Infections - pathogen 
unspecified 
Superinfection     x       
Injury, poisoning and 
procedural 
complications 
Injuries NEC Tendon rupture         x   
Procedural related injuries 
and complications NEC 
Serum sickness         x   
Investigations Cardiac and vascular 
investigations (excl enzyme 
tests) 
Electrocardiogram QT 
prolonged 
          x 
Enzyme investigations NEC Blood alkaline 
phosphatase increased 
    x       
Gastrointestinal investigations Amylase increased       x     
Haematology investigations 
(incl blood groups) 
 International normalised 
ratio increased 
          x 
Hepatobiliary investigations Blood bilirubin increased     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not known 
Transaminases increased     x       
Metabolism and 
nutrition disorders 
Appetite and general 
nutritional disorders 
Decreased appetite     x       
Glucose metabolism disorders 
(incld diabetes mellitus) 
Hyperglycaemia       x     
Hypoglycaemia       x     
Musculoskeletal and 
connective tissue 
disorders 
Joint disorders Arthritis       x     
Muscle disorders Hypertonia       x     
Muscle spasms       x     
Muscular weakness         x   
Myasthenia gravis         x   
Musculoskeletal and 
connective tissue disorders 
NEC 
Musculoskeletal pain     x       
Tendon, ligament and 
cartilage disorders 
Tendonitis         x   
Nervous system 
disorders 
Cranial nerve disorders (excl 
neoplasms) 
Olfactory nerve disorder         x   
Headaches Migraine         x   
Increased intracranial 
pressure and hydrocephalus 
 Intracranial pressure 
increased  
        x   
Benign intracranial 
hypertension 
        x   
Movement disorders (incl 
parkinsonism) 
Tremor       x     
Neurological disorders NEC Coordination abnormal         x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not known 
Dysaesthesia       x     
Dysgeusia     x       
Gait disturbance         x   
Hypoaesthesia       x     
Paraesthesia       x     
Seizures (incl subtypes) Seizure       x     
Psychiatric disorders Anxiety disorders and 
symptoms 
Agitation     x       
Anxiety       x     
Changes in physical activity Psychomotor 
hyperactivity 
    x       
Deliria (incl confusion) Confusional state       x     
Depressed mood disorders 
and disturbances 
Depression       x     
Disturbances in thinking and 
perception 
Hallucination       x     
Schizophrenia and other 
psychotic disorders 
Psychotic disorder         x   
Sleep disorders and 
disturbances 
Abnormal dreams       x     
Sleep disorder     x       
Renal and urinary 
disorders 
Nephropathies Tubulointerstitial 
nephritis 
      x     
Renal disorders (excl 
nephropathies) 
Renal failure       x     
Renal impairment     x       
Crystalluria       x     
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not known 
Urinary tract signs and 
symptoms 
Haematuria       x     
Respiratory, thoracic 
and mediastinal 
disorders 
Respiratory disorders NEC Dyspnoea       x     
Skin and 
subcutaneous tissue 
disorders 
Angioedema and urticaria Urticaria     x       
Epidermal and dermal 
conditions 
Acute generalised 
exanthematous 
pustulosis 
          x 
Erythema multiforme         x   
Pruritus     x       
Stevens-Johnson 
syndrome 
        x   
Toxic epidermal 
necrolysis 
        x   
Skin and subcutaneous tissue 
disorders NEC 
Erythema nodosum         x   
Skin appendage conditions Hyperhidrosis       x     
Skin vascular abnormalities Petechiae         x   
Surgical and medical 
procedures 
Vascular therapeutic 
procedures 
Vasodilation procedure       x     
Vascular disorders Decreased and nonspecific 
blood pressure disorders and 
shock 
Hypotension       x     
Syncope       x     
Vascular inflammations Vasculitis         x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not known 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 39: All adverse reactions recorded in summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category - biologics: anti-
TNFα 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Blood and lymphatic 
system disorders 
Anaemias nonhaemolytic and 
marrow depression 
Anaemia   x         
Pancytopenia       x     
Haemolyses and related 
conditions 
Haemolytic anaemia       x     
Platelet disorders Immune 
thrombocytopenic 
purpura 
    x x     
Thrombocytopenia   x x       
Thrombotic 
thrombocytopenic 
purpura 
      x     
Spleen, lymphatic and 
reticuloendothelial system 
disorders 
Lymphadenopathy   x         
White blood cell disorders agranulocytosis       x     
Leukocytosis   x         
Leukopenia x x   x     
Lymphocytosis     x       
Lymphopenia     x       
Neutropenia   x         
Cardiac disorders Cardiac arrhythmias Arrhythmia     x       
Bradycardia     x       
Cardiac arrest       x     
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Tachycardia   x         
Cardiac disorders signs and 
symptoms 
Cyanosis       x     
Palpitations   x         
Coronary artery disorders Myocardial ischaemia           x 
Heart failures Cardiac failure     x       
Pericardial disorders Pericardial effusion       x     
Ear and labyrinth 
disorders 
Hearing disorders Deafness     x       
Inner ear and VIIIth cranial 
nerve disorders 
Tinnitus     x       
Vertigo   x         
Eye disorders Eye disorders NEC Eye swelling   x         
Periorbital oedema     x       
Ocular infections, irritations 
and inflammations 
Blepharitis   x         
Conjunctivitis   x         
Endophthalmitis       x     
Hordeolum     x       
Keratitis     x       
Vision disorders Blindness           x 
Diplopia     x       
Visual impairment   x         
Gastrointestinal 
disorders 
Gastrointestinal 
haemorrhages NEC 
Gastrointestinal 
haemorrhage 
  x         
Gastrointestinal motility and 
defaecation conditions 
Gastrooesophageal reflux 
disease 
  x         
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Gastrointestinal signs and 
symptoms 
Dysphagia     x       
Gastrointestinal ulceration 
and perforation 
Intestinal perforation     x x     
Oral soft tissue conditions Cheilitis     x       
Salivary gland conditions Sjogren's syndrome   x         
General disorders and 
administration site 
conditions  
General system disorders NEC Chest pain   x         
Chills   x         
Face oedema     x       
Granuloma       x     
Inflammation     x       
Infusion related reaction x           
Oedema   x         
Tissue disorders NEC Impaired healing   x x       
Hepatobiliary disorders Gallbladder disorders Cholecystitis     x       
Hepatic and hepatobiliary 
disorders 
Autoimmune hepatitis       x     
Hepatic failure           x 
Hepatic function 
abnormal 
  x         
Hepatic steatosis     x       
Hepatitis     x x     
Hepatitis B       x     
Hepatocellular injury     x       
Jaundice       x     
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Immune system 
disorders 
Allergic conditions Allergic respiratory 
system 
  x         
Anaphylactic reaction     x x     
Anaphylactic shock       x     
Immune disorders NEC Sarcoidosis     x x     
Infections and 
infestations 
Bacterial infectious disorders Bacterial infection   x x       
Cellulitis   x         
Furuncle       x     
Fungal infectious disorders Candida infection   x         
Fungal infection   x x       
Infections - pathogen 
unspecified 
Arthritis infective   x         
Diverticulitis     x       
Impetigo   x         
Infection parasitic       x     
Lower respiratory tract 
infection 
  x         
Meningitis       x     
Necrotising fasciitis   x         
Neurological infection     x       
Oral infection   x         
Paronychia   x         
Vaccine breakthrough 
infection 
          x 
Viral infectious disorders Hepatitis B       x     
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Herpes zoster   x         
Viral infection x           
Investigations Enzyme investigations NEC Blood lactate 
dehydrogenase increased 
  x         
Haematology investigations 
(incl blood groups) 
Activated partial 
thromboplastin time 
prolonged 
  x         
Hepatobiliary investigations Blood bilirubin increased     x       
Immunology and allergy 
investigations 
Autoantibody positive   x x       
Complement factor 
abnormal 
      x     
Lipid analyses Lipids increased x           
Metabolic, nutritional and 
blood gas investigations 
Blood uric acid increased   x         
Water, electrolyte and mineral 
investigations 
Blood sodium abnormal   x         
Metabolism and 
nutrition disorders 
Bone, calcium, magnesium 
and phosphorus metabolism 
disorders 
Hypocalcaemia   x         
Hypophosphataemia   x         
Electrolyte and fluid balance 
conditions 
Hypokalaemia   x         
Glucose metabolism disorders 
(incld diabetes mellitus) 
Hyperglycaemia   x         
Musculoskeletal and 
connective tissue 
disorders 
Connective tissue disorders 
(excl congenital) 
Systematic lupus 
erythematosus 
    x       
Muscle disorders Rhabdomyolysis     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Musculoskeletal and 
connective tissue disorders 
NEC 
Musculoskeletal pain x           
Neoplasms benign, 
malignant and 
unspecified (incl cysts 
and polyps) 
Leukaemias Leukaemia       x     
Lymphomas Hodgkin's disease Hodgkin's disease       x     
Lymphomas non-Hodgkin's T-
cell 
Hepatosplenic T-cell 
lymphoma 
          x 
Lymphomas non-Hodgkin's 
unspecified histology 
Non-Hodgkin's lymphoma       x     
Miscellaneous and site 
unspecified neoplasms benign 
Benign neoplasm   x         
Reproductive neoplasms 
female malignant and 
unspecified 
Cervix carcinoma       x     
Skin neoplasms malignant and 
unspecified 
Malignant melanoma     x x     
Neuroendocrine 
carcinoma of the skin 
          x 
Skin cancer   x         
Nervous system 
disorders 
Central nervous system 
infections and inflammations 
Myelitis transverse       x     
Central nervous system 
vascular disorders 
Cerebrovascular 
accidents 
    x       
Headaches Migraine   x         
Mental impairment disorders Amnesia     x       
Movement disorders (incl 
parkinsonism) 
Tremor     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Neurological disorders NEC Agitation     x       
Hypoaesthesia   x         
Paraesthesia   x         
Somnolence     x       
Peripheral neuropathies Neuropathy peripheral     x       
Seizures (incl subtypes) Seizure     x       
Spinal cord and nerve root 
disorders 
Nerve root compression   x         
Psychiatric disorders Anxiety disorders and 
symptoms 
Anxiety   x         
Nervousness     x       
Deliria (incl confusion) Confusional state     x       
Mood disorders and 
disturbances NEC 
Apathy       x     
Mood altered   x         
Renal and urinary 
disorders 
Renal disorders (excl 
nephropathies) 
Pyelonephritis     x       
Renal impairment   x         
Urinary tract signs and 
symptoms 
Haematuria   x         
Urinary tract signs and 
symptoms 
Nocturia     x       
Reproductive system 
and breast disorders 
Sexual function and fertility 
disorders 
Erectile dysfunction     x       
Bronchial disorders (excl 
neoplasms) 
Asthma   x         
Bronchospasm       x     
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Respiratory, thoracic 
and mediastinal 
disorders 
Chronic obstructive 
pulmonary disease 
    x       
Lower respiratory tract 
disorders (excl obstruction 
and infection) 
Interstitial lung disease     x   x   
Pulmonary fibrosis       x     
Pulmonary oedema       x     
Pleural disorders Pleural effusion     x x     
Pleurisy       x     
Upper respiratory tract 
disorders (excl infections) 
Epistaxis   x         
Skin and subcutaneous 
tissue disorders 
Angioedema and urticaria Angioedema       x     
Cornification and dystrophic 
skin disorders 
Hyperkeratosis     x       
Cutaneous neoplasms benign Skin papilloma     x       
Epidermal and dermal 
conditions 
Dermatitis   x         
Dermatomyositis         x x 
Dry skin   x         
Psoriasis   x         
Scar     x       
Stevens-Johnson 
syndrome 
      x     
Toxic epidermal 
necrolysis 
      x     
Skin and subcutaneous tissue 
infections and infestations 
Fungal skin infection   x         
Onychomycosis     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Skin appendage conditions Hyperhidrosis   x         
Night sweats     x       
Onychoclasis   x         
Rosacea     x       
Seborrhoea     x       
Skin vascular abnormalities Ecchymosis   x         
Petechiae       x     
Epidermal and dermal 
conditions 
Contusion   x         
Dermatitis bullous     x       
Erythema multiforme       x     
Pigmentation disorders Pigmentation disorder     x       
Skin vascular abnormalities Cutaneous vasculitis       x     
Flushing   x         
Vascular disorders Aneurysms and artery 
dissections 
aortic aneurysm      x       
Arteriosclerosis, stenosis, 
vascular insufficiency and 
necrosis 
Arterial occlusive disease     x       
Peripheral ischaemia     x       
Vasospasm       x     
Decreased and nonspecific 
blood pressure disorders and 
shock 
Circulatory collapse       x     
Hypotension   x         
Syncope     x       
Embolism and thrombosis Thrombophlebitis     x       
Vascular disorders NEC Hot flush   x         
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Vascular haemorrhagic 
disorders 
Haematoma   x x       
Vascular hypertensive 
disorders 
Hypertension   x         
Vascular inflammations Vasculitis     x x     
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified     
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 40: All adverse reactions recorded in summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category – corticosteroids 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Blood and 
lymphatic system 
disorders 
White blood cell disorders Granulocytosis       x     
Lymphopenia 
   
x 
  
Monocytopenia       x     
Cardiac disorders Coronary artery disorders Myocardial infarction           x 
Heart failures Cardiac failure congestive 
     
x 
Myocardial disorders Myocardial rupture           x 
Endocrine 
disorders 
Adrenal gland disorders Adrenal insufficiency 
     
x 
Steroid withdrawal syndrome 
     
x 
Hypothalamus and pituitary 
gland disorders 
Hypopituitarism           x 
Eye disorders Anterior eye structural 
change, deposit and 
degeneration 
Cataract 
   
x x x 
Cataract subcapsular   x         
Corneal thinning           x 
Glaucoma and ocular 
hypertension 
Glaucoma 
   
x x x 
Ocular structural change, 
deposit and degeneration 
NEC 
Chorioretinopathy 
     
x 
Exophthalmos           x 
Scleral thinning           x 
Gastrointestinal 
disorders 
Gastrointestinal conditions 
NEC 
Gastric disorder           x 
Gastrointestinal 
haemorrhages NEC 
Gastric haemorrhage 
     
x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Gastrointestinal 
inflammatory conditions 
Oesophagitis           x 
Gastrointestinal ulceration 
and perforation 
Gastroduodenal ulcer 
    
x x 
Peptic ulcer 
 
x 
    
General system 
disorders and 
administration 
conditions 
General system disorders 
NEC 
Asthenia 
    
x 
 
Fatigue         x x 
Influenza like illness 
  
x 
   
Malaise         x x 
Oedema peripheral 
    
x 
 
Tissue disorders NEC Impaired healing 
 
x 
   
x 
Immune system 
disorders 
Allergic conditions Anaphylactic reaction         x   
Drug hypersensitivity 
     
x 
Infections   Oropharyngeal candidiasis       x     
Infections - pathogen 
unspecified 
Infection susceptibility 
increased 
  x       x 
Opportunistic infection  
     
x 
Mycobacterial infectious 
disorders 
Tuberculosis 
     
x 
Injury, poisoning 
and procedural 
complications 
Bone and joint injuries Spinal compression fracture 
     
x 
Injuries NEC Tendon rupture           x 
Investigations Hepatobiliary investigations Hepatic enzyme increased           x 
Metabolic, nutritional and 
blood gas investigations 
Carbohydrate tolerance 
decreased 
          x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Neurological, special senses 
and psychiatric 
investigations 
Intraocular pressure increased 
     
x 
Water, electrolyte and 
mineral investigations 
Urine calcium increased 
     
x 
Metabolism and 
nutrition disorders 
Acid-base disorders Alkalosis hypokalaemic           x 
Metabolic acidosis 
     
x 
Electrolyte and fluid balance 
conditions 
Sodium retention 
 
x 
    
Glucose metabolism 
disorders (incl diabetes 
mellitus) 
Glucose tolerance impaired 
     
x 
Increased insulin requirement           x 
Lipid metabolism disorders Epidural lipomatosis 
     
x 
Musculoskeletal 
and connective 
tissue disorders 
Bone disorders (excl 
congenital and fractures) 
Osteonecrosis         x x 
Osteoporosis 
 
x 
 
x x x 
Fractures Pathological fracture 
     
x 
Muscle disorders Muscle twitching 
 
x 
    
Myalgia   x     x x 
Myopathy 
     
x 
Musculoskeletal and 
connective tissue disorders 
NEC 
Growth retardation             
Joint disorders Arthralgia 
 
x 
   
x 
Neoplasms benign, 
malignant and 
Soft tissue neoplasms 
malignant and unspecified 
Kaposi's sarcoma           x 
468 
 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
unspecified (incl 
cysts and polyps) 
Nervous system 
disorders 
Increased intracranial 
pressure and hydrocephalus 
Benign intracranial 
hypertension 
   
x x 
 
Intracranial pressure increased            x 
Mental impairment 
disorders 
Amnesia 
     
x 
Neurological disorders NEC Somnolence     x       
Seizures (incl subtypes) Seizure 
     
x 
Psychiatric 
disorders 
Anxiety disorders and 
symptoms 
Anxiety           x 
Nervousness 
 
x 
    
Cognitive and attention 
disorders and disturbances 
Cognitive disorder           x 
Deliria (incl confusion) Confusional state 
     
x 
Mood disorders and 
disturbances NEC 
Affective disorder   x         
Euphoric mood 
 
x 
   
x 
Irritability   x       x 
Personality disorders and 
disturbances in behaviour 
Personality change 
     
x 
Psychiatric and behavioural 
symptoms NEC 
Abnormal behaviour           x 
Psychiatric disorders NEC Mental disorder 
     
x 
Schizophrenia and other 
psychotic disorders 
Psychotic behaviour           x 
Psychotic disorder 
     
x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Reproductive system and breast disorders Menstruation irregular           x 
Respiratory, 
thoracic and 
mediastinal 
disorders 
Pulmonary vascular 
disorders 
Pulmonary embolism 
     
x 
Respiratory disorders NEC Hiccups           x 
Skin and 
subcutaneous 
tissue disorders 
Angioedema and urticaria Angioedema 
     
x 
Cornification and dystrophic 
skin disorders 
Skin atrophy   x         
Epidermal and dermal 
conditions 
Allergic exanthema 
 
x 
   
x 
Dermatitis contact 
 
x 
   
x 
Erythema           x 
Pruritus 
     
x 
Skin reaction 
 
x 
    
Skin and subcutaneous 
tissue disorders NEC 
Lipodystrophies 
   
x 
  
Skin vascular abnormalities Ecchymosis 
 
x 
   
x 
Petechiae 
 
x 
   
x 
Telangiectasia 
     
x 
Vascular disorders Decreased and nonspecific 
blood pressure disorders and 
shock 
Hypotension           x 
Embolism and thrombosis Embolism arterial 
     
x 
Thrombosis 
     
x 
Vascular inflammations Vasculitis         x X 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified   
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 41: All adverse reactions recorded in summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category - 
immunosuppressives: antimetabolites 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Blood and lymphatic 
system disorders 
Anaemias nonhaemolytic 
and marrow depression 
Anaemia megaloblastic       x     
Aplastic anaemia       x     
Bone marrow failure       x     
Pancytopenia       x     
White blood cell disorders agranulocytosis       x     
Granulocytopenia       x     
Gastrointestinal 
disorders 
Gastrointestinal ulceration 
and perforation 
Gastrointestinal ulcer         x   
Malabsorption conditions Steatorrhoea     x       
Oral soft tissue conditions Mouth ulceration       x     
Hepatobiliary 
disorders 
Hepatic and hepatobiliary 
disorders 
Cholestasis   x x       
Hepatic necrosis       x     
Liver disorder   x         
Liver injury       x     
Venoocclusive liver disease       x     
Infections and 
infestations 
Bacterial infectious disorders Bacterial infection     x       
Fungal infectious disorders Fungal infection     x       
Metabolism and 
nutrition disorders 
Appetite and general 
nutrition disorders 
Decreased appetite x   x       
Neoplasms benign, 
malignant and 
Leukaemias Acute myeloid leukaemia       x x   
Lymphomas non-Hodgkin's 
T-cell 
Hepatosplenic T-cell 
lymphoma 
        x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
unspecified (incl 
cysts and polyps) 
Lymphomas non-Hodgkin's 
unspecified histology 
Non-Hodgkin's lymphoma   x   x     
Metastases Metastasis         x   
Miscellaneous and site 
unspecified neoplasms 
malignant and unspecified 
Squamous cell carcinoma   x         
Reproductive neoplasms 
female malignant and 
unspecified 
Cervix carcinoma   x   x     
Vulval cancer   x         
Skin neoplasms malignant 
and unspecified 
Skin cancer       x     
Soft tissue neoplasms 
malignant and unspecified 
Kaposi's sarcoma   x         
Sarcoma       x     
Reproductive 
system and breast 
disorders 
Sexual function and fertility 
disorders 
Oligospermia         x   
Respiratory, thoracic 
and mediastinal 
disorders 
Lower respiratory tract 
disorders (excl obstruction 
and infection) 
Interstitial lung disease       x     
Pneumonitis         x   
Skin and 
subcutaneous tissue 
disorders 
Epidermal and dermal 
conditions 
Acute febrile neutrophilic 
dermatosis 
          x 
Photosensitivity reaction       x     
Stevens-Johnson syndrome       x x   
Toxic epidermal necrolysis       x x   
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; NEC – 
not elsewhere classified   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 42: All adverse reactions recorded in summary of product characteristics (SPCs), but not in Crohn’s disease trials, by frequency category - 
immunosuppressives: methotrexate 
SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Blood and lymphatic 
system disorders 
Anaemias nonhaemolytic 
and marrow depression 
Anaemia   x         
Anaemia megaloblastic       x     
Aplastic anaemia         x   
Bone marrow failure         x   
Pancytopenia     x       
Haematopoietic neoplasms 
(excl leukaemias and 
lymphomas) 
Lymphoproliferative 
disorder 
        x   
Spleen, lymphatic and 
reticuloendothelial system 
disorders 
Lymphadenopathy         x   
White blood cell disorders agranulocytosis     x       
Eosinophilia         x   
Cardiac disorders Pericardial disorders Cardiac tamponade       x     
Pericardial effusion       x     
Pericarditis       x     
Ear and labyrinth 
disorders 
Inner ear and VIIIth cranial 
nerve disorders 
Vertigo     x       
Eye disorders Eye disorders NEC Lacrimation increased         x   
Periorbital oedema         x   
Ocular infections, 
irritations and 
inflammations 
Blepharitis         x   
Conjunctivitis         x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Ocular sensory symptoms 
NEC 
Photophobia         x   
Retina, choroid and 
vitreous haemorrhages and 
vascular disorders 
Retinopathy         x   
Vision disorders Blindness         x   
Visual impairment       x     
Gastrointestinal 
disorders 
Dental and gingival 
conditions 
Gingivitis       x     
Gastrointestinal 
haemorrhages NEC 
Gastrointestinal 
haemorrhage 
    x       
Haematemesis         x   
Melaena       x     
Gastrointestinal 
inflammatory conditions 
Enteritis       x     
Gastrointestinal motility 
and defaecation conditions 
Megacolon         x   
Gastrointestinal ulceration 
and perforation 
Gastrointestinal ulcer     x       
Malabsorption conditions Malabsorption     x       
Oral soft tissue conditions Stomatitis x           
General disorders and 
administration site 
conditions  
Tissue disorders NEC Impaired healing         x   
Hepatobiliary disorders Acute hepatic failure         x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Hepatic and hepatobiliary 
disorders 
Chronic hepatitis         x   
Hepatic cirrhosis     x       
Hepatic failure         x   
Hepatic fibrosis     x       
Hepatic steatosis     x       
Hepatotoxicity       x     
Herpes simplex hepatitis         x   
Immune system 
disorders 
Allergic conditions Anaphylactic shock     x       
Anaphylactoid reaction     x       
Hypersensitivity     x       
Immune disorders NEC Hypersensitivity vasculitis     x       
Immunodeficiency 
syndromes 
Hypogammaglobulinaemia         x   
Immunosuppression         x   
Infections and 
infestations 
Bacterial infectious 
disorders 
Furuncle         x   
Nocardiosis         x   
Fungal infectious disorders Pneumocystis jirovecii 
pneumonia 
        x x 
Infections - pathogen 
unspecified 
Opportunistic infection          x   
Pharyngitis       x     
Sepsis         x   
Viral infectious disorders Herpes zoster   x x       
Injury, poisoning and 
procedural 
complications 
Exposures, chemical 
injuries and poisoning 
Toxicity to various agents     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Investigations Protein and chemistry 
analyses NEC 
Blood albumin decreased     x       
Renal and urinary tract 
investigations and 
urinalyses 
Blood creatinine increased       x     
Blood urea increased       x     
Metabolism and 
nutrition disorders 
Appetite and general 
nutritional disorders 
Decreased appetite x           
Glucose metabolism 
disorders (incl diabetes 
mellitus) 
Diabetes mellitus       x     
Metabolism disorders NEC Metabolic disorder           x 
Purine and pyrimidine 
metabolism disorders 
Hyperuricaemia       x     
Musculoskeletal and 
connective tissue 
disorders 
Bone disorders (excl 
congenital and fractures) 
Osteoporosis     x       
Fractures Stress fracture       x     
Muscle disorders Muscular weakness         x   
Neoplasms benign, 
malignant and 
unspecified (incl cysts 
and polyps) 
Neoplasm related 
morbidities 
Tumour lysis syndrome         x   
Nervous system 
disorders 
Encephalopathies Encephalopathy     x       
Increased intracranial 
pressure and 
hydrocephalus 
Brain oedema           x 
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Movement disorders (incl 
parkinsonism) 
Paresis       x     
Neurological disorders NEC Dysgeusia         x   
Meningism         x   
Paraesthesia         x   
Somnolence   x         
Seizures (incl subtypes) Seizure     x       
Central nervous system 
infections and 
inflammations 
Meningitis aseptic         x   
Pregnancy, puerperium 
and perinatal 
conditions 
Abortions and stillbirths Abortion           x 
Foetal death           x 
Foetal complications Foetal damage           x 
Psychiatric disorders Cognitive and attention 
disorders and disturbances 
Cognitive disorder         x   
Deliria (incl confusion) Confusional state     x       
Depressed mood disorders 
and disturbances 
Depression     x       
Mood disorders and 
disturbances NEC 
Mood altered       x     
Schizophrenia and other 
psychotic disorders 
Psychotic disorder           x 
Sexual dysfunctions, 
disturbances and gender 
identity disorders 
Loss of libido         x   
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Renal and urinary 
disorders 
Bladder and bladder neck 
disorders (excl calculi) 
Cystitis noninfective     x       
Renal disorders (excl 
nephropathies) 
Anuria       x     
Azotaemia       x     
Oliguria       x     
Renal failure       x     
Urinary tract signs and 
symptoms 
Dysuria     x       
Proteinuria         x   
Reproductive system 
and breast disorders 
Breast disorders Gynaecomastia         x   
Female reproductive tract 
infections and 
inflammations 
Vaginal inflammation     x       
Menstrual cycle and 
uterine bleeding disorders 
Menstrual disorder         x   
Sexual function and fertility 
disorders 
Erectile dysfunction         x   
Infertility         x   
Oligospermia         x   
Vulvovaginal disorders 
(excl infections and 
inflammations) 
Vaginal discharge         x   
Vaginal ulceration     x       
Respiratory, thoracic 
and mediastinal 
disorders 
Bronchial disorders (excl 
neoplasms) 
Asthma       x     
Chronic obstructive 
pulmonary disease 
        x   
Acute pulmonary oedema           x 
Alveolitis   x         
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Lower respiratory tract 
disorders (excl obstruction 
and infection) 
Interstitial lung disease   x         
Pulmonary fibrosis     x       
Pleural disorders Pleural effusion         x   
Respiratory disorders NEC Apnoea       x     
Dyspnoea         x   
Skin and subcutaneous 
tissue disorders 
Angioedema and urticaria Urticaria     x       
Epidermal and dermal 
conditions 
Dermatitis exfoliative           x 
Dermatitis herpetiformis     x       
Erythema   x         
Erythema multiforme       x     
Photosensitivity reaction     x       
Pruritus   x         
Psoriasis     x       
Rash   x         
Rash erythematous       x     
Skin necrosis           x 
Stevens-Johnson syndrome     x       
Toxic epidermal necrolysis     x       
Pigmentation disorders Pigmentation disorder       x     
Skin hyperpigmentation     x       
Skin and subcutaneous 
tissue disorders NEC 
Rheumatoid nodule     x       
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SOC HLGT PT Very 
common 
Common Uncommon Rare Very 
rare 
Frequency 
not 
known 
Skin and subcutaneous 
tissue infections and 
infestations 
Paronychia         x   
Skin vascular abnormalities Ecchymosis       x     
Petechiae       x   x 
Telangiectasia         x   
Vascular disorders Decreased and nonspecific 
blood pressure disorders 
and shock 
Hypotension       x     
Embolism and thrombosis Embolism       x     
Vascular haemorrhagic 
disorders 
Haemorrhage           x 
Vascular inflammations Vasculitis     x       
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term NEC – 
not elsewhere classified  
Frequency: VERY COMMON, ≥ 1/10; COMMON, ≥ 1/100 to < 1/10; UNCOMMON≥ 1/1,000 to < 1/100; RARE, 1/10,000 to < 1/1,000; VERY RARE, < 
1/10,000; and frequency not known, cannot be estimated from the available data. 
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Appendix table 43: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) - 5-ASAs 
SOC HLGT PT Recorded as 
potential 
ADR 
Blood and lymphatic system disorders Platelet disorders Thrombocytosis X 
Eye disorders Eye disorders NEC Dry eye  
Gastrointestinal disorders Anal and rectal conditions NEC Proctalgia  
Gastrointestinal inflammatory conditions Crohn's disease  
Enteritis  
Gastrointestinal motility and defaecation conditions Diarrhoea haemorrhagic X 
Gastrointestinal signs and symptoms Abdominal distension  
Abnormal faeces X 
Gastrointestinal stenosis and obstruction 
 
Ileus  
Intestinal obstruction  
Intestinal stenosis  
Subileus  
Oral soft tissue conditions Oral pain  
Tongue conditions Glossodynia  
General disorders and administration 
conditions 
General system disorders NEC 
 
Asthenia X 
Chest discomfort  
Chills  
Feeling abnormal  
Hernia  
Malaise  
Oedema X 
Stenosis  
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SOC HLGT PT Recorded as 
potential 
ADR 
Therapeutic and nontherapeutic effects (excl toxicity) Drug intolerance X 
Hepatobiliary disorders Hepatic and hepatobiliary disorders Hepatomegaly  
Infections and infestations Infections - pathogen unspecified 
 
Abscess  
Peritonitis  
Pyuria X 
Sepsis  
Injury, poisoning and procedural 
complications 
Procedural related injuries and complications NEC Intestinal anastomosis 
complication 
 
Investigations Physical examination and organ system status topics Weight decreased X 
Protein and chemistry analyses NEC C-reactive protein increased X 
Renal and urinary tract investigations and urinalyses Blood creatinine increased  
Metabolism and nutrition disorders Lipid metabolism disorders Hyperlipidaemia X 
Musculoskeletal and connective tissue 
disorders 
Muscle disorders Muscle spasms  
Musculoskeletal and connective tissue disorders NEC Back pain X 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Reproductive neoplasms female malignant and 
unspecified 
Ovarian cancer  
Reproductive neoplasms male malignant and 
unspecified 
Benign neoplasm of epididymis  
Pregnancy, puerperium and perinatal 
conditions 
Pregnancy, labour, delivery and postpartum conditions Pregnancy  
Psychiatric disorders Sexual dysfunctions, disturbances and gender identity 
disorders 
Libido decreased  
Suicidal and self-injurious behaviours NEC Completed suicide  
Renal and urinary disorders Urolithiases Nephrolithiasis  
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SOC HLGT PT Recorded as 
potential 
ADR 
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Dermatitis  
Skin appendage conditions Night sweats  
Surgical and medical procedures Therapeutic procedures and supportive care NEC Surgery  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; ADR 
– adverse drug reaction; NEC – not elsewhere classified 
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Appendix table 44: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) - antibiotics: macrolides 
SOC HLGT PT Recorded as 
potential ADR 
Gastrointestinal disorders Gastrointestinal inflammatory conditions Crohn's disease  
Infections and infestations Fungal infectious disorders Vulvovaginal candidiasis  
Infections and infestations Infections - pathogen unspecified Anal abscess  
Musculoskeletal and connective tissue disorders Joint disorders Arthralgia  
Surgical and medical procedures 
 
Therapeutic procedures and supportive care NEC 
 
Hospitalisation  
Surgery  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – preferred term; 
ADR – adverse drug reaction; NEC – not elsewhere classified 
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Appendix table 45: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) - antibiotics: nitroimidazole derivatives 
SOC HLGT PT Recorded as 
potential ADR 
Cardiac disorders Coronary artery disorders Angina pectoris  
Endocrine disorders Adrenal gland disorders Cushingoid X 
Cushing's syndrome  
Gastrointestinal disorders Anal and rectal conditions NEC Anorectal discomfort  
Proctalgia  
Gastrointestinal haemorrhages NEC Rectal haemorrhage  
Gastrointestinal inflammatory conditions Crohn's disease  
Gastrointestinal signs and symptoms Abdominal pain upper  
Oral soft tissue conditions Oral pain  
Tongue conditions Glossitis  
General disorders and 
administration conditions 
General system disorders NEC Fatigue  
Oedema X 
Pain  
Hepatobiliary disorders Hepatic and hepatobiliary disorders Hepatotoxicity  
Infections and infestations Bacterial infectious disorders Furuncle  
Fungal infectious disorders Oral candidiasis  
Infections - pathogen unspecified Abdominal abscess  
Abscess  
Anal abscess  
Nasopharyngitis  
Urinary tract infection  
Vaginal infection  
Viral infectious disorders Hepatitis C  
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SOC HLGT PT Recorded as 
potential ADR 
Investigations Haematology investigations (incl blood groups) White blood cell count decreased  
Hepatobiliary investigations Alanine aminotransferase 
increased 
 
Liver function test increased  
Physical examination and organ system status topics Weight decreased  
Musculoskeletal and connective 
tissue disorders 
Musculoskeletal and connective tissue disorders NEC Fistula  
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) 
Miscellaneous and site unspecified neoplasms malignant 
and unspecified 
Adenocarcinoma  
Nervous system disorders Movement disorders (incl parkinsonism) Parkinson's disease  
Neurological disorders NEC Agitation  
Burning sensation  
Peripheral neuropathies Neuropathy peripheral  
Sleep disturbances (incl subtypes) Insomnia X 
Skin and subcutaneous tissue 
disorders 
Skin appendage conditions Acne X 
Alopecia  
Skin vascular abnormalities Purpura X 
Surgical and medical procedures Therapeutic procedures and supportive care NEC Abscess drainage  
Vascular disorders Embolism and thrombosis Deep vein thrombosis  
 Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred 
terms); PT – preferred term; ADR – adverse drug reaction; NEC – not elsewhere classified 
 
  
488 
 
Appendix table 46: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) - antibiotics: quinolones 
SOC HLGT PT Reported as 
possible ADR 
Endocrine disorders Adrenal gland disorders Cushingoid X 
Cushing's syndrome  
Gastrointestinal disorders Gastrointestinal inflammatory conditions Crohn's disease  
Gastrointestinal signs and symptoms Abdominal pain  
Oral soft tissue conditions Oral pain  
Tongue conditions Glossitis  
General disorders and administration 
conditions 
General system disorders NEC Fatigue  
Pain  
Infections and infestations Fungal infectious disorders Fungal infection  
Mucocutaneous candidiasis  
Onychomycosis  
Oral candidiasis  
Vulvovaginal candidiasis  
Infections - pathogen unspecified Abscess  
Anal abscess  
Infection  
Nasopharyngitis  
Opportunistic infection   
Upper respiratory tract infection  
Vaginal infection  
Viral infectious disorders Anogenital warts  
Herpes simplex  
Oral herpes  
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SOC HLGT PT Reported as 
possible ADR 
Injury, poisoning and procedural 
complications 
Procedural related injuries and complications 
NEC 
Anastomic leak  
Infusion related reaction X 
Stomal hernia  
Investigations Physical examination and organ system status 
topics 
Weight decreased  
Musculoskeletal and connective tissue 
disorders 
Musculoskeletal and connective tissue 
disorders NEC 
Fistula  
Tendon, ligament and cartilage disorders Tendon pain  
Nervous system disorders Central nervous system vascular disorders Superior sagittal sinus thrombosis  
Neurological disorders NEC Agitation  
Sleep disturbances (incl subtypes) Insomnia X 
Skin and subcutaneous tissue disorders Skin appendage conditions Acne  
Skin vascular abnormalities Purpura X 
Surgical and medical procedures Gastrointestinal therapeutic procedures Colectomy  
Therapeutic procedures and supportive care 
NEC 
Hospitalisation  
Surgery  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – 
preferred term; ADR – adverse drug reaction; NEC – not elsewhere classified 
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Appendix table 47: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) - biologics: anti-TNFα 
SOC HLGT PT Reported 
as 
possible 
ADR 
Endocrine disorders Adrenal gland disorders Cushingoid X 
Eye disorders Vision disorders Vision blurred  
Gastrointestinal disorders Anal and rectal conditions NEC Anal fissure  
Gastrointestinal haemorrhages NEC Haematochezia  
Gastrointestinal inflammatory conditions Crohn's disease  
Gastrointestinal signs and symptoms Abdominal distension  
Abdominal pain upper  
Abdominal tenderness  
Flatulence  
Gastrointestinal stenosis and obstruction Anal stenosis  
Ileus  
Intestinal obstruction  
Oral soft tissue conditions Aphthous ulcer  
General disorders and administration 
conditions 
Administration site reactions Injection site bruising X 
Injection site erythema X 
Injection site haemorrhage X 
Injection site irritation X 
Injection site pain X 
Injection site pruritus X 
Fatal outcomes Death  
General system disorders NEC Chest discomfort X 
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SOC HLGT PT Reported 
as 
possible 
ADR 
Chest pain X 
Flushing X 
Multiple organ dysfunction syndrome  
Oedema peripheral  
Therapeutic and nontherapeutic effects (excl toxicity) Drug intolerance  
Hepatobiliary disorders Gallbladder disorders Cholelithiasis  
Immune system disorders Allergic conditions Type IV hypersensitivity reaction X 
Infections and infestations Bacterial infectious disorders Legionella infection  
Listeriosis  
Nocardiosis  
Staphylococcal sepsis  
Fungal infectious disorders Aspergillus infection  
Blastomycosis  
Coccidioidomycosis  
Histoplasmosis  
Mucocutaneous candidiasis  
Onychomycosis  
Pneumocystis jirovecii pneumonia  
Vulvovaginal candidiasis  
Infections - pathogen unspecified Abdominal abscess  
Abdominal wall abscess  
Abscess  
Anal abscess  
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SOC HLGT PT Reported 
as 
possible 
ADR 
Appendicitis  
Bronchitis  
Gastroenteritis  
Gastrointestinal infection  
Infection  
Infectious colitis  
Liver abscess  
Nasopharyngitis  
Pelvic abscess  
Pelvic inflammatory disease  
Peritonitis  
Pharyngitis X 
Pneumonia X 
Pyelonephritis  
Rhinitis  
Skin infection  
Mycobacterial infectious disorders Pulmonary tuberculosis  
Viral infectious disorders Anogenital warts  
Cytomegalovirus infection  
Hepatitis C  
Herpes simplex  
Herpes virus infection  
Oral herpes  
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SOC HLGT PT Reported 
as 
possible 
ADR 
Injury, poisoning and procedural 
complications 
Injuries NEC Contusion  
Procedural related injuries and complications NEC Infusion related reaction  
Post procedural complication  
Procedural pain  
Stomal hernia  
Investigations Gastrointestinal investigations Pancreatic enzymes increased  
Hepatobiliary investigations Alanine aminotransferase abnormal  
Liver function test abnormal X 
Liver function test increased  
Immunology and allergy investigations Antinuclear antibody positive  
Double stranded DNA antibody  
Musculoskeletal and soft tissue investigations (excl 
enzyme tests) 
Bone density decreased  
Physical examination and organ system status topics Weight decreased  
Toxicology and therapeutic drug monitoring Drug specific antibody present  
Metabolism and nutrition disorders Appetite and general nutritional disorders Hyperphagia X 
Malnutrition  
Musculoskeletal and connective 
tissue disorders 
Musculoskeletal and connective tissue disorders NEC Anal fistula  
Fistula  
Pain in extremity  
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Breast neoplasms malignant and unspecified (incl 
nipple) 
Breast cancer  
Gastrointestinal neoplasms malignant and unspecified Rectal adenocarcinoma  
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SOC HLGT PT Reported 
as 
possible 
ADR 
Rectal cancer  
Haematopoietic neoplasms (excl leukaemias and 
lymphomas) 
Haematological malignancy  
Lymphomas non-Hodgkin's T-cell  Natural killer-cell lymphoblastic 
lymphoma 
 
Miscellaneous and site unspecified neoplasms 
malignant and unspecified 
Carcinoma in situ  
Neoplasm  
Neoplasm malignant X 
Squamous cell carcinoma  
Renal and urinary tract neoplasms malignant and 
unspecified 
Bladder cancer  
Renal cell carcinoma  
Skin neoplasms malignant and unspecified Basal cell carcinoma  
Neoplasm skin  
Nervous system disorders Central nervous system vascular disorders Superior sagittal sinus thrombosis  
Neurological disorders NEC Dysgeusia  
Sensory loss  
Syncope  
Pregnancy, puerperium and perinatal 
conditions 
Abortions and stillbirths Abortion spontaneous  
Pregnancy, labour, delivery and postpartum 
conditions 
Pregnancy  
Psychiatric disorders Mood disorders and disturbances NEC Mood swings X 
Respiratory, thoracic and mediastinal 
disorders 
Respiratory disorders NEC Laryngeal pain  
Pulmonary mass   
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SOC HLGT PT Reported 
as 
possible 
ADR 
Skin and subcutaneous tissue 
disorders 
Epidermal and dermal conditions Dermatitis atopic  
Skin lesion  
Skin and subcutaneous tissue disorders NEC Skin ulcer  
Skin appendage conditions Acne  
Skin vascular abnormalities Hypersensitivity vasculitis  
Surgical and medical procedures Gastrointestinal therapeutic procedures Appendicectomy  
Intestinal resection  
Therapeutic procedures and supportive care NEC Antibiotic therapy  
Fistula repair  
Hospitalisation  
Surgery  
Vascular disorders Embolism and thrombosis Venous thrombosis  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – 
preferred term; ADR – adverse drug reaction; NEC – not elsewhere classified 
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Appendix table 48: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) – corticosteroids 
SOC HLGT PT Reported 
as a 
possible 
ADR 
Blood and lymphatic system 
disorders 
Anaemias nonhaemolytic and marrow depression Anaemia X 
Coagulopathies and bleeding diatheses (excl 
thrombocytopenic) 
Increased tendency to bruise X 
Endocrine disorders Adrenal gland disorders Adrenal disorder  
Thyroid gland disorders Hyperthyroidism  
Eye disorders Vision disorders Visual impairment  
Gastrointestinal disorders Abdominal hernias and other abdominal wall conditions Inguinal hernia  
Dental and gingival conditions Tooth disorder  
Gastrointestinal conditions NEC Anal fistula  
Gastrointestinal haemorrhages NEC Melaena X 
Gastrointestinal inflammatory conditions Crohn's disease  
Gastrointestinal motility and defaecation conditions Diarrhoea haemorrhagic  
Gastrointestinal signs and symptoms Abdominal mass  
Abdominal pain upper  
Flatulence  
Vomiting X 
Gastrointestinal stenosis and obstruction Ileus  
Intestinal obstruction  
Gastrointestinal ulceration and perforation Duodenal ulcer  
Salivary gland conditions Dry mouth X 
General disorders and 
administration site conditions  
General system disorders NEC Chills  
Flushing X 
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SOC HLGT PT Reported 
as a 
possible 
ADR 
Influenza like illness  
Oedema X 
Oedema peripheral X 
Infections and infestations Fungal infectious disorders Oral candidiasis  
Vulvovaginal candidiasis X 
Infections - pathogen unspecified Anal abscess X 
Conjunctivitis X 
Mesenteric abscess  
Nasopharyngitis  
Psoas abscess  
Respiratory tract infection  
Sinusitis  
Viral infectious disorders Respiratory tract infection viral  
Viral infection  
Injury, poisoning and procedural 
complications 
Bone and joint injuries Hand fracture X 
Investigations Endocrine investigations (incl sex hormones) Blood cortisol abnormal  
Blood cortisol decreased X 
Haematology investigations (incl blood groups) Haemoglobin decreased  
White blood cell count increased X 
Hepatobiliary investigations Alanine aminotransferase 
increased 
X 
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SOC HLGT PT Reported 
as a 
possible 
ADR 
Aspartate aminotransferase 
increased 
X 
Physical examination and organ system status topics Weight increased  
Protein and chemistry analyses NEC Blood albumin decreased  X 
C-reactive protein increased  
Protein total decreased X 
Renal and urinary tract investigations and urinalyses Blood creatinine increased X 
Water, electrolyte and mineral investigations Blood calcium decreased X 
Metabolism and nutrition 
disorders 
Appetite and general nutritional disorders Decreased appetite X 
Bone, calcium, magnesium and phosphorus metabolism 
disorders 
Hypocalcaemia X 
Lipid metabolism disorders Lipohypertrophy X 
Musculoskeletal and connective 
tissue disorders 
Joint disorders Arthritis  
Joint swelling X 
Musculoskeletal and connective tissue disorders NEC Back pain X 
Fistula  
Nervous system disorders Demyelinating disorders Multiple sclerosis  
Pregnancy, puerperium and 
perinatal conditions 
Maternal complications of pregnancy Ectopic pregnancy  
Pregnancy, labour, delivery and postpartum conditions Pregnancy  
Unintended pregnancy  
Psychiatric disorders Mood disorders and disturbances NEC Affect lability X 
Mood altered X 
Menstrual cycle and uterine bleeding disorders Metrorrhagia  
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SOC HLGT PT Reported 
as a 
possible 
ADR 
Reproductive system and breast 
disorders 
Vulvovaginal disorders (excl infections and inflammations) Bartholin's cyst  
Respiratory, thoracic and 
mediastinal disorders 
Respiratory disorders NEC Laryngeal pain  
Oropharyngeal pain  
Upper respiratory tract disorders (excl infections) Nasal mucosal ulcer X 
Skin and subcutaneous tissue 
disorders 
Angioedema and urticaria Swelling face  
Epidermal and dermal conditions Eczema X 
Skin appendage conditions Alopecia X 
Hair growth abnormal X 
Hypertrichosis X 
Surgical and medical procedures Head and neck therapeutic procedures Dental operation  
Therapeutic procedures and supportive care NEC Hospitalisation  
Vascular disorders Vascular disorders NEC Flushing  
Hot flush X 
Vascular hypertensive disorders Hypertensive crisis  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – 
preferred term; ADR – adverse drug reaction; NEC – not elsewhere classified 
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Appendix table 49: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) - immunosuppressives: antimetabolites 
SOC HLGT PT Reported as a 
possible ADR 
Blood and lymphatic system 
disorders 
Anaemias nonhaemolytic and marrow 
depression 
Anaemia macrocytic  
White blood cell disorders Lymphopenia  
Neutropenia  
Cardiac disorders Coronary artery disorders Angina pectoris  
Ear and labyrinth disorders Inner ear and VIIIth cranial nerve disorders Vertigo  
Endocrine disorders Adrenal gland disorders Cushingoid x 
Eye disorders Anterior eye structural change, deposit and 
degeneration 
Cataract x 
Gastrointestinal disorders Anal and rectal conditions NEC Anal fissure  
Proctalgia  
Exocrine pancreas conditions Pancreatitis acute  
Gastrointestinal haemorrhages NEC Gastrointestinal haemorrhage  
Gastrointestinal inflammatory conditions Crohn's disease  
Gastrointestinal motility and defaecation 
conditions 
Constipation  
Gastrointestinal signs and symptoms Abdominal pain  
Abdominal pain upper  
Abdominal symptom  
Dyspepsia  
Flatulence  
Gastrointestinal stenosis and obstruction Intestinal obstruction  
Subileus  
Administration site reactions Injection site reaction x 
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SOC HLGT PT Reported as a 
possible ADR 
General disorders and 
administration conditions 
Body temperature conditions Pyrexia  
General system disorders NEC Asthenia  
Facial pain  
Fatigue  
Influenza like illness  
Malaise  
Swelling  
Therapeutic and nontherapeutic effects (excl 
toxicity) 
Drug intolerance  
Hepatobiliary disorders Bile duct disorders Biliary colic  
Hepatic and hepatobiliary disorders Hepatitis acute  
Immune system disorders Allergic conditions Seasonal allergy  
Infections and infestations Bacterial infectious disorders Clostridium difficile infection  
Infections - pathogen unspecified Abdominal abscess  
Anal abscess  
Appendicitis  
Conjunctivitis  
Eye infection  
Gastroenteritis  
Gastrointestinal infection  
Hordeolum  
Infection  
Pneumonia  
Respiratory tract infection  
Rhinitis  
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SOC HLGT PT Reported as a 
possible ADR 
Skin infection  
Upper respiratory tract infection  
Urinary tract infection  
Vaginal infection  
Viral infectious disorders Hepatitis C  
Herpes virus infection  
Herpes zoster  
Influenza  
Lower respiratory tract infection viral  
Injury, poisoning and procedural 
complications 
Bone and joint injuries Fracture  
Injuries NEC Arthropod sting  
Procedural related injuries and complications 
NEC 
Post procedural complication x 
Investigations Endocrine investigations (incl sex hormones) Blood cortisol decreased  
Enzyme investigations NEC Blood alkaline phosphatase increased  
Gastrointestinal investigations Amylase increased  
Lipase increased  
Haematology investigations (incl blood 
groups) 
Platelet count decreased  
White blood cell count decreased x 
Hepatobiliary investigations Alanine aminotransferase increased  
Aspartate aminotransferase increased  
Gamma-glutamyltransferase increased  
Hepatic enzyme increased  
Liver function test increased  
Transaminases increased x 
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SOC HLGT PT Reported as a 
possible ADR 
Metabolic, nutritional and blood gas 
investigations 
Blood glucose abnormal   
Musculoskeletal and soft tissue investigations 
(excl enzyme tests) 
Bone density decreased x 
Physical examination and organ system status 
topics 
Weight increased  
Protein and chemistry analyses NEC C-reactive protein increased  
Metabolism and nutrition 
disorders 
Appetite and general nutritional disorders Hyperphagia x 
Glucose metabolism disorders (incld diabetes 
mellitus) 
Hyperglycaemia  
Iron and trace metal metabolism Iron deficiency  
Metabolism disorders NEC Hyperamylasasemia  
Musculoskeletal and connective 
tissue disorders 
Bone disorders (excl congenital and fractures) Osteoporosis  
Joint disorders Arthralgia  
Joint stiffness  
Muscle disorders Muscle spasms  
Myalgia  
Musculoskeletal and connective tissue 
disorders NEC 
Anal fistula  
Back pain  
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Reproductive neoplasms male malignant and 
unspecified 
Prostate cancer  
Nervous system disorders Demyelinating disorders Demyelination  
Headaches Headache  
Movement disorders (incl parkinsonism) Parkinson's disease  
Neurological disorders NEC Dysgeusia  
Paraesthesia x 
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SOC HLGT PT Reported as a 
possible ADR 
Post herpetic neuralgia  
Sensory loss  
Sleep disturbances (incl subtypes) Insomnia  
Spinal cord and nerve root disorders Sciatica  
Pregnancy, puerperium and 
perinatal conditions 
Abortions and stillbirths Abortion spontaneous  
Pregnancy, labour, delivery and postpartum 
conditions 
Pregnancy  
Psychiatric disorders Anxiety disorders and symptoms Nervousness  
Deliria (incl confusion) Confusional state  
Depressed mood disorders and disturbances Depression  
Mood disorders and disturbances NEC Mood swings x 
Sleep disorders and disturbances Sleep disorder  
Renal and urinary disorders Nephropathies Glomerulonephritis  
Reproductive system and breast 
disorders 
Menstrual cycle and uterine bleeding 
disorders 
Dysmenorrhoea  
Sexual function and fertility disorders Sexual dysfunction  
Respiratory, thoracic and 
mediastinal disorders 
Respiratory disorders NEC Cough  
Laryngeal pain  
Upper respiratory tract disorders (excl 
infections) 
Rhinitis allergic  
Skin and subcutaneous tissue 
disorders 
Epidermal and dermal conditions Eczema  
Pruritus  
Rash  
Skin appendage conditions Acne x 
Surgical and medical procedures Gastrointestinal therapeutic procedures Hernia repair  
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SOC HLGT PT Reported as a 
possible ADR 
Intestinal resection  
Head and neck therapeutic procedures Tooth extraction  
Toothache  
Therapeutic procedures and supportive care 
NEC 
Fistula repair  
Hospitalisation  
Surgery x 
Vascular disorders Arteriosclerosis, stenosis, vascular 
insufficiency and necrosis 
Peripheral coldness  
Decreased and nonspecific blood pressure 
disorders and shock 
Hypotension  
Vascular inflammations Phlebitis  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – 
preferred term; ADR – adverse drug reaction; NEC – not elsewhere classified 
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Appendix table 50: All adverse events recorded in Crohn’s disease trials, but not in summary of product characteristics (SPCs) - immunosuppressives: methotrexate 
SOC HLGT PT Reported as 
a possible 
ADR 
Cardiac disorders Coronary artery disorders Myocardial infarction  
Gastrointestinal disorders Exocrine pancreas conditions Pancreatitis acute  
Gastrointestinal haemorrhages NEC Haematochezia  
Gastrointestinal inflammatory conditions Crohn's disease  
Gastrointestinal motility and defaecation 
conditions 
Constipation  
Gastrointestinal signs and symptoms Abdominal distension  
General disorders and administration 
conditions 
General system disorders NEC Asthenia  
Influenza like illness  
Oedema peripheral  
Infections and infestations Infections - pathogen unspecified Anal abscess  
Infection  
Nasopharyngitis  
Respiratory tract infection  
Viral infectious disorders Influenza  
Injury, poisoning and procedural 
complications 
Injuries NEC Contusion  
Procedural related injuries and complications 
NEC 
Infusion related reaction x 
Procedural pain  
Investigations Enzyme investigations NEC Blood alkaline phosphatase 
increased 
 
Hepatobiliary investigations Alanine aminotransferase abnormal  
Alanine aminotransferase increased  
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SOC HLGT PT Reported as 
a possible 
ADR 
Aspartate aminotransferase 
increased 
 
Gamma-glutamyltransferase 
increased 
 
Liver function test abnormal  
Transaminases increased  
Musculoskeletal and soft tissue investigations 
(excl enzyme tests) 
Bone density decreased  
Toxicology and therapeutic drug monitoring Drug specific antibody present  
Musculoskeletal and connective tissue 
disorders 
Musculoskeletal and connective tissue disorders 
NEC 
Back pain  
Pain in extremity  
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
Miscellaneous and site unspecified neoplasms 
malignant and unspecified 
Carcinoma in situ  
Neoplasm malignant  
Nervous system disorders Cranial nerve disorders (excl neoplasms) Optic neuritis  
Neurological disorders NEC Dizziness  
Syncope  
Peripheral neuropathies Polyneuropathy  
Respiratory, thoracic and mediastinal 
disorders 
Lower respiratory tract disorders (excl 
obstruction and infection) 
Pneumonitis  
Pulmonary vascular disorders Pulmonary embolism  
Respiratory disorders NEC Cough  
Laryngeal pain  
Skin and subcutaneous tissue disorders Epidermal and dermal conditions Rash  
Skin lesion  
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SOC HLGT PT Reported as 
a possible 
ADR 
Surgical and medical procedures Gastrointestinal therapeutic procedures Intestinal resection  
Therapeutic procedures and supportive care 
NEC 
Surgery  
Vascular disorders Embolism and thrombosis Venous thrombosis  
Note: SOC – System Organ Classification; HLGT – Higher Level Group Term (clinical grouping of multiple preferred terms); PT – 
preferred term; ADR – adverse drug reaction; NEC – not elsewhere classified 
 
 
